
<html lang="en"     class="pb-page"  data-request-id="c9a5caa7-e761-4d2e-bcb4-3082e8afa594"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;issue:issue:10.1021/jmcmar.2018.61.issue-23;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;article:article:10.1021/acs.jmedchem.8b01387"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Design, Synthesis, and Characterization of Globular Orphan Nuclear Receptor Regulator with Biological Activity in Soft Tissue Sarcoma" /></meta><meta name="dc.Creator" content="Mao  Ye" /></meta><meta name="dc.Creator" content="Santosh K.  Misra" /></meta><meta name="dc.Creator" content="Arun K.  De" /></meta><meta name="dc.Creator" content="Fatemeh  Ostadhossein" /></meta><meta name="dc.Creator" content="Kuldeep  Singh" /></meta><meta name="dc.Creator" content="Laurie  Rund" /></meta><meta name="dc.Creator" content="Lawrence  Schook" /></meta><meta name="dc.Creator" content="Dipanjan  Pan" /></meta><meta name="dc.Description" content="Sarcomas are rare and heterogeneous cancer variants of mesenchymal origin. Their genetic heterogeneity coupled with uncertain histogenesis makes them difficult to treat and results in poor prognosi..." /></meta><meta name="Description" content="Sarcomas are rare and heterogeneous cancer variants of mesenchymal origin. Their genetic heterogeneity coupled with uncertain histogenesis makes them difficult to treat and results in poor prognosi..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="October 30, 2018" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.8b01387" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2018 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b01387" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.8b01387" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b01387" /></link>
        
    
    

<title>Design, Synthesis, and Characterization of Globular Orphan Nuclear Receptor Regulator with Biological Activity in Soft Tissue Sarcoma | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.8b01387" /></meta><meta property="og:title" content="Design, Synthesis, and Characterization of Globular Orphan Nuclear Receptor Regulator with Biological Activity in Soft Tissue Sarcoma" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-23/acs.jmedchem.8b01387/20181207/images/large/jm-2018-013879_0009.jpeg" /></meta><meta property="og:description" content="Sarcomas are rare and heterogeneous cancer variants of mesenchymal origin. Their genetic heterogeneity coupled with uncertain histogenesis makes them difficult to treat and results in poor prognosis. In this work, we show that structure-based drug discovery involving computational modeling can be used to identify a new retinoid X receptor (RXR) agonist ligand with a bis(indolyl)methane scaffold. This agent co-self-assembles with an amphiphilic diblock copolymer resulting in nanoparticles (Nano-RXR) with excellent kinetic stability, which were evaluated for efficacy and safety in transformed sarcoma cells, 63-3 Cre and 141-10 Cre of pig origin, and in rodent xenograft models. Responses at gene and protein levels established the treatment approach as a highly effective RXR agonist across cell, rodent, and “Oncopig” models. Interestingly, Nano-RXR was not only able to modulate metabolic and transporter genes related to orphan nuclear receptors but also played a major role in modulating programmed cell death in sarcomas developed in Oncopigs." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.8b01387"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.8b01387">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.8b01387&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.8b01387&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.8b01387&amp;href=/doi/10.1021/acs.jmedchem.8b01387" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2018</span><span class="cit-fg-volume">, 61</span><span class="cit-fg-issue">, 23</span><span class="cit-fg-pageRange">, 10739-10752</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/61/23" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.8b01373" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.8b01398" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Design, Synthesis, and Characterization of Globular Orphan Nuclear Receptor Regulator with Biological Activity in Soft Tissue Sarcoma</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Mao Ye</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mao Ye</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Bioengineering, University of Illinois at Urbana−Champaign, Urbana, Illinois 61801, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mao++Ye">Mao Ye</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Santosh K. Misra</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Santosh K. Misra</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Bioengineering, University of Illinois at Urbana−Champaign, Urbana, Illinois 61801, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Santosh+K.++Misra">Santosh K. Misra</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-3313-4895" title="Orcid link">http://orcid.org/0000-0002-3313-4895</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Arun K. De</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Arun K. De</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Animal Sciences, University of Illinois at Urbana−Champaign, Urbana, Illinois 61801, United States</div><div class="loa-info-affiliations-info">Agricultural Animal Care and Use Program, University of Illinois at Urbana−Champaign, Urbana, Illinois 61801, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Arun+K.++De">Arun K. De</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Fatemeh Ostadhossein</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Fatemeh Ostadhossein</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Bioengineering, University of Illinois at Urbana−Champaign, Urbana, Illinois 61801, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Fatemeh++Ostadhossein">Fatemeh Ostadhossein</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kuldeep Singh</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kuldeep Singh</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Veterinary Diagnostic Laboratory, University of Illinois at Urbana−Champaign, Urbana, Illinois 61801, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kuldeep++Singh">Kuldeep Singh</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Laurie Rund</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Laurie Rund</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Animal Sciences, University of Illinois at Urbana−Champaign, Urbana, Illinois 61801, United States</div><div class="loa-info-affiliations-info">Agricultural Animal Care and Use Program, University of Illinois at Urbana−Champaign, Urbana, Illinois 61801, United States</div><div class="loa-info-affiliations-info">Veterinary Diagnostic Laboratory, University of Illinois at Urbana−Champaign, Urbana, Illinois 61801, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Laurie++Rund">Laurie Rund</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Lawrence Schook</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Lawrence Schook</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Animal Sciences, University of Illinois at Urbana−Champaign, Urbana, Illinois 61801, United States</div><div class="loa-info-affiliations-info">Agricultural Animal Care and Use Program, University of Illinois at Urbana−Champaign, Urbana, Illinois 61801, United States</div><div class="loa-info-affiliations-info">Veterinary Diagnostic Laboratory, University of Illinois at Urbana−Champaign, Urbana, Illinois 61801, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Lawrence++Schook">Lawrence Schook</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Dipanjan Pan</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Dipanjan Pan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Bioengineering, University of Illinois at Urbana−Champaign, Urbana, Illinois 61801, United States</div><div class="loa-info-affiliations-info">Beckman Institute of Advanced Science and Technology, University of Illinois at Urbana−Champaign, Urbana, Illinois 61801, United States</div><div class="loa-info-affiliations-info">Mills Breast Cancer Institute, Carle Foundation Hospital, 502 N. Busey, Urbana, Illinois 61801, United States</div><div class="loa-info-affiliations-info">Department of Materials Science and Engineering, University of Illinois at Urbana−Champaign, Urbana, Illinois 61801, United States</div><div class="loa-info-affiliations-info">Carle-Illinois College of Medicine, Urbana, Illinois 61801, United States</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#42262b32232c28232c022b2e2e2b2c2d2b316c272637"><span class="__cf_email__" data-cfemail="42262b32232c28232c022b2e2e2b2c2d2b316c272637">[email protected]</span></a></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Dipanjan++Pan">Dipanjan Pan</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-0175-4704" title="Orcid link">http://orcid.org/0000-0003-0175-4704</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b01387&amp;href=/doi/10.1021%2Facs.jmedchem.8b01387" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2018</span></span><span class="cit-volume">, 61</span><span class="cit-issue">, 23</span><span class="cit-pageRange">, 10739–10752</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">October 30, 2018</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>5 September 2018</li><li><span class="item_label"><b>Published</b> online</span>30 October 2018</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 13 December 2018</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.8b01387" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01387</a></div><div class="article_header-article-copyright"><strong>Copyright © 2018 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D10739%26pageCount%3D14%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DMao%2BYe%252C%2BSantosh%2BK.%2BMisra%252C%2BArun%2BK.%2BDe%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D61%26issueNum%3D23%26contentID%3Dacs.jmedchem.8b01387%26title%3DDesign%252C%2BSynthesis%252C%2Band%2BCharacterization%2Bof%2BGlobular%2BOrphan%2BNuclear%2BReceptor%2BRegulator%2Bwith%2BBiological%2BActivity%2Bin%2BSoft%2BTissue%2BSarcoma%26numPages%3D14%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D10752%26publicationDate%3DDecember%2B2018">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.8b01387"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">973</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">1</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.8b01387" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Design, Synthesis, and Characterization of Globular Orphan Nuclear Receptor Regulator with Biological Activity in Soft Tissue Sarcoma&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Mao&quot;,&quot;last_name&quot;:&quot;Ye&quot;},{&quot;first_name&quot;:&quot;Santosh&quot;,&quot;last_name&quot;:&quot;K. Misra&quot;},{&quot;first_name&quot;:&quot;Arun&quot;,&quot;last_name&quot;:&quot;K. De&quot;},{&quot;first_name&quot;:&quot;Fatemeh&quot;,&quot;last_name&quot;:&quot;Ostadhossein&quot;},{&quot;first_name&quot;:&quot;Kuldeep&quot;,&quot;last_name&quot;:&quot;Singh&quot;},{&quot;first_name&quot;:&quot;Laurie&quot;,&quot;last_name&quot;:&quot;Rund&quot;},{&quot;first_name&quot;:&quot;Lawrence&quot;,&quot;last_name&quot;:&quot;Schook&quot;},{&quot;first_name&quot;:&quot;Dipanjan&quot;,&quot;last_name&quot;:&quot;Pan&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2018&quot;,&quot;month&quot;:&quot;10&quot;,&quot;day&quot;:&quot;30&quot;,&quot;issue&quot;:&quot;23&quot;,&quot;volume&quot;:&quot;61&quot;,&quot;pages&quot;:&quot;10739-10752&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.8b01387&quot;},&quot;abstract&quot;:&quot;Sarcomas are rare and heterogeneous cancer variants of mesenchymal origin. Their genetic heterogeneity coupled with uncertain histogenesis makes them difficult to treat and results in poor prognosis. In this work, we show that structure-based drug discovery involving computational modeling can be used to identify a new retinoid X receptor (RXR) agonist ligand with a bis(indolyl)methane scaffold. This agent co-self-assembles with an amphiphilic diblock copolymer resulting in nanoparticles (Nano-RXR) with excellent kinetic stability, which were evaluated for efficacy and safety in transformed sarcoma cells, 63-3 Cre and 141-10 Cre of pig origin, and in rodent xenograft models. Responses at gene and protein levels established the treatment approach as a highly effective RXR agonist across cell, rodent, and “Oncopig” models. Interestingly, Nano-RXR was not only able to modulate metabolic and transporter genes related to orphan nuclear receptors but also played a major role in modulating programmed cell death in s&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b01387&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b01387" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b01387&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b01387" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b01387&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b01387" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b01387&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b01387&amp;href=/doi/10.1021/acs.jmedchem.8b01387" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.8b01387" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.8b01387" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (9 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01387&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.8b01387%26sid%3Dliteratum%253Aachs%26pmid%3D30375864%26genre%3Darticle%26aulast%3DYe%26date%3D2018%26atitle%3DDesign%252C%2BSynthesis%252C%2Band%2BCharacterization%2Bof%2BGlobular%2BOrphan%2BNuclear%2BReceptor%2BRegulator%2Bwith%2BBiological%2BActivity%2Bin%2BSoft%2BTissue%2BSarcoma%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D61%26issue%3D23%26spage%3D10739%26epage%3D10752%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290758" title="Anatomy">Anatomy</a>,</li><li><a href="/action/doSearch?ConceptID=292589" title="Agonists">Agonists</a>,</li><li><a href="/action/doSearch?ConceptID=292143" title="Metabolism">Metabolism</a>,</li><li><a href="/action/doSearch?ConceptID=292153" title="Tumors">Tumors</a>,</li><li><a href="/action/doSearch?ConceptID=292186" title="Receptors">Receptors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/61/23" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-23/jmcmar.2018.61.issue-23/20181213/jmcmar.2018.61.issue-23.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-23/acs.jmedchem.8b01387/20181207/images/medium/jm-2018-013879_0009.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-23/acs.jmedchem.8b01387/20181207/images/large/jm-2018-013879_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01387&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Sarcomas are rare and heterogeneous cancer variants of mesenchymal origin. Their genetic heterogeneity coupled with uncertain histogenesis makes them difficult to treat and results in poor prognosis. In this work, we show that structure-based drug discovery involving computational modeling can be used to identify a new retinoid X receptor (RXR) agonist ligand with a bis(indolyl)methane scaffold. This agent co-self-assembles with an amphiphilic diblock copolymer resulting in nanoparticles (Nano-RXR) with excellent kinetic stability, which were evaluated for efficacy and safety in transformed sarcoma cells, 63-3 Cre and 141-10 Cre of pig origin, and in rodent xenograft models. Responses at gene and protein levels established the treatment approach as a highly effective RXR agonist across cell, rodent, and “Oncopig” models. Interestingly, Nano-RXR was not only able to modulate metabolic and transporter genes related to orphan nuclear receptors but also played a major role in modulating programmed cell death in sarcomas developed in Oncopigs.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_32267" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_32267" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Sarcomas generally require surgical resection and radiation as standard care in high-risk patients.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Despite aggressive intervention, nearly 50% of patients suffer from recurrent disease leading to death. Some sarcomas are sensitive to chemotherapy with greatly improved treatment results. One such group of sarcomas where chemotherapy increased survival from 20% to 70% is localized osteosarcoma.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> The effectiveness of immunotherapy in the metastatic soft tissue sarcomas is also being evaluated in clinical trials.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Despite this promise, the last two decades have seen a plateau in this progress, and chemotherapy has not altered the poor patient outcome associated with metastatic disease. There is no universally accepted neoadjuvant therapy standard of care.<a onclick="showRef(event, 'ref2 ref3 ref4 ref5 ref6 ref7 ref8 ref9 ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref2 ref3 ref4 ref5 ref6 ref7 ref8 ref9 ref10 ref11">(2−11)</a> Though several clinical studies indicated that neoadjuvant therapy with doxorubicin (DOX) and ifosfamide (AIM), epirubicin and ifosfamide, or doxorubicin, ifosfamide, and dacarbazine (MAID) with or without radiation therapy improved survival in high-risk patients, none of the phase III randomized trials offered unequivocal positive results for neoadjuvant therapy in soft tissue sarcomas, making these chemotherapy trials heterogeneous and outcomes conflicting. Furthermore, the response of older patients toward current medication is constrained by factors such as the associated toxicity. This plus other comorbodities arising from chemotherapy warrants the pursuit of novel therapies for this aggressive disease. Future progress may include the discovery of new cytotoxic chemotherapeutics and development of targeted therapies with controlled release pathways.<a onclick="showRef(event, 'ref12 ref13 ref14 ref15 ref16 ref17 ref18 ref19 ref20 ref21 ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref12 ref13 ref14 ref15 ref16 ref17 ref18 ref19 ref20 ref21 ref22 ref23">(12−23)</a> An evaluation of their role in metabolic and transport gene regulation and their effective induction of genes in the programmed cell death cascade would enhance their utility in future clinical trials.</div><div class="NLM_p">Retinoid X receptor (RXR) is a master regulator of multiple biological processes due to the formation of heterodimers with other nuclear receptors. RXR ligands or rexinoids are found to activate permissive heterodimers, or subordinate to the partner ligand in nonpermissive heterodimers to act cooperatively or synergistically. The negative cooperativity in RXR–thyroid hormone receptor (TR) heterodimers has been found to be due to the allosteric repression of TR by rexinoids. In general, agonists, partial agonists, and antagonists exert different roles in the heterodimers by strengthening or disrupting the interaction surface with co-regulators. The activity of the partial agonists and antagonists could depend on the cellular context and the nature of co-regulators. Thus use of partial antagonists or agonists to overcome undesired effects of rexinoids is a promising new avenue for therapy. For instance, bexarotene and alitretinoin (9-<i>cis</i>-retinoic acid) are in the clinic for topical and systemic treatment of cutaneous T cell lymphoma (CTCL) and for the topical treatment of Kaposi’s sarcoma and systemic treatment of refractory chronic hand eczema, respectively. RXR modulators also hold therapeutic potential for the treatment of diabetes and obesity, as well as atherosclerosis, other cardiovascular indications, and inflammatory diseases, but important secondary effects have been noted in rodent models, among them hypertriglyceridemia, suppression of the thyroid hormone axis, and induction of hepatomegaly. Recently described therapeutic options for rexinoids in cancer and neurodegeneration have opened exciting avenues for drug design and discovery of this important family of modulators. Nuclear hormone receptors, including RXR and peroxisome proliferator-activated receptor (PPAR), represent therapeutic targets in sarcoma. RXRs have been considered as “auxiliary” receptors that enhance DNA binding of retinoic acid receptor (RAR) and other nuclear hormone receptors, including PPARγ. More recent studies, however, showed that selective activation of RXR could lead to transcriptional activation, apoptosis, and redifferentiation of embryonal carcinoma cells and that the effects of RAR and RXR selective agents in combination had synergistic effects. PPARγ receptors have been studied in primary human tissues with positive immunostaining for PPARγ in 14/14 nevi, 10/11 primary sarcoma lesions, and 6/8 sarcoma metastases. Similarly, high in vitro and in vivo activities were reported on PPARγ expressing sarcoma cells with significant reduction in cell proliferation.</div><div class="NLM_p">Toward this aim, we provide an “in silico to in vivo” approach to identify and synthesize an RXR agonist. Furthermore, we developed it as a nanotherapy<a onclick="showRef(event, 'ref24 ref25 ref26 ref27 ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref24 ref25 ref26 ref27 ref28 ref29">(24−29)</a> treatment for “soft” tissue sarcoma, which can provide potent and controlled delivery of the newly discovered retinoid X-receptor (RXR)-selective agonist (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>a). RXR-selective agonists with new chemistry and approach were identified through structure-based drug discovery and computational modeling to transcriptionally activate the orphan nuclear receptor target.<a onclick="showRef(event, 'ref30 ref31 ref32 ref33 ref34 ref35 ref36 ref37 ref38 ref39 ref40'); return false;" href="javascript:void(0);" class="ref ref30 ref31 ref32 ref33 ref34 ref35 ref36 ref37 ref38 ref39 ref40">(30−40)</a> The delivery of the potent agent has been accomplished by a micellar polymeric nanoparticle. The structurally new scaffold-based RXR selective agonist is different from either bexarotene or alitretinoin (9-<i>cis</i>-retinoic acid)-based structures, basic frames for most reported RXR ligands. Our results demonstrated significant efficacy in vitro. In order to realize the translational supremacy of the work, the agents were studied simultaneously in a rodent and a transgenic swine model (Oncopigs) of soft tissue sarcoma.<a onclick="showRef(event, 'ref41 ref42 ref43'); return false;" href="javascript:void(0);" class="ref ref41 ref42 ref43">(41−43)</a> The Oncopig provides an inducible and reproducible tumor model in a large animal that is comparable to humans in both size and physiology and is being used for development, validation, safety, and efficacy assessment of the RXR agent intended for human translation. Studies with rodent and Oncopig models elucidate mechanistic insights into the modulations of RXRα PPAR transcriptional activation and downstream target genes along with genes involved in phase-I, phase-II, and phase-III metabolism and transport regulation in treated and control tumor tissues (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>b).</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-23/acs.jmedchem.8b01387/20181207/images/medium/jm-2018-013879_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-23/acs.jmedchem.8b01387/20181207/images/large/jm-2018-013879_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Outline of planned research to evaluate in vitro and in vivo efficiencies. (a) Progression of computational, chemical, and biological experiments and (b) summary of gene regulations expected from newly designed RXR agonist in vivo. In-silico studies to identify RXR agonist through lead optimization. (c) Elongated shape of RAR and (d) globular shape of RXR structures; (e) Molcad Surfaces of <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1MVC">1MVC</a>, RXR agonist conformation crystal structure and (f) ligand interaction pictures of docking structures of compound <b>8</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-23/acs.jmedchem.8b01387/20181207/images/large/jm-2018-013879_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01387&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_33825" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_33825" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Structure-Based Design, Lead Optimization, and Synthesis of RXR Agonists</h3><div class="NLM_p">Due to the high similarity of RXR and RAR structures, the selectivity of RXR over RAR is the key for the design of RXR ligands. Computationally, the RAR structure has an elongated shape (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>c), whereas RXR is globular and “L” shaped (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>e). The interactions between the hinge region of the ligand and residues C432 and I268 are important for RXR selectivity. The Molcad surface picture in <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>d shows a relatively large L-shaped binding cavity in RXR structure, with hydrogen bond and ion–salt interactions on one end and a hydrophobic interaction on the other end. The thiol group from C432 forms a hydrogen bond with the oxygen in the bridge of a known RXR modulator SR11237 (alternatively called BMS649), making an important contribution to maintain the “L” shape of the structure. This suggests that an RXR agonist with an indole as the hydrophobic ring and another indole as the bridge substituent could be successfully derived from the bis(indolyl)methane moiety via structure-based lead optimization approach. Through computational modeling (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01387/suppl_file/jm8b01387_si_001.pdf" class="ext-link">Flow charts S1 and S2</a>), we predicted that compound <b>8</b> could be a proper RXR ligand due to the ion–salt and hydrogen bond interactions with R316 and A327, and the hydrophobic interactions with I345, F346, and V349. Moreover, the N atom in the 1-methylindole of compound <b>8</b> forms a hydrogen bond with C432, and the 1-methyl group forms hydrophobic interactions with N306 and W305. <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>f shows the ligand interactions of compound <b>8</b> with residues in the <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1MVC">1MVC</a> (crystal structure of the human RXRα ligand binding domain bound to the synthetic agonist compound BMS 649 and a coactivator peptide) structure. Based on these observations, compound <b>8</b> was synthesized as a structurally optimized RXR ligand. Our lead candidate is one of the first RXR agonists with an indole as the hydrophobic ring and another indole as the bridge substituent. Increasing the length of the bridge by a double bond makes stronger hydrogen bonds of the carboxylic acid with residues in the target. In addition, we anticipate that N-methylation makes stronger hydrophobic interactions. The flexible bridge between the hydrophobic end and the COOH end will make the compound more RXR selective.</div><div class="NLM_p">For the synthesis of RXR-agonist <b>8</b> (RXR-<b>8</b>), aryl bromide <b>5</b> with acrolein diethyl acetal in the presence of <i>n</i>-Bu<sub>4</sub>OAc, K<sub>2</sub>CO<sub>3</sub>, KCl, and DMF catalyzed by Pd(OAc)<sub>2</sub> afforded cinnamaldehyde <b>6</b> in 73% yield. Bis(indolyl)methane compound <b>7</b> was obtained in 81% yield from <b>6</b> and 1-methylindole catalyzed by molecular iodine in CH<sub>3</sub>CN at room temperature. Hydrolysis of <b>7</b> with LiOH·H<sub>2</sub>O in methanol and acidification afforded the final product <b>8</b> in 91% yield (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>, HRMS <i>m</i>/<i>z</i> [M + H] <sup>+</sup> calcd for C<sub>26</sub>H<sub>23</sub>N<sub>2</sub>O<sub>2</sub>S 427.1480, found 427.1468) (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01387/suppl_file/jm8b01387_si_001.pdf" class="ext-link">Figure S1a</a>). The compound was also thoroughly characterized by 1D <sup>1</sup>H (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01387/suppl_file/jm8b01387_si_001.pdf" class="ext-link">Figure S1b</a>) and <sup>13</sup>C (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01387/suppl_file/jm8b01387_si_001.pdf" class="ext-link">Figure S1c</a>) nuclear magnetic resonance (NMR) spectroscopy.</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-23/acs.jmedchem.8b01387/20181207/images/medium/jm-2018-013879_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-23/acs.jmedchem.8b01387/20181207/images/large/jm-2018-013879_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Chemical Synthesis and Characterization of Compound <b>8</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-23/acs.jmedchem.8b01387/20181207/images/large/jm-2018-013879_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01387&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>For the designed RXR-agonist <b>8</b>, aryl bromide <b>5</b> with acrolein diethyl acetal in the presence of <i>n</i>-Bu<sub>4</sub>OAc, K<sub>2</sub>CO<sub>3</sub>, KCl, and DMF catalyzed by Pd(OAc)<sub>2</sub> afforded cinnamaldehyde <b>6</b> in 73% yield. Bis(indolyl)methane compound <b>7</b> was obtained in 81% yield from <b>6</b> and 1-methylindole catalyzed by molecular iodine in CH<sub>3</sub>CN at room temperature. Hydrolysis of <b>7</b> with LiOH·H<sub>2</sub>O in methanol and acidification afforded the final product <b>8</b> in 91% yield.</p></p></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> Synthesis of Nano-RXR</h3><div class="NLM_p">We introduced a strategy for synthesizing nanoscopic RXR agonists based on “rigid cored” micelles (RCMs).<a onclick="showRef(event, 'ref44 ref45 ref46 ref47 ref48'); return false;" href="javascript:void(0);" class="ref ref44 ref45 ref46 ref47 ref48">(44−48)</a> In brief, Nano-RXR were produced by the molecular co-self-assembly of amphiphilic PS<sub>67</sub>-<i>b</i>-PAA<sub>27</sub> (polystyrene-<i>b</i>-poly(acrylic acid)) and polyoxyethylene (20) cetyl ether. (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A) In a typical procedure, polyethylene glycol cetyl ether (0.5 mg) was melted at 65 °C for 5 min, and then 1 mL of water was added dropwise while stirring the mixture. The micellar suspension was allowed to stir for 20 min at 1150 rpm. A solution of amphiphilic diblock copolymer (PS<sub>67</sub>-<i>b</i>-PAA<sub>27</sub>) and the solution of RXR-<b>8</b> was prepared to achieve 2.5 mM in chloroform followed by dropwise addition to the mixture. The solution was left to stir overnight to evaporate the organic solvents; additional water was added, and the suspension was stored at 4 °C overnight for curing the core of the particle. Arresting the core of these polymeric-based nanoassemblies reduces the flexibility of the nanoconstruct leading to a more robust arrangement for systemic administration. The characterization of Nano-RXR was performed for hydrodynamic diameter, dry state morphology, height profile, and ordered assembly.</div><figure id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-23/acs.jmedchem.8b01387/20181207/images/medium/jm-2018-013879_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-23/acs.jmedchem.8b01387/20181207/images/large/jm-2018-013879_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Physicochemical characterization of Nano-RXR. (A) Synthesis of rigid nanoparticles loaded with RXR-8 to prepare Nano-RXR; (B) hydrodynamic diameter of Nano-RXR compared to nanoparticles; (C) TEM image (drop deposited over carbon grid) of Nano-RXR; (D) stability of nanoparticles and Nano-RXR formulations in 5% and 10% (v/v) concentration of fetal bovine serum (FBS); (E) XRD pattern of nanoparticles and effect of RXR-8 loading in nanoassembly.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-23/acs.jmedchem.8b01387/20181207/images/large/jm-2018-013879_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01387&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">This resulted in hydrodynamic size of Nano-RXR as 32 ± 6 nm and a bigger assembly of rigid cored micelles (RCM) at 45 ± 5 nm (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>B). This sub-100 nm spheroidal anhydrous morphology of Nano-RXR was further confirmed by transmission electron microscopy and found to be ∼20 ± 5 nm in the anhydrous state (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>C). The stability of nanoparticles and Nano-RXR formulations in 5% and 10% (v/v) concentration of fetal bovine serum (FBS) showed greater stability of Nano-RXR compared to nanoparticle alone (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>D). Retinoid X receptor (RXR) agonist ligand with a bis(indolyl)methane scaffold co-self-assembled with PS<sub>67</sub>-<i>b</i>-PAA<sub>27</sub> resulting in nanoparticles with excellent kinetic stability through π–π stacking and hydrophobic interactions. The incorporation of RXR molecules in nanoassembly was further confirmed by XRD pattern of Nano-RXR and nanoparticles (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>E). It was observed that Nano-RXR showed greater order with <i>d</i>-spacing at a higher value of 38.5 nm compared to a common peak with <i>d</i> spacing of 35 nm in case of nanoparticles alone. It is likely that the incorporation of RXR agonist in the nanoassembly makes wider repeating units in Nano-RXR. This representative X-ray diffraction study revealed the incorporation of RXR agonist molecules inside intralayer arrangements of micelles. Shelf life stability (in vial) of the nanoparticles was monitored over time (0, 7, 14, and 30 days and over six months) by observing the changes in hydrodynamic diameters, zeta potential, and polydispersity, and these were found not to be changing to any considerable extent (data not shown).</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> In Vitro Cell Toxicity Assay for Evaluating Efficacy of the RXR-Selective Agonist</h3><div class="NLM_p">Cell toxicity studies were performed using MTT assay on sarcoma cells (63-3 cre and 141-10 cre) and compared with effects on their noncancerous counterparts (63-3 and 141-10) generated from Oncopig tissues (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>a,b). RXR-<b>8</b> and Nano-RXR were added to cultures at concentrations of RXR ranging from 3.125 to 100 μM for 48 h prior to performing the MTT assay. Empty nanoparticles were added at an equivalent amount as a negative control. Nanoparticle encapsulated RXR-<b>8</b> demonstrated increased cytotoxicity over that of RXR-<b>8</b> alone (<i>p</i> ≤ 0.01). Comparison of the effects of these agents on controls (nontransformed 63-3 and 141-10) and matched transformed cell lines (63-3 Cre and 141-10 Cre) were determined by measuring half-maximal inhibitory concentrations (IC<sub>50</sub>). The observed maximum effects of Nano-RXR treatment in 63-3 Cre with minimum IC<sub>50</sub> value was 44 ± 2.2 compared to 38 ± 2.5 μM in the case of 141-10 Cre. To evaluate the selectivity of Nano-RXR toward sarcoma cells, MTT assays were also performed in noncancerous cells of same origin, 63-3 and 141-10. It was found that IC<sub>50</sub> for Nano-RXR in 63-3 was significantly higher (<i>p</i> = 0.001) at 70 ± 3.5 compared to 44 ± 2.2 in 63-3 Cre (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>a) and 100 ± 5 μM for 141-10 compared to 38 ± 2.5 μM in 141-10 Cre (<i>p</i> = 0.0001) (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>b). These evaluations reveal not only a greater toxicity response for Nano-RXR compared to free RXR in sarcoma cells but elevated selectivity against noncancerous cells of same origin.</div><figure id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-23/acs.jmedchem.8b01387/20181207/images/medium/jm-2018-013879_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-23/acs.jmedchem.8b01387/20181207/images/large/jm-2018-013879_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Cytotoxic effect of Nano-RXR and RXR on porcine sarcoma cell lines. RXR and Nano-RXR were used at various concentrations of RXR ranging from 3.125 to 100 μM for 48 h before performing the MTT assay. Nanoparticles alone at equivalent amount were used as negative control to evaluate the safety pattern of nanoparticles in the same conditions. Biostatistical analysis showed nanoparticle-based improvement enhanced cell growth inhibition with <i>p</i> value of 0.01 as **. As an indication of cytotoxic selectivity with lowering in IC<sub>50</sub> values, Nano-RXR showed statistically lower IC<sub>50</sub> in (a) 63-3 Cre and (b) 141-10 Cre cells compared to that in noncancerous cells of the same origin, 63-3 and 141-10, respectively. <i>p</i> Values of 0.001 and 0.0001 are shown as *** and ****, respectively, as obtained after unpaired <i>t</i> test. In vivo tumor regression studies in mouse and subsequent effects on protein expression. (c) Timeline of the in vivo experiment in rodent xenograft model; (d) weight percentages of group of animals used for tumor regression studies; (e) survival (%) of group of animals treated with RXR or Nano-RXR compared to controls on 18th day of experiment; (f) tumor volume regression after treatment with RXR and Nano-RXR; nanoparticles alone (RCM) or untreated animals were used as controls; (g) protein expression in tissues collected from treated and untreated groups of animals: (1) buffer; (2) RCM; (3) RXR; (4) Nano-RXR as obtained from (i) tumor tissue and (ii) tissue collected from liver.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-23/acs.jmedchem.8b01387/20181207/images/large/jm-2018-013879_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01387&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> Oncopig Cancer Model of Soft Tissue Sarcoma</h3><div class="NLM_p last">The Oncopig cancer model (OCM) was developed as a model of human disease because pigs are similar in size, anatomy, metabolism, and genetics compared to humans. This line of pigs carries an inducible KRASG12D and TP53R167H transgene, allowing for soft tissue sarcoma modeling in a spatial and temporal manner.<a onclick="showRef(event, 'ref50 ref43'); return false;" href="javascript:void(0);" class="ref ref50 ref43">(50,43)</a> This study utilized both Oncopig soft tissue sarcoma cell lines (fibroblast origin) and in vivo tumors (leiomyosarcoma). Both of these have been shown to have similar transcriptional alterations as do human STS including altered TP53 signaling, Wnt signaling activation, and some master regulators such as FOSL1 which have been identified as potential therapeutic targets.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a></div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> In Vivo Tumor Regression in Rodent Using Nano-RXR</h3><div class="NLM_p last">An in vivo study to evaluate the effects of RXR-<b>8</b> and Nano-RXR on tumor growth was completed utilizing a porcine tumor cell xenograft into SCID mice. The tumorigenic sarcoma line 63-1 (sarcoma cells) was injected subcutaneously into two sites per mouse. When tumors reached approximately 5 × 5 mm, each tumors was injected with buffer, RCM, RXR-<b>8</b>, or Nano-RXR (total four injections, on day 0, 4, 8, and 12 with 40 μL containing RXR-<b>8</b> concentration of 62.5 μg/mL), and tumor volume was monitored by caliper measurements through day 35 before euthanization of the animals (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>c). Body weight measurement of mice revealed no significant loss in any group (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>d). Treatment with either RXR-<b>8</b> or Nano-RXR increased survival time of the mice and retarded the tumor volume when compared to untreated animals or those receiving nanoparticles alone (RCM). Treatment with Nano-RXR was more effective in reducing tumor volume compared to RXR-<b>8</b> alone (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>f). Protein expression analysis clearly showed the upregulation of RXRs with maximum effect in level of RXRα and RXRβ for collected tumors at the end of the tumor regression experiment, while effects were minimal in liver tissue collected from the same animals (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>g).</div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Safety Profile and Tumor Regression Efficiency in Pig Model</h3><div class="NLM_p">It was observed that none of the formulations at these doses (4 mL; 0.5 mg of RXR/kg) produced any significant toxic changes in any of the clinical chemistries of the Oncopigs treated (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01387/suppl_file/jm8b01387_si_001.pdf" class="ext-link">Table S1</a>). A transient increase in CPK, total bilirubin, and glucose were seen following the treatments, which returned to normal with longer time interval (24 h). Histopathological evaluations performed on various organ tissues collected from these animals were found to be within normal animal variations (See details in <a href="/doi/suppl/10.1021/acs.jmedchem.8b01387/suppl_file/jm8b01387_si_001.pdf" class="ext-link">Supporting Information</a>). To study the tumor regression efficiency, the volume of the tumors was determined from ultrasound images after different treatments. On day 0 (17 days after AdCre injection), a single tumor on each animal was injected with either buffer, RXR-<b>8</b>, or Nano-RXR, which was followed by 2 additional injections on days 3 and 10 (1 mL volume of 62.5 μg/mL). The tumor size was evaluated for 13 days after the first injection (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>a). Tumors were first identified based on palpation and visual inspection (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>b) and then by ultrasound (US) imaging. Tumor sizes were visualized by US imaging; tumor (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>d) treated with buffer alone continued to grow until the end of the study (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>e), whereas tumor (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>f) treated with Nano-RXR had significantly retarded growth (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>g).</div><figure id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-23/acs.jmedchem.8b01387/20181207/images/medium/jm-2018-013879_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-23/acs.jmedchem.8b01387/20181207/images/large/jm-2018-013879_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. In vivo tumor regression studies in pig and post-treatment effects on protein expression. (a) Timeline of in vivo experiment in onco-pig model. (b) Tumor appearance on day 1 of buffer injection. (c) Tumor volume regression after treatment with RXR and Nano-RXR; animals treated with buffer were used as controls. Ultrasound imaging to follow the tumor growth after treatment with buffer on (d) day 1 and (e) day 13 and animals treated with Nano-RXR on (f) day 1 and (g) day 13. (h) Protein expression in tissues collected from treated and untreated group of animals: (1) Buffer; (2) RXR; (3) Nano-RXR as obtained from tumor tissue and tissue collected from liver.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-23/acs.jmedchem.8b01387/20181207/images/large/jm-2018-013879_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01387&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Further US imaging was done to accurately identify the treatment region so that tissue was dissected appropriately for gross pathology and histology analysis. The tumor volume was found to be significantly (<i>p</i> < 0.001) lower following RXR-<b>8</b> or Nano-RXR treatment when compared to buffer (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>c). Nano-RXR was more effective compared to RXR-<b>8</b> alone. Animals were inspected daily for body weight and behavioral changes and showed no change. At day 13, immediately after imaging, animals were euthanized; tumors were resected and weighed, and half of the tissue was snap frozen in liquid N<sub>2</sub> prior to storage at −80 °C, while other half was put in formalin (10%). Formalin samples were harvested for histopathological analysis. The treatment region plus boundary (1–2 cm) was dissected and used for the pathological analysis. Frozen samples were used for extracting RNA and protein for expression studies. Protein expression analysis clearly showed the upregulation of RXRs with maximum effect on levels of RXRα and RXRγ for collected tumors at the end of the tumor regression experiment, while effects were minimal in liver tissues collected from the same animals (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>h).</div><div class="NLM_p last">Expression of protein from tumor post-treatment in animal models gives additional proof for the activity of small molecule and nanotherapeutics through certain cellular cascades. An extensive protein expression analysis was performed on tumors collected from the mouse model post-treatment and sacrifice. RXR protein level was found to increase significantly (<i>p</i> < 0.05) post-Nano-RXR treatment compared to RXR-<b>8</b> or nanoparticles. Protein level changes were noted to be maximal for RXRα, while RXRβ and RXRγ showed little or no effect. Protein expression was also measured in liver tissue of the treated animals, and it was found that the expression levels were not significantly different across different treatment groups. This signifies that the RXR agonist mediated upregulation of RXRα in the animal model for tumor tissues causing tumor regression as an after effect. Effect and side effects<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> of Nano-RXR treatment in Oncopigs were evaluated by post-treatment necropsies and histopathology (see details in <a href="/doi/suppl/10.1021/acs.jmedchem.8b01387/suppl_file/jm8b01387_si_001.pdf" class="ext-link">Supporting Information</a>).</div></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Differential Expression of Drug Metabolism, Regulation, and Transport Genes</h3><div class="NLM_p">Differential gene expression was studied for genes involved in drug metabolism, regulation, and transport. Drug clearance and pharmacokinetics are highly regulated by the drug metabolism route, which in turn can affect the clinical efficiency and drug toxicity.<a onclick="showRef(event, 'ref50 ref51'); return false;" href="javascript:void(0);" class="ref ref50 ref51">(50,51)</a> During metabolism of drug, it undergoes two phases: Initially, in phase I, the drug experiences oxidation due to the oxidative pathways and therefore becomes more a polar substance. Specifically, cytochrome P450 (CYP) monooxygenases, a major class of membrane-associated heme proteins, have an essential role in exerting oxidative metabolism in a wide gamut of xenobiotics and endogenous compounds.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> P450 enzymes responsible for drug metabolism have been extensively studied in pig liver, and it was determined that the main subcategories are 1A1, 1A2, 2A19, 2C33, 2C49, 2E1, 3A, and 7A1.<a onclick="showRef(event, 'ref53 ref54 ref55'); return false;" href="javascript:void(0);" class="ref ref53 ref54 ref55">(53−55)</a> On the other hand, in phase II metabolism, conjugation with hydrophilic compounds occurs, which leads to improved polarity and water solubility. This would ultimately increase the chances of excretion in bile and urine for detoxification.<a onclick="showRef(event, 'ref56 ref57'); return false;" href="javascript:void(0);" class="ref ref56 ref57">(56,57)</a> Toward this, we identified genes responsive to the treatment of ligand Nano-RXR and RXR-<b>8</b>, including orphan nuclear receptors (regulators), RXRα, RXRβ, RXRγ, CAR, PPARα, PPARγ, FXR, pregnane X receptor (PXR), genes involved in phase I drug metabolism (oxidation reactions), for example, CYP1A1, CYP1A2, CYP2A19, CYP2B22, CYP2C33, CYP2C49, CYP2E1, CYP3A, and CYP7A1, and genes involved in phase II drug metabolism (conjugation reactions), for example, glutathione-S-transferase, SULTA1, and transporters such as ABCB1 and ABCC2. Significant upregulation (3–20-fold) of all the three isoforms of RXR was observed in treated porcine livers over that of control liver (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>–<named-content content-type="anchor" rid="fig6" type="simple"></named-content><a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>). Nuclear hormone receptors, namely, the farnesoid X receptor (FXR), the liver X receptors (LXRs), and the peroxisome proliferator-activated receptors (PPARs) are a class of ligand-activated transcription factors involved in regulation of hepatic lipid metabolism.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> There are several biological processes that are regulated in liver, such as bile acid synthesis and metabolism, lipoprotein metabolism, lipogenesis, and fatty acid degradation, controlled by these hormones. Moreover, they turn on the gene transcription when complexed with the retinoid X receptor, RXR, and next by activation of the heterodimeric complex to initiate the response elements in the DNA.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> It was found that ligand Nano-RXR and RXR-<b>8</b> both could induce overexpression of PPARα (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>t), and PPARγ (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>u) and FXR (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>s) showed no significant change, whereas LXR (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>r) showed significant decrease in gene expression.</div><figure id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-23/acs.jmedchem.8b01387/20181207/images/medium/jm-2018-013879_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-23/acs.jmedchem.8b01387/20181207/images/large/jm-2018-013879_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. RXR and Nano-RXR induced transcriptional alteration of genes involved in phase-I and phase-II drug metabolism, phase-III transport, and nuclear receptors in liver measured by qPCR. Real time (RT)-PCR was performed to analyze the expression of the 21 genes. Fold change in transcript upon RXR or Nano-RXR treatment is presented with respect to control. CYP2C33, CYP2E1, and PXR were downregulated, SULTA1, FXR, and PPARγ were unchanged, and the rest of the genes were upregulated. The values and error bars represent average and standard deviations of three independent sets of experiments. One-way analysis of variance (ANOVA) followed by Bonferroni post-test was performed to determine significant differences among control and treatments. <i>p</i> Values of 0.05, 0.01, 0.001 and 0.0001 are shown as *, **, *** and ****, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-23/acs.jmedchem.8b01387/20181207/images/large/jm-2018-013879_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01387&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-23/acs.jmedchem.8b01387/20181207/images/medium/jm-2018-013879_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-23/acs.jmedchem.8b01387/20181207/images/large/jm-2018-013879_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. RXR and Nano-RXR induced transcriptional alteration of genes involved in phase-I and phase-II drug metabolism, phase-III transport, and nuclear receptors in tumor measured by qPCR. Real time RT-PCR was performed to analyze the expression of the 21 genes. Fold change in transcript upon RXR or Nano-RXR treatment is presented with respect to control. FXR was downregulated, CYP1A2 was unchanged, and all the other genes were upregulated by treatment. The values and error bars represent average and standard deviations of three independent sets of experiments. One-way analysis of variance (ANOVA) followed by Bonferroni post-test was performed to determine significant differences among control and treatments. <i>p</i> Values of 0.05, 0.01, 0.001 and 0.0001 are shown as *, **, *** and ****, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-23/acs.jmedchem.8b01387/20181207/images/large/jm-2018-013879_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01387&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-23/acs.jmedchem.8b01387/20181207/images/medium/jm-2018-013879_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-23/acs.jmedchem.8b01387/20181207/images/large/jm-2018-013879_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. (a–e) RXR and Nano-RXR induced transcriptional alteration of downstream target genes measured by qPCR. Real time RT-PCR was performed to analyze the expression of the six genes. Fold change in transcript upon RXR or Nano-RXR treatment is presented with respect to control. CRBP-1, CRABP-1, PEPCK1, and PEPCK2 were upregulated, and BTG2 and CIP1 were downregulated by treatment (<i>n</i> = 3). One-way analysis of variance (ANOVA) followed by Bonferroni post-test was done to determine significant differences among control and treatments where <i>n</i> = 3. <i>p</i> Values of 0.05, 0.01, 0.001 and 0.0001 are shown as *, **, *** and ****, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-23/acs.jmedchem.8b01387/20181207/images/large/jm-2018-013879_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01387&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Transcript levels of all the three RXR isoforms were higher in Nano-RXR treated liver than RXR-<b>8</b> treated liver. All the studied genes except CYP2C33 and CYP2E1, which were involved in phase I drug metabolism, were upregulated in ligand treated livers when compared to that of control liver. Significant difference between Nano-RXR and RXR-<b>8</b> was observed for most of the genes involved in phase I drug metabolism. Whereas glutathione-S-transferase was significantly upregulated in ligand treated groups compared to the control group, no difference in transcript level of SULTA1 was observed among the groups. The mRNA levels of two transporters (ABCB1, ABCC2) were increased in treated liver over that of control liver for both treatment with RXR-<b>8</b> and Nano-RXR with higher effect in the case of Nano-RXR (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>o). CAR and PPARα were upregulated in ligand treated groups compared with control; no differences in FXR and PPARγ were observed, and PXR was downregulated in treated groups. This clearly confirms the involvement of ligand Nano-RXR and RXR-<b>8</b> through RXR and other gene cascade pathways of the porcine liver.</div></div><div id="sec2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Differential Expression of Drug Metabolism, Regulation, and Transport Genes from Control and Treated Tumor Tissues</h3><div class="NLM_p last">We also studied the differential gene expression of genes that are involved in drug metabolism, regulation, and transport in treated and control tumor tissues. The expression of RXRγ, CYP1A1, CYP2C33, CYP2E1, CAR, PXR, PPARG, and ABCC2 was not detected in control tumor. The differential expression patterns of the other genes were similar to that of liver mentioned above. Significant upregulation in RXRα and β was observed in ligand treated tumors in comparison to control tumor. In case of genes involved in phase I drug metabolism, all the studied genes except CYP1A2 were upregulated in treated groups compared to control group. The two genes involved in phase II drug metabolism (SULTA1 and glutathione-S-transferase) and transporter ABCB1 were upregulated in treated groups. PPARα was upregulated but FXR was downregulated in treated groups compared with control group.</div></div><div id="sec2_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Effect of Nano-RXR and RXR-<b>8</b> on Downstream Target Genes in Liver</h3><div class="NLM_p">In the present study, we have analyzed the differential expression of six downstream target genes of RXR, CRBP-1, CRABP-1, BTG2, CIP1, PEPCK1, and PEPCK2, in liver samples from control pigs and Nano-RXR and RXR-<b>8</b> treated Oncopigs. Upregulation of CRBP-1, CRABP-1, PEPCK1, and PEPCK2 were observed in treated liver whereas BTG2 and CIP1 were downregulated (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>). Significant difference between Nano-RXR and RXR-<b>8</b> was found in CRABP-1 and PEPCK2.</div><div class="NLM_p">The heterodimer of RARs with RXRs works as a transcription factor to regulate the target genes of RA. They tend to bind to DNA sequences called RA-response elements localized with the promoter of target genes.<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> Cellular retinol binding protein 2 and fatty acid binding protein 5 are responsible for the partitioning of RAs between the two receptors. These proteins specially deliver RAs from the cytosol to nuclear RAR and RXR, followed by the activation of a variety of downstream target genes like upregulation of CRBP-1, PEPCK, and CRABP-1 after RXR treatment.</div><div class="NLM_p">It has recently been demonstrated that retinoids regulate the gene for the gluconeogenic enzyme, cytosolic phosphoenolpyruvate carboxykinase (PEPCK, EC 4.1.1.32), in liver.<a onclick="showRef(event, 'ref61 ref62 ref63 ref64'); return false;" href="javascript:void(0);" class="ref ref61 ref62 ref63 ref64">(61−64)</a> One of the target genes that RAR and RXR family would bind to are the ones encoding cytosolic PEPCK. It contains specific retinoic acid response elements (RAREs) in the 5′-flanking sequence.</div><div class="NLM_p last">CIP1 encodes a potent cyclin-dependent kinase inhibitor and inhibits the activity of cyclin–cyclin-dependent kinase 2 or −cyclin-dependent kinase 4 complexes. As a result of this activity, CIP1 functions as a regulator of cell cycle progression at G1. The tumor suppressor protein p53 tightly controls the expression of this gene and helps to mediate the p53-dependent cell cycle G1 phase arrest under various stress stimuli.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_78161" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_78161" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">We present an “in silico to in vivo” approach to discover, synthesize, and deliver highly potent payloads of retinoid-selective receptor (RXR) agonists specifically to sarcoma cells while minimizing off-target effects and toxicity by nanoparticle-enabled delivery. RXR-selective agonists were identified through structure-based drug discovery involving computational modeling studies for transcriptional activation of orphan nuclear receptor. The chemical synthesis of the agent was accomplished followed by inclusion of these molecules into stable micellar particles for nanoenabled delivery. Once the in vitro efficacy was established, a holistic approach was adopted to establish their potency first in a mouse model and then in a translational transgenic Oncopig cancer model of sarcoma.<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> Oncopig represents a genetically malleable large animal model with high similarity of anatomy, physiology, metabolism, and genetics to human. To our knowledge, a study to evaluate actual tumor treatment response to RXR therapy in a large animal has never been done due to the lack of an appropriate tumor model. Our results suggest that this agent induced modulations of expression of RXR related genes in tumor as well as in liver of treated animals including rodents and Oncopigs. As RXR forms a heterodimer with other orphan nuclear receptors to induce expression of drug metabolism genes, the expression of several other nuclear receptors also increased. A significant upregulation of phase I drug metabolism genes (CYP isoforms) also was reported with a few exceptions supporting the no-retention possibility of newly synthesized drug molecule RXR-<b>8</b> and negating the possibility of retention related toxicities in subjects. In general, the Nano-RXR was more effective than the RXR-<b>8</b> drug alone in tumor regression, gene expression, and protein modulation. We anticipate that outcome of this work would have a necessary advancement of significant translational impact to achieve the survival of patients with soft tissue sarcoma.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_76243" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_76243" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Materials</h3><div class="NLM_p last">Unless otherwise mentioned, all chemicals and reagents were obtained from Sigma-Aldrich, Inc. (St. Louis, MO), and used with no more purification. The hydrodynamic diameter was measured on a Malvern Zetasizer instrument operating with a 633 nm laser. Zeta potential measurement was done on a Malvern Zetasizer instrument (Nanoseries, Malvern Instruments Ltd., United Kingdom). The TEM images were acquired on a JEOL 2100 Cryo TEM using Gatan UltraScan 2k × 2k CCD. The XRD data was collected on instrument Siemens-Bruker D5000 diffractometer and analyzed using software Jade X-ray analysis. The absorbance reading of MTT cell viability assay was done on a plate reader (Synergy HT, Bio-Tek). Bright field imaging was done using microscope DMI3000 B, Leica Microsystems, Buffalo Grove, IL.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Structure-Based Design, Lead Optimization, and Synthesis of RXR Agonists</h3><div class="NLM_p last">In order to identify the better RXR agonist with high binding affinity and selectivity, hydrogen bond, ion-salt, and hydrophobic interactions of the bis(indolyl)methane framework and globular shape of RXR were fine-tuned as depicted in <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>c–f. Changes in structural units were made at the bridge region, hydrophobic end, and carboxylic acid end: (1) phenyl instead of thiophene; (2) hydrogen and isopropyl instead of methyl; (3) 2,4-thiazolidinedione instead of carboxylic group. Three-dimensional structures of prospective DIM-arenes were constructed using the SKETCH module in Sybyl 7.1 (Tripos, St. Louis, MO, USA). Energy was minimized with the Tripos force-field using the conjugated gradient method until a convergence value of 0.005 kcal/mol was achieved. Subsequently, docking was performed on docking program AutoDock 4.0. A 50 point grid map in the <i>x</i>, <i>y</i>, and <i>z</i> directions was created using the Arg316 residue of the RXRa LBD (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1MVC">1MVC</a>) as the central residue and 0.375 as the grid spacing. A distance-dependent function of the dielectric constant was used for the energetic map calculations. In order to identify the ligand’s torsion angle, the AutoDockTools suite was utilized, and Gasteiger and Kollman partial atomic charges to DIM-arenes and the RXRa LBD were assigned, respectively. One hundred independent docking runs were performed for each DIM-arene using the Lamarckian genetic algorithm and a maximum number of 2 500 000 energy evaluations. Other parameters were assigned default values, implemented by the program. Cluster analysis performed on the results from 100 runs gave a root-mean-square tolerance of 2, validating the significance of the program.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Synthesis of Bis(indolyl)methane-based RXR Agonist</h3><div id="sec4_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19"> Synthesis and Characterization of <b>6</b> (Precursor)</h4><div class="NLM_p last">To a stirred solution of <b>5</b>, ethyl 5-bromothiophene-2-carboxylate (352.7 mg, 1.5 mmol), in 10 mL of DMF were added acrolein diethyl acetal (585 mg, 4.5 mmol), nBu<sub>4</sub>NOAc (862 mg, 3 mmol), K<sub>2</sub>CO<sub>3</sub> (310.5 mg, 2.25 mmol), KCl (111.8 mg, 1.5 mmol), and Pd(OAc)<sub>2</sub> (10.1 mg, 0.045 mmol). The mixture was stirred for 1.5 h at 90 °C. After cooling, 2 N HCl was slowly added, and the reaction mixture was stirred at room temperature for 10 min. Then, it was diluted with EtOAc and washed with water. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. The residue was purified by chromatography (hexane/EtOAc 8:1) to give the product as a white solid (255 mg, 81% yield). HRMS: <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>10</sub>H<sub>11</sub>O<sub>3</sub>S 211.0429, found 211.0429.</div></div><div id="sec4_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> Synthesis and Characterization of RXR-<b>8</b></h4><div class="NLM_p last">Aldehyde (210 mg, 1.00 mmol), 1-methylindole (262 mg, 2.00 mmol), and I<sub>2</sub> (25.38 mg, 0.1 mmol) in MeCN (3 mL) was stirred for 2 h, at which time TLC indicated complete reaction. The mixture was treated with 5% Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub>(aq) (5 mL) and extracted with EtOAc (3 × 5 mL). The extract was washed (H<sub>2</sub>O and brine) and dried. Concentration and chromatography (33% EtOAc/hexane) afforded <b>7</b> as a tan solid (36.83 mg, yield: 81%) HRMS: <i>m</i>/<i>z</i> [M + H]<sup>+</sup> calcd for C<sub>28</sub>H<sub>27</sub>N<sub>2</sub>O<sub>2</sub>S 455.1793, found 455.1784. Lithium hydroxide monohydrate (21 mg, 0.5 mmol) was added to a solution of <b>7</b> (45.46 mg, 0.1 mmol) in MeOH. This mixture was heated at reflux under nitrogen for 3 h, cooled to room temperature, acidified with 1 N HCl, and extracted with EtOAc. The extract was washed (H<sub>2</sub>O and brine). Concentration and drying gave the pure carboxylic acid (RXR-<b>8</b>) as tan solid (38.8 mg, yield 91%). HRMS: <i>m</i>/<i>z</i> [M + H]+ calcd for C<sub>26</sub>H<sub>23</sub>N<sub>2</sub>O<sub>2</sub>S 427.1480, found 427.1468. Elemental analysis: calcd for C<sub>26</sub>H<sub>23</sub>N<sub>2</sub>O<sub>2</sub>S C 73.21%, H 5.2%, and N 6.57%; found C 73.42%, H 5.52%, and N 7.06%. From the elemental analysis results, purity of the compound RXR-<b>8</b> was found to be ≥95%.</div></div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Dynamic Light Scattering</h3><div class="NLM_p last">Average hydrodynamic diameter distributions for Nano-RXR were determined using a Malvern Zetasizer nanoseries, Nano ZS90, with fixed angle of 90°. The stability of the nanoparticles was assessed by measuring the hydrodynamic diameter at 0, 24, 48, 72, 96, and 120 h postsynthesis (<i>n</i> = 5).</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> Zeta Potential Determination</h3><div class="NLM_p last">Zeta potential (ζ) values for the Nano-RXR formulations were determined with a nanoseries Malvern Zetasizer zeta potential analyzer. The data for the dialyzed nanoparticles (MWCO 20 kDa dialysis tubing, Spectrum Laboratories, Rancho Dominguez, CA) was collected in the phase analysis light scattering (PALS) mode using the Smoluchowski equation for ζ potential determination. The mean and SD value of 10 data accumulations were reported.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> Transmission Electron Microscopy</h3><div class="NLM_p last">To observe the morphology of Nano-RXR, transmission electron microscopy (TEM) was performed. The sample was deposited on a carbon coated Cu grid and negatively stained with uranyl acetate.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> X-ray Diffraction Studies</h3><div class="NLM_p last">The ordered behavior of Nano-RXR was determined by X-ray diffraction measurement. The aqueous suspension of each formulation was drop cast on a microscopic glass slide and fully dried. X-ray diffraction (XRD) of was performed using the θ–2θ configuration on a Siemens-Bruker D5000 diffractometer. The X-ray beam was generated with a Cu anode, and the Cu Kα beam of wavelength 1.5418 Å was used for the experiments. Scans were performed for 2θ range of 2 to 50.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> MTT Assay</h3><div class="NLM_p last">The cytotoxic effects of RXR and Nano-RXR were evaluated on control porcine fibroblast lines (63-3, 141-10) and compared with matched transformed (AdCre treated 63-3 Cre, 141-10 Cre) sarcoma cell lines. The in vitro cytotoxicity was determined by the MTT assay.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> Tetrazolium MTT (3-(4, 5-dimethylthiazolyl-2)-2,5-diphenyl-tetrazolium bromide) is converted to purple formazan crystals as a result of dehydrogenase enzymes in the metabolically active cells.<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> The salt was solubilized in DMSO, and the absorbance at 570 nm was recorded. For the MTT assay, cell lines were seeded in a 96 well plate (1 × 10<sup>4</sup> cell/well) in basal medium, and after 24 h of adherence, the cells were treated with various concentrations (0 to 100 μM) of RXR and Nano-RXR and incubated for another 48 or 72 h at 37 °C in an atmosphere of 5% CO<sub>2</sub> in air. At the appropriate time, the medium was removed, 200 μL of PBS was used to wash the cells, and 100 μL MTT solution (1 mg/mL) was added to each well followed by incubation for 4 h under condition mentioned above. Then the MTT containing media was removed, and the formazan crystals were dissolved with 200 μL of DMSO. Absorbance was measured at 570 nm using microplate reader.</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> AdCre Induction of Tumors in Pigs</h3><div class="NLM_p last">All animal studies and procedures were approved by the University of Illinois IACUC. Under sedation, Oncopigs were injected intramuscularly (IM) in the upper part of left and right legs. Ad5CMVCre-eGFP (AdCre) (Gene Transfer Vector Core, University of Iowa) was diluted with minimal essential medium (MEM, GIBCO) to a final concentration of 2 × 10<sup>9</sup> PFU/mL, and 2 mM calcium chloride (to a final concentration of 0.01 M) was added, mixed, and allowed to incubate at room temperature for 15 min prior to injection. All injections were completed before 45 min of incubation, injection sites were monitored daily, and ultrasound measurements were made on day 10 postinjection. Ultrasound imaging and palpation were used to monitor the growth of the tumor following injection.</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> RXR and Nano-RXR Treatments in Oncopigs</h3><div class="NLM_p last">Beginning on day 0 (17 days post-AdCre-injection), the animals were sedated, and tumors were imaged by ultrasound to accurately measure and to guide needle placement to ensure that the therapy was administered directly into the tumor. Each animal was treated with a 1 mL volume of 62.5 μg/mL of RXR or RXR in the form of Nano-RXR or 1 mL of saline directly into tumors. These measurements and treatments were repeated on days 3 and 10. On day 13, the animals were euthanized, and full gross necropsies were performed. Tissues were collected in 10% neutral buffer formalin for histopathology.</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> Safety of RXR, Nano-RXR, and Nanoparticles in Pigs</h3><div class="NLM_p last">Side effects generated by various nanoparticle mediated drug delivery treatments are always one of the major concerns in moving forward with a therapy and are best investigated in large animal models prior to clinical trials. We performed an initial safety profile study using primary histopathology to assess toxic changes using primary histopathology from the drug (RXR-8) or nanoparticle loaded drug treatments. The initial safety profile study was conducted to assess toxic side effects in various organs using histopathology and serum chemistry. Four 4 month old male pigs weighing approximately 68 kg/each were treated with saline, nanoparticles, RXR and Nano-RXR (4 mL; 0.5 mg of RXR/kg). Serum samples were collected at 1 h and 24 h postinjection. Animals were euthanized 30 days postinjection. Pentobarbital was administered at a dose of 100 mg/kg IV into the jugular vein of pig to sacrifice the animals. For each animal, a full range of organ samples was collected and fixed in neutral buffered 10% formalin for examination by light microscopy.</div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> Quantitative Real-Time PCR</h3><div class="NLM_p">Total RNA was isolated from porcine liver tissue and tumor using RNeasy Mini Kit (Qiagen) according to manufacturer’s protocol. RNA pellets were dissolved in nuclease-free water and stored at −80 °C until analysis. Quality of the RNA was determined by using a Nano Drop spectrophotometer and analyzed by an Agilent 2100 Bioanalyzer using an RNA Nano bioanalyzer chip to determine RNA integrity as well as the presence of absence of gDNA by the Carver High-Throughput DNA Sequencing and Genotyping Unit (HTS lab, University of Illinois, Urbana, IL, USA). Only RNA samples with an RNA integrity number (RIN) greater than 7 were used for the study. The concentration of the RNA was determined by Qubit RNA HS Assay Kit (Thermo Fisher Scientific, Life Technologies) as per manufacturer’s protocol.</div><div class="NLM_p">Reverse transcription of RNA was performed from 1 μg of total RNA in the presence of RNase inhibitor, random hexamer primers (50 ng/μL), deoxynucleotides (dNTPs, 10 mM), SuperScript III reverse transcriptase (200 U/μL), and reverse transcriptase buffer in a 20 μL final reaction volume using SuperScript III First-Strand Synthesis System for RT-PCR kit (Invitrogen, Life Technologies, IN, USA).</div><div class="NLM_p last">Relative quantification of the genes was performed using Power SYBR green PCR Master Mix (2×) (Applied Biosystems) in Taqman ABI 7900 Real-Time PCR system (Applied Biosystems). The housekeeping genes GAPDH and β-actin were used as endogenous controls to normalize for RNA loading or differences in reverse transcription efficiency. The specificity of all primer pairs was checked by melting curves of the amplified products. In order to calculate the primer efficiency, each gene was first amplified in five scalar dilutions (1:10 v/v) of a control cDNA. <i>C</i><sub>t</sub> values of each dilution were plotted against the arbitrary number of copies, and the slope of the resulting linear graph was utilized to calculate the efficiency. Amplification reaction efficiency of each sample was checked to be similar to or higher than 1.6. The relative expression levels were calculated with respect to the normalized expression of the controls by delta delta Ct (ΔΔ<i>C</i><sub>t</sub>) method.</div></div><div id="sec4_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> Statistical Analysis</h3><div class="NLM_p last">Statistical significance of differences between control and test samples was evaluated using one-way or two-way ANOVA using GraphPad Prizm 5.0 with Bonferroni post-test analysis as applicable. Results were considered statistically significant when the <i>p</i> value was less than 0.05 and represented as *, **, and *** for <i>p</i> values of <0.05, 0.01, and 0.001, respectively.</div></div><div id="sec4_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> Histopathological Analyses on Oncopig Tissues after Nano-RXR Treatments</h3><div class="NLM_p last">Microscopic diagnoses revealed that most lesions within these piglets are background lesions. Mild chronic interstitial nephritis was only present in pigs that received RXR agonist and Nano-RXR. Ovarian zona granulosa apoptosis in RXR and Nano-RXR treated pigs is likely an incidental background lesion. A free RXR drug treated animal had a focal myocardial degeneration, which could be secondary to intracardiac euthanasia. Cardiotoxicity associated with RXR agents is not known. Complement activation and secondary myocardial degeneration have been reported in pigs that received various forms of nanoparticles. A similar lesion was not present in pigs that received nanoparticles in this study, which indicates safety of the nanoparticles in a large animal model.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i32"><a href="/doi/suppl/10.1021/acs.jmedchem.8b01387" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_60348" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_60348" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.8b01387" class="ext-link">10.1021/acs.jmedchem.8b01387</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Method for selection of compounds for virtual screening, chemical characterization, mass and NMR spectra, histopathology results, and clinical pathology results from Oncopigs with different treatments (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01387/suppl_file/jm8b01387_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula string (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01387/suppl_file/jm8b01387_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b01387/suppl_file/jm8b01387_si_001.pdf">jm8b01387_si_001.pdf (599.5 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b01387/suppl_file/jm8b01387_si_002.csv">jm8b01387_si_002.csv (0.12 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.8b01387" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_73841" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_73841" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dipanjan Pan</span> - <span class="hlFld-Affiliation affiliation">Department
of Bioengineering, University of Illinois
at Urbana−Champaign, Urbana, Illinois 61801, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Beckman
Institute of Advanced Science and Technology, University of Illinois at Urbana−Champaign, Urbana, Illinois 61801, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Mills Breast
Cancer Institute, Carle Foundation Hospital, 502 N. Busey, Urbana, Illinois 61801, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Materials Science and Engineering, University
of Illinois at Urbana−Champaign, Urbana, Illinois 61801, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Carle-Illinois
College of Medicine, Urbana, Illinois 61801, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-0175-4704" title="Orcid link">http://orcid.org/0000-0003-0175-4704</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#62060b12030c08030c220b0e0e0b0c0d0b114c070617"><span class="__cf_email__" data-cfemail="02666b72636c68636c426b6e6e6b6c6d6b712c676677">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mao Ye</span> - <span class="hlFld-Affiliation affiliation">Department
of Bioengineering, University of Illinois
at Urbana−Champaign, Urbana, Illinois 61801, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Santosh K. Misra</span> - <span class="hlFld-Affiliation affiliation">Department
of Bioengineering, University of Illinois
at Urbana−Champaign, Urbana, Illinois 61801, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-3313-4895" title="Orcid link">http://orcid.org/0000-0002-3313-4895</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Arun K. De</span> - <span class="hlFld-Affiliation affiliation">Department
of Animal Sciences, University of Illinois
at Urbana−Champaign, Urbana, Illinois 61801, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Agricultural
Animal Care and Use Program, University
of Illinois at Urbana−Champaign, Urbana, Illinois 61801, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Fatemeh Ostadhossein</span> - <span class="hlFld-Affiliation affiliation">Department
of Bioengineering, University of Illinois
at Urbana−Champaign, Urbana, Illinois 61801, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kuldeep Singh</span> - <span class="hlFld-Affiliation affiliation">Veterinary
Diagnostic Laboratory, University of Illinois
at Urbana−Champaign, Urbana, Illinois 61801, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Laurie Rund</span> - <span class="hlFld-Affiliation affiliation">Department
of Animal Sciences, University of Illinois
at Urbana−Champaign, Urbana, Illinois 61801, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Agricultural
Animal Care and Use Program, University
of Illinois at Urbana−Champaign, Urbana, Illinois 61801, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Veterinary
Diagnostic Laboratory, University of Illinois
at Urbana−Champaign, Urbana, Illinois 61801, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lawrence Schook</span> - <span class="hlFld-Affiliation affiliation">Department
of Animal Sciences, University of Illinois
at Urbana−Champaign, Urbana, Illinois 61801, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Agricultural
Animal Care and Use Program, University
of Illinois at Urbana−Champaign, Urbana, Illinois 61801, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Veterinary
Diagnostic Laboratory, University of Illinois
at Urbana−Champaign, Urbana, Illinois 61801, United States</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>M.Y., S.K.M., and A.K.D. contributed equally.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interest(s): Prof. Pan is the founder of three University start-ups; however, none of these entities supported this work.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i34">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_20161" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_20161" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank Frederick Seitz Materials Research Laboratory for materials characterization techniques (DLS, ζ-potential, TEM, and XRD), Noyes lab for NMR studies, Division of Animal Resources (DAR) for animal studies, and Veterinary medicine, UIUC, for histopathology facility. This project has been partially funded by University of Illinois and National Institutes of Health (Grant 1R42HL135965–01A1 (D. Pan)). We also extend ours thanks to Children’s Discovery Institute for financial assistance and American Heart Association via the Grant No. 18pre34080003/2018.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviation Used</td></tr><tr><td class="NLM_term">RCM</td><td class="NLM_def"><p class="first last">rigid cored micelle</p></td></tr><tr><td class="NLM_term">OCM</td><td class="NLM_def"><p class="first last">Oncopig cancer model</p></td></tr><tr><td class="NLM_term">ANOVA</td><td class="NLM_def"><p class="first last">one-way analysis of variance</p></td></tr><tr><td class="NLM_term">DOX</td><td class="NLM_def"><p class="first last">doxorubicin</p></td></tr><tr><td class="NLM_term">AIM</td><td class="NLM_def"><p class="first last">ifosfamide</p></td></tr><tr><td class="NLM_term">CTCL</td><td class="NLM_def"><p class="first last">cutaneous T cell lymphoma</p></td></tr><tr><td class="NLM_term">RA</td><td class="NLM_def"><p class="first last">retinoic acid</p></td></tr><tr><td class="NLM_term">calcd</td><td class="NLM_def"><p class="first last">calculated</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i36">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_23717" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_23717" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 67 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matushansky, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maki, R. G.</span></span> <span> </span><span class="NLM_article-title">Fighting Cancer through the Study of Sarcomas</span>. <i>Am. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>93</i></span>,  <span class="NLM_fpage">414</span>– <span class="NLM_lpage">421</span>, <span class="refDoi"> DOI: 10.1511/2005.55.972</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1511%2F2005.55.972" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2005&pages=414-421&author=I.+Matushanskyauthor=R.+G.+Maki&title=Fighting+Cancer+through+the+Study+of+Sarcomas&doi=10.1511%2F2005.55.972"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1511%2F2005.55.972&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1511%252F2005.55.972%26sid%3Dliteratum%253Aachs%26aulast%3DMatushansky%26aufirst%3DI.%26aulast%3DMaki%26aufirst%3DR.%2BG.%26atitle%3DFighting%2520Cancer%2520through%2520the%2520Study%2520of%2520Sarcomas%26jtitle%3DAm.%2520Sci.%26date%3D2005%26volume%3D93%26spage%3D414%26epage%3D421%26doi%3D10.1511%2F2005.55.972" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nathenson, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sausville, E.</span></span> <span> </span><span class="NLM_article-title">Looking for Answers: the Current Status of Neoadjuvant Treatment in Localized Soft Tissue Sarcomas</span>. <i>Cancer Chemother. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">895</span>– <span class="NLM_lpage">919</span>, <span class="refDoi"> DOI: 10.1007/s00280-016-3055-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1007%2Fs00280-016-3055-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=27206640" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=1%3ACAS%3A528%3ADC%252BC28XosVaksbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2016&pages=895-919&author=M.+J.+Nathensonauthor=E.+Sausville&title=Looking+for+Answers%3A+the+Current+Status+of+Neoadjuvant+Treatment+in+Localized+Soft+Tissue+Sarcomas&doi=10.1007%2Fs00280-016-3055-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Looking for answers: the current status of neoadjuvant treatment in localized soft tissue sarcomas</span></div><div class="casAuthors">Nathenson, Michael J.; Sausville, Edward</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">895-919</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: Sarcomas are a rare and heterogeneous variant of cancer.  The std. of care treatment involves surgical resection with radiation in high-risk patients.  Despite appropriate treatment approx. 50 % of patients will suffer and die from recurrent disease.  The purpose of this article is to review the current evidence concerning the use of neoadjuvant chemotherapy with or without radiation in soft tissue sarcomas.  Methods: An in-depth literature search was conducted using Ovid Medline and PubMed.  Results: The most active chemotherapeutic agents in sarcoma are anthracyclines and ifosfamide.  Adjuvant chemotherapy trials show only minimal benefit.  Neoadjuvant chemotherapy offers the potential advantage of reducing the extent of surgery, increasing the limb salvage rate, early exposure of micrometastatic disease to chemotherapy, and assessment of tumor response to chemotherapy.  Some retrospective and phase II trials suggest a benefit to neoadjuvant chemotherapy.  Unfortunately, no clearly pos. phase III prospectively randomized trials exist for neoadjuvant therapy in soft tissue sarcomas.  Conclusions: The current neoadjuvant chemotherapy trials that do exist are heterogeneous resulting in conflicting results.  However, neoadjuvant chemotherapy with or without radiation can be considered in patients with high-risk disease in an attempt to improve long-term outcomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkXik8NbG62bVg90H21EOLACvtfcHk0li5i9zFcVW2cg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XosVaksbc%253D&md5=c87c1b06e84cd5fe2f959f71d3849cd8</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1007%2Fs00280-016-3055-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-016-3055-1%26sid%3Dliteratum%253Aachs%26aulast%3DNathenson%26aufirst%3DM.%2BJ.%26aulast%3DSausville%26aufirst%3DE.%26atitle%3DLooking%2520for%2520Answers%253A%2520the%2520Current%2520Status%2520of%2520Neoadjuvant%2520Treatment%2520in%2520Localized%2520Soft%2520Tissue%2520Sarcomas%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2016%26volume%3D78%26spage%3D895%26epage%3D919%26doi%3D10.1007%2Fs00280-016-3055-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tseng, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somaiah, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engleman, E. G.</span></span> <span> </span><span class="NLM_article-title">Potential for Immunotherapy in Soft Tissue Sarcoma</span>. <i>Hum. Vaccines Immunother.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">3117</span>– <span class="NLM_lpage">3124</span>, <span class="refDoi"> DOI: 10.4161/21645515.2014.983003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.4161%2F21645515.2014.983003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=25625925" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=3117-3124&author=W.+W.+Tsengauthor=N.+Somaiahauthor=E.+G.+Engleman&title=Potential+for+Immunotherapy+in+Soft+Tissue+Sarcoma&doi=10.4161%2F21645515.2014.983003"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.4161%2F21645515.2014.983003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252F21645515.2014.983003%26sid%3Dliteratum%253Aachs%26aulast%3DTseng%26aufirst%3DW.%2BW.%26aulast%3DSomaiah%26aufirst%3DN.%26aulast%3DEngleman%26aufirst%3DE.%2BG.%26atitle%3DPotential%2520for%2520Immunotherapy%2520in%2520Soft%2520Tissue%2520Sarcoma%26jtitle%3DHum.%2520Vaccines%2520Immunother.%26date%3D2014%26volume%3D10%26spage%3D3117%26epage%3D3124%26doi%3D10.4161%2F21645515.2014.983003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiseman, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erlandson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trotz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubansky, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albritton, K.</span></span> <span> </span><span class="NLM_article-title">Gemcitabine Radiosensitization after High-Dose Samarium for Osteoblastic Osteosarcoma</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">6895</span>– <span class="NLM_lpage">6900</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-05-0628</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1158%2F1078-0432.CCR-05-0628" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=16203780" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVKiurrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=6895-6900&author=P.+M.+Andersonauthor=G.+A.+Wisemanauthor=L.+Erlandsonauthor=V.+Rodriguezauthor=B.+Trotzauthor=S.+A.+Dubanskyauthor=K.+Albritton&title=Gemcitabine+Radiosensitization+after+High-Dose+Samarium+for+Osteoblastic+Osteosarcoma&doi=10.1158%2F1078-0432.CCR-05-0628"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Gemcitabine Radiosensitization after High-Dose Samarium for Osteoblastic Osteosarcoma</span></div><div class="casAuthors">Anderson, Peter M.; Wiseman, Gregory A.; Erlandson, Linda; Rodriguez, Vilmarie; Trotz, Barbara; Dubansky, Stephen A.; Albritton, Karen</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">19, Pt. 1</span>),
    <span class="NLM_cas:pages">6895-6900</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Osteoblastic metastases and osteosarcoma can avidly conc. bone-seeking radiopharmaceuticals.  We sought to increase effectiveness of high-dose 153Samarium ethylenediaminetetramethylenephosphonate (153Sm-EDTMP, Quadramet) on osteosarcomas using a radiosensitizer, gemcitabine.  Fourteen patients with osteoblastic lesions were treated with 30 mCi/kg 153Sm-EDTMP.  Gemcitabine was administered 1 day after samarium infusion.  Residual total body radioactivity was within the safe range of <3.6 mCi on day +14 (1.1±0.4 mCi; range, 0.67-1.8 mCi).  All patients received autologous stem cell reinfusion 2 wk after 153Sm to correct expected grade 4 hematopoietic toxicity.  Peripheral blood progenitor cells were infused in 11 patients; three patients had marrow infused.  Blood count recovery was uneventful after peripheral blood progenitor cells in 11 of 11 patients.  Toxicity from a single infusion of gemcitabine (1,500 mg/m2) in combination with 153Sm-EDTMP was minimal (pancytopenia).  However, toxicity from a daily gemcitabine regimen (250 mg/m2/d x 4-5 days) was excessive (grade 3 mucositis) in one of two patients.  There were no reported episodes of hemorrhagic cystitis (hematuria) or nephrotoxicity.  At the 6- to 8-wk follow-up, there were six partial remissions, two mixed responses, and six patients with progressive disease.  In the 12 patients followed >1 yr, there have been no durable responses.  Thus, although high-dose 153Sm-EDTMP + gemcitabine has moderate palliative activity (improved pain; radiol. responses) in this poor-risk population, addnl. measures of local and systemic control are required for durable control of relapsed osteosarcoma with osteoblastic lesions.  The strategy of radioactive drug binding to a target followed by a radiosensitizer may provide synergy and improved response rate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSL-nvfRsnfLVg90H21EOLACvtfcHk0lhjldQJClSSRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVKiurrL&md5=699182dc8a4661cf51850e77b0aefdf7</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-05-0628&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-05-0628%26sid%3Dliteratum%253Aachs%26aulast%3DAnderson%26aufirst%3DP.%2BM.%26aulast%3DWiseman%26aufirst%3DG.%2BA.%26aulast%3DErlandson%26aufirst%3DL.%26aulast%3DRodriguez%26aufirst%3DV.%26aulast%3DTrotz%26aufirst%3DB.%26aulast%3DDubansky%26aufirst%3DS.%2BA.%26aulast%3DAlbritton%26aufirst%3DK.%26atitle%3DGemcitabine%2520Radiosensitization%2520after%2520High-Dose%2520Samarium%2520for%2520Osteoblastic%2520Osteosarcoma%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2005%26volume%3D11%26spage%3D6895%26epage%3D6900%26doi%3D10.1158%2F1078-0432.CCR-05-0628" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Akatsuka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wada, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kokai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawaguchi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamashiro, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawada, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamawaki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishii, S.</span></span> <span> </span><span class="NLM_article-title">Erbb2 Expression is Correlated with Increased Survival of Patients with Osteosarcoma</span>. <i>Cancer</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>94</i></span>,  <span class="NLM_fpage">1397</span>– <span class="NLM_lpage">1404</span>, <span class="refDoi"> DOI: 10.1002/cncr.10360</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1002%2Fcncr.10360" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2002&pages=1397-1404&author=T.+Akatsukaauthor=T.+Wadaauthor=Y.+Kokaiauthor=S.+Kawaguchiauthor=K.+Isuauthor=K.+Yamashiroauthor=T.+Yamashitaauthor=N.+Sawadaauthor=S.+Yamawakiauthor=S.+Ishii&title=Erbb2+Expression+is+Correlated+with+Increased+Survival+of+Patients+with+Osteosarcoma&doi=10.1002%2Fcncr.10360"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1002%2Fcncr.10360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcncr.10360%26sid%3Dliteratum%253Aachs%26aulast%3DAkatsuka%26aufirst%3DT.%26aulast%3DWada%26aufirst%3DT.%26aulast%3DKokai%26aufirst%3DY.%26aulast%3DKawaguchi%26aufirst%3DS.%26aulast%3DIsu%26aufirst%3DK.%26aulast%3DYamashiro%26aufirst%3DK.%26aulast%3DYamashita%26aufirst%3DT.%26aulast%3DSawada%26aufirst%3DN.%26aulast%3DYamawaki%26aufirst%3DS.%26aulast%3DIshii%26aufirst%3DS.%26atitle%3DErbb2%2520Expression%2520is%2520Correlated%2520with%2520Increased%2520Survival%2520of%2520Patients%2520with%2520Osteosarcoma%26jtitle%3DCancer%26date%3D2002%26volume%3D94%26spage%3D1397%26epage%3D1404%26doi%3D10.1002%2Fcncr.10360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiseman, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dispenzieri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arndt, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartmann, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smithson, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullan, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruland, O. S.</span></span> <span> </span><span class="NLM_article-title">High-Dose Samarium-153 Ethylene Diamine Tetramethylene Phosphonate: Low Toxicity of Skeletal Irradiation in Patients with Osteosarcoma and Bone Metastases</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">189</span>– <span class="NLM_lpage">196</span>, <span class="refDoi"> DOI: 10.1200/JCO.2002.20.1.189</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1200%2FJCO.2002.20.1.189" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=11773169" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=1%3ACAS%3A528%3ADC%252BD38XnsFeruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2002&pages=189-196&author=P.+M.+Andersonauthor=G.+A.+Wisemanauthor=A.+Dispenzieriauthor=C.+A.+Arndtauthor=L.+C.+Hartmannauthor=W.+A.+Smithsonauthor=B.+P.+Mullanauthor=O.+S.+Bruland&title=High-Dose+Samarium-153+Ethylene+Diamine+Tetramethylene+Phosphonate%3A+Low+Toxicity+of+Skeletal+Irradiation+in+Patients+with+Osteosarcoma+and+Bone+Metastases&doi=10.1200%2FJCO.2002.20.1.189"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">High-dose samarium-153 ethylene diamine tetramethylene phosphonate: Low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases</span></div><div class="casAuthors">Anderson, Peter M.; Wiseman, Gregory A.; Dispenzieri, Angela; Arndt, Carola A. S.; Hartmann, Lynn C.; Smithson, William A.; Mullan, Brian P.; Bruland, Oyvind S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">189-196</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Samarium-153 ethylene diamine tetramethylene phosphonate (153Sm-EDTMP), a bone-seeking radiopharmaceutical, provides therapeutic irradn. to osteoblastic bone metastases.  Because the dose-limiting toxicity of 153Sm-EDTMP is thrombocytopenia, a dose-escalation trial using peripheral-blood progenitor cells (PBPCs) or marrow support was conducted to treat metastatic bone cancer.  Patients with locally recurrent or metastatic osteosarcoma or skeletal metastases avid on bone scan were treated with 1, 3, 4.5, 6, 12, 19, or 30 mCi/kg of 153Sm-EDTMP.  Thirty patients were treated with 153Sm-EDTMP.  Transient symptoms of hypocalcemia were seen at 30 mCi/kg.  Ests. of radioisotope bound to bone surfaces and marrow radiation dose were linear with injected amt. of 153Sm-EDTMP.  Cytopenias also occurred in all subjects and were dose-related.  At day + 13 after 153Sm-EDTMP, residual whole-body radioactivity was 1% to 65% of whole-body radioactivity considered safe for PBPC infusion, 3.6 mCi.  After PBPC or marrow infusion on day + 14 after 153Sm-EDTMP, recovery of hematopoiesis was problematic in two patients at the 30 mCi/kg dose infused with less than 2 X 106 CD34+/kg on day + 14, but not in other patients.  Redn. or elimination of opiates for pain was seen in all patients.  Patients had no adverse changes in appetite or performance status.  153Sm-EDTMP with PBPC support can provide bone-specific therapeutic irradn. (ests. of 39 to 241 Gy).  Hematol. toxicity at 30 mCi 153Sm-EDTMP/kg requires PBPC grafts with more than 2 X 106 CD34+/kg to overcome myeloablative effects of skeletal irradn.  Nonhematol. side effects are minimal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruNsJ-Ss84ibVg90H21EOLACvtfcHk0lhjldQJClSSRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XnsFeruw%253D%253D&md5=e4466be01392edd123ce0b39c73dc169</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1200%2FJCO.2002.20.1.189&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2002.20.1.189%26sid%3Dliteratum%253Aachs%26aulast%3DAnderson%26aufirst%3DP.%2BM.%26aulast%3DWiseman%26aufirst%3DG.%2BA.%26aulast%3DDispenzieri%26aufirst%3DA.%26aulast%3DArndt%26aufirst%3DC.%2BA.%26aulast%3DHartmann%26aufirst%3DL.%2BC.%26aulast%3DSmithson%26aufirst%3DW.%2BA.%26aulast%3DMullan%26aufirst%3DB.%2BP.%26aulast%3DBruland%26aufirst%3DO.%2BS.%26atitle%3DHigh-Dose%2520Samarium-153%2520Ethylene%2520Diamine%2520Tetramethylene%2520Phosphonate%253A%2520Low%2520Toxicity%2520of%2520Skeletal%2520Irradiation%2520in%2520Patients%2520with%2520Osteosarcoma%2520and%2520Bone%2520Metastases%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2002%26volume%3D20%26spage%3D189%26epage%3D196%26doi%3D10.1200%2FJCO.2002.20.1.189" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burgert, E. O.,  Jr</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nesbit, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garnsey, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gehan, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrmann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vietti, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cangir, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tefft, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, P.</span></span> <span> </span><span class="NLM_article-title">Multimodal Therapy for the Management of Nonpelvic, Localized Ewing’s Sarcoma of Bone: Intergroup Study IESS-II</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1514</span>– <span class="NLM_lpage">1524</span>, <span class="refDoi"> DOI: 10.1200/JCO.1990.8.9.1514</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1200%2FJCO.1990.8.9.1514" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=2099751" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=1%3ACAS%3A280%3ADyaK3czmt1WltQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1990&pages=1514-1524&author=E.+O.+Burgertauthor=M.+E.+Nesbitauthor=L.+A.+Garnseyauthor=E.+A.+Gehanauthor=J.+Herrmannauthor=T.+J.+Viettiauthor=A.+Cangirauthor=M.+Tefftauthor=R.+Evansauthor=P.+Thomas&title=Multimodal+Therapy+for+the+Management+of+Nonpelvic%2C+Localized+Ewing%E2%80%99s+Sarcoma+of+Bone%3A+Intergroup+Study+IESS-II&doi=10.1200%2FJCO.1990.8.9.1514"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Multimodal therapy for the management of nonpelvic, localized Ewing's sarcoma of bone: intergroup study IESS-II</span></div><div class="casAuthors">Burgert E O Jr; Nesbit M E; Garnsey L A; Gehan E A; Herrmann J; Vietti T J; Cangir A; Tefft M; Evans R; Thomas P</div><div class="citationInfo"><span class="NLM_cas:title">Journal of clinical oncology : official journal of the American Society of Clinical Oncology</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1514-24</span>
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    </div><div class="casAbstract">Two hundred fourteen eligible patients with previously untreated, localized Ewing's sarcoma of bone were randomized on IESS-II to receive Adriamycin (ADR; doxorubicin; Adria Laboratories, Columbus, OH), cyclophosphamide, vincristine, and dactinomycin by either a high-dose intermittent method (treatment [trt] 1) or a moderate-dose continuous method (trt 2) similar to the four-drug arm of IESS-I.  Patient characteristics (sex, primary site, type of surgery) were stratified at the time of registration; these and other patient characteristics (age, time from symptoms to diagnosis, race) were distributed similarly between treatments.  Surgical resection was encouraged, but not mandatory.  Local radiation therapy was the same as for IESS-I.  The median follow-up time is 5.6 years.  The overall outcome was significantly better on trt 1 than on trt 2.  At 5 years, the estimated percentages of patients who were disease-free, relapse-free, and surviving were 68%, 73%, and 77% for trt 1 and 48%, 56%, and 63% for trt 2 (P = .02, .03, and .05, respectively).  The major reason for treatment failure for both treatment groups was the development of metastatic disease.  The lung was the most common site of metastases followed by bone sites.  The combined incidence of severe or worse toxicity (67%) was comparable between the treatments; however, severe or worse cardiovascular toxicity was significantly greater on trt 1.  Tne only treatment-associated deaths (N = 3) were on trt 1 and were cardiac-related.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRMLN3XNXXtEcSzjBFCN0BJfW6udTcc2eYTDse8rAkk-Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK3czmt1WltQ%253D%253D&md5=64dde0b2f89f1a9d054f202127ea25d8</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1200%2FJCO.1990.8.9.1514&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.1990.8.9.1514%26sid%3Dliteratum%253Aachs%26aulast%3DBurgert%26aufirst%3DE.%2BO.%26aulast%3DNesbit%26aufirst%3DM.%2BE.%26aulast%3DGarnsey%26aufirst%3DL.%2BA.%26aulast%3DGehan%26aufirst%3DE.%2BA.%26aulast%3DHerrmann%26aufirst%3DJ.%26aulast%3DVietti%26aufirst%3DT.%2BJ.%26aulast%3DCangir%26aufirst%3DA.%26aulast%3DTefft%26aufirst%3DM.%26aulast%3DEvans%26aufirst%3DR.%26aulast%3DThomas%26aufirst%3DP.%26atitle%3DMultimodal%2520Therapy%2520for%2520the%2520Management%2520of%2520Nonpelvic%252C%2520Localized%2520Ewing%25E2%2580%2599s%2520Sarcoma%2520of%2520Bone%253A%2520Intergroup%2520Study%2520IESS-II%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D1990%26volume%3D8%26spage%3D1514%26epage%3D1524%26doi%3D10.1200%2FJCO.1990.8.9.1514" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ferrari, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smeland, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercuri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertoni, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Longhi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruggieri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvegard, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Picci, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capanna, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernini, G.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Neoadjuvant Chemotherapy with High-Dose Ifosfamide, High-Dose Methotrexate, Cisplatin, And Doxorubicin for Patients with Localized Osteosarcoma of the Extremity: A Joint Study by the Italian and Scandinavian Sarcoma Groups</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">8845</span>– <span class="NLM_lpage">8852</span>, <span class="refDoi"> DOI: 10.1200/JCO.2004.00.5785</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1200%2FJCO.2004.00.5785" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=16246977" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=1%3ACAS%3A280%3ADC%252BD2Mnlt1Gqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=8845-8852&author=S.+Ferrariauthor=S.+Smelandauthor=M.+Mercuriauthor=F.+Bertoniauthor=A.+Longhiauthor=P.+Ruggieriauthor=T.+A.+Alvegardauthor=P.+Picciauthor=R.+Capannaauthor=G.+Bernini&title=Neoadjuvant+Chemotherapy+with+High-Dose+Ifosfamide%2C+High-Dose+Methotrexate%2C+Cisplatin%2C+And+Doxorubicin+for+Patients+with+Localized+Osteosarcoma+of+the+Extremity%3A+A+Joint+Study+by+the+Italian+and+Scandinavian+Sarcoma+Groups&doi=10.1200%2FJCO.2004.00.5785"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups</span></div><div class="casAuthors">Ferrari Stefano; Smeland Sigbjorn; Mercuri Mario; Bertoni Franco; Longhi Alessandra; Ruggieri Pietro; Alvegard Thor A; Picci Piero; Capanna Rodolfo; Bernini Gabriella; Muller Cristoph; Tienghi Amelia; Wiebe Thomas; Comandone Alessandro; Bohling Tom; Del Prever Adalberto Brach; Brosjo Otte; Bacci Gaetano; Saeter Gunnar</div><div class="citationInfo"><span class="NLM_cas:title">Journal of clinical oncology : official journal of the American Society of Clinical Oncology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">8845-52</span>
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    </div><div class="casAbstract">PURPOSE:  To explore the effect of high-dose ifosfamide in first-line treatment for patients < or = 40 years of age with nonmetastatic osteosarcoma of the extremity.  PATIENTS AND METHODS:  From March 1997 to September 2000, 182 patients were evaluated.  Primary treatment consisted of two blocks of high-dose ifosfamide (15 g/m2), methotrexate (12 g/m2), cisplatin (120 mg/m2), and doxorubicin (75 mg/m2).  Postoperatively, patients received two cycles of doxorubicin (90 mg/m2), and three cycles each of high-dose ifosfamide, methotrexate, and cisplatin (120 to 150 mg/m2).  Granulocyte colony-stimulating factor support was mandatory after the high-dose ifosfamide/cisplatin/doxorubicin combination.  RESULTS:  No disease progression was recorded during primary chemotherapy, 164 patients (92%) underwent limb-salvage surgery, four patients (2%) underwent rotation plasty, and 11 patients (6%) had limbs amputated.  Three (1.6%) patients died as a result of treatment-related toxicity, and one died as a result of pulmonary embolism after pathologic fracture.  Grade 4 neutropenia and thrombocytopenia followed 52% and 31% of all courses, respectively, and mild to severe nephrotoxicity was recorded in 19 patients (10%).  The median received dose-intensity compared with protocol was 0.82.  With a median follow-up of 55 months, the 5-year probability of event-free survival was 64% (95% CI, 57% to 71%) and overall survival was 77% (95% CI, 67% to 81%), whereas seven patients (4%) experienced local recurrence.  CONCLUSION:  The addition of high-dose ifosfamide to methotrexate, cisplatin, and doxorubicin in the preoperative phase is feasible, but with major renal and hematologic toxicities, and survival rates similar to those obtained with four-drug regimens using standard-dose ifosfamide.  Italian Sarcoma Group/Scandinavian Sarcoma Group study I showed that in a multicenter setting, more than 90% of patients with osteosarcoma of the extremity can undergo conservative surgery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRTzI9O1e9KT1Zoq0fPSOTvfW6udTcc2eYTDse8rAkk-Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2Mnlt1Gqtw%253D%253D&md5=3fdde0ca71453e1940e56d1e4b64ebe5</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1200%2FJCO.2004.00.5785&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2004.00.5785%26sid%3Dliteratum%253Aachs%26aulast%3DFerrari%26aufirst%3DS.%26aulast%3DSmeland%26aufirst%3DS.%26aulast%3DMercuri%26aufirst%3DM.%26aulast%3DBertoni%26aufirst%3DF.%26aulast%3DLonghi%26aufirst%3DA.%26aulast%3DRuggieri%26aufirst%3DP.%26aulast%3DAlvegard%26aufirst%3DT.%2BA.%26aulast%3DPicci%26aufirst%3DP.%26aulast%3DCapanna%26aufirst%3DR.%26aulast%3DBernini%26aufirst%3DG.%26atitle%3DNeoadjuvant%2520Chemotherapy%2520with%2520High-Dose%2520Ifosfamide%252C%2520High-Dose%2520Methotrexate%252C%2520Cisplatin%252C%2520And%2520Doxorubicin%2520for%2520Patients%2520with%2520Localized%2520Osteosarcoma%2520of%2520the%2520Extremity%253A%2520A%2520Joint%2520Study%2520by%2520the%2520Italian%2520and%2520Scandinavian%2520Sarcoma%2520Groups%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2005%26volume%3D23%26spage%3D8845%26epage%3D8852%26doi%3D10.1200%2FJCO.2004.00.5785" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gorlick, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huvos, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heller, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aledo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beardsley, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Healey, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyers, P. A.</span></span> <span> </span><span class="NLM_article-title">Expression of HER2/Erbb-2 Correlates with Survival in Osteosarcoma</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">2781</span>– <span class="NLM_lpage">2788</span>, <span class="refDoi"> DOI: 10.1200/JCO.1999.17.9.2781</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1200%2FJCO.1999.17.9.2781" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10561353" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=1%3ACAS%3A280%3ADC%252BD3c%252FjtVSrsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1999&pages=2781-2788&author=R.+Gorlickauthor=A.+G.+Huvosauthor=G.+Hellerauthor=A.+Aledoauthor=G.+P.+Beardsleyauthor=J.+H.+Healeyauthor=P.+A.+Meyers&title=Expression+of+HER2%2FErbb-2+Correlates+with+Survival+in+Osteosarcoma&doi=10.1200%2FJCO.1999.17.9.2781"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Expression of HER2/erbB-2 correlates with survival in osteosarcoma</span></div><div class="casAuthors">Gorlick R; Huvos A G; Heller G; Aledo A; Beardsley G P; Healey J H; Meyers P A</div><div class="citationInfo"><span class="NLM_cas:title">Journal of clinical oncology : official journal of the American Society of Clinical Oncology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2781-8</span>
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    </div><div class="casAbstract">PURPOSE:  In osteosarcoma, prognostic factors at diagnosis other than clinical stage have not been clearly identified.  The aim of this study was to determine whether human epidermal growth factor receptor 2 (HER2)/erbB-2, p-glycoprotein, or p53 expression correlated with histologic response to preoperative chemotherapy or event-free survival.  PATIENTS AND METHODS:  We performed a retrospective immunohistochemical study on material obtained from patients treated on the Memorial Sloan-Kettering Cancer Center T12 protocol between 1986 and 1993.  Paraffin-embedded tissue was identified from 53 patients (73% of patients enrolled onto protocol) and stained for HER2/erbB-2, p53, and p-glycoprotein expression using standard monoclonal antibodies and methods.  RESULTS:  At the time of initial biopsy, 20 (42.6%) of 47 samples demonstrated high levels of HER2/erbB-2 expression.  Higher frequencies of expression were observed in samples from patients with metastatic disease at presentation and at the time of relapse.  Expression of HER2/erbB-2 correlated with a significantly worse histologic response (P =.03).  In patients presenting with nonmetastatic disease, expression of HER2/erbB-2 at the time of initial biopsy was associated with a significantly decreased event-free survival (47% v 79% at 5 years, P =.05). p53 and p-glycoprotein expression did not correlate with histologic response or patient event-free survival.  CONCLUSION:  The correlation of HER2/erbB-2 expression with histologic response to preoperative chemotherapy and event-free survival in this study suggests that HER2/erbB-2 should be evaluated prospectively as a prognostic indicator.  The correlation also suggests that clinical trials of antibodies that target this receptor, such as recombinant humanized anti-HER2 monoclonal antibody (Herceptin; Genentech, San Francisco, CA), should be considered for the treatment of osteosarcoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTJCWG9F5gqCNts4TFFB11gfW6udTcc2eZNFGJ4m-vzVbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3c%252FjtVSrsA%253D%253D&md5=4a6955692246eb1b83143e9f7db9b249</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1200%2FJCO.1999.17.9.2781&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.1999.17.9.2781%26sid%3Dliteratum%253Aachs%26aulast%3DGorlick%26aufirst%3DR.%26aulast%3DHuvos%26aufirst%3DA.%2BG.%26aulast%3DHeller%26aufirst%3DG.%26aulast%3DAledo%26aufirst%3DA.%26aulast%3DBeardsley%26aufirst%3DG.%2BP.%26aulast%3DHealey%26aufirst%3DJ.%2BH.%26aulast%3DMeyers%26aufirst%3DP.%2BA.%26atitle%3DExpression%2520of%2520HER2%252FErbb-2%2520Correlates%2520with%2520Survival%2520in%2520Osteosarcoma%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D1999%26volume%3D17%26spage%3D2781%26epage%3D2788%26doi%3D10.1200%2FJCO.1999.17.9.2781" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grier, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krailo, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarbell, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Link, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fryer, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pritchard, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gebhardt, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickman, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perlman, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyers, P. A.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Addition of Ifosfamide and Etoposide to Standard Chemotherapy for Ewing’s Sarcoma and Primitive Neuroectodermal Tumor of Bone</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>348</i></span>,  <span class="NLM_fpage">694</span>– <span class="NLM_lpage">701</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa020890</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1056%2FNEJMoa020890" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=12594313" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhtlWjt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=348&publication_year=2003&pages=694-701&author=H.+E.+Grierauthor=M.+D.+Krailoauthor=N.+J.+Tarbellauthor=M.+P.+Linkauthor=C.+J.+Fryerauthor=D.+J.+Pritchardauthor=M.+C.+Gebhardtauthor=P.+S.+Dickmanauthor=E.+J.+Perlmanauthor=P.+A.+Meyers&title=Addition+of+Ifosfamide+and+Etoposide+to+Standard+Chemotherapy+for+Ewing%E2%80%99s+Sarcoma+and+Primitive+Neuroectodermal+Tumor+of+Bone&doi=10.1056%2FNEJMoa020890"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone</span></div><div class="casAuthors">Grier, Holcombe E.; Krailo, Mark D.; Tarbell, Nancy J.; Link, Michael P.; Fryer, Christopher J. H.; Pritchard, Douglas J.; Gebhardt, Mark C.; Dickman, Paul S.; Perlman, Elizabeth J.; Meyers, Paul A.; Donaldson, Sarah S.; Moore, Sheila; Rausen, Aaron R.; Vietti, Teresa J.; Miser, James S.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">348</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">694-701</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Ewing's sarcoma and primitive neuroectodermal tumor of bone are closely related, highly malignant tumors of children, adolescents, and young adults.  A new drug combination, ifosfamide and etoposide, was highly effective in patients with Ewing's sarcoma or primitive neuroectodermal tumor of bone who had a relapse after std. therapy.  We designed a study to test whether the addn. of these drugs to a std. regimen would improve the survival of patients with newly diagnosed disease.  Methods: Patients 30 yr old or younger with Ewing's sarcoma, primitive neuroectodermal tumor of bone, or primitive sarcoma of bone were eligible.  The patients were randomly assigned to receive 49 wk of std. chemotherapy with doxorubicin, vincristine, cyclophosphamide, and dactinomycin or exptl. therapy with these four drugs alternating with courses of ifosfamide and etoposide.  Results: A total of 518 patients met the eligibility requirements.  Of 120 patients with metastatic disease, 62 were randomly assigned to the std.-therapy group and 58 to the exptl.-therapy group.  There was no significant difference in five-year event-free survival between the treatment groups (P = 0.81).  Among the 398 patients with nonmetastatic disease, the mean (±SE) five-year event-free survival among the 198 patients in the exptl.-therapy group was 69 ± 3 percent, as compared with 54 ± 4 percent among the 200 patients in the std.-therapy group (P = 0.005).  Overall survival was also significantly better among patients in the exptl.-therapy group (72 ± 3.4 percent vs. 61 ± 3.6 percent in the std.-therapy group, P = 0.01).  Conclusions: The addn. of ifosfamide and etoposide to a std. regimen does not affect the outcome for patients with metastatic disease, but it significantly improves the outcome for patients with nonmetastatic Ewing's sarcoma, primitive neuroectodermal tumor of bone, or primitive sarcoma of bone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9-41yaquvoLVg90H21EOLACvtfcHk0ljOxcA6OSE6Ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhtlWjt70%253D&md5=0bd0ba73197360811241a4798036a6e9</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa020890&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa020890%26sid%3Dliteratum%253Aachs%26aulast%3DGrier%26aufirst%3DH.%2BE.%26aulast%3DKrailo%26aufirst%3DM.%2BD.%26aulast%3DTarbell%26aufirst%3DN.%2BJ.%26aulast%3DLink%26aufirst%3DM.%2BP.%26aulast%3DFryer%26aufirst%3DC.%2BJ.%26aulast%3DPritchard%26aufirst%3DD.%2BJ.%26aulast%3DGebhardt%26aufirst%3DM.%2BC.%26aulast%3DDickman%26aufirst%3DP.%2BS.%26aulast%3DPerlman%26aufirst%3DE.%2BJ.%26aulast%3DMeyers%26aufirst%3DP.%2BA.%26atitle%3DAddition%2520of%2520Ifosfamide%2520and%2520Etoposide%2520to%2520Standard%2520Chemotherapy%2520for%2520Ewing%25E2%2580%2599s%2520Sarcoma%2520and%2520Primitive%2520Neuroectodermal%2520Tumor%2520of%2520Bone%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2003%26volume%3D348%26spage%3D694%26epage%3D701%26doi%3D10.1056%2FNEJMoa020890" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Le
Deley, M.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guinebretière, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gentet, J.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pacquement, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pichon, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marec-Bérard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Entz-Werlé, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brugières, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanel, D.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">SFOP OS94: A Randomised Trial Comparing Preoperative High-Dose Methotrexate Plus Doxorubicin to High-Dose Methotrexate Plus Etoposide and Ifosfamide in Osteosarcoma Patients</span>. <i>Eur. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">752</span>– <span class="NLM_lpage">761</span>, <span class="refDoi"> DOI: 10.1016/j.ejca.2006.10.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1016%2Fj.ejca.2006.10.023" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2007&pages=752-761&author=M.-C.+Le%0ADeleyauthor=J.-M.+Guinebreti%C3%A8reauthor=J.-C.+Gentetauthor=H.+Pacquementauthor=F.+Pichonauthor=P.+Marec-B%C3%A9rardauthor=N.+Entz-Werl%C3%A9author=C.+Schmittauthor=L.+Brugi%C3%A8resauthor=D.+Vanel&title=SFOP+OS94%3A+A+Randomised+Trial+Comparing+Preoperative+High-Dose+Methotrexate+Plus+Doxorubicin+to+High-Dose+Methotrexate+Plus+Etoposide+and+Ifosfamide+in+Osteosarcoma+Patients&doi=10.1016%2Fj.ejca.2006.10.023"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.ejca.2006.10.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejca.2006.10.023%26sid%3Dliteratum%253Aachs%26aulast%3DLe%2BDeley%26aufirst%3DM.-C.%26aulast%3DGuinebreti%25C3%25A8re%26aufirst%3DJ.-M.%26aulast%3DGentet%26aufirst%3DJ.-C.%26aulast%3DPacquement%26aufirst%3DH.%26aulast%3DPichon%26aufirst%3DF.%26aulast%3DMarec-B%25C3%25A9rard%26aufirst%3DP.%26aulast%3DEntz-Werl%25C3%25A9%26aufirst%3DN.%26aulast%3DSchmitt%26aufirst%3DC.%26aulast%3DBrugi%25C3%25A8res%26aufirst%3DL.%26aulast%3DVanel%26aufirst%3DD.%26atitle%3DSFOP%2520OS94%253A%2520A%2520Randomised%2520Trial%2520Comparing%2520Preoperative%2520High-Dose%2520Methotrexate%2520Plus%2520Doxorubicin%2520to%2520High-Dose%2520Methotrexate%2520Plus%2520Etoposide%2520and%2520Ifosfamide%2520in%2520Osteosarcoma%2520Patients%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2007%26volume%3D43%26spage%3D752%26epage%3D761%26doi%3D10.1016%2Fj.ejca.2006.10.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Susa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milane, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amiji, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hornicek, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, Z.</span></span> <span> </span><span class="NLM_article-title">Nanoparticles: A Promising Modality in the Treatment of Sarcomas</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">260</span>– <span class="NLM_lpage">272</span>, <span class="refDoi"> DOI: 10.1007/s11095-010-0173-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1007%2Fs11095-010-0173-z" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2011&pages=260-272&author=M.+Susaauthor=L.+Milaneauthor=M.+M.+Amijiauthor=F.+J.+Hornicekauthor=Z.+Duan&title=Nanoparticles%3A+A+Promising+Modality+in+the+Treatment+of+Sarcomas&doi=10.1007%2Fs11095-010-0173-z"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1007%2Fs11095-010-0173-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11095-010-0173-z%26sid%3Dliteratum%253Aachs%26aulast%3DSusa%26aufirst%3DM.%26aulast%3DMilane%26aufirst%3DL.%26aulast%3DAmiji%26aufirst%3DM.%2BM.%26aulast%3DHornicek%26aufirst%3DF.%2BJ.%26aulast%3DDuan%26aufirst%3DZ.%26atitle%3DNanoparticles%253A%2520A%2520Promising%2520Modality%2520in%2520the%2520Treatment%2520of%2520Sarcomas%26jtitle%3DPharm.%2520Res.%26date%3D2011%26volume%3D28%26spage%3D260%26epage%3D272%26doi%3D10.1007%2Fs11095-010-0173-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eaves, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Currier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cripe, T. P.</span></span> <span> </span><span class="NLM_article-title">Preclinical Evaluation of Nanoparticle Albumin-Bound Paclitaxel for Treatment of Pediatric Bone Sarcoma</span>. <i>Pediatric blood & cancer</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">2096</span>– <span class="NLM_lpage">2098</span>, <span class="refDoi"> DOI: 10.1002/pbc.25062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1002%2Fpbc.25062" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2014&pages=2096-2098&author=L.+M.+Wagnerauthor=H.+Yinauthor=D.+Eavesauthor=M.+Currierauthor=T.+P.+Cripe&title=Preclinical+Evaluation+of+Nanoparticle+Albumin-Bound+Paclitaxel+for+Treatment+of+Pediatric+Bone+Sarcoma&doi=10.1002%2Fpbc.25062"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1002%2Fpbc.25062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpbc.25062%26sid%3Dliteratum%253Aachs%26aulast%3DWagner%26aufirst%3DL.%2BM.%26aulast%3DYin%26aufirst%3DH.%26aulast%3DEaves%26aufirst%3DD.%26aulast%3DCurrier%26aufirst%3DM.%26aulast%3DCripe%26aufirst%3DT.%2BP.%26atitle%3DPreclinical%2520Evaluation%2520of%2520Nanoparticle%2520Albumin-Bound%2520Paclitaxel%2520for%2520Treatment%2520of%2520Pediatric%2520Bone%2520Sarcoma%26jtitle%3DPediatric%2520blood%2520%2526%2520cancer%26date%3D2014%26volume%3D61%26spage%3D2096%26epage%3D2098%26doi%3D10.1002%2Fpbc.25062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seitoku, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwadera, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamba, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamagata, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akasaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kusaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yawaka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iida, J.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Estimation of Biocompatibility of Nano-Sized Ceramic Particles with Osteoblasts, Osteosarcomas and Hepatocytes by Static and Time-Lapse Observation</span>. <i>J. Biomed. Nanotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">472</span>– <span class="NLM_lpage">480</span>, <span class="refDoi"> DOI: 10.1166/jbn.2016.2190</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1166%2Fjbn.2016.2190" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=27280245" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVKlt7rP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=472-480&author=S.+Abeauthor=E.+Seitokuauthor=N.+Iwaderaauthor=Y.+Hambaauthor=S.+Yamagataauthor=T.+Akasakaauthor=T.+Kusakaauthor=S.+Inoueauthor=Y.+Yawakaauthor=J.+Iida&title=Estimation+of+Biocompatibility+of+Nano-Sized+Ceramic+Particles+with+Osteoblasts%2C+Osteosarcomas+and+Hepatocytes+by+Static+and+Time-Lapse+Observation&doi=10.1166%2Fjbn.2016.2190"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Estimation of biocompatibility of nano-sized ceramic particles with osteoblasts, osteosarcomas and hepatocytes by static and time-lapse observation</span></div><div class="casAuthors">Abe, Shigeaki; Seitoku, Eri; Iwadera, Nobuki; Hamba, Yusuke; Yamagata, Shuichi; Akasaka, Tsukasa; Kusaka, Teruo; Inoue, Satoshi; Yawaka, Yasutaka; Iida, Junichiro; Sano, Hidehiko; Yonezawa, Tetsu; Yoshida, Yasuhiro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biomedical Nanotechnology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">472-480</span>CODEN:
                <span class="NLM_cas:coden">JBNOAB</span>;
        ISSN:<span class="NLM_cas:issn">1550-7033</span>.
    
            (<span class="NLM_cas:orgname">American Scientific Publishers</span>)
        </div><div class="casAbstract">We assessed the biocompatibility of nano-sized ceramic particles with several cells types.  Though these particles have less than 100 nm in diam., they act as submicron-sized particles in saline by aggregation that was estd. using laser diffraction particle size anal. (LDS). they act as submicro-sized particles in saline by aggregation based on laser diffraction particle size anal. (LDS).  Several types of cells (osteoblasts, osteosarcoma and hepatocyte cells) were exposed to these particles and their cytocompatibility was estd.  Not only the cytotoxic assay but also their static and dynamic morphol. under nanoparticles exposure were investigated.  The intercellular uptake of particles was detd. using a confocal fluorescence microscope.  The particles used in this study did not inhibit cellular activity or growth even when their concns. were high.  Only copper oxide particles caused acute cytotoxicity depending on the particle size.  The cytotoxicity assay, dynamic behavior of the nanoparticle-exposed cells and their examn. under a confocal fluorescence microscope suggests that the irritative reaction was induced by contact between the cells and particles, whereas eluted copper ions are not dominant factor.  These results indicate that nano-sized particles used in this study have excellent biocompatibility except copper oxide ones.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomwSUM7xsZ-bVg90H21EOLACvtfcHk0li3tsEWPGihEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVKlt7rP&md5=7a66b4e30c38b94075aafef3371a8b90</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1166%2Fjbn.2016.2190&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1166%252Fjbn.2016.2190%26sid%3Dliteratum%253Aachs%26aulast%3DAbe%26aufirst%3DS.%26aulast%3DSeitoku%26aufirst%3DE.%26aulast%3DIwadera%26aufirst%3DN.%26aulast%3DHamba%26aufirst%3DY.%26aulast%3DYamagata%26aufirst%3DS.%26aulast%3DAkasaka%26aufirst%3DT.%26aulast%3DKusaka%26aufirst%3DT.%26aulast%3DInoue%26aufirst%3DS.%26aulast%3DYawaka%26aufirst%3DY.%26aulast%3DIida%26aufirst%3DJ.%26atitle%3DEstimation%2520of%2520Biocompatibility%2520of%2520Nano-Sized%2520Ceramic%2520Particles%2520with%2520Osteoblasts%252C%2520Osteosarcomas%2520and%2520Hepatocytes%2520by%2520Static%2520and%2520Time-Lapse%2520Observation%26jtitle%3DJ.%2520Biomed.%2520Nanotechnol.%26date%3D2016%26volume%3D12%26spage%3D472%26epage%3D480%26doi%3D10.1166%2Fjbn.2016.2190" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunda, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Askhatova, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farokhzad, O. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parangi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, J.</span></span> <span> </span><span class="NLM_article-title">Theranostic Near-Infrared Fluorescent Nanoplatform for Imaging and Systemic Sirna Delivery to Metastatic Anaplastic Thyroid Cancer</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>113</i></span>,  <span class="NLM_fpage">7750</span>– <span class="NLM_lpage">7755</span>, <span class="refDoi"> DOI: 10.1073/pnas.1605841113</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1073%2Fpnas.1605841113" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=27342857" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFentrbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2016&pages=7750-7755&author=Y.+Liuauthor=V.+Gundaauthor=X.+Zhuauthor=X.+Xuauthor=J.+Wuauthor=D.+Askhatovaauthor=O.+C.+Farokhzadauthor=S.+Parangiauthor=J.+Shi&title=Theranostic+Near-Infrared+Fluorescent+Nanoplatform+for+Imaging+and+Systemic+Sirna+Delivery+to+Metastatic+Anaplastic+Thyroid+Cancer&doi=10.1073%2Fpnas.1605841113"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Theranostic near-infrared fluorescent nanoplatform for imaging and systemic siRNA delivery to metastatic anaplastic thyroid cancer</span></div><div class="casAuthors">Liu, Yanlan; Gunda, Viswanath; Zhu, Xi; Xu, Xiaoding; Wu, Jun; Askhatova, Diana; Farokhzad, Omid C.; Parangi, Sareh; Shi, Jinjun</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">28</span>),
    <span class="NLM_cas:pages">7750-7755</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Anaplastic thyroid cancer (ATC), one of the most aggressive solid tumors, is characterized by rapid tumor growth and severe metastasis to other organs.  Owing to the lack of effective treatment options, ATC has a mortality rate of ∼100% and median survival of less than 5 mo.  RNAi nanotechnol. represents a promising strategy for cancer therapy through nanoparticle (NP) -mediated delivery of RNAi agents (e.g., siRNA) to solid tumors for specific silencing of target genes driving growth and/or metastasis.  Nevertheless, the clin. success of RNAi cancer nanotherapies remains elusive in large part because of the suboptimal systemic siRNA NP delivery to tumors and the fact that tumor heterogeneity produces variable NP accumulation and thus, therapeutic response.  To address these challenges, the authors here present an innovative theranostic NP platform composed of a near-IR (NIR) fluorescent polymer for effective in vivo siRNA delivery to ATC tumors and simultaneous tracking of the tumor accumulation by noninvasive NIR imaging.  The NIR polymeric NPs are small (∼50 nm), show long blood circulation and high tumor accumulation, and facilitate tumor imaging.  Systemic siRNA delivery using these NPs efficiently silences the expression of V-Raf murine sarcoma viral oncogene homolog B (BRAF) in tumor tissues and significantly suppresses tumor growth and metastasis in an orthotopic mouse model of ATC.  These results suggest that this theranostic NP system could become an effective tool for NIR imaging-guided siRNA delivery for personalized treatment of advanced malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5s5UIc3a6kbVg90H21EOLACvtfcHk0li3tsEWPGihEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFentrbM&md5=3dcd1a8ae78921319165abb95498fdc6</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1605841113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1605841113%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DGunda%26aufirst%3DV.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DAskhatova%26aufirst%3DD.%26aulast%3DFarokhzad%26aufirst%3DO.%2BC.%26aulast%3DParangi%26aufirst%3DS.%26aulast%3DShi%26aufirst%3DJ.%26atitle%3DTheranostic%2520Near-Infrared%2520Fluorescent%2520Nanoplatform%2520for%2520Imaging%2520and%2520Systemic%2520Sirna%2520Delivery%2520to%2520Metastatic%2520Anaplastic%2520Thyroid%2520Cancer%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2016%26volume%3D113%26spage%3D7750%26epage%3D7755%26doi%3D10.1073%2Fpnas.1605841113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Makridis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tziomaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Topouridou, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yavropoulou, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yovos, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalogirou, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samaras, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angelakeris, M.</span></span> <span> </span><span class="NLM_article-title">A Novel Strategy Combining Magnetic Particle Hyperthermia Pulses with Enhanced Performance Binary Ferrite Carriers for Effective In Vitro Manipulation of Primary Human Osteogenic Sarcoma Cells</span>. <i>Int. J. Hyperthermia</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">778</span>– <span class="NLM_lpage">785</span>, <span class="refDoi"> DOI: 10.1080/02656736.2016.1216183</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1080%2F02656736.2016.1216183" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=27442884" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlaksLvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2016&pages=778-785&author=A.+Makridisauthor=M.+Tziomakiauthor=K.+Topouridouauthor=M.+P.+Yavropoulouauthor=J.+G.+Yovosauthor=O.+Kalogirouauthor=T.+Samarasauthor=M.+Angelakeris&title=A+Novel+Strategy+Combining+Magnetic+Particle+Hyperthermia+Pulses+with+Enhanced+Performance+Binary+Ferrite+Carriers+for+Effective+In+Vitro+Manipulation+of+Primary+Human+Osteogenic+Sarcoma+Cells&doi=10.1080%2F02656736.2016.1216183"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">A novel strategy combining magnetic particle hyperthermia pulses with enhanced performance binary ferrite carriers for effective in vitro manipulation of primary human osteogenic sarcoma cells</span></div><div class="casAuthors">Makridis, Antonios; Tziomaki, Magdalini; Topouridou, Konstantina; Yavropoulou, Maria P.; Yovos, John G.; Kalogirou, Orestis; Samaras, Theodoros; Angelakeris, Mavroeidis</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Hyperthermia</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">778-785</span>CODEN:
                <span class="NLM_cas:coden">IJHYEQ</span>;
        ISSN:<span class="NLM_cas:issn">0265-6736</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">The present study examines the heating efficiency of a combination of manganese or cobalt ferrites in a binary (Co- or Mn-) ferrite nanoparticle form with magnetite, covered with citric acid to improve biocompatibility.  The nanoparticle synthesis is based on the aq. co-pptn. of proper salts, a facile, low-cost, environmentally friendly and high yield synthetic approach.  By detailed structural and magnetic characterization, the direct influence of structural and magnetic features on magnetic hyperthermia concludes to optimum heating efficiency.  At a second stage, best performing magnetic nanoparticles undergo in vitro testing in three cell lines: one cancer cell line and two ref. healthy cell lines.  Both binary ferrite (MnFe2O4/Fe3O4 and CoFe2O4/Fe3O4) appear to be internalised and well tolerated by the cells while a versatile hyperthermia protocol is attempted in an effort to further improve their in vitro performance.  Within this protocol, hyperthermia sequences are split in two runs with an intermediate 48 h time interval cell incubation stage while in each run a variable field mode (single or multiple pulses) is applied.  Single-pulse field mode represents a typical hyperthermia application scheme where cells undergo the thermal shock continuously.  On the other hand multiple-pulses mode refers to multiple, much shorter in duration AC field changes (field ON/OFFs), at each hyperthermia run, resulting eventually in high heating rate and much more harmful cell treatment.  Consequently, we propose a novel series of improved performance heat mediators based on ferrite structures which show max. efficiency at cancer cells when combined with a versatile multiple-pulse hyperthermia module.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQyWFFVq0IorVg90H21EOLACvtfcHk0ljtJAB-wH5VQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlaksLvI&md5=1042c4e8fa340b0e564df755a502c765</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1080%2F02656736.2016.1216183&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F02656736.2016.1216183%26sid%3Dliteratum%253Aachs%26aulast%3DMakridis%26aufirst%3DA.%26aulast%3DTziomaki%26aufirst%3DM.%26aulast%3DTopouridou%26aufirst%3DK.%26aulast%3DYavropoulou%26aufirst%3DM.%2BP.%26aulast%3DYovos%26aufirst%3DJ.%2BG.%26aulast%3DKalogirou%26aufirst%3DO.%26aulast%3DSamaras%26aufirst%3DT.%26aulast%3DAngelakeris%26aufirst%3DM.%26atitle%3DA%2520Novel%2520Strategy%2520Combining%2520Magnetic%2520Particle%2520Hyperthermia%2520Pulses%2520with%2520Enhanced%2520Performance%2520Binary%2520Ferrite%2520Carriers%2520for%2520Effective%2520In%2520Vitro%2520Manipulation%2520of%2520Primary%2520Human%2520Osteogenic%2520Sarcoma%2520Cells%26jtitle%3DInt.%2520J.%2520Hyperthermia%26date%3D2016%26volume%3D32%26spage%3D778%26epage%3D785%26doi%3D10.1080%2F02656736.2016.1216183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiao, J.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, P.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.-Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, C.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H.-L.</span></span> <span> </span><span class="NLM_article-title">In Vivo Synergistic Antitumor Effect and Safety of Sirna and Lonidamine Dual-Loaded Hierarchical Targeted Nanoparticles</span>. <i>Int. J. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>506</i></span>,  <span class="NLM_fpage">207</span>– <span class="NLM_lpage">213</span>, <span class="refDoi"> DOI: 10.1016/j.ijpharm.2016.04.056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1016%2Fj.ijpharm.2016.04.056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=27113867" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=1%3ACAS%3A528%3ADC%252BC28XntVCrs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=506&publication_year=2016&pages=207-213&author=B.-F.+Zhangauthor=L.+Xingauthor=J.-B.+Qiaoauthor=P.-F.+Cuiauthor=F.-Z.+Wangauthor=J.-L.+Zhangauthor=C.-X.+Xuauthor=H.-L.+Jiang&title=In+Vivo+Synergistic+Antitumor+Effect+and+Safety+of+Sirna+and+Lonidamine+Dual-Loaded+Hierarchical+Targeted+Nanoparticles&doi=10.1016%2Fj.ijpharm.2016.04.056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">In vivo synergistic antitumor effect and safety of siRNA and lonidamine dual-loaded hierarchical targeted nanoparticles</span></div><div class="casAuthors">Zhang, Bing-Feng; Xing, Lei; Qiao, Jian-Bin; Cui, Peng-Fei; Wang, Feng-Zhen; Zhang, Jia-Liang; Xu, Cheng-Xiong; Jiang, Hu-Lin</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Pharmaceutics (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">506</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">207-213</span>CODEN:
                <span class="NLM_cas:coden">IJPHDE</span>;
        ISSN:<span class="NLM_cas:issn">0378-5173</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Based on development of nano-delivery system, co-delivery of chemotherapeutic drug and small interfering RNA (siRNA) has exerted a promising advantage in cancer therapy.  In this work, the superiority of synergistic therapy and safety of the hierarchical targeted co-delivery system loaded with siRNA and lonidamine (LND) were evaluated.  The in vivo tumor accumulation ability and cancer growth inhibition effect of the polymer-blend nanocarriers were evaluated by a H22 s.c. sarcoma model.  Moreover, hematoxylin and eosin (H&E) staining and transferase-mediated dUTP nick end-labeling (TUNEL) staining of tumor sections from each group were compared to assess the therapeutic efficacy.  The dual-loaded nanocarriers had better tumor accumulation ability, remarkably inhibited growth of solid tumor in a synergistic manner, even significantly decreased hepatotoxicity of LND, and had good in vivo biocompatibility whereas LND alone showed serious hepatotoxicity.  We believed that the dual-loaded hierarchical targeted delivery system with high effectiveness and biocompatibility would provide a promising approach for cancer combination therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUSZDq9uggZ7Vg90H21EOLACvtfcHk0ljtJAB-wH5VQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XntVCrs78%253D&md5=580610a42e5386a954b093d6c08e624c</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.ijpharm.2016.04.056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijpharm.2016.04.056%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DB.-F.%26aulast%3DXing%26aufirst%3DL.%26aulast%3DQiao%26aufirst%3DJ.-B.%26aulast%3DCui%26aufirst%3DP.-F.%26aulast%3DWang%26aufirst%3DF.-Z.%26aulast%3DZhang%26aufirst%3DJ.-L.%26aulast%3DXu%26aufirst%3DC.-X.%26aulast%3DJiang%26aufirst%3DH.-L.%26atitle%3DIn%2520Vivo%2520Synergistic%2520Antitumor%2520Effect%2520and%2520Safety%2520of%2520Sirna%2520and%2520Lonidamine%2520Dual-Loaded%2520Hierarchical%2520Targeted%2520Nanoparticles%26jtitle%3DInt.%2520J.%2520Pharm.%26date%3D2016%26volume%3D506%26spage%3D207%26epage%3D213%26doi%3D10.1016%2Fj.ijpharm.2016.04.056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reed, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokat, K. M.</span></span> <span> </span><span class="NLM_article-title">Targeting Osteosarcoma</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">18100</span>, <span class="refDoi"> DOI: 10.1073/pnas.1420596111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1073%2Fpnas.1420596111" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2014&pages=18100&author=D.+E.+Reedauthor=K.+M.+Shokat&title=Targeting+Osteosarcoma&doi=10.1073%2Fpnas.1420596111"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1420596111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1420596111%26sid%3Dliteratum%253Aachs%26aulast%3DReed%26aufirst%3DD.%2BE.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26atitle%3DTargeting%2520Osteosarcoma%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2014%26volume%3D111%26spage%3D18100%26doi%3D10.1073%2Fpnas.1420596111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">González-Fernández, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imbuluzqueta, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patiño-García, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanco-Prieto, M.</span></span> <span> </span><span class="NLM_article-title">Antitumoral-Lipid-Based Nanoparticles: A Platform for Future Application in Osteosarcoma Therapy</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">6104</span>– <span class="NLM_lpage">6124</span>, <span class="refDoi"> DOI: 10.2174/1381612821666151027152534</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.2174%2F1381612821666151027152534" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=6104-6124&author=Y.+Gonz%C3%A1lez-Fern%C3%A1ndezauthor=E.+Imbuluzquetaauthor=A.+Pati%C3%B1o-Garc%C3%ADaauthor=M.+Blanco-Prieto&title=Antitumoral-Lipid-Based+Nanoparticles%3A+A+Platform+for+Future+Application+in+Osteosarcoma+Therapy&doi=10.2174%2F1381612821666151027152534"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.2174%2F1381612821666151027152534&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1381612821666151027152534%26sid%3Dliteratum%253Aachs%26aulast%3DGonz%25C3%25A1lez-Fern%25C3%25A1ndez%26aufirst%3DY.%26aulast%3DImbuluzqueta%26aufirst%3DE.%26aulast%3DPati%25C3%25B1o-Garc%25C3%25ADa%26aufirst%3DA.%26aulast%3DBlanco-Prieto%26aufirst%3DM.%26atitle%3DAntitumoral-Lipid-Based%2520Nanoparticles%253A%2520A%2520Platform%2520for%2520Future%2520Application%2520in%2520Osteosarcoma%2520Therapy%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2015%26volume%3D21%26spage%3D6104%26epage%3D6124%26doi%3D10.2174%2F1381612821666151027152534" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhuang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span> <span> </span><span class="NLM_article-title">Polymeric Nanocarriers for Drug Delivery in Osteosarcoma Treatment</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">5187</span>– <span class="NLM_lpage">5197</span>, <span class="refDoi"> DOI: 10.2174/1381612821666150923095618</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.2174%2F1381612821666150923095618" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=5187-5197&author=X.+Guauthor=J.+Dingauthor=Z.+Zhangauthor=Q.+Liauthor=X.+Zhuangauthor=X.+Chen&title=Polymeric+Nanocarriers+for+Drug+Delivery+in+Osteosarcoma+Treatment&doi=10.2174%2F1381612821666150923095618"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.2174%2F1381612821666150923095618&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1381612821666150923095618%26sid%3Dliteratum%253Aachs%26aulast%3DGu%26aufirst%3DX.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DZhuang%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DX.%26atitle%3DPolymeric%2520Nanocarriers%2520for%2520Drug%2520Delivery%2520in%2520Osteosarcoma%2520Treatment%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2015%26volume%3D21%26spage%3D5187%26epage%3D5197%26doi%3D10.2174%2F1381612821666150923095618" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Akhtar, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahamed, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alhadlaq, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alrokayan, S. A.</span></span> <span> </span><span class="NLM_article-title">Glutathione Replenishing Potential of Ceo2 Nanoparticles in Human Breast and Fibrosarcoma Cells</span>. <i>J. Colloid Interface Sci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>453</i></span>,  <span class="NLM_fpage">21</span>– <span class="NLM_lpage">27</span>, <span class="refDoi"> DOI: 10.1016/j.jcis.2015.04.049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1016%2Fj.jcis.2015.04.049" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=453&publication_year=2015&pages=21-27&author=M.+J.+Akhtarauthor=M.+Ahamedauthor=H.+A.+Alhadlaqauthor=M.+M.+Khanauthor=S.+A.+Alrokayan&title=Glutathione+Replenishing+Potential+of+Ceo2+Nanoparticles+in+Human+Breast+and+Fibrosarcoma+Cells&doi=10.1016%2Fj.jcis.2015.04.049"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.jcis.2015.04.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jcis.2015.04.049%26sid%3Dliteratum%253Aachs%26aulast%3DAkhtar%26aufirst%3DM.%2BJ.%26aulast%3DAhamed%26aufirst%3DM.%26aulast%3DAlhadlaq%26aufirst%3DH.%2BA.%26aulast%3DKhan%26aufirst%3DM.%2BM.%26aulast%3DAlrokayan%26aufirst%3DS.%2BA.%26atitle%3DGlutathione%2520Replenishing%2520Potential%2520of%2520Ceo2%2520Nanoparticles%2520in%2520Human%2520Breast%2520and%2520Fibrosarcoma%2520Cells%26jtitle%3DJ.%2520Colloid%2520Interface%2520Sci.%26date%3D2015%26volume%3D453%26spage%3D21%26epage%3D27%26doi%3D10.1016%2Fj.jcis.2015.04.049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duan, Z.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Polymeric Nanoparticle-Based Delivery of Microrna-199a-3p Inhibits Proliferation and Growth of Osteosarcoma Cells</span>. <i>Int. J. Nanomed.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">2913</span>– <span class="NLM_lpage">2924</span>, <span class="refDoi"> DOI: 10.2147/IJN.S79143</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.2147%2FIJN.S79143" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=25931818" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=1%3ACAS%3A528%3ADC%252BC2MXotVyltrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=2913-2924&author=Z.+Duan&title=Polymeric+Nanoparticle-Based+Delivery+of+Microrna-199a-3p+Inhibits+Proliferation+and+Growth+of+Osteosarcoma+Cells&doi=10.2147%2FIJN.S79143"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Polymeric nanoparticle-based delivery of microRNA-199a-3p inhibits proliferation and growth of osteosarcoma cells</span></div><div class="casAuthors">Zhang, Linlin; Iyer, Arun K.; Yang, Xiaoqian; Kobayashi, Eisuke; Guo, Yuqi; Mankin, Henry; Hornicek, Francis J.; Amiji, Mansoor M.; Duan, Zhenfeng</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Nanomedicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2913-2924</span>CODEN:
                <span class="NLM_cas:coden">IJNNHQ</span>;
        ISSN:<span class="NLM_cas:issn">1178-2013</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Our prior screening of microRNAs (miRs) identified that miR-199a-3p expression is reduced in osteosarcoma cells, one of the most common types of bone tumor.  MiR-199a-3p exhibited functions of tumor cell growth inhibition, suggesting the potential application of miR-199a-3p as an anticancer agent.  In the study reported here, we designed and developed a lipid-modified dextran-based polymeric nanoparticle platform for encapsulation of miRs, and detd. the efficiency and efficacy of delivering miR-199a-3p into osteosarcoma cells.  In addn., another potent miR, let-7a, which also displayed tumor suppressive ability, was selected as a candidate miR for evaluation.  Fluorescence microscopy studies and real-time polymerase chain reaction results showed that dextran nanoparticles could deliver both miR-199a-3p and let-7a into osteosarcoma cell lines (KHOS and U-2OS) successfully.  Western blotting anal. and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays demonstrated that dextran nanoparticles loaded with miRs could efficiently downregulate the expression of target proteins and effectively inhibit the growth and proliferation of osteosarcoma cells.  These results demonstrate that a lipid-modified dextran-based polymeric nanoparticle platform may be an effective nonviral carrier for potential miR-based anticancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFuaSfnWjgtrVg90H21EOLACvtfcHk0ljHjR1HOhg63g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXotVyltrg%253D&md5=ee35fe68362839e254bc5782a7b2061e</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.2147%2FIJN.S79143&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FIJN.S79143%26sid%3Dliteratum%253Aachs%26aulast%3DDuan%26aufirst%3DZ.%26atitle%3DPolymeric%2520Nanoparticle-Based%2520Delivery%2520of%2520Microrna-199a-3p%2520Inhibits%2520Proliferation%2520and%2520Growth%2520of%2520Osteosarcoma%2520Cells%26jtitle%3DInt.%2520J.%2520Nanomed.%26date%3D2015%26volume%3D10%26spage%3D2913%26epage%3D2924%26doi%3D10.2147%2FIJN.S79143" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, X.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, S.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, M.</span></span> <span> </span><span class="NLM_article-title">Paclitaxel and Etoposide Co-Loaded Polymeric Nanoparticles for the Effective Combination Therapy Against Human Osteosarcoma</span>. <i>J. Nanobiotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">22</span>, <span class="refDoi"> DOI: 10.1186/s12951-015-0086-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1186%2Fs12951-015-0086-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=25880868" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=1%3ACAS%3A280%3ADC%252BC2MjltVOiug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2015&pages=22&author=B.+Wangauthor=X.-C.+Yuauthor=S.-F.+Xuauthor=M.+Xu&title=Paclitaxel+and+Etoposide+Co-Loaded+Polymeric+Nanoparticles+for+the+Effective+Combination+Therapy+Against+Human+Osteosarcoma&doi=10.1186%2Fs12951-015-0086-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Paclitaxel and etoposide co-loaded polymeric nanoparticles for the effective combination therapy against human osteosarcoma</span></div><div class="casAuthors">Wang Bing; Yu Xiu-Chun; Xu Song-Feng; Xu Ming</div><div class="citationInfo"><span class="NLM_cas:title">Journal of nanobiotechnology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">22</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The combination of chemotherapeutic drugs with different pharmacological action has emerged as a promising therapeutic strategy in the treatment of cancers.  Present study examines the antitumor potential of paclitaxel (PTX) and etoposide (ETP)-loaded PLGA nanoparticles for the treatment of osteosarcoma.  RESULTS:  The resulting drug-loaded PLGA NP exhibited a nanosize dimension with uniform spherical morphology.  The NP exhibited a sustained release profile for both PTX and ETP throughout the study period without any sign of initial burst release.  The combinational drug-loaded PLGA NP enhanced the cytotoxic effect in MG63 and Saos-2 osteosarcoma cell lines, in comparison to either native drug alone or in cocktail combinations.  Additionally, NPs showed an appreciable uptake in MG63 cells in a time-based manner.  Co-delivery of anticancer drugs resulted in enhanced cell cycle arrest and cell apoptosis.  The results clearly showed that combinational drugs remarkably improved the therapeutic index of chemotherapeutic drugs.  The greater inhibitory effect of nanoparticle combination would be of great advantage during systemic cancer therapy.  CONCLUSION:  Taken together, our study demonstrated that PTX-ETP/PLGA NP based combination therapy holds significant potential towards the treatment of osteosarcoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQsFwAQGN_t4Djk2McQZ6XmfW6udTcc2eZNshoJNpy7kLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MjltVOiug%253D%253D&md5=52ac22c4313eb07722a594603602c25b</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1186%2Fs12951-015-0086-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12951-015-0086-4%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DB.%26aulast%3DYu%26aufirst%3DX.-C.%26aulast%3DXu%26aufirst%3DS.-F.%26aulast%3DXu%26aufirst%3DM.%26atitle%3DPaclitaxel%2520and%2520Etoposide%2520Co-Loaded%2520Polymeric%2520Nanoparticles%2520for%2520the%2520Effective%2520Combination%2520Therapy%2520Against%2520Human%2520Osteosarcoma%26jtitle%3DJ.%2520Nanobiotechnol.%26date%3D2015%26volume%3D13%26spage%3D22%26doi%3D10.1186%2Fs12951-015-0086-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wójcik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewandowski, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Król, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pawłowski, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mieczkowski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lechowski, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zabielska, K.</span></span> <span> </span><span class="NLM_article-title">Enhancing Anti-Tumor Efficacy of Doxorubicin by Non-Covalent Conjugation to Gold Nanoparticles - In Vitro Studies on Feline Fibrosarcoma Cell Lines</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>, <span class="NLM_elocation-id">e0124955</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0124955</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1371%2Fjournal.pone.0124955" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&author=M.+W%C3%B3jcikauthor=W.+Lewandowskiauthor=M.+Kr%C3%B3lauthor=K.+Paw%C5%82owskiauthor=J.+Mieczkowskiauthor=R.+Lechowskiauthor=K.+Zabielska&title=Enhancing+Anti-Tumor+Efficacy+of+Doxorubicin+by+Non-Covalent+Conjugation+to+Gold+Nanoparticles+-+In+Vitro+Studies+on+Feline+Fibrosarcoma+Cell+Lines&doi=10.1371%2Fjournal.pone.0124955"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0124955&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0124955%26sid%3Dliteratum%253Aachs%26aulast%3DW%25C3%25B3jcik%26aufirst%3DM.%26aulast%3DLewandowski%26aufirst%3DW.%26aulast%3DKr%25C3%25B3l%26aufirst%3DM.%26aulast%3DPaw%25C5%2582owski%26aufirst%3DK.%26aulast%3DMieczkowski%26aufirst%3DJ.%26aulast%3DLechowski%26aufirst%3DR.%26aulast%3DZabielska%26aufirst%3DK.%26atitle%3DEnhancing%2520Anti-Tumor%2520Efficacy%2520of%2520Doxorubicin%2520by%2520Non-Covalent%2520Conjugation%2520to%2520Gold%2520Nanoparticles%2520-%2520In%2520Vitro%2520Studies%2520on%2520Feline%2520Fibrosarcoma%2520Cell%2520Lines%26jtitle%3DPLoS%2520One%26date%3D2015%26volume%3D10%26doi%3D10.1371%2Fjournal.pone.0124955" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zabielska-Koczywąs, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wojtalewicz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lechowski, R.</span></span> <span> </span><span class="NLM_article-title">Current Knowledge on Feline Injection-Site Sarcoma Treatment</span>. <i>Acta Vet. Scand.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">47</span>, <span class="refDoi"> DOI: 10.1186/s13028-017-0315-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1186%2Fs13028-017-0315-y" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2017&pages=47&author=K.+Zabielska-Koczyw%C4%85sauthor=A.+Wojtalewiczauthor=R.+Lechowski&title=Current+Knowledge+on+Feline+Injection-Site+Sarcoma+Treatment&doi=10.1186%2Fs13028-017-0315-y"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1186%2Fs13028-017-0315-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13028-017-0315-y%26sid%3Dliteratum%253Aachs%26aulast%3DZabielska-Koczyw%25C4%2585s%26aufirst%3DK.%26aulast%3DWojtalewicz%26aufirst%3DA.%26aulast%3DLechowski%26aufirst%3DR.%26atitle%3DCurrent%2520Knowledge%2520on%2520Feline%2520Injection-Site%2520Sarcoma%2520Treatment%26jtitle%3DActa%2520Vet.%2520Scand.%26date%3D2017%26volume%3D59%26spage%3D47%26doi%3D10.1186%2Fs13028-017-0315-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Z.</span></span> <span> </span><span class="NLM_article-title">Poly(lactic-co-glycolic acid) Nanoparticles Conjugated with CD133 Aptamers for Targeted Salinomycin Delivery to CD133+ Osteosarcoma Cancer Stem Cells</span>. <i>Int. J. Nanomed.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">2537</span>, <span class="refDoi"> DOI: 10.2147/IJN.S78498</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.2147%2FIJN.S78498" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=25848270" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=1%3ACAS%3A528%3ADC%252BC2MXotVylt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=2537&author=M.+Niauthor=M.+Xiongauthor=X.+Zhangauthor=G.+Caiauthor=H.+Chenauthor=Q.+Zengauthor=Z.+Yu&title=Poly%28lactic-co-glycolic+acid%29+Nanoparticles+Conjugated+with+CD133+Aptamers+for+Targeted+Salinomycin+Delivery+to+CD133%2B+Osteosarcoma+Cancer+Stem+Cells&doi=10.2147%2FIJN.S78498"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Poly(lactic-co-glycolic acid) nanoparticles conjugated with CD133 aptamers for targeted salinomycin delivery to CD133+ osteosarcoma cancer stem cells</span></div><div class="casAuthors">Ni, Miaozhong; Xiong, Min; Zhang, Xinchao; Cai, Guoping; Chen, Huaiwen; Zeng, Qingmin; Yu, Zuochong</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Nanomedicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2537-2554</span>CODEN:
                <span class="NLM_cas:coden">IJNNHQ</span>;
        ISSN:<span class="NLM_cas:issn">1178-2013</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Background: Cancer stem cells (CSCs) possess the characteristics assocd. with normal stem cells and are responsible for cancer initiation, recurrence, and metastasis.  CD133 is regarded as a CSCs marker of osteosarcoma, which is the most common primary bone malignancy in childhood and adolescence.  Salinomycin, a polyether ionophore antibiotic, has been shown to kill various CSCs, including osteosarcoma CSCs.  However, salinomycin displayed poor aq. soly. that hinders its clin. application.  The objective of this study was to develop salinomycin-loaded nanoparticles to eliminate CD133+ osteosarcoma CSCs.  Methods: The salinomycin-loaded PEGylated poly(lactic-co-glycolic acid) nanoparticles (SAL-NP) conjugated with CD133 aptamers (Ap-SAL-NP) were developed by an emulsion/solvent evapn. method, and the targeting and cytotoxicity of Ap-SAL-NP to CD133+ osteosarcoma CSCs were evaluated.  Results: The nanoparticles are of desired particle size (∼150 nm), drug encapsulation efficiency (∼50%), and drug release profile.  After 48 h treatment of the Saos-2 CD133+ osteosarcoma cells with drugs formulated in Ap-SAL-NP, SAL-NP, and salinomycin, the concns. needed to kill 50% of the incubated cells were found to be 2.18, 10.72, and 5.07 μg/mL, resp., suggesting that Ap-SAL-NP could be 4.92 or 2.33 fold more effective than SAL-NP or salinomycin, resp.  In contrast, Ap-SAL-NP was as effective as SAL-NP, and less effective than salinomycin in Saos-2 CD133- cells, suggesting that Ap-SAL-NP possess specific cytotoxicity toward Saos-2 CD133+ cells.  Ap-SAL-NP showed the best therapeutic effect in Saos-2 osteosarcoma xenograft mice, compared with SAL-NP or salinomycin.  Significantly, Ap-SAL-NP could selectively kill CD133+ osteosarcoma CSCs both in vitro and in vivo, as reflected by the tumorsphere formation and proportion of Saos-2 CD133+ cells.  Conclusion: Our results suggest that CD133 is a potential target for drug delivery to osteosarcoma CSCs and that it is possible to significantly inhibit the osteosarcoma growth by killing CD133+ osteosarcoma CSCs.  We demonstrated that Ap-SAL-NP have the potential to target and kill CD133+ osteosarcoma CSCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGvATMB5n44rVg90H21EOLACvtfcHk0lgN-LuJtU169w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXotVylt7s%253D&md5=6243f2f8a5b11e454145c31684d1a1ed</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.2147%2FIJN.S78498&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FIJN.S78498%26sid%3Dliteratum%253Aachs%26aulast%3DNi%26aufirst%3DM.%26aulast%3DXiong%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DCai%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DZeng%26aufirst%3DQ.%26aulast%3DYu%26aufirst%3DZ.%26atitle%3DPoly%2528lactic-co-glycolic%2520acid%2529%2520Nanoparticles%2520Conjugated%2520with%2520CD133%2520Aptamers%2520for%2520Targeted%2520Salinomycin%2520Delivery%2520to%2520CD133%252B%2520Osteosarcoma%2520Cancer%2520Stem%2520Cells%26jtitle%3DInt.%2520J.%2520Nanomed.%26date%3D2015%26volume%3D10%26spage%3D2537%26doi%3D10.2147%2FIJN.S78498" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ling, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span> <span> </span><span class="NLM_article-title">Long-Circulating Iodinated Albumin-Gadolinium Nanoparticles as Enhanced Magnetic Resonance and Computed Tomography Imaging Probes for Osteosarcoma Visualization</span>. <i>Anal. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">4299</span>– <span class="NLM_lpage">4304</span>, <span class="refDoi"> DOI: 10.1021/ac504752a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ac504752a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2015&pages=4299-4304&author=Q.+Wangauthor=L.+Lvauthor=Z.+Lingauthor=Y.+Wangauthor=Y.+Liuauthor=L.+Liauthor=G.+Liuauthor=L.+Shenauthor=J.+Yanauthor=Y.+Wang&title=Long-Circulating+Iodinated+Albumin-Gadolinium+Nanoparticles+as+Enhanced+Magnetic+Resonance+and+Computed+Tomography+Imaging+Probes+for+Osteosarcoma+Visualization&doi=10.1021%2Fac504752a"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fac504752a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fac504752a%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DLv%26aufirst%3DL.%26aulast%3DLing%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DShen%26aufirst%3DL.%26aulast%3DYan%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DY.%26atitle%3DLong-Circulating%2520Iodinated%2520Albumin-Gadolinium%2520Nanoparticles%2520as%2520Enhanced%2520Magnetic%2520Resonance%2520and%2520Computed%2520Tomography%2520Imaging%2520Probes%2520for%2520Osteosarcoma%2520Visualization%26jtitle%3DAnal.%2520Chem.%26date%3D2015%26volume%3D87%26spage%3D4299%26epage%3D4304%26doi%3D10.1021%2Fac504752a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bertrand, J.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pioche-Durieu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ayala, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petit, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girard, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malvy, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Cam, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treussart, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnault, J.-C.</span></span> <span> </span><span class="NLM_article-title">Plasma Hydrogenated Cationic Detonation Nanodiamonds Efficiently Deliver to Human Cells in Culture Functional Sirna Targeting the Ewing Sarcoma Junction Oncogene</span>. <i>Biomaterials</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">93</span>– <span class="NLM_lpage">98</span>, <span class="refDoi"> DOI: 10.1016/j.biomaterials.2014.12.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1016%2Fj.biomaterials.2014.12.007" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2015&pages=93-98&author=J.-R.+Bertrandauthor=C.+Pioche-Durieuauthor=J.+Ayalaauthor=T.+Petitauthor=H.+A.+Girardauthor=C.+P.+Malvyauthor=E.+Le+Camauthor=F.+Treussartauthor=J.-C.+Arnault&title=Plasma+Hydrogenated+Cationic+Detonation+Nanodiamonds+Efficiently+Deliver+to+Human+Cells+in+Culture+Functional+Sirna+Targeting+the+Ewing+Sarcoma+Junction+Oncogene&doi=10.1016%2Fj.biomaterials.2014.12.007"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.biomaterials.2014.12.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biomaterials.2014.12.007%26sid%3Dliteratum%253Aachs%26aulast%3DBertrand%26aufirst%3DJ.-R.%26aulast%3DPioche-Durieu%26aufirst%3DC.%26aulast%3DAyala%26aufirst%3DJ.%26aulast%3DPetit%26aufirst%3DT.%26aulast%3DGirard%26aufirst%3DH.%2BA.%26aulast%3DMalvy%26aufirst%3DC.%2BP.%26aulast%3DLe%2BCam%26aufirst%3DE.%26aulast%3DTreussart%26aufirst%3DF.%26aulast%3DArnault%26aufirst%3DJ.-C.%26atitle%3DPlasma%2520Hydrogenated%2520Cationic%2520Detonation%2520Nanodiamonds%2520Efficiently%2520Deliver%2520to%2520Human%2520Cells%2520in%2520Culture%2520Functional%2520Sirna%2520Targeting%2520the%2520Ewing%2520Sarcoma%2520Junction%2520Oncogene%26jtitle%3DBiomaterials%26date%3D2015%26volume%3D45%26spage%3D93%26epage%3D98%26doi%3D10.1016%2Fj.biomaterials.2014.12.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Altucci, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gronemeyer, H.</span></span> <span> </span><span class="NLM_article-title">The Promise of Retinoids to Fight Against Cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">181</span>– <span class="NLM_lpage">193</span>, <span class="refDoi"> DOI: 10.1038/35106036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1038%2F35106036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=11902573" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=1%3ACAS%3A528%3ADC%252BD38XlvF2qtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2001&pages=181-193&author=L.+Altucciauthor=H.+Gronemeyer&title=The+Promise+of+Retinoids+to+Fight+Against+Cancer&doi=10.1038%2F35106036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">The promise of retinoids to fight against cancer</span></div><div class="casAuthors">Altucci, Lucia; Gronemeyer, Hinrich</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">181-193</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Retinoids have a reputation for being both detrimental and beneficial: they are teratogens, but they also have tumor-suppressive capacity.  Cell biol. and genetics have significantly improved our understanding of the mechanisms that underlie the anti-proliferative action of retinoids.  Recent elucidation of the pathways that are activated by retinoids will help us to exploit the beneficial aspects of this powerful class of compds. for cancer therapy and prevention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmzWqVZp9bDbVg90H21EOLACvtfcHk0lg-l4NToUmWng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlvF2qtrw%253D&md5=d0c150df52bfb7f7e283e5bd660ccdff</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1038%2F35106036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35106036%26sid%3Dliteratum%253Aachs%26aulast%3DAltucci%26aufirst%3DL.%26aulast%3DGronemeyer%26aufirst%3DH.%26atitle%3DThe%2520Promise%2520of%2520Retinoids%2520to%2520Fight%2520Against%2520Cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2001%26volume%3D1%26spage%3D181%26epage%3D193%26doi%3D10.1038%2F35106036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Klopper, J.
P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berenz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hays, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pugazhenthi, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Said, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haugen, B. R.</span></span> <span> </span><span class="NLM_article-title">Retinoid and Thiazolidinedione Therapies in Melanoma: An Analysis of Differential Response Based on Nuclear Hormone Receptor Expression</span>. <i>Mol. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">16</span>, <span class="refDoi"> DOI: 10.1186/1476-4598-8-16</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1186%2F1476-4598-8-16" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=19267912" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=1%3ACAS%3A280%3ADC%252BD1M3gvVSrug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=16&author=J.%0AP.+Klopperauthor=V.+Sharmaauthor=A.+Berenzauthor=W.+R.+Haysauthor=M.+Loiauthor=U.+Pugazhenthiauthor=S.+Saidauthor=B.+R.+Haugen&title=Retinoid+and+Thiazolidinedione+Therapies+in+Melanoma%3A+An+Analysis+of+Differential+Response+Based+on+Nuclear+Hormone+Receptor+Expression&doi=10.1186%2F1476-4598-8-16"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Retinoid and thiazolidinedione therapies in melanoma: an analysis of differential response based on nuclear hormone receptor expression</span></div><div class="casAuthors">Klopper Joshua P; Sharma Vibha; Berenz Andrew; Hays William R; Loi Michele; Pugazhenthi Umarani; Said Sherif; Haugen Bryan R</div><div class="citationInfo"><span class="NLM_cas:title">Molecular cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">16</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Metastatic melanoma has a high mortality rate and suboptimal therapeutic options.  Molecular targeting may be beneficial using the rexinoid LGD1069, a retinoid x receptor selective agonist, and thiazolidinediones (TZD), PPARgamma selective ligands, as novel treatments.  RESULTS:  Mouse xenograft models with human melanoma cell lines [A375(DRO) or M14(5-16)] were treated for 4 weeks with daily vehicle, RXR agonist (rexinoid, LGD1069, 30 mg/kg/d), PPARgamma agonist (TZD, rosiglitazone, 10 mg/kg/d) or combination.  A375(DRO) tumor growth was significantly inhibited by either ligand alone and the combination had an additive effect.  M14(5-16) tumors only responded to LGD1069 100 mg/kg/day.  A375(DRO) sublines resistant to rexinoid, TZD and combination were generated and all three sublines had reduced PPARgamma expression but preserved RXR expression. shRNA knockdown of PPARgamma or RXRgamma attenuated the rexinoid, TZD and combination ligand-mediated decreased proliferation in A375(DRO) cells.  Rexinoid (LGD1069) and retinoid (TTNPB) treatment of M14(5-16) cells resulted in decreased proliferation that was additive with combination of both rexinoid and retinoid. shRNA knockdown of RXRgamma resulted in a decreased response to either ligand.  CONCLUSION:  A375 (DRO) melanoma cell growth is inhibited by rexinoid and TZD treatment, and this response is dependent on RXR and PPARgamma receptor expression.  M14 (5-16) melanoma cell growth is inhibited by rexinoid and retinoid treatment, and this response is dependent on RXR expression.  These findings may help guide molecular-based treatment strategies in melanoma and provide insight for mechanisms of resistance to nuclear receptor targeted therapies in certain cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSChxG7abhlkP3jf77P2BG3fW6udTcc2eb8B1wJr-9ksbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1M3gvVSrug%253D%253D&md5=4285b5c8dd43b1132d3dd64c5f25219e</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1186%2F1476-4598-8-16&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1476-4598-8-16%26sid%3Dliteratum%253Aachs%26aulast%3DKlopper%26aufirst%3DJ.%2BP.%26aulast%3DSharma%26aufirst%3DV.%26aulast%3DBerenz%26aufirst%3DA.%26aulast%3DHays%26aufirst%3DW.%2BR.%26aulast%3DLoi%26aufirst%3DM.%26aulast%3DPugazhenthi%26aufirst%3DU.%26aulast%3DSaid%26aufirst%3DS.%26aulast%3DHaugen%26aufirst%3DB.%2BR.%26atitle%3DRetinoid%2520and%2520Thiazolidinedione%2520Therapies%2520in%2520Melanoma%253A%2520An%2520Analysis%2520of%2520Differential%2520Response%2520Based%2520on%2520Nuclear%2520Hormone%2520Receptor%2520Expression%26jtitle%3DMol.%2520Cancer%26date%3D2009%26volume%3D8%26spage%3D16%26doi%3D10.1186%2F1476-4598-8-16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mohan, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aherne, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baird, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winter, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, E. P.</span></span> <span> </span><span class="NLM_article-title">Molecular Pathways: The Role of NR4A Orphan Nuclear Receptors in Cancer</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">3223</span>– <span class="NLM_lpage">3228</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-11-2953</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1158%2F1078-0432.CCR-11-2953" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=22566377" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=1%3ACAS%3A528%3ADC%252BC38Xos1OltL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=3223-3228&author=H.+M.+Mohanauthor=C.+M.+Aherneauthor=A.+C.+Rogersauthor=A.+W.+Bairdauthor=D.+C.+Winterauthor=E.+P.+Murphy&title=Molecular+Pathways%3A+The+Role+of+NR4A+Orphan+Nuclear+Receptors+in+Cancer&doi=10.1158%2F1078-0432.CCR-11-2953"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Pathways: The Role of NR4A Orphan Nuclear Receptors in Cancer</span></div><div class="casAuthors">Mohan, Helen M.; Aherne, Carol M.; Rogers, Ailin C.; Baird, Alan W.; Winter, Des C.; Murphy, Evelyn P.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3223-3228</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Nuclear receptors are of integral importance in carcinogenesis.  Manipulation of classic ligand-activated nuclear receptors, such as estrogen receptor blockade in breast cancer, is an important established cancer therapy.  Orphan nuclear receptors, such as nuclear family 4 subgroup A (NR4A) receptors, have no known natural ligand(s).  These elusive receptors are increasingly recognized as mol. switches in cell survival and a mol. link between inflammation and cancer.  NR4A receptors act as transcription factors, altering expression of downstream genes in apoptosis (Fas-ligand, TRAIL), proliferation, DNA repair, metab., cell migration, inflammation (interleukin-8), and angiogenesis (VEGF).  NR4A receptors are modulated by multiple cell-signaling pathways, including protein kinase A/CREB, NF-κB, phosphoinositide 3-kinase/AKT, c-jun-NH2-kinase, Wnt, and mitogen-activated protein kinase pathways.  NR4A receptor effects are context and tissue specific, influenced by their levels of expression, posttranslational modification, and interaction with other transcription factors (RXR, PPAR-Υ).  The subcellular location of NR4A "nuclear receptors" is also important functionally; novel roles have been described in the cytoplasm where NR4A proteins act both indirectly and directly on the mitochondria to promote apoptosis via Bcl-2.  NR4A receptors are implicated in a wide variety of malignancies, including breast, lung, colon, bladder, and prostate cancer; glioblastoma multiforme; sarcoma; and acute and/or chronic myeloid leukemia.  NR4A receptors modulate response to conventional chemotherapy and represent an exciting frontier for chemotherapeutic intervention, as novel agents targeting NR4A receptors have now been developed.  This review provides a concise clin. overview of current knowledge of NR4A signaling in cancer and the potential for therapeutic manipulation.  Clin Cancer Res; 18(12); 3223-8. ©2012 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqduV_DWcG-SbVg90H21EOLACvtfcHk0lg-l4NToUmWng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xos1OltL4%253D&md5=682575a12521bbfd252fcdb2c3c1f8fd</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-2953&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-2953%26sid%3Dliteratum%253Aachs%26aulast%3DMohan%26aufirst%3DH.%2BM.%26aulast%3DAherne%26aufirst%3DC.%2BM.%26aulast%3DRogers%26aufirst%3DA.%2BC.%26aulast%3DBaird%26aufirst%3DA.%2BW.%26aulast%3DWinter%26aufirst%3DD.%2BC.%26aulast%3DMurphy%26aufirst%3DE.%2BP.%26atitle%3DMolecular%2520Pathways%253A%2520The%2520Role%2520of%2520NR4A%2520Orphan%2520Nuclear%2520Receptors%2520in%2520Cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D3223%26epage%3D3228%26doi%3D10.1158%2F1078-0432.CCR-11-2953" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benchetrit, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bianchini, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michiels, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, N.</span></span> <span> </span><span class="NLM_article-title">Peroxisome Proliferator-Activated Receptor Β/Δ (Pparβ/Δ) is Highly Expressed in Liposarcoma and Promotes Migration and Proliferation</span>. <i>Journal of pathology</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>224</i></span>,  <span class="NLM_fpage">575</span>– <span class="NLM_lpage">588</span>, <span class="refDoi"> DOI: 10.1002/path.2910</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1002%2Fpath.2910" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=224&publication_year=2011&pages=575-588&author=K.+D.+Wagnerauthor=M.+Benchetritauthor=L.+Bianchiniauthor=J.+F.+Michielsauthor=N.+Wagner&title=Peroxisome+Proliferator-Activated+Receptor+%CE%92%2F%CE%94+%28Ppar%CE%B2%2F%CE%94%29+is+Highly+Expressed+in+Liposarcoma+and+Promotes+Migration+and+Proliferation&doi=10.1002%2Fpath.2910"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1002%2Fpath.2910&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpath.2910%26sid%3Dliteratum%253Aachs%26aulast%3DWagner%26aufirst%3DK.%2BD.%26aulast%3DBenchetrit%26aufirst%3DM.%26aulast%3DBianchini%26aufirst%3DL.%26aulast%3DMichiels%26aufirst%3DJ.%2BF.%26aulast%3DWagner%26aufirst%3DN.%26atitle%3DPeroxisome%2520Proliferator-Activated%2520Receptor%2520%25CE%2592%252F%25CE%2594%2520%2528Ppar%25CE%25B2%252F%25CE%2594%2529%2520is%2520Highly%2520Expressed%2520in%2520Liposarcoma%2520and%2520Promotes%2520Migration%2520and%2520Proliferation%26jtitle%3DJournal%2520of%2520pathology%26date%3D2011%26volume%3D224%26spage%3D575%26epage%3D588%26doi%3D10.1002%2Fpath.2910" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gallagher, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keighley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tancabelic, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garimella, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Templeton, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tawfik, O.</span></span> <span> </span><span class="NLM_article-title">Clinicopathologic Correlation of Vitamin D Receptor Expression with Retinoid X Receptor and MIB-1 Expression in Primary and Metastatic Osteosarcoma</span>. <i>Ann. Diagn. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">323</span>– <span class="NLM_lpage">329</span>, <span class="refDoi"> DOI: 10.1016/j.anndiagpath.2012.01.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1016%2Fj.anndiagpath.2012.01.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=22542077" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=1%3ACAS%3A280%3ADC%252BC38rovVensg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2012&pages=323-329&author=R.+Gallagherauthor=J.+Keighleyauthor=J.+Tancabelicauthor=R.+Garimellaauthor=D.+Pinsonauthor=K.+Templetonauthor=O.+Tawfik&title=Clinicopathologic+Correlation+of+Vitamin+D+Receptor+Expression+with+Retinoid+X+Receptor+and+MIB-1+Expression+in+Primary+and+Metastatic+Osteosarcoma&doi=10.1016%2Fj.anndiagpath.2012.01.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Clinicopathologic correlation of vitamin D receptor expression with retinoid X receptor and MIB-1 expression in primary and metastatic osteosarcoma</span></div><div class="casAuthors">Gallagher Ryan; Keighley John; Tancabelic Jakica; Garimella Rama; Pinson David; Templeton Kimberly; Tawfik Ossama</div><div class="citationInfo"><span class="NLM_cas:title">Annals of diagnostic pathology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">323-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Vitamin D, in addition to its effects on bone, is important in cell cycle regulation.  Vitamin D receptor (VDR) has been identified in breast, prostate, and colon cancers, as well as in canine and human osteosarcoma (OS) cell lines; however, it has not been well investigated in human OS-archived specimens.  We correlated VDR, retinoid X receptor (RXR), and MIB-1 (Ki-67) expression in 110 archived OS cases with several clinicopathologic parameters including patient's age, sex, tumor location, tumor grade, and type and metastatic status.  The expression of VDR and RXR was identified in human OS tissue obtained from primary and metastatic OS archival tissue.  No statistically significant difference was found in VDR expression in relation with tumor grade, type, age, sex, or location.  The expression of RXR was highest in higher-grade (P = .0006) and metastatic tumors but remained unchanged when correlated with tumor type, age, sex, or location.  The expression of MIB-1 was statistically elevated in higher-grade tumors (P = .001), patients 25 years or younger (P = .04), tumors located in extremities (P = .005), and metastatic lesions, but was not impacted by tumor type or patient's sex.  Proliferative activity was significantly reduced after treatment, as the mean MIB-1 expression dropped from 11% in primary biopsy samples to 6% in resection specimens.  There appears to be a relationship between proliferative tumor activity and tumor grade, location, and metastasis.  Additional studies on the analysis of the effects of vitamin D and RXR on OS proliferation, apoptosis, and differentiation are critical to further evaluate their potential role in OS treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTqdAtsrJvhRhWfpMXQLRstfW6udTcc2eZPtsJuouVPOLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38rovVensg%253D%253D&md5=a91754d560784e9e913f7cc47cb6b7a3</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.anndiagpath.2012.01.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.anndiagpath.2012.01.001%26sid%3Dliteratum%253Aachs%26aulast%3DGallagher%26aufirst%3DR.%26aulast%3DKeighley%26aufirst%3DJ.%26aulast%3DTancabelic%26aufirst%3DJ.%26aulast%3DGarimella%26aufirst%3DR.%26aulast%3DPinson%26aufirst%3DD.%26aulast%3DTempleton%26aufirst%3DK.%26aulast%3DTawfik%26aufirst%3DO.%26atitle%3DClinicopathologic%2520Correlation%2520of%2520Vitamin%2520D%2520Receptor%2520Expression%2520with%2520Retinoid%2520X%2520Receptor%2520and%2520MIB-1%2520Expression%2520in%2520Primary%2520and%2520Metastatic%2520Osteosarcoma%26jtitle%3DAnn.%2520Diagn.%2520Pathol.%26date%3D2012%26volume%3D16%26spage%3D323%26epage%3D329%26doi%3D10.1016%2Fj.anndiagpath.2012.01.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, B.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuo, G.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Q.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Synergistic Antitumor Effect of the Activated Ppargamma and Retinoid Receptors on Human Osteosarcoma</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">2235</span>– <span class="NLM_lpage">2245</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-09-2499</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1158%2F1078-0432.CCR-09-2499" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=20371684" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=1%3ACAS%3A528%3ADC%252BC3cXkslSmtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=2235-2245&author=B.-C.+Heauthor=L.+Chenauthor=G.-W.+Zuoauthor=W.+Zhangauthor=Y.+Biauthor=J.+Huangauthor=Y.+Wangauthor=W.+Jiangauthor=Q.+Luoauthor=Q.+Shi&title=Synergistic+Antitumor+Effect+of+the+Activated+Ppargamma+and+Retinoid+Receptors+on+Human+Osteosarcoma&doi=10.1158%2F1078-0432.CCR-09-2499"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Synergistic Antitumor Effect of the Activated PPARγ and Retinoid Receptors on Human Osteosarcoma</span></div><div class="casAuthors">He, Bai-Cheng; Chen, Liang; Zuo, Guo-Wei; Zhang, Wenli; Bi, Yang; Huang, Jiayi; Wang, Yi; Jiang, Wei; Luo, Qing; Shi, Qiong; Zhang, Bing-Qiang; Liu, Bo; Lei, Xia; Luo, Jinyong; Luo, Xiaoji; Wagner, Eric R.; Kim, Stephanie H.; He, Connie J.; Hu, Yawen; Shen, Jikun; Zhou, Qixin; Rastegar, Farbod; Deng, Zhong-Liang; Luu, Hue H.; He, Tong-Chuan; Haydon, Rex C.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2235-2245</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: Osteosarcoma is the most common primary malignancy of bone.  The long-term survival of osteosarcoma patients hinges on our ability to prevent and/or treat recurrent and metastatic lesions.  Here, we investigated the activation of peroxisome proliferator-activated receptor γ (PPARγ) and retinoid receptors as a means of differentiation therapy for human osteosarcoma.  Exptl. Design: We examd. the endogenous expression of PPARγ and retinoid receptors in a panel of osteosarcoma cells.  Ligands or adenovirus-mediated overexpression of these receptors were tested to inhibit proliferation and induce apoptosis of osteosarcoma cells.  Osteosarcoma cells overexpressing the receptors were introduced into an orthotopic tumor model.  The effect of these ligands on osteoblastic differentiation was further investigated.  RESULTS: Endogenous expression of PPARγ and isotypes of retinoic acid receptor (RAR) and retinoid X receptor (RXR) is detected in most osteosarcoma cells.  Troglitazone, 9-cis retinoic acid (RA), and all-trans RA, as well as overexpression of PPARγ, RARα, and RXRα, inhibit osteosarcoma cell proliferation and induce apoptosis.  A synergistic inhibitory effect on osteosarcoma cell proliferation is obsd. between troglitazone and retinoids, as well as with the overexpression pairs of PPARγ/RARα, or PPARγ/RXRα.  Overexpression of PPARγ, RARα, RXRα, or in combinations inhibits osteosarcoma tumor growth and cell proliferation in vivo.  Retinoids (and to a lesser extent, troglitazone) are shown to promote osteogenic differentiation of osteosarcoma cells and mesenchymal stem cells.  CONCLUSIONS: Activation of PPARγ, RARα, and RXRα may act synergistically on inhibiting osteosarcoma cell proliferation and tumor growth, which is at least partially mediated by promoting osteoblastic differentiation of osteosarcoma cells.  Clin Cancer Res; 16(8); 2235-45.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBTaI2YHJNArVg90H21EOLACvtfcHk0lhu3u0lltekVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXkslSmtbs%253D&md5=71632e7a8c14faa697c822f84bcfd8f8</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-09-2499&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-09-2499%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DB.-C.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DZuo%26aufirst%3DG.-W.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DBi%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DW.%26aulast%3DLuo%26aufirst%3DQ.%26aulast%3DShi%26aufirst%3DQ.%26atitle%3DSynergistic%2520Antitumor%2520Effect%2520of%2520the%2520Activated%2520Ppargamma%2520and%2520Retinoid%2520Receptors%2520on%2520Human%2520Osteosarcoma%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2010%26volume%3D16%26spage%3D2235%26epage%3D2245%26doi%3D10.1158%2F1078-0432.CCR-09-2499" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Querfeld, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagelli, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuzel, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guitart, J.</span></span> <span> </span><span class="NLM_article-title">Bexarotene in the Treatment of Cutaneous T-Cell Lymphoma</span>. <i>Expert Opin. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">907</span>– <span class="NLM_lpage">915</span>, <span class="refDoi"> DOI: 10.1517/14656566.7.7.907</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1517%2F14656566.7.7.907" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=16634713" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=1%3ACAS%3A528%3ADC%252BD28Xkt12hu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2006&pages=907-915&author=C.+Querfeldauthor=L.+V.+Nagelliauthor=S.+T.+Rosenauthor=T.+M.+Kuzelauthor=J.+Guitart&title=Bexarotene+in+the+Treatment+of+Cutaneous+T-Cell+Lymphoma&doi=10.1517%2F14656566.7.7.907"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Bexarotene in the treatment of cutaneous T-cell lymphoma</span></div><div class="casAuthors">Querfeld, Christiane; Nagelli, Lakshmi V.; Rosen, Steven T.; Kuzel, Timothy M.; Guitart, Joan</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">907-915</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Primary cutaneous T-cell lymphomas encompass a spectrum of non-Hodgkin's lymphomas that are characterized by clonal proliferation of skin-homing malignant T lymphocytes.  Mycosis fungoides and the leukemic variant Sezary syndrome, collectively referred to as cutaneous T-cell lymphomas, are the most common entities.  No curative therapy exists and patients ultimately develop advanced or relapsed disease that is refractory to std. treatment options.  Therefore, there is a great need for the development of novel emerging therapies.  Bexarotene is the first synthetic nuclear retinoid X receptor-selective retinoid approved by the FDA for the treatment of refractory cutaneous T-cell lymphoma in all stages, as both an oral capsule and a topical gel formulation.  Bexarotene was found to induce apoptosis in a variety of preclin. in vitro and in vivo models including cutaneous T-cell lymphoma cells, and has shown efficacy in two multi-center, open-label Phase II - III clin. trials for early and advanced stages of cutaneous T-cell lymphoma in patients who have failed or were refractory to std. therapies.  New insights into the immunomodulatory function of bexarotene have indicated opportunities for combined treatment with IFN-α, denileukin diftitox or phototherapy.  This article reviews the biol. properties, pharmacokinetics, clin. efficacy, safety and role of bexarotene in the treatment of cutaneous T-cell lymphoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAVJxHGrgWcbVg90H21EOLACvtfcHk0lhpbWFJz9nK6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xkt12hu7c%253D&md5=8034a83261443a60bed1982005411d68</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1517%2F14656566.7.7.907&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14656566.7.7.907%26sid%3Dliteratum%253Aachs%26aulast%3DQuerfeld%26aufirst%3DC.%26aulast%3DNagelli%26aufirst%3DL.%2BV.%26aulast%3DRosen%26aufirst%3DS.%2BT.%26aulast%3DKuzel%26aufirst%3DT.%2BM.%26aulast%3DGuitart%26aufirst%3DJ.%26atitle%3DBexarotene%2520in%2520the%2520Treatment%2520of%2520Cutaneous%2520T-Cell%2520Lymphoma%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2006%26volume%3D7%26spage%3D907%26epage%3D915%26doi%3D10.1517%2F14656566.7.7.907" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michaels, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheinfeld, N.</span></span> <span> </span><span class="NLM_article-title">Alitretinoin: A Comprehensive Review</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">437</span>– <span class="NLM_lpage">443</span>, <span class="refDoi"> DOI: 10.1517/13543784.17.3.437</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1517%2F13543784.17.3.437" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2008&pages=437-443&author=C.+Chengauthor=J.+Michaelsauthor=N.+Scheinfeld&title=Alitretinoin%3A+A+Comprehensive+Review&doi=10.1517%2F13543784.17.3.437"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1517%2F13543784.17.3.437&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.17.3.437%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DC.%26aulast%3DMichaels%26aufirst%3DJ.%26aulast%3DScheinfeld%26aufirst%3DN.%26atitle%3DAlitretinoin%253A%2520A%2520Comprehensive%2520Review%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2008%26volume%3D17%26spage%3D437%26epage%3D443%26doi%3D10.1517%2F13543784.17.3.437" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haydon, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breyer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peabody, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montag, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simon, M. A.</span></span> <span> </span><span class="NLM_article-title">Nuclear Receptor Agonists as Potential Differentiation Therapy Agents for Human Osteosarcoma</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1288</span>– <span class="NLM_lpage">1294</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=12006550" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=1%3ACAS%3A528%3ADC%252BD38XksVWjs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2002&pages=1288-1294&author=R.+C.+Haydonauthor=L.+Zhouauthor=T.+Fengauthor=B.+Breyerauthor=H.+Chengauthor=W.+Jiangauthor=A.+Ishikawaauthor=T.+Peabodyauthor=A.+Montagauthor=M.+A.+Simon&title=Nuclear+Receptor+Agonists+as+Potential+Differentiation+Therapy+Agents+for+Human+Osteosarcoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Nuclear receptor agonists as potential differentiation therapy agents for human osteosarcoma</span></div><div class="casAuthors">Haydon, Rex C.; Zhou, Lan; Feng, Tao; Breyer, Benjamin; Cheng, Hongwei; Jiang, Wei; Ishikawa, Akira; Peabody, Terrance; Montag, Anthony; Simon, Michael A.; He, Tong-Chuan</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1288-1294</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">This study was designed to investigate whether nuclear receptor agonists can be used as potential differentiation therapy agents for human osteosarcoma.  Four osteosarcoma cell lines (143B, MNNG/HOS; MG-63; and TE-85) were treated with proliferator-activated receptor. (PPAR)-γ agonists, troglitazone and ciglitazone, and a retinoid X receptor (RXR) ligand; 9-cis retinoic acid.  The proliferation and induction of apoptosis in the treated cells were assessed, as was the induction of alk. phosphatase, a differentiation marker of osteoblasts.  The expression of PPARγ was readily detected in all tested osteosarcoma lines.  On treatment with the PPARγ and RXR ligands, all four osteosarcoma lines exhibited a significantly reduced proliferation rate and cell viability.  Among the four lines; 143B and MNNG/HOS were shown to be more sensitive to ligand-induced apoptosis, as demonstrated by the Crystal Violet and Hoechst staining assays.  Of the three tested ligands, troglitazone was shown to be the most effective in inducing cell death, followed by 9-cis retinoic acid.  Moreover, a strong synergistic effect on the induction of cell death was obsd. when both troglitazone and 9-cis retinoic-acid or ciglitazone and 9-cis retinoic acid were administered to osteosarcoma cells.  Troglitazone was shown to effectively induce alk. phosphatase activity, a well-characterized-hallmark for osteoblastic differentiation.  Our findings suggest that PPARγ and/or RXR ligands may be used as efficacious adjuvant therapeutic agents for primary osteosarcoma, as well as potential chemopreventive agents for preventing the recurrence and metastasis of osteosarcoma after the surgical removal of the primary tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrY6HncZQjxr7Vg90H21EOLACvtfcHk0lhpbWFJz9nK6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XksVWjs7s%253D&md5=2d48a0a4171364e3e55252a97328edec</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHaydon%26aufirst%3DR.%2BC.%26aulast%3DZhou%26aufirst%3DL.%26aulast%3DFeng%26aufirst%3DT.%26aulast%3DBreyer%26aufirst%3DB.%26aulast%3DCheng%26aufirst%3DH.%26aulast%3DJiang%26aufirst%3DW.%26aulast%3DIshikawa%26aufirst%3DA.%26aulast%3DPeabody%26aufirst%3DT.%26aulast%3DMontag%26aufirst%3DA.%26aulast%3DSimon%26aufirst%3DM.%2BA.%26atitle%3DNuclear%2520Receptor%2520Agonists%2520as%2520Potential%2520Differentiation%2520Therapy%2520Agents%2520for%2520Human%2520Osteosarcoma%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2002%26volume%3D8%26spage%3D1288%26epage%3D1294" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nagpal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masood, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, G. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friant, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandraratna, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gill, P. S.</span></span> <span> </span><span class="NLM_article-title">Retinoid Antagonism of NF-IL6: Insight into the Mechanism of Antiproliferative Effects of Retinoids in Kaposi’s Sarcoma</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">4159</span>– <span class="NLM_lpage">4168</span>, <span class="refDoi"> DOI: 10.1128/MCB.17.7.4159</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1128%2FMCB.17.7.4159" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=9199351" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=1%3ACAS%3A528%3ADyaK2sXktFOmtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1997&pages=4159-4168&author=S.+Nagpalauthor=J.+Caiauthor=T.+Zhengauthor=S.+Patelauthor=R.+Masoodauthor=G.+Y.+Linauthor=S.+Friantauthor=A.+Johnsonauthor=D.+L.+Smithauthor=R.+Chandraratnaauthor=P.+S.+Gill&title=Retinoid+Antagonism+of+NF-IL6%3A+Insight+into+the+Mechanism+of+Antiproliferative+Effects+of+Retinoids+in+Kaposi%E2%80%99s+Sarcoma&doi=10.1128%2FMCB.17.7.4159"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Retinoid antagonism of NF-IL6: insight into the mechanism of antiproliferative effects of retinoids in Kaposi's sarcoma</span></div><div class="casAuthors">Nagpal, Sunil; Cai, Jie; Zheng, Tong; Patel, Sheetal; Masood, Rizwan; Lin, George Y.; Friant, Sylvie; Johnson, Alan; Smith, D. Lynne; Chandraratna, Roshantha A. S.; Gill, Parkash S.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">4159-4168</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">All-trans-retinoic acid (RA) is active in the treatment of Kaposi's sarcoma (KS), and retinoids inhibit KS cell growth in vitro.  To understand the mechanism of retinoid action in KS, we studied the expression of autocrine growth factors of KS cells after RA treatment.  We demonstrate that RA and its synthetic analogs inhibit the proliferation of KS cells by inhibiting the mRNA and protein levels of interleukin-6 (IL-6), an autocrine growth factor for KS cells.  We further demonstrate that nuclear retinoid receptors (RA receptors [RARs] and retinoid receptors [RXRs]) inhibit IL-6 promoter action by antagonizing the enhancer action of NF-IL6, a basic domain leucine zipper transcription factor belonging to the family of CAAT enhancer binding proteins.  Furthermore, RARs and RXRs do not bind in vitro to an NF-IL6 binding site.  However, the secondary folded structure of the DNA binding domain of RAR and RXR is obligatory for inhibiting NF-IL6 activity.  Thus, NF-IL6 is a potential therapeutic target for the treatment of KS.  Finally, using receptor-selective synthetic retinoids, we demonstrate that NF-IL6 antagonism and transactivation are separable functions of RARα, thus indicating that synthetic retinoids with properties of NF-IL6 antagonism but lacking transactivation capabilities can be synthesized.  Such retinoids might increase therapeutic potential in KS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGHId7-xIvcLVg90H21EOLACvtfcHk0lhpbWFJz9nK6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXktFOmtrs%253D&md5=b032b416b9dd473b7c757f96f0ff5e59</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1128%2FMCB.17.7.4159&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.17.7.4159%26sid%3Dliteratum%253Aachs%26aulast%3DNagpal%26aufirst%3DS.%26aulast%3DCai%26aufirst%3DJ.%26aulast%3DZheng%26aufirst%3DT.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DMasood%26aufirst%3DR.%26aulast%3DLin%26aufirst%3DG.%2BY.%26aulast%3DFriant%26aufirst%3DS.%26aulast%3DJohnson%26aufirst%3DA.%26aulast%3DSmith%26aufirst%3DD.%2BL.%26aulast%3DChandraratna%26aufirst%3DR.%26aulast%3DGill%26aufirst%3DP.%2BS.%26atitle%3DRetinoid%2520Antagonism%2520of%2520NF-IL6%253A%2520Insight%2520into%2520the%2520Mechanism%2520of%2520Antiproliferative%2520Effects%2520of%2520Retinoids%2520in%2520Kaposi%25E2%2580%2599s%2520Sarcoma%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D1997%26volume%3D17%26spage%3D4159%26epage%3D4168%26doi%3D10.1128%2FMCB.17.7.4159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tontonoz, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forman, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarraf, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brun, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altiok, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oppenheim, H.</span></span> <span> </span><span class="NLM_article-title">Terminal Differentiation of Human Liposarcoma Cells Induced by Ligands for Peroxisome Proliferator-Activated Receptor Gamma and the Retinoid X Receptor</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>94</i></span>,  <span class="NLM_fpage">237</span>– <span class="NLM_lpage">241</span>, <span class="refDoi"> DOI: 10.1073/pnas.94.1.237</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1073%2Fpnas.94.1.237" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=1997&pages=237-241&author=P.+Tontonozauthor=S.+Singerauthor=B.+M.+Formanauthor=P.+Sarrafauthor=J.+A.+Fletcherauthor=C.+D.+Fletcherauthor=R.+P.+Brunauthor=E.+Muellerauthor=S.+Altiokauthor=H.+Oppenheim&title=Terminal+Differentiation+of+Human+Liposarcoma+Cells+Induced+by+Ligands+for+Peroxisome+Proliferator-Activated+Receptor+Gamma+and+the+Retinoid+X+Receptor&doi=10.1073%2Fpnas.94.1.237"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1073%2Fpnas.94.1.237&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.94.1.237%26sid%3Dliteratum%253Aachs%26aulast%3DTontonoz%26aufirst%3DP.%26aulast%3DSinger%26aufirst%3DS.%26aulast%3DForman%26aufirst%3DB.%2BM.%26aulast%3DSarraf%26aufirst%3DP.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26aulast%3DFletcher%26aufirst%3DC.%2BD.%26aulast%3DBrun%26aufirst%3DR.%2BP.%26aulast%3DMueller%26aufirst%3DE.%26aulast%3DAltiok%26aufirst%3DS.%26aulast%3DOppenheim%26aufirst%3DH.%26atitle%3DTerminal%2520Differentiation%2520of%2520Human%2520Liposarcoma%2520Cells%2520Induced%2520by%2520Ligands%2520for%2520Peroxisome%2520Proliferator-Activated%2520Receptor%2520Gamma%2520and%2520the%2520Retinoid%2520X%2520Receptor%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1997%26volume%3D94%26spage%3D237%26epage%3D241%26doi%3D10.1073%2Fpnas.94.1.237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Salbert, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fanjul, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piedrafita, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfahl, M.</span></span> <span> </span><span class="NLM_article-title">Retinoic Acid Receptors and Retinoid X Receptor-Alpha Down-Regulate the Transforming Growth Factor-Beta 1 Promoter by Antagonizing AP-1 Activity</span>. <i>Mol. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1347</span>– <span class="NLM_lpage">1356</span>, <span class="refDoi"> DOI: 10.1210/mend.7.10.8264664</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1210%2Fmend.7.10.8264664" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=8264664" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=1%3ACAS%3A528%3ADyaK2cXhtlKm" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1993&pages=1347-1356&author=G.+Salbertauthor=A.+Fanjulauthor=F.+J.+Piedrafitaauthor=X.+P.+Luauthor=S.-J.+Kimauthor=P.+Tranauthor=M.+Pfahl&title=Retinoic+Acid+Receptors+and+Retinoid+X+Receptor-Alpha+Down-Regulate+the+Transforming+Growth+Factor-Beta+1+Promoter+by+Antagonizing+AP-1+Activity&doi=10.1210%2Fmend.7.10.8264664"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Retinoic acid receptors and retinoid X receptor-α down-regulate the transforming growth factor-β1 promoter by antagonizing AP-1 activity</span></div><div class="casAuthors">Salbert, Gilles; Fanjul, Andrea; Piedrafita, F. Javier; Lu, Xian Ping; Kim, Seong Jin; Tran, Paul; Pfahl, Magnus</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Endocrinology</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1347-56</span>CODEN:
                <span class="NLM_cas:coden">MOENEN</span>;
        ISSN:<span class="NLM_cas:issn">0888-8809</span>.
    </div><div class="casAbstract">Overexpression of the multifunctional growth factor transforming growth factor-β1 (TGFβ1) has been connected to numerous diseases in human.  TGFβ1 expression is largely governed by three AP-1 binding sites located in two different promoters of this gene.  The authors have examd. the ability of retinoid receptors to inhibit the activity of the two promoters (esp. the promoter 1) by cotransfection assays in the hepatocellular carcinoma cell line HepG2.  When the TGFβ1 promoter activity is induced by 12-O-tetradecanoyl phorbol-13-acetate (an activator of AP-1-controlled gene transcription), this activity can be strongly repressed by retinoic acid receptor-α (RARα), RARβ, or retinoid X receptor-α (RXRα) as well as other members of the nuclear receptor family.  Repression was hormone dependent and a function of receptor concn.  Heterodimerization of RARα or RARβ with RXRα did not modify the inhibition activities of these receptors, indicating that heterodimer formation is not required for antagonizing of AP-1 activity.  On further examg. the anti-AP-1 activity of RXRα the authors obsd. that three different AP-1-controlled promoters (TGFβ1, collagenase, and cFos) can be inhibited.  Using gel shift assays, the authors demonstrated that RXRα inhibits Jun and Fos DNA binding and that 9-cis-RA enhances this inhibition, suggesting that a mechanism involving direct protein-protein interaction between RXR and AP-1 components mediates the inhibitory effect obsd. in vivo.  Transfection analyses with RXRα point mutations revealed that residues L422, C432, and, to a lesser extent, residues L418 and L430, are involved in ligand-induced anti-AP1 activity of RXRα in vivo.  Thus both types of retinoid receptors can inhibit AP-1-activated promoters, including the TGFβ1 gene promoter, via a mechanism that involves protein-protein interaction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXBKiJLDQPw7Vg90H21EOLACvtfcHk0lj3YiRW1aQUXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXhtlKm&md5=8c375ca6e8185972ad91e57dcf557d8b</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1210%2Fmend.7.10.8264664&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fmend.7.10.8264664%26sid%3Dliteratum%253Aachs%26aulast%3DSalbert%26aufirst%3DG.%26aulast%3DFanjul%26aufirst%3DA.%26aulast%3DPiedrafita%26aufirst%3DF.%2BJ.%26aulast%3DLu%26aufirst%3DX.%2BP.%26aulast%3DKim%26aufirst%3DS.-J.%26aulast%3DTran%26aufirst%3DP.%26aulast%3DPfahl%26aufirst%3DM.%26atitle%3DRetinoic%2520Acid%2520Receptors%2520and%2520Retinoid%2520X%2520Receptor-Alpha%2520Down-Regulate%2520the%2520Transforming%2520Growth%2520Factor-Beta%25201%2520Promoter%2520by%2520Antagonizing%2520AP-1%2520Activity%26jtitle%3DMol.%2520Endocrinol.%26date%3D1993%26volume%3D7%26spage%3D1347%26epage%3D1356%26doi%3D10.1210%2Fmend.7.10.8264664" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schook, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rund, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Begnini, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Remião, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seixas, F. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collares, T.</span></span> <span> </span><span class="NLM_article-title">Emerging Technologies to Create Inducible and Genetically Defined Porcine Cancer Models</span>. <i>Front. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">28</span>, <span class="refDoi"> DOI: 10.3389/fgene.2016.00028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.3389%2Ffgene.2016.00028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=26973698" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmvFKrtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=28&author=L.+B.+Schookauthor=L.+Rundauthor=K.+R.+Begniniauthor=M.+H.+Remi%C3%A3oauthor=F.+K.+Seixasauthor=T.+Collares&title=Emerging+Technologies+to+Create+Inducible+and+Genetically+Defined+Porcine+Cancer+Models&doi=10.3389%2Ffgene.2016.00028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging technologies to create inducible and genetically defined porcine cancer models</span></div><div class="casAuthors">Schook, Lawrence B.; Rund, Laurie; Begnini, Karine R.; Remiao, Mariana H.; Seixas, Fabiana K.; Collares, Tiago</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Genetics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">28/1-28/7</span>CODEN:
                <span class="NLM_cas:coden">FGREBR</span>;
        ISSN:<span class="NLM_cas:issn">1664-8021</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">There is an emerging need for new animal models that address unmet translational cancer research requirements.  Transgenic porcine models provide an exceptional opportunity due to their genetic, anat., and physiol. similarities with humans.  Due to recent advances in the sequencing of domestic animal genomes and the development of new organism cloning technologies, it is now very feasible to utilize pigs as a malleable species, with similar anat. and physiol. features with humans, in which to develop cancer models.  In this review, we discuss genetic modification technologies successfully used to produce porcine biomedical models, in particular the Cre-loxP System as well as major advances and perspectives the CRISPR/Cas9 System.  Recent advancements in porcine tumor modeling and genome editing will bring porcine models to the forefront of translational cancer research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpt3BQVu6i0_LVg90H21EOLACvtfcHk0lj3YiRW1aQUXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmvFKrtLc%253D&md5=ec2982695d12080a2d22fa00279d734d</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.3389%2Ffgene.2016.00028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffgene.2016.00028%26sid%3Dliteratum%253Aachs%26aulast%3DSchook%26aufirst%3DL.%2BB.%26aulast%3DRund%26aufirst%3DL.%26aulast%3DBegnini%26aufirst%3DK.%2BR.%26aulast%3DRemi%25C3%25A3o%26aufirst%3DM.%2BH.%26aulast%3DSeixas%26aufirst%3DF.%2BK.%26aulast%3DCollares%26aufirst%3DT.%26atitle%3DEmerging%2520Technologies%2520to%2520Create%2520Inducible%2520and%2520Genetically%2520Defined%2520Porcine%2520Cancer%2520Models%26jtitle%3DFront.%2520Genet.%26date%3D2016%26volume%3D7%26spage%3D28%26doi%3D10.3389%2Ffgene.2016.00028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schachtschneider, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madsen, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rund, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groenen, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schook, L. B.</span></span> <span> </span><span class="NLM_article-title">Adult Porcine Genome-Wide DNA Methylation Patterns Support Pigs as a Biomedical Model</span>. <i>BMC Genomics</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">743</span>, <span class="refDoi"> DOI: 10.1186/s12864-015-1938-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1186%2Fs12864-015-1938-x" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=743&author=K.+M.+Schachtschneiderauthor=O.+Madsenauthor=C.+Parkauthor=L.+A.+Rundauthor=M.+A.+Groenenauthor=L.+B.+Schook&title=Adult+Porcine+Genome-Wide+DNA+Methylation+Patterns+Support+Pigs+as+a+Biomedical+Model&doi=10.1186%2Fs12864-015-1938-x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1186%2Fs12864-015-1938-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12864-015-1938-x%26sid%3Dliteratum%253Aachs%26aulast%3DSchachtschneider%26aufirst%3DK.%2BM.%26aulast%3DMadsen%26aufirst%3DO.%26aulast%3DPark%26aufirst%3DC.%26aulast%3DRund%26aufirst%3DL.%2BA.%26aulast%3DGroenen%26aufirst%3DM.%2BA.%26aulast%3DSchook%26aufirst%3DL.%2BB.%26atitle%3DAdult%2520Porcine%2520Genome-Wide%2520DNA%2520Methylation%2520Patterns%2520Support%2520Pigs%2520as%2520a%2520Biomedical%2520Model%26jtitle%3DBMC%2520Genomics%26date%3D2015%26volume%3D16%26spage%3D743%26doi%3D10.1186%2Fs12864-015-1938-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schook, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collares, T. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodrigues, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rund, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schachtschneider, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seixas, F. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, K. D.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">A Genetic Porcine Model of Cancer</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>, <span class="NLM_elocation-id">e0128864</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0128864</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1371%2Fjournal.pone.0128864" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=26132737" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVSrtbvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&author=L.+B.+Schookauthor=T.+V.+Collaresauthor=W.+Huauthor=Y.+Liangauthor=F.+M.+Rodriguesauthor=L.+A.+Rundauthor=K.+M.+Schachtschneiderauthor=F.+K.+Seixasauthor=K.+Singhauthor=K.+D.+Wells&title=A+Genetic+Porcine+Model+of+Cancer&doi=10.1371%2Fjournal.pone.0128864"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">A genetic porcine model of cancer</span></div><div class="casAuthors">Schook, Lawrence B.; Collares, Tiago V.; Hu, Wenping; Liang, Ying; Rodrigues, Fernanda M.; Rund, Laurie A.; Schachtschneider, Kyle M.; Seixas, Fabiana K.; Singh, Kuldeep; Wells, Kevin D.; Walters, Eric M.; Prather, Randall S.; Counter, Christopher M.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">e0128864/1-e0128864/18</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">The large size of the pig and its similarity in anatomy, physiol., metab., and genetics to humans make it an ideal platform to develop a genetically defined, large animal model of cancer.  To this end, we created a transgenic "oncopig" line encoding Cre recombinase inducible porcine transgenes encoding KRASG12D and TP53R167H, which represent a commonly mutated oncogene and tumor suppressor in human cancers, resp.  Treatment of cells derived from these oncopigs with the adenovirus encoding Cre (AdCre) led to KRASG12D and TP53R167H expression, which rendered the cells transformed in culture and tumorigenic when engrafted into immunocompromised mice.  Finally, injection of AdCre directly into these oncopigs led to the rapid and reproducible tumor development of mesenchymal origin.  Transgenic animals receiving AdGFP (green fluorescent protein) did not have any tumor mass formation or altered histopathol.  This oncopig line could thus serve as a genetically malleable model for potentially a wide spectrum of cancers, while controlling for temporal or spatial genesis, which should prove invaluable to studies previously hampered by the lack of a large animal model of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOz8pzO1zIeLVg90H21EOLACvtfcHk0lgsFb7KImOh7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVSrtbvK&md5=38764903085778d6a194a879b735bfa2</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0128864&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0128864%26sid%3Dliteratum%253Aachs%26aulast%3DSchook%26aufirst%3DL.%2BB.%26aulast%3DCollares%26aufirst%3DT.%2BV.%26aulast%3DHu%26aufirst%3DW.%26aulast%3DLiang%26aufirst%3DY.%26aulast%3DRodrigues%26aufirst%3DF.%2BM.%26aulast%3DRund%26aufirst%3DL.%2BA.%26aulast%3DSchachtschneider%26aufirst%3DK.%2BM.%26aulast%3DSeixas%26aufirst%3DF.%2BK.%26aulast%3DSingh%26aufirst%3DK.%26aulast%3DWells%26aufirst%3DK.%2BD.%26atitle%3DA%2520Genetic%2520Porcine%2520Model%2520of%2520Cancer%26jtitle%3DPLoS%2520One%26date%3D2015%26volume%3D10%26doi%3D10.1371%2Fjournal.pone.0128864" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Misra, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, D.</span></span> <span> </span><span class="NLM_article-title">Defined Nanoscale Chemistry Influences Delivery of Peptidotoxins for Cancer Therapy</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>, <span class="NLM_elocation-id">e0125908</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0125908</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1371%2Fjournal.pone.0125908" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&author=S.+K.+Misraauthor=M.+Yeauthor=S.+Kimauthor=D.+Pan&title=Defined+Nanoscale+Chemistry+Influences+Delivery+of+Peptidotoxins+for+Cancer+Therapy&doi=10.1371%2Fjournal.pone.0125908"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0125908&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0125908%26sid%3Dliteratum%253Aachs%26aulast%3DMisra%26aufirst%3DS.%2BK.%26aulast%3DYe%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DPan%26aufirst%3DD.%26atitle%3DDefined%2520Nanoscale%2520Chemistry%2520Influences%2520Delivery%2520of%2520Peptidotoxins%2520for%2520Cancer%2520Therapy%26jtitle%3DPLoS%2520One%26date%3D2015%26volume%3D10%26doi%3D10.1371%2Fjournal.pone.0125908" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Misra, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, D.</span></span> <span> </span><span class="NLM_article-title">Enriched Inhibition of Cancer and Stem-Like Cancer Cells via STAT-3 Modulating Niclocelles</span>. <i>Nanoscale</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">7127</span>, <span class="refDoi"> DOI: 10.1039/C5NR00403A</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1039%2FC5NR00403A" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2015&pages=7127&author=S.+K.+Misraauthor=T.+W.+Jensenauthor=D.+Pan&title=Enriched+Inhibition+of+Cancer+and+Stem-Like+Cancer+Cells+via+STAT-3+Modulating+Niclocelles&doi=10.1039%2FC5NR00403A"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1039%2FC5NR00403A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC5NR00403A%26sid%3Dliteratum%253Aachs%26aulast%3DMisra%26aufirst%3DS.%2BK.%26aulast%3DJensen%26aufirst%3DT.%2BW.%26aulast%3DPan%26aufirst%3DD.%26atitle%3DEnriched%2520Inhibition%2520of%2520Cancer%2520and%2520Stem-Like%2520Cancer%2520Cells%2520via%2520STAT-3%2520Modulating%2520Niclocelles%26jtitle%3DNanoscale%26date%3D2015%26volume%3D7%26spage%3D7127%26doi%3D10.1039%2FC5NR00403A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Misra, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kus, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, D.</span></span> <span> </span><span class="NLM_article-title">Nanoscopic Poly-DNA-Cleaver for Breast Cancer Regression with Induced Oxidative Damage</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">4218</span>, <span class="refDoi"> DOI: 10.1021/mp500444c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp500444c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtl2gt7fE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2014&pages=4218&author=S.+K.+Misraauthor=J.+Kusauthor=S.+Kimauthor=D.+Pan&title=Nanoscopic+Poly-DNA-Cleaver+for+Breast+Cancer+Regression+with+Induced+Oxidative+Damage&doi=10.1021%2Fmp500444c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Nanoscopic Poly-DNA-Cleaver for Breast Cancer Regression with Induced Oxidative Damage</span></div><div class="casAuthors">Misra, Santosh K.; Kus, Joseph; Kim, Sumin; Pan, Dipanjan</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4218-4227</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel strategy for efficient "nanodelivery" of DNA-cleaving mols. for breast cancer regression is presented here.  The synthetic methodol. can be tweaked for controlled delivery and better bioavailability of EDs of these DNA-cleaving agents through a defined self-assembled polymeric nanoarchitecture.  In vitro studies in ER+ and ER- breast cancer human cell lines confirmed an efficient "nano"-delivery of DNA-cleaving mols. and indicated their capability to mediate oxidative damage to nucleobases and/or to the 2-deoxyribose moiety.  Prepd. E-poly-DNA-cleaver and C-poly-DNA-cleaver were found to be interacting with plasmid DNA pBR322 (pDNA) and active to cause oxidative cleavage of pDNA in the presence of ascorbic acid and H2O2.  They were found to be significantly active as DNA cleaving agents in vitro and showed highly improved cancer regression in MCF-7 and MD-MB231 cancer cells compared to small mol. DNA cleaver.  Surface conjugated nanoparticles were found to be more effective than noncovalent encapsulation and the small mol. agent, whereas in all the cases RCM was significantly inactive toward DNA cleavage.  Blood contact complement activation properties were evaluated to gauge their likelihood to promote acute toxicity following systemic administration.  The complement activation analyses together with the blood smear study confirm the feasibility of using these poly-DNA-cleavers without risk of induced immune response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLITqK6UGsv7Vg90H21EOLACvtfcHk0lgsFb7KImOh7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtl2gt7fE&md5=c7854be1785bdcfc550788da20777960</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Fmp500444c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp500444c%26sid%3Dliteratum%253Aachs%26aulast%3DMisra%26aufirst%3DS.%2BK.%26aulast%3DKus%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DPan%26aufirst%3DD.%26atitle%3DNanoscopic%2520Poly-DNA-Cleaver%2520for%2520Breast%2520Cancer%2520Regression%2520with%2520Induced%2520Oxidative%2520Damage%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2014%26volume%3D11%26spage%3D4218%26doi%3D10.1021%2Fmp500444c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Misra, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, D.</span></span> <span> </span><span class="NLM_article-title">Highly Efficient Anti-Cancer Therapy Using Scorpion ’NanoVenin’</span>. <i>Chem. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">13220</span>, <span class="refDoi"> DOI: 10.1039/C4CC04748F</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1039%2FC4CC04748F" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2014&pages=13220&author=S.+K.+Misraauthor=M.+Yeauthor=S.+Kimauthor=D.+Pan&title=Highly+Efficient+Anti-Cancer+Therapy+Using+Scorpion+%E2%80%99NanoVenin%E2%80%99&doi=10.1039%2FC4CC04748F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1039%2FC4CC04748F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC4CC04748F%26sid%3Dliteratum%253Aachs%26aulast%3DMisra%26aufirst%3DS.%2BK.%26aulast%3DYe%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DPan%26aufirst%3DD.%26atitle%3DHighly%2520Efficient%2520Anti-Cancer%2520Therapy%2520Using%2520Scorpion%2520%25E2%2580%2599NanoVenin%25E2%2580%2599%26jtitle%3DChem.%2520Commun.%26date%3D2014%26volume%3D50%26spage%3D13220%26doi%3D10.1039%2FC4CC04748F" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Misra, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghoshal, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gartia, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bromfield, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tangella, K. V.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Trimodal Therapy: Combining Hyperthermia with Repurposed Bexarotene and Ultrasound for Treating Liver Cancer</span>. <i>ACS Nano</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">10695</span>, <span class="refDoi"> DOI: 10.1021/acsnano.5b05974</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsnano.5b05974" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2015&pages=10695&author=S.+K.+Misraauthor=G.+Ghoshalauthor=M.+R.+Gartiaauthor=Z.+Wuauthor=A.+K.+Deauthor=M.+Yeauthor=C.+R.+Bromfieldauthor=E.+M.+Williamsauthor=K.+Singhauthor=K.+V.+Tangella&title=Trimodal+Therapy%3A+Combining+Hyperthermia+with+Repurposed+Bexarotene+and+Ultrasound+for+Treating+Liver+Cancer&doi=10.1021%2Facsnano.5b05974"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Facsnano.5b05974&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsnano.5b05974%26sid%3Dliteratum%253Aachs%26aulast%3DMisra%26aufirst%3DS.%2BK.%26aulast%3DGhoshal%26aufirst%3DG.%26aulast%3DGartia%26aufirst%3DM.%2BR.%26aulast%3DWu%26aufirst%3DZ.%26aulast%3DDe%26aufirst%3DA.%2BK.%26aulast%3DYe%26aufirst%3DM.%26aulast%3DBromfield%26aufirst%3DC.%2BR.%26aulast%3DWilliams%26aufirst%3DE.%2BM.%26aulast%3DSingh%26aufirst%3DK.%26aulast%3DTangella%26aufirst%3DK.%2BV.%26atitle%3DTrimodal%2520Therapy%253A%2520Combining%2520Hyperthermia%2520with%2520Repurposed%2520Bexarotene%2520and%2520Ultrasound%2520for%2520Treating%2520Liver%2520Cancer%26jtitle%3DACS%2520Nano%26date%3D2015%26volume%3D9%26spage%3D10695%26doi%3D10.1021%2Facsnano.5b05974" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Szebeni, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bedőcs, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rozsnyay, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiszhár, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urbanics, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosivall, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garbuzenko, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Báthori, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tóth, M.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Liposome-Induced Complement Activation and Related Cardiopulmonary Distress in Pigs: Factors Promoting Reactogenicity of Doxil and Ambisome</span>. <i>Nanomedicine</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">176</span>– <span class="NLM_lpage">184</span>, <span class="refDoi"> DOI: 10.1016/j.nano.2011.06.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1016%2Fj.nano.2011.06.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=21704590" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=1%3ACAS%3A528%3ADC%252BC38Xos12gsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2012&pages=176-184&author=J.+Szebeniauthor=P.+Bed%C5%91csauthor=Z.+Rozsnyayauthor=Z.+Weiszh%C3%A1rauthor=R.+Urbanicsauthor=L.+Rosivallauthor=R.+Cohenauthor=O.+Garbuzenkoauthor=G.+B%C3%A1thoriauthor=M.+T%C3%B3th&title=Liposome-Induced+Complement+Activation+and+Related+Cardiopulmonary+Distress+in+Pigs%3A+Factors+Promoting+Reactogenicity+of+Doxil+and+Ambisome&doi=10.1016%2Fj.nano.2011.06.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Liposome-induced complement activation and related cardiopulmonary distress in pigs: factors promoting reactogenicity of Doxil and AmBisome</span></div><div class="casAuthors">Szebeni, Janos; Bedocs, Peter; Rozsnyay, Zoltan; Weiszhar, Zsoka; Urbanics, Rudolf; Rosivall, Laszlo; Cohen, Rivka; Garbuzenko, Olga; Bathori, Gyoergy; Toth, Miklos; Buenger, Rolf; Barenholz, Yechezkel</div><div class="citationInfo"><span class="NLM_cas:title">Nanomedicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">176-184</span>CODEN:
                <span class="NLM_cas:coden">NANOBF</span>;
        ISSN:<span class="NLM_cas:issn">1549-9634</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Hypersensitivity reactions to liposomal drugs, often obsd. with Doxil and AmBisome, can arise from activation of the complement (C) system by phospholipid bilayers.  To understand the mechanism of this adverse immune reaction called C activation-related pseudoallergy (CARPA), we analyzed the relationship among liposome features, C activation in human serum in vitro, and liposome-induced cardiovascular distress in pigs, a model for human CARPA.  Among the structural variables (surface charge, presence of satd., unsatd., and PEGylated phospholipids, and cisplatin vs. doxorubicin inside liposomes), high neg. surface charge and the presence of doxorubicin were significant contributors to reactogenicity both in vitro and in vivo.  Morphol. anal. suggested that the effect of doxorubicin might be indirect, via distorting the sphericity of liposomes and, if leaked, causing aggregation.  The parallelism among C activation, cardiopulmonary reactions in pigs, and high rate of hypersensitivity reactions to Doxil and AmBisome in humans strengthens the utility of the applied tests in predicting the risk of CARPA.  From the Clin. Editor: The authors studied complement activation-related pseudoallergy (CARPA) in a porcine model and demonstrate that high neg. surface charge and drug effects leading to distortion of liposome sphericity might be the most crit. factors leading to CARPA.  The applied tests might be used to predict CARPA in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrx9nzjUZ7LrbVg90H21EOLACvtfcHk0lg_zcUGg9TzhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xos12gsg%253D%253D&md5=fdc3ede58cda2959a7f83e7daa82f0a6</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2Fj.nano.2011.06.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nano.2011.06.003%26sid%3Dliteratum%253Aachs%26aulast%3DSzebeni%26aufirst%3DJ.%26aulast%3DBed%25C5%2591cs%26aufirst%3DP.%26aulast%3DRozsnyay%26aufirst%3DZ.%26aulast%3DWeiszh%25C3%25A1r%26aufirst%3DZ.%26aulast%3DUrbanics%26aufirst%3DR.%26aulast%3DRosivall%26aufirst%3DL.%26aulast%3DCohen%26aufirst%3DR.%26aulast%3DGarbuzenko%26aufirst%3DO.%26aulast%3DB%25C3%25A1thori%26aufirst%3DG.%26aulast%3DT%25C3%25B3th%26aufirst%3DM.%26atitle%3DLiposome-Induced%2520Complement%2520Activation%2520and%2520Related%2520Cardiopulmonary%2520Distress%2520in%2520Pigs%253A%2520Factors%2520Promoting%2520Reactogenicity%2520of%2520Doxil%2520and%2520Ambisome%26jtitle%3DNanomedicine%26date%3D2012%26volume%3D8%26spage%3D176%26epage%3D184%26doi%3D10.1016%2Fj.nano.2011.06.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Edwardson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narendrula, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chewchuk, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mispel-Beyer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mapletoft, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parissenti, M.</span></span> <span> </span><span class="NLM_article-title">Role of Drug Metabolism in the Cytotoxicity and Clinical Efficacy of Anthracyclines</span>. <i>Curr. Drug Metab.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">412</span>– <span class="NLM_lpage">426</span>, <span class="refDoi"> DOI: 10.2174/1389200216888150915112039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.2174%2F1389200216888150915112039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=26321196" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1OntL7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=412-426&author=D.+Edwardsonauthor=R.+Narendrulaauthor=S.+Chewchukauthor=K.+Mispel-Beyerauthor=J.+Mapletoftauthor=M.+Parissenti&title=Role+of+Drug+Metabolism+in+the+Cytotoxicity+and+Clinical+Efficacy+of+Anthracyclines&doi=10.2174%2F1389200216888150915112039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Role of Drug Metabolism in the Cytotoxicity and Clinical Efficacy of Anthracyclines</span></div><div class="casAuthors">Edwardson, Derek W.; Narendrula, Rashmi; Chewchuk, Simon; Mispel-Beyer, Kyle; Mapletoft, Jonathan P. J.; Parissenti, Amadeo M.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">412-426</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>;
        ISSN:<span class="NLM_cas:issn">1389-2002</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Many clin. studies involving anti-tumor agents neglect to consider how these agents are metabolized within the host and whether the creation of specific metabolites alters drug therapeutic properties or toxic side effects.  However, this is not the case for the anthracycline class of chemotherapy drugs.  This review describes the various enzymes involved in the one electron (semi-quinone) or two electron (hydroxylation) redn. of anthracyclines, or in their reductive deglycosidation into deoxyaglycones.  The effects of these redns. on drug antitumor efficacy and toxic side effects are also discussed.  Current evidence suggests that the one electron redn. of anthracyclines augments both their tumor toxicity and their toxicity towards the host, in particular their cardiotoxicity.  In contrast, the two electron redn. (hydroxylation) of anthracyclines strongly reduces their ability to kill tumor cells, while augmenting cardiotoxicity through their accumulation within cardiomyocytes and their direct effects on excitation/contraction coupling within the myocytes.  The reductive deglycosidation of anthracyclines appears to inactivate the drug and only occurs under rare, anaerobic conditions.  This knowledge has resulted in the identification of important new approaches to improve the therapeutic index of anthracyclines, in particular by inhibiting their cardiotoxocity.  The true utility of these approaches in the management of cancer patients undergoing anthracycline-based chemotherapy remains unclear, although one such agent (the iron chelator dexrazoxane) has recently been approved for clin. use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooT776_1sdTLVg90H21EOLACvtfcHk0lg_zcUGg9TzhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1OntL7I&md5=c4461a532b86122b73084d23e226a854</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.2174%2F1389200216888150915112039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389200216888150915112039%26sid%3Dliteratum%253Aachs%26aulast%3DEdwardson%26aufirst%3DD.%26aulast%3DNarendrula%26aufirst%3DR.%26aulast%3DChewchuk%26aufirst%3DS.%26aulast%3DMispel-Beyer%26aufirst%3DK.%26aulast%3DMapletoft%26aufirst%3DJ.%26aulast%3DParissenti%26aufirst%3DM.%26atitle%3DRole%2520of%2520Drug%2520Metabolism%2520in%2520the%2520Cytotoxicity%2520and%2520Clinical%2520Efficacy%2520of%2520Anthracyclines%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2015%26volume%3D16%26spage%3D412%26epage%3D426%26doi%3D10.2174%2F1389200216888150915112039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gomez-Lechon, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castell, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donato, M. T.</span></span> <span> </span><span class="NLM_article-title">Hepatocytes--The Choice to Investigate Drug Metabolism and Toxicity in Man: In Vitro Variability as a Reflection of In Vivo</span>. <i>Chem.-Biol. Interact.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>168</i></span>,  <span class="NLM_fpage">30</span>– <span class="NLM_lpage">50</span>, <span class="refDoi"> DOI: 10.1016/j.cbi.2006.10.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1016%2Fj.cbi.2006.10.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=17134688" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=1%3ACAS%3A528%3ADC%252BD2sXkvFGlsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=168&publication_year=2007&pages=30-50&author=M.+J.+Gomez-Lechonauthor=J.+V.+Castellauthor=M.+T.+Donato&title=Hepatocytes%2D%2DThe+Choice+to+Investigate+Drug+Metabolism+and+Toxicity+in+Man%3A+In+Vitro+Variability+as+a+Reflection+of+In+Vivo&doi=10.1016%2Fj.cbi.2006.10.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatocytes-the choice to investigate drug metabolism and toxicity in man: In vitro variability as a reflection of in vivo</span></div><div class="casAuthors">Gomez-Lechon, Maria Jose; Castell, Jose Vicente; Donato, Maria Teresa</div><div class="citationInfo"><span class="NLM_cas:title">Chemico-Biological Interactions</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">168</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">30-50</span>CODEN:
                <span class="NLM_cas:coden">CBINA8</span>;
        ISSN:<span class="NLM_cas:issn">0009-2797</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">A review.  The pharmaceutical industry is committed to marketing safer drugs with fewer side effects, predictable pharmacokinetic properties and quantifiable drug-drug interactions.  Drug metab. is a major determinant of drug clearance and interindividual pharmacokinetic differences, and an indirect determinant of the clin. efficacy and toxicity of drugs.  Progressive advances in the knowledge of metabolic routes and enzymes responsible for drug biotransformation have contributed to understanding the great metabolic variations existing in human beings.  Phenotypic as well genotypic differences in the expression of the enzymes involved in drug metab. are the main causes of this variability.  However, only a minor part of phenotypic variability in man is attributable to gene polymorphisms, thus making the definition of a normal liver complex.  At present, the use of human in vitro hepatic models at early preclin. stages means that the process of selecting drug candidates is becoming much more rational.  Cultured human hepatocytes are considered to be the closest model to human liver.  However, the fact that hepatocytes are located in a microenvironment that differs from that of the cell in the liver raises the question: to what extent does drug metab. variability obsd. in vitro actually reflect that of the liver in vivo By comparing the metab. of a model compd. both in vitro and in vivo in the same individual, a good correlation between the in vitro and in vivo relative abundance of oxidized metabolites and the hydrolysis of the compd. was obsd.  Thus, it is reasonable to consider that the variability obsd. in human hepatocytes reflects the existing phenotypic heterogeneity of the P 450 expression in human liver.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvhJ2qFxCzGbVg90H21EOLACvtfcHk0lgEW9oGBcd8vQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXkvFGlsrc%253D&md5=bc5080c29e7129fc15dbc26d9527d4e3</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2Fj.cbi.2006.10.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbi.2006.10.013%26sid%3Dliteratum%253Aachs%26aulast%3DGomez-Lechon%26aufirst%3DM.%2BJ.%26aulast%3DCastell%26aufirst%3DJ.%2BV.%26aulast%3DDonato%26aufirst%3DM.%2BT.%26atitle%3DHepatocytes--The%2520Choice%2520to%2520Investigate%2520Drug%2520Metabolism%2520and%2520Toxicity%2520in%2520Man%253A%2520In%2520Vitro%2520Variability%2520as%2520a%2520Reflection%2520of%2520In%2520Vivo%26jtitle%3DChem.-Biol.%2520Interact.%26date%3D2007%26volume%3D168%26spage%3D30%26epage%3D50%26doi%3D10.1016%2Fj.cbi.2006.10.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Szotáková, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baliharová, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamka, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nožinová, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wsól, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velí, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Machala, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neča, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Souček, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Šusová, S.</span></span> <span> </span><span class="NLM_article-title">Comparison of In Vitro Activities of Biotransformation Enzymes in Pig, Cattle, Goat and Sheep</span>. <i>Res. Vet. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">43</span>– <span class="NLM_lpage">51</span>, <span class="refDoi"> DOI: 10.1016/S0034-5288(03)00143-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1016%2FS0034-5288%2803%2900143-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=14659728" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=1%3ACAS%3A528%3ADC%252BD3sXpsVSmtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2004&pages=43-51&author=B.+Szot%C3%A1kov%C3%A1author=V.+Baliharov%C3%A1author=J.+Lamkaauthor=E.+No%C5%BEinov%C3%A1author=V.+Ws%C3%B3lauthor=J.+Vel%C3%ADauthor=M.+Machalaauthor=J.+Ne%C4%8Daauthor=P.+Sou%C4%8Dekauthor=S.+%C5%A0usov%C3%A1&title=Comparison+of+In+Vitro+Activities+of+Biotransformation+Enzymes+in+Pig%2C+Cattle%2C+Goat+and+Sheep&doi=10.1016%2FS0034-5288%2803%2900143-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of in vitro activities of biotransformation enzymes in pig, cattle, goat and sheep</span></div><div class="casAuthors">Szotakova, B.; Baliharova, V.; Lamka, J.; Nozinova, E.; Wsol, V.; Velik, J.; Machala, M.; Neca, J.; Soucek, P.; Susova, S.; Skalova, L.</div><div class="citationInfo"><span class="NLM_cas:title">Research in Veterinary Science</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">43-51</span>CODEN:
                <span class="NLM_cas:coden">RVTSA9</span>;
        ISSN:<span class="NLM_cas:issn">0034-5288</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">In vitro activities of cytochromes P 450 (7-alkyl/aryloxyresorufin dealkyl(aryl)ases, testosterone hydroxylase/oxidase, 6-chlorzoxazone hydroxylase, 7-methoxy-4-trifluoromethyl-coumarin demethylase, and lauric acid hydroxylases), reductases of carbonyl group (toward metyrapone, daunorubicin, glyceraldehyde, and 4-pyridine-carboxaldehyde) and conjugation enzymes (p-nitrophenol-UDP-glucuronosyl transferase, 1-chloro-2,4-dinitrobenzene glutathione-S-transferase) in young adults, males, non-castrated (N=6) farm animals were studied and compared.  Presence of proteins cross-reacting with anti-human CYP3A4, CYP2C9, and CYP2E1 IgG was detected in all farm species.  Bovine microsomes differed from other microsomes of farm species in very high 7-ethoxyresorufin-O-deethylase activity (CYP1A1/2).  Significantly higher 7-methoxy-4-trifluoromethyl-coumarin demethylase (2-3 times) and 12-lauric acid hydroxylases (4-10 times) activities (probably corresponding to CYP2C and CYP4A, resp.) were found in ovine microsomes.  The highest 6β-testosterone hydroxylase activity, which is usually considered to be a CYP3A activity marker, was found in pig.  Reductases of all farm animals display considerable ability to reduce carbonyl group of xenobiotics.  Significant differences in level and activity of many biotransformation enzymes tested suggest that extrapolation of pharmacokinetic data obtained in one species to another (even related) could be misleading.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwA0Hh30F1NbVg90H21EOLACvtfcHk0lgEW9oGBcd8vQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXpsVSmtbg%253D&md5=05a8e17f6f6cbde39953ec2b8f02334f</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2FS0034-5288%2803%2900143-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0034-5288%252803%252900143-7%26sid%3Dliteratum%253Aachs%26aulast%3DSzot%25C3%25A1kov%25C3%25A1%26aufirst%3DB.%26aulast%3DBaliharov%25C3%25A1%26aufirst%3DV.%26aulast%3DLamka%26aufirst%3DJ.%26aulast%3DNo%25C5%25BEinov%25C3%25A1%26aufirst%3DE.%26aulast%3DWs%25C3%25B3l%26aufirst%3DV.%26aulast%3DVel%25C3%25AD%26aufirst%3DJ.%26aulast%3DMachala%26aufirst%3DM.%26aulast%3DNe%25C4%258Da%26aufirst%3DJ.%26aulast%3DSou%25C4%258Dek%26aufirst%3DP.%26aulast%3D%25C5%25A0usov%25C3%25A1%26aufirst%3DS.%26atitle%3DComparison%2520of%2520In%2520Vitro%2520Activities%2520of%2520Biotransformation%2520Enzymes%2520in%2520Pig%252C%2520Cattle%252C%2520Goat%2520and%2520Sheep%26jtitle%3DRes.%2520Vet.%2520Sci.%26date%3D2004%26volume%3D76%26spage%3D43%26epage%3D51%26doi%3D10.1016%2FS0034-5288%2803%2900143-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Achour, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barber, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rostami-Hodjegan, A.</span></span> <span> </span><span class="NLM_article-title">Cytochrome P450 Pig Liver Pie: Determination of Individual Cytochrome P450 Isoform Contents in Microsomes from Two Pig Livers Using Liquid Chromatography in Conjunction with Mass Spectrometry</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">2130</span>– <span class="NLM_lpage">2134</span>, <span class="refDoi"> DOI: 10.1124/dmd.111.040618</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1124%2Fdmd.111.040618" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2011&pages=2130-2134&author=B.+Achourauthor=J.+Barberauthor=A.+Rostami-Hodjegan&title=Cytochrome+P450+Pig+Liver+Pie%3A+Determination+of+Individual+Cytochrome+P450+Isoform+Contents+in+Microsomes+from+Two+Pig+Livers+Using+Liquid+Chromatography+in+Conjunction+with+Mass+Spectrometry&doi=10.1124%2Fdmd.111.040618"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1124%2Fdmd.111.040618&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.111.040618%26sid%3Dliteratum%253Aachs%26aulast%3DAchour%26aufirst%3DB.%26aulast%3DBarber%26aufirst%3DJ.%26aulast%3DRostami-Hodjegan%26aufirst%3DA.%26atitle%3DCytochrome%2520P450%2520Pig%2520Liver%2520Pie%253A%2520Determination%2520of%2520Individual%2520Cytochrome%2520P450%2520Isoform%2520Contents%2520in%2520Microsomes%2520from%2520Two%2520Pig%2520Livers%2520Using%2520Liquid%2520Chromatography%2520in%2520Conjunction%2520with%2520Mass%2520Spectrometry%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2011%26volume%3D39%26spage%3D2130%26epage%3D2134%26doi%3D10.1124%2Fdmd.111.040618" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Werck-Reichhart, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feyereisen, R.</span></span> <span> </span><span class="NLM_article-title">Cytochromes P450: A Success Story</span>. <i>Genome biology</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">reviews3003.1</span>, <span class="refDoi"> DOI: 10.1186/gb-2000-1-6-reviews3003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1186%2Fgb-2000-1-6-reviews3003" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2000&pages=reviews3003.1&author=D.+Werck-Reichhartauthor=R.+Feyereisen&title=Cytochromes+P450%3A+A+Success+Story&doi=10.1186%2Fgb-2000-1-6-reviews3003"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1186%2Fgb-2000-1-6-reviews3003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fgb-2000-1-6-reviews3003%26sid%3Dliteratum%253Aachs%26aulast%3DWerck-Reichhart%26aufirst%3DD.%26aulast%3DFeyereisen%26aufirst%3DR.%26atitle%3DCytochromes%2520P450%253A%2520A%2520Success%2520Story%26jtitle%3DGenome%2520biology%26date%3D2000%26volume%3D1%26spage%3Dreviews3003.1%26doi%3D10.1186%2Fgb-2000-1-6-reviews3003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ortiz
de Montellano, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Voss, J. J.</span></span> <span> </span><span class="NLM_article-title">Oxidizing Species in the Mechanism of Cytochrome P450</span>. <i>Nat. Prod. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">477</span>– <span class="NLM_lpage">493</span>, <span class="refDoi"> DOI: 10.1039/b101297p</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1039%2Fb101297p" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=12195813" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=1%3ACAS%3A280%3ADC%252BD38vjvValsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2002&pages=477-493&author=P.+R.+Ortiz%0Ade+Montellanoauthor=J.+J.+De+Voss&title=Oxidizing+Species+in+the+Mechanism+of+Cytochrome+P450&doi=10.1039%2Fb101297p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Oxidizing species in the mechanism of cytochrome P450</span></div><div class="casAuthors">Ortiz de Montellano Paul R; De Voss James J</div><div class="citationInfo"><span class="NLM_cas:title">Natural product reports</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">477-93</span>
        ISSN:<span class="NLM_cas:issn">0265-0568</span>.
    </div><div class="casAbstract">This review discusses the mechanisms of oxygen activation by cytochrome P450 enzymes, the possible catalytic roles of the various iron--oxygen species formed in the catalytic cycle, and progress in understanding the mechanisms of hydrocarbon hydroxylation, heteroatom oxidation, and olefin epoxidation.  The focus of the review is on recent results, but earlier work is discussed as appropriate.  The literature through to February 2002 is surveyed, and 175 referenced are cited.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSHGez5WBT-VIMcDoIzZtNkfW6udTcc2ea5AxZgDLJ2i7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD38vjvValsQ%253D%253D&md5=acd16cba1ce2d49c97e4a828cb606ec1</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1039%2Fb101297p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fb101297p%26sid%3Dliteratum%253Aachs%26aulast%3DOrtiz%2Bde%2BMontellano%26aufirst%3DP.%2BR.%26aulast%3DDe%2BVoss%26aufirst%3DJ.%2BJ.%26atitle%3DOxidizing%2520Species%2520in%2520the%2520Mechanism%2520of%2520Cytochrome%2520P450%26jtitle%3DNat.%2520Prod.%2520Rep.%26date%3D2002%26volume%3D19%26spage%3D477%26epage%3D493%26doi%3D10.1039%2Fb101297p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ashla, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoshikawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuchiya, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashiguchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Enjoji, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamuta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taketomi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maehara, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shomori, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurimasa, A.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Genetic Analysis of Expression Profile Involved in Retinoid Metabolism in Non-Alcoholic Fatty Liver Disease</span>. <i>Hepatol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">594</span>– <span class="NLM_lpage">604</span>, <span class="refDoi"> DOI: 10.1111/j.1872-034X.2010.00646.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1111%2Fj.1872-034X.2010.00646.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=20618457" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1aqurfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2010&pages=594-604&author=A.+A.+Ashlaauthor=Y.+Hoshikawaauthor=H.+Tsuchiyaauthor=K.+Hashiguchiauthor=M.+Enjojiauthor=M.+Nakamutaauthor=A.+Taketomiauthor=Y.+Maeharaauthor=K.+Shomoriauthor=A.+Kurimasa&title=Genetic+Analysis+of+Expression+Profile+Involved+in+Retinoid+Metabolism+in+Non-Alcoholic+Fatty+Liver+Disease&doi=10.1111%2Fj.1872-034X.2010.00646.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Genetic analysis of expression profile involved in retinoid metabolism in non-alcoholic fatty liver disease</span></div><div class="casAuthors">Ashla, An Afida; Hoshikawa, Yoshiko; Tsuchiya, Hiroyuki; Hashiguchi, Koich; Enjoji, Munechika; Nakamuta, Makoto; Taketomi, Akinobu; Maehara, Yoshihiko; Shomori, Kohei; Kurimasa, Akihiro; Hisatome, Ichiro; Ito, Hisao; Shiota, Goshi</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">594-604</span>CODEN:
                <span class="NLM_cas:coden">HPRSFM</span>;
        ISSN:<span class="NLM_cas:issn">1386-6346</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The patients with non-alc. fatty liver disease (NAFLD) have been reported to be at greater risk for progression to chronic liver disease including liver cirrhosis (LC).  To examine the mechanisms for the progression of NAFLD, a genetic anal. of hepatic expression profile in retinoid metab. in NAFLD was performed since the loss of retinoid signaling is assocd. with the progression of liver disease via reactive oxygen species (ROS) generation.  51 Genes, which are assocd. with retinoid metab. and action, were examd. in 36 subjects including 17 patients with simple steatosis, 11 with non-alc. steatohepatitis (NASH) and 8 controls were examd. by real-time reverse transcriptase polymerase chain reaction.  Immunohistochem. study was also done by 3 kinds of antibodies.  Higher expression of CRBP1 LRAT, DGT1/2, and CES1 in NAFLD suggests that mutual conversion between retinyl ester and retinal occurs actively.  Expression of ADH1/2/3, RDH5/10/11, DHRS3, and RALDH1/3 was increased in NAFLD, suggesting that oxidn. process from retinol to all-trans retinoic acid (ATRA) was enhanced.  Importantly, greater expression of CYP26A1 indicated that degrdn. of ATRA was enhanced in NAFLD.  Further, expression of SOD1/2, catalase, thioredoxin and uncoupling protein 2 was also enhanced.  Hyperdynamic state of retinoid metab. is present in the liver tissues with NAFLD, which may be a putative mechanism by which NAFLD progresses to chronic liver disease including LC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPnCE1zD7mC7Vg90H21EOLACvtfcHk0lgEZvOopNPGcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1aqurfK&md5=f09228bd1a48a3fe81886523570a7dd5</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1111%2Fj.1872-034X.2010.00646.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1872-034X.2010.00646.x%26sid%3Dliteratum%253Aachs%26aulast%3DAshla%26aufirst%3DA.%2BA.%26aulast%3DHoshikawa%26aufirst%3DY.%26aulast%3DTsuchiya%26aufirst%3DH.%26aulast%3DHashiguchi%26aufirst%3DK.%26aulast%3DEnjoji%26aufirst%3DM.%26aulast%3DNakamuta%26aufirst%3DM.%26aulast%3DTaketomi%26aufirst%3DA.%26aulast%3DMaehara%26aufirst%3DY.%26aulast%3DShomori%26aufirst%3DK.%26aulast%3DKurimasa%26aufirst%3DA.%26atitle%3DGenetic%2520Analysis%2520of%2520Expression%2520Profile%2520Involved%2520in%2520Retinoid%2520Metabolism%2520in%2520Non-Alcoholic%2520Fatty%2520Liver%2520Disease%26jtitle%3DHepatol.%2520Res.%26date%3D2010%26volume%3D40%26spage%3D594%26epage%3D604%26doi%3D10.1111%2Fj.1872-034X.2010.00646.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pan, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoeppner, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, J. Y.</span></span> <span> </span><span class="NLM_article-title">Induction of Phosphoenolpyruvate Carboxykinase Gene Expression by Retinoic Acid in an Adult Rat Hepatocyte Line</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">10883</span>– <span class="NLM_lpage">10888</span>, <span class="refDoi"> DOI: 10.1021/bi00501a004</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi00501a004" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=1990&pages=10883-10888&author=C.+J.+Panauthor=W.+Hoeppnerauthor=J.+Y.+Chou&title=Induction+of+Phosphoenolpyruvate+Carboxykinase+Gene+Expression+by+Retinoic+Acid+in+an+Adult+Rat+Hepatocyte+Line&doi=10.1021%2Fbi00501a004"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1021%2Fbi00501a004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi00501a004%26sid%3Dliteratum%253Aachs%26aulast%3DPan%26aufirst%3DC.%2BJ.%26aulast%3DHoeppner%26aufirst%3DW.%26aulast%3DChou%26aufirst%3DJ.%2BY.%26atitle%3DInduction%2520of%2520Phosphoenolpyruvate%2520Carboxykinase%2520Gene%2520Expression%2520by%2520Retinoic%2520Acid%2520in%2520an%2520Adult%2520Rat%2520Hepatocyte%2520Line%26jtitle%3DBiochemistry%26date%3D1990%26volume%3D29%26spage%3D10883%26epage%3D10888%26doi%3D10.1021%2Fbi00501a004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kalaany, N. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mangelsdorf, D. J.</span></span> <span> </span><span class="NLM_article-title">LXRS and FXR: The Yin And Yang of Cholesterol and Fat Metabolism</span>. <i>Annu. Rev. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">159</span>– <span class="NLM_lpage">191</span>, <span class="refDoi"> DOI: 10.1146/annurev.physiol.68.033104.152158</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1146%2Fannurev.physiol.68.033104.152158" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2006&pages=159-191&author=N.+Y.+Kalaanyauthor=D.+J.+Mangelsdorf&title=LXRS+and+FXR%3A+The+Yin+And+Yang+of+Cholesterol+and+Fat+Metabolism&doi=10.1146%2Fannurev.physiol.68.033104.152158"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1146%2Fannurev.physiol.68.033104.152158&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.physiol.68.033104.152158%26sid%3Dliteratum%253Aachs%26aulast%3DKalaany%26aufirst%3DN.%2BY.%26aulast%3DMangelsdorf%26aufirst%3DD.%2BJ.%26atitle%3DLXRS%2520and%2520FXR%253A%2520The%2520Yin%2520And%2520Yang%2520of%2520Cholesterol%2520and%2520Fat%2520Metabolism%26jtitle%3DAnnu.%2520Rev.%2520Physiol.%26date%3D2006%26volume%3D68%26spage%3D159%26epage%3D191%26doi%3D10.1146%2Fannurev.physiol.68.033104.152158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Desvergne, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wahli, W.</span></span> <span> </span><span class="NLM_article-title">Peroxisome Proliferator-Activated Receptors: Nuclear Control of Metabolism</span>. <i>Endocr. Rev.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">649</span>– <span class="NLM_lpage">688</span>, <span class="refDoi"> DOI: 10.1210/edrv.20.5.0380</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1210%2Fedrv.20.5.0380" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10529898" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=1%3ACAS%3A528%3ADyaK1MXmvFalsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=1999&pages=649-688&author=B.+Desvergneauthor=W.+Wahli&title=Peroxisome+Proliferator-Activated+Receptors%3A+Nuclear+Control+of+Metabolism&doi=10.1210%2Fedrv.20.5.0380"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Peroxisome proliferator-activated receptors: nuclear control of metabolism</span></div><div class="casAuthors">Desvergne, Beatrice; Wahli, Walter</div><div class="citationInfo"><span class="NLM_cas:title">Endocrine Reviews</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">649-688</span>CODEN:
                <span class="NLM_cas:coden">ERVIDP</span>;
        ISSN:<span class="NLM_cas:issn">0163-769X</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">A review, with 408 refs., on the mol. and physiol. aspects of peroxisome proliferator-activated receptors (PPAR).  Mol. aspects included: PPAR isotype identity, genomic organization, and chromosomal localization; DNA binding properties; ligand binding properties; pathways for activation; and PPAR transactivation properties.  Physiol. aspects included: differential expression of PPAR mRNAs; PPAR target genes and functions in fatty acid metab.; PPARs and control of inflammatory responses; PPARs and atherosclerosis; PPARs and development of the fetal epidermal permeability barrier; and PPARs, carcinogenesis, and control of the cell cycle.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGot4PfN8bZDDbVg90H21EOLACvtfcHk0lgEZvOopNPGcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXmvFalsLo%253D&md5=0007e3aa3bab709ad1eb1621d2c6cc38</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1210%2Fedrv.20.5.0380&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fedrv.20.5.0380%26sid%3Dliteratum%253Aachs%26aulast%3DDesvergne%26aufirst%3DB.%26aulast%3DWahli%26aufirst%3DW.%26atitle%3DPeroxisome%2520Proliferator-Activated%2520Receptors%253A%2520Nuclear%2520Control%2520of%2520Metabolism%26jtitle%3DEndocr.%2520Rev.%26date%3D1999%26volume%3D20%26spage%3D649%26epage%3D688%26doi%3D10.1210%2Fedrv.20.5.0380" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imai, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forman, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samuels, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Granner, D. K.</span></span> <span> </span><span class="NLM_article-title">A Retinoic Acid Response Element is Part of a Pleiotropic Domain in the Phosphoenolpyruvate Carboxykinase Gene</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>88</i></span>,  <span class="NLM_fpage">2184</span>– <span class="NLM_lpage">2188</span>, <span class="refDoi"> DOI: 10.1073/pnas.88.6.2184</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1073%2Fpnas.88.6.2184" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=1991&pages=2184-2188&author=P.+C.+Lucasauthor=R.+M.+O%E2%80%99Brienauthor=J.+A.+Mitchellauthor=C.+M.+Davisauthor=E.+Imaiauthor=B.+M.+Formanauthor=H.+H.+Samuelsauthor=D.+K.+Granner&title=A+Retinoic+Acid+Response+Element+is+Part+of+a+Pleiotropic+Domain+in+the+Phosphoenolpyruvate+Carboxykinase+Gene&doi=10.1073%2Fpnas.88.6.2184"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1073%2Fpnas.88.6.2184&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.88.6.2184%26sid%3Dliteratum%253Aachs%26aulast%3DLucas%26aufirst%3DP.%2BC.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DR.%2BM.%26aulast%3DMitchell%26aufirst%3DJ.%2BA.%26aulast%3DDavis%26aufirst%3DC.%2BM.%26aulast%3DImai%26aufirst%3DE.%26aulast%3DForman%26aufirst%3DB.%2BM.%26aulast%3DSamuels%26aufirst%3DH.%2BH.%26aulast%3DGranner%26aufirst%3DD.%2BK.%26atitle%3DA%2520Retinoic%2520Acid%2520Response%2520Element%2520is%2520Part%2520of%2520a%2520Pleiotropic%2520Domain%2520in%2520the%2520Phosphoenolpyruvate%2520Carboxykinase%2520Gene%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1991%26volume%3D88%26spage%3D2184%26epage%3D2188%26doi%3D10.1073%2Fpnas.88.6.2184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hall, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noisin, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Granner, D. K.</span></span> <span> </span><span class="NLM_article-title">Activation of the Phosphoenolpyruvate Carboxykinase Gene Retinoic Acid Response Element is Dependent on a Retinoic Acid Receptor/Coregulator Complex</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">5527</span>– <span class="NLM_lpage">5535</span>, <span class="refDoi"> DOI: 10.1128/MCB.12.12.5527</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1128%2FMCB.12.12.5527" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=1333043" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=1%3ACAS%3A528%3ADyaK3sXltlCltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=1992&pages=5527-5535&author=R.+K.+Hallauthor=D.+K.+Scottauthor=E.+L.+Noisinauthor=P.+C.+Lucasauthor=D.+K.+Granner&title=Activation+of+the+Phosphoenolpyruvate+Carboxykinase+Gene+Retinoic+Acid+Response+Element+is+Dependent+on+a+Retinoic+Acid+Receptor%2FCoregulator+Complex&doi=10.1128%2FMCB.12.12.5527"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of the phosphoenolpyruvate carboxykinase gene retinoic acid response element is dependent on a retinoic acid receptor/coregulator complex</span></div><div class="casAuthors">Hall, Robert K.; Scott, Donald K.; Noisin, Edouard L.; Lucas, Peter C.; Granner, Daryl K.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5527-35</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    </div><div class="casAbstract">The accessory factor 1 (AF1) element is an upstream retranscriptional control region that plays a role in the response of the phosphoenolpyruvate carboxykinase (PEPCK) gene to both glucocorticoids and retinoic acid.  Retinoic acid receptor alpha (RARα) binds to a sequence within the AF1 element, TGACCT (site B), that is a consensus retinoic acid response element (RARE) half-site.  A similar DNA sequence, TGGCCG (site C), located 1 bp downstream of site B, is not involved in the binding of RARα monomers or dimers but is required for the constitution of a functional RARE.  Site C is also required for the formation of a complex involving RARα and a liver nuclear factor designated CR, for coregulators.  Mutational anal. of the AF1 element shows that the RARα/CR complex is the trans-acting unit that mediates the retinoic acid response of the PEPCK gene.  Another member of the retinoid receptor family, retinoid X receptor alpha (RXRα), can also form a complex with RARα and the AF1 element.  Several observations, including the observation that RXRα antibody interacts with CR, indicate that RXRα and CR are identical or closely related proteins.  Though RXRα forms a complex with RARα and the AF1 element, the AF1 element is functionally distinguishable from a retinoid X response element.  Thus, the AF1 element contains an RARE that mediates a retinoic acid response by binding an RARα/coregulator complex; this coregulator is presumably RXRα.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGob71gbk_YDabVg90H21EOLACvtfcHk0ljycFFoBqeAsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXltlCltw%253D%253D&md5=57bf4bdaa514c530b48adc50bbd6e3a9</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1128%2FMCB.12.12.5527&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.12.12.5527%26sid%3Dliteratum%253Aachs%26aulast%3DHall%26aufirst%3DR.%2BK.%26aulast%3DScott%26aufirst%3DD.%2BK.%26aulast%3DNoisin%26aufirst%3DE.%2BL.%26aulast%3DLucas%26aufirst%3DP.%2BC.%26aulast%3DGranner%26aufirst%3DD.%2BK.%26atitle%3DActivation%2520of%2520the%2520Phosphoenolpyruvate%2520Carboxykinase%2520Gene%2520Retinoic%2520Acid%2520Response%2520Element%2520is%2520Dependent%2520on%2520a%2520Retinoic%2520Acid%2520Receptor%252FCoregulator%2520Complex%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D1992%26volume%3D12%26spage%3D5527%26epage%3D5535%26doi%3D10.1128%2FMCB.12.12.5527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shin, D.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tao, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGrane, M. M.</span></span> <span> </span><span class="NLM_article-title">Effects of Vitamin A Deficiency and Retinoic Acid Treatment on Expression of a Phosphoenolpyruvate Carboxykinase-Bovine Growth Hormone Gene in Transgenic Mice</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>213</i></span>,  <span class="NLM_fpage">706</span>– <span class="NLM_lpage">714</span>, <span class="refDoi"> DOI: 10.1006/bbrc.1995.2188</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1006%2Fbbrc.1995.2188" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=213&publication_year=1995&pages=706-714&author=D.-J.+Shinauthor=A.+Taoauthor=M.+M.+McGrane&title=Effects+of+Vitamin+A+Deficiency+and+Retinoic+Acid+Treatment+on+Expression+of+a+Phosphoenolpyruvate+Carboxykinase-Bovine+Growth+Hormone+Gene+in+Transgenic+Mice&doi=10.1006%2Fbbrc.1995.2188"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1006%2Fbbrc.1995.2188&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fbbrc.1995.2188%26sid%3Dliteratum%253Aachs%26aulast%3DShin%26aufirst%3DD.-J.%26aulast%3DTao%26aufirst%3DA.%26aulast%3DMcGrane%26aufirst%3DM.%2BM.%26atitle%3DEffects%2520of%2520Vitamin%2520A%2520Deficiency%2520and%2520Retinoic%2520Acid%2520Treatment%2520on%2520Expression%2520of%2520a%2520Phosphoenolpyruvate%2520Carboxykinase-Bovine%2520Growth%2520Hormone%2520Gene%2520in%2520Transgenic%2520Mice%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D1995%26volume%3D213%26spage%3D706%26epage%3D714%26doi%3D10.1006%2Fbbrc.1995.2188" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wolchok, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kluger, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callahan, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Postow, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizvi, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesokhin, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Segal, N. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ariyan, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, R.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reed, K.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Nivolumab Plus Ipilimumab in Advanced Melanoma</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>369</i></span>,  <span class="NLM_fpage">122</span>– <span class="NLM_lpage">133</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1302369</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1056%2FNEJMoa1302369" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=23724867" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1ektbrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=369&publication_year=2013&pages=122-133&author=J.+D.+Wolchokauthor=H.+Klugerauthor=M.+K.+Callahanauthor=M.+A.+Postowauthor=N.+A.+Rizviauthor=A.+M.+Lesokhinauthor=N.+H.+Segalauthor=C.+E.+Ariyanauthor=R.-A.+Gordonauthor=K.+Reed&title=Nivolumab+Plus+Ipilimumab+in+Advanced+Melanoma&doi=10.1056%2FNEJMoa1302369"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Nivolumab plus ipilimumab in advanced melanoma</span></div><div class="casAuthors">Wolchok, Edd D.; Kluger, Harriet; Callahan, Margaret K.; Postow, Michael A.; Rizvi, Naiyer A.; Lesokhln, Alexander M.; Segal, Nell H.; Ariyan, Charlotte E.; Gordon, Ruth-Ann; Reed, Kathleen; Burke, Matthew M.; Caldwell, Anne; Kronenberg, Stephanie A.; Agunwamba, Blessing U.; Zhang, Xiaoling; Lowy, Israel; Inzunza, Hector David; Feely, William; Horak, Christine E.; Hong, Quan; Korman, Alan J.; Wigginton, Jon M.; Gupta, Ashok; Sznol, Mario</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">369</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">122-133</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND In patients with melanoma, ipilimumab (an antibody against cytotoxic T-lymphocyte-assocd. antigen 4 [CTLA-4]) prolongs overall survival, and nivolumab (an antibody against the programmed death 1 [PD-1] receptor) produced durable tumor regression in a phase I trial.  On the basis of their distinct immunol. mechanisms of action and supportive preclin. data, we conducted a phase 1 trial of nivolumab combined with ipilimumab in patients with advanced melanoma.  METHODS We administered i.v. doses of nivolumab and ipilimumab in patients every 3 wk for 4 doses, followed by nivolumab alone every 3 wk for 4 doses (concur- rent regimen).  The combined treatment was subsequently administered every 12 wk for up to 8 doses.  In a sequenced regimen, patients previously treated with ipilimumab received nivolumab every 2 wk for up to 48 doses.  RESULTS A total of 53 patients received concurrent therapy with nivolumab and ipilimumab, and 33 received sequenced treatment The objective-response rate (according to modified World Health Organization criteria) for all patients in the concurrent-regimen group was 40%.  Evidence of clin. activity (conventional, unconfirmed, or immune-related response or stable disease for ≥24 wk) was obsd. in 65% of patients.  At the max. doses that were assocd. with an acceptable level of adverse events (nivolumab at a dose of 1 mg per kg of body wt. and ipilimumab at a dose of 3 mg per kg), 53% of patients had an objective response, all with tumor redn. of 80% or more.  Grade 3 or 4 adverse events related to therapy occurred In 53% of patients in the concurrent-regimen group but were qual. similar to previous experience with monotherapy and were generally reversible.  Among patients in the sequenced-regimen group, 18% had grade 3 or 4 adverse events related to therapy and the objective-response rate was 20%.  CONCLUSIONS Concurrent therapy with nivolumab and ipilimumab had a manageable safety pro- file and provided clin. activity that appears to be distinct from that in published data on monotherapy, with rapid and deep tumor regression in a substantial proportion of patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9OCEoj7t5FrVg90H21EOLACvtfcHk0ljycFFoBqeAsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1ektbrF&md5=c17b746e817f6676913d59dd058f5ff1</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1302369&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1302369%26sid%3Dliteratum%253Aachs%26aulast%3DWolchok%26aufirst%3DJ.%2BD.%26aulast%3DKluger%26aufirst%3DH.%26aulast%3DCallahan%26aufirst%3DM.%2BK.%26aulast%3DPostow%26aufirst%3DM.%2BA.%26aulast%3DRizvi%26aufirst%3DN.%2BA.%26aulast%3DLesokhin%26aufirst%3DA.%2BM.%26aulast%3DSegal%26aufirst%3DN.%2BH.%26aulast%3DAriyan%26aufirst%3DC.%2BE.%26aulast%3DGordon%26aufirst%3DR.-A.%26aulast%3DReed%26aufirst%3DK.%26atitle%3DNivolumab%2520Plus%2520Ipilimumab%2520in%2520Advanced%2520Melanoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2013%26volume%3D369%26spage%3D122%26epage%3D133%26doi%3D10.1056%2FNEJMoa1302369" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Topalian, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sznol, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDermott, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kluger, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carvajal, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharfman, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brahmer, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atkins, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powderly, J. D.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Survival, Durable Tumor Remission, and Long-Term Safety in Patients with Advanced Melanoma Receiving Nivolumab</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">1020</span>– <span class="NLM_lpage">1030</span>, <span class="refDoi"> DOI: 10.1200/JCO.2013.53.0105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1200%2FJCO.2013.53.0105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=24590637" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpsVSku74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2014&pages=1020-1030&author=S.+L.+Topalianauthor=M.+Sznolauthor=D.+F.+McDermottauthor=H.+M.+Klugerauthor=R.+D.+Carvajalauthor=W.+H.+Sharfmanauthor=J.+R.+Brahmerauthor=D.+P.+Lawrenceauthor=M.+B.+Atkinsauthor=J.+D.+Powderly&title=Survival%2C+Durable+Tumor+Remission%2C+and+Long-Term+Safety+in+Patients+with+Advanced+Melanoma+Receiving+Nivolumab&doi=10.1200%2FJCO.2013.53.0105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab</span></div><div class="casAuthors">Topalian, Suzanne L.; Sznol, Mario; McDermott, David F.; Kluger, Harriet M.; Carvajal, Richard D.; Sharfman, William H.; Brahmer, Julie R.; Lawrence, Donald P.; Atkins, Michael B.; Powderly, John D.; Leming, Philip D.; Lipson, Evan J.; Puzanov, Igor; Smith, David C.; Taube, Janis M.; Wigginton, Jon M.; Kollia, Georgia D.; Gupta, Ashok; Pardoll, Drew M.; Sosman, Jeffrey A.; Hodi, F. Stephen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1020-1030</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose Programmed cell death 1 (PD-1) is an inhibitory receptor expressed by activated T cells that downmodulates effector functions and limits the generation of immune memory.  PD-1 blockade can mediate tumor regression in a substantial proportion of patients with melanoma, but it is not known whether this is assocd. with extended survival or maintenance of response after treatment is discontinued.  Patients and Methods Patients with advanced melanoma (N = 107) enrolled between 2008 and 2012 received i.v. nivolumab in an outpatient setting every 2 wk for up to 96 wk and were obsd. for overall survival, long-term safety, and response duration after treatment discontinuation.  Results Median overall survival in nivolumab-treated patients (62% with two to five prior systemic therapies) was 16.8 mo, and 1- and 2-yr survival rates were 62% and 43%, resp.  Among 33 patients with objective tumor regressions (31%), the Kaplan-Meier estd. median response duration was 2 years.  Seventeen patients discontinued therapy for reasons other than disease progression, and 12 (71%) of 17 maintained responses off-therapy for at least 16 wk (range, 16 to 56+ weeks).  Objective response and toxicity rates were similar to those reported previously; in an extended anal. of all 306 patients treated on this trial (including those with other cancer types), exposure-adjusted toxicity rates were not cumulative.  Conclusion Overall survival following nivolumab treatment in patients with advanced treatment-refractory melanoma compares favorably with that in literature studies of similar patient populations.  Responses were durable and persisted after drug discontinuation.  Long-term safety was acceptable.  Ongoing randomized clin. trials will further assess the impact of nivolumab therapy on overall survival in patients with metastatic melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCsu2eYts347Vg90H21EOLACvtfcHk0liF7xEgfZoTaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpsVSku74%253D&md5=11ebaafb4dec008334b6445949d0d939</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1200%2FJCO.2013.53.0105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2013.53.0105%26sid%3Dliteratum%253Aachs%26aulast%3DTopalian%26aufirst%3DS.%2BL.%26aulast%3DSznol%26aufirst%3DM.%26aulast%3DMcDermott%26aufirst%3DD.%2BF.%26aulast%3DKluger%26aufirst%3DH.%2BM.%26aulast%3DCarvajal%26aufirst%3DR.%2BD.%26aulast%3DSharfman%26aufirst%3DW.%2BH.%26aulast%3DBrahmer%26aufirst%3DJ.%2BR.%26aulast%3DLawrence%26aufirst%3DD.%2BP.%26aulast%3DAtkins%26aufirst%3DM.%2BB.%26aulast%3DPowderly%26aufirst%3DJ.%2BD.%26atitle%3DSurvival%252C%2520Durable%2520Tumor%2520Remission%252C%2520and%2520Long-Term%2520Safety%2520in%2520Patients%2520with%2520Advanced%2520Melanoma%2520Receiving%2520Nivolumab%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2014%26volume%3D32%26spage%3D1020%26epage%3D1030%26doi%3D10.1200%2FJCO.2013.53.0105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schachtschneider, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mäkeläinen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madsen, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rund, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groenen, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schook, L. B.</span></span> <span> </span><span class="NLM_article-title">Oncopig Soft-Tissue Sarcomas Recapitulate Key Transcriptional Features of Human Sarcomas</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">2624</span>, <span class="refDoi"> DOI: 10.1038/s41598-017-02912-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1038%2Fs41598-017-02912-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=28572589" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=1%3ACAS%3A280%3ADC%252BC1cnktVynsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=2624&author=K.+M.+Schachtschneiderauthor=Y.+Liuauthor=S.+M%C3%A4kel%C3%A4inenauthor=O.+Madsenauthor=L.+A.+Rundauthor=M.+A.+Groenenauthor=L.+B.+Schook&title=Oncopig+Soft-Tissue+Sarcomas+Recapitulate+Key+Transcriptional+Features+of+Human+Sarcomas&doi=10.1038%2Fs41598-017-02912-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Oncopig Soft-Tissue Sarcomas Recapitulate Key Transcriptional Features of Human Sarcomas</span></div><div class="casAuthors">Schachtschneider Kyle M; Liu Yingkai; Rund Laurie A; Schook Lawrence B; Schachtschneider Kyle M; Makelainen Suvi; Madsen Ole; Groenen Martien A M; Schachtschneider Kyle M; Schook Lawrence B; Liu Yingkai; Makelainen Suvi</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">2624</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Human soft-tissue sarcomas (STS) are rare mesenchymal tumors with a 5-year survival rate of 50%, highlighting the need for further STS research.  Research has been hampered by limited human sarcoma cell line availability and the large number of STS subtypes, making development of STS cell lines and animal models representative of the diverse human STS subtypes critical.  Pigs represent ideal human disease models due to their similar size, anatomy, metabolism, and genetics compared to humans.  The Oncopig encodes inducible KRAS (G12D) and TP53 (R167H) transgenes, allowing for STS modeling in a spatial and temporal manner.  This study utilized Oncopig STS cell line (fibroblast) and tumor (leiomyosarcoma) RNA-seq data to compare Oncopig and human STS expression profiles.  Altered expression of 3,360 and 7,652 genes was identified in Oncopig STS cell lines and leiomyosarcomas, respectively.  Transcriptional hallmarks of human STS were observed in Oncopig STS, including altered TP53 signaling, Wnt signaling activation, and evidence of epigenetic reprogramming.  Furthermore, master regulators of Oncopig STS expression were identified, including FOSL1, which was previously identified as a potential human STS therapeutic target.  These results demonstrate the Oncopig STS model's ability to mimic human STS transcriptional profiles, providing a valuable resource for sarcoma research and cell line development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRJ_SCYdyBBVO3MPKNEWB5RfW6udTcc2eZH74Q1be2BL7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cnktVynsw%253D%253D&md5=b8b0fab10c643f83ce57d890d1d2a2c6</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1038%2Fs41598-017-02912-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-017-02912-9%26sid%3Dliteratum%253Aachs%26aulast%3DSchachtschneider%26aufirst%3DK.%2BM.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DM%25C3%25A4kel%25C3%25A4inen%26aufirst%3DS.%26aulast%3DMadsen%26aufirst%3DO.%26aulast%3DRund%26aufirst%3DL.%2BA.%26aulast%3DGroenen%26aufirst%3DM.%2BA.%26aulast%3DSchook%26aufirst%3DL.%2BB.%26atitle%3DOncopig%2520Soft-Tissue%2520Sarcomas%2520Recapitulate%2520Key%2520Transcriptional%2520Features%2520of%2520Human%2520Sarcomas%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26spage%3D2624%26doi%3D10.1038%2Fs41598-017-02912-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ian, F. R.</span></span> <i>Culture of Animal Cells: A Manual of Basic Technique and Specialized Applications</i>; <span class="NLM_publisher-name">Wiley-Sons</span>: <span class="NLM_publisher-loc">New York</span>, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=F.+R.+Ian&title=Culture+of+Animal+Cells%3A+A+Manual+of+Basic+Technique+and+Specialized+Applications"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DIan%26aufirst%3DF.%2BR.%26btitle%3DCulture%2520of%2520Animal%2520Cells%253A%2520A%2520Manual%2520of%2520Basic%2520Technique%2520and%2520Specialized%2520Applications%26pub%3DWiley-Sons%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">van
Meerloo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaspers, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cloos, J.</span></span> <span> </span><span class="NLM_article-title">Cell Sensitivity Assays: The MTT Assay</span>. <i>Methods Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>731</i></span>,  <span class="NLM_fpage">237</span>– <span class="NLM_lpage">245</span>, <span class="refDoi"> DOI: 10.1007/978-1-61779-080-5_20</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1007%2F978-1-61779-080-5_20" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=21516412" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=1%3ACAS%3A528%3ADC%252BC3MXntVyqtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=731&publication_year=2011&pages=237-245&author=J.+van%0AMeerlooauthor=G.+J.+Kaspersauthor=J.+Cloos&title=Cell+Sensitivity+Assays%3A+The+MTT+Assay&doi=10.1007%2F978-1-61779-080-5_20"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Cell sensitivity assays: the MTT assay</span></div><div class="casAuthors">van Meerloo, Johan; Kaspers, Gertjan J. L.; Cloos, Jacqueline</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Molecular Biology (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">731</span>
        (<span class="NLM_cas:issue">Cancer Cell Culture</span>),
    <span class="NLM_cas:pages">237-245</span>CODEN:
                <span class="NLM_cas:coden">MMBIED</span>;
        ISSN:<span class="NLM_cas:issn">1064-3745</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The MTT (3-[4,5-dimethylthiazol-2-yl]-2,5 di-Ph tetrazolium bromide) assay is based on the conversion of MTT into formazan crystals by living cells, which dets. mitochondrial activity.  Since for most cell populations the total mitochondrial activity is related to the no. of viable cells, this assay is broadly used to measure the in vitro cytotoxic effects of drugs on cell lines or primary patient cells.  In this chapter the protocol of the assay is described including important considerations relevant for each step of the assay as well as its limitations and possible applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprO-kUg91O_7Vg90H21EOLACvtfcHk0liF7xEgfZoTaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXntVyqtbk%253D&md5=f88b391a65df5cb01b3bba486c55ce96</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1007%2F978-1-61779-080-5_20&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-61779-080-5_20%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2BMeerloo%26aufirst%3DJ.%26aulast%3DKaspers%26aufirst%3DG.%2BJ.%26aulast%3DCloos%26aufirst%3DJ.%26atitle%3DCell%2520Sensitivity%2520Assays%253A%2520The%2520MTT%2520Assay%26jtitle%3DMethods%2520Mol.%2520Biol.%26date%3D2011%26volume%3D731%26spage%3D237%26epage%3D245%26doi%3D10.1007%2F978-1-61779-080-5_20" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 1 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ellen P.  Neff</span>. </span><span class="cited-content_cbyCitation_article-title">Cancer modeling thinks big with the pig. </span><span class="cited-content_cbyCitation_journal-name">Lab Animal</span><span> <strong>2019,</strong> <em>48 </em>
                                    (3)
                                     , 75-78. <a href="https://doi.org/10.1038/s41684-019-0246-5" title="DOI URL">https://doi.org/10.1038/s41684-019-0246-5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41684-019-0246-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41684-019-0246-5%26sid%3Dliteratum%253Aachs%26jtitle%3DLab%2520Animal%26atitle%3DCancer%252Bmodeling%252Bthinks%252Bbig%252Bwith%252Bthe%252Bpig%26aulast%3DNeff%26aufirst%3DEllen%2BP.%26date%3D2019%26date%3D2019%26volume%3D48%26issue%3D3%26spage%3D75%26epage%3D78" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-23/acs.jmedchem.8b01387/20181207/images/medium/jm-2018-013879_0009.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-23/acs.jmedchem.8b01387/20181207/images/large/jm-2018-013879_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01387&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-23/acs.jmedchem.8b01387/20181207/images/medium/jm-2018-013879_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-23/acs.jmedchem.8b01387/20181207/images/large/jm-2018-013879_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Outline of planned research to evaluate in vitro and in vivo efficiencies. (a) Progression of computational, chemical, and biological experiments and (b) summary of gene regulations expected from newly designed RXR agonist in vivo. In-silico studies to identify RXR agonist through lead optimization. (c) Elongated shape of RAR and (d) globular shape of RXR structures; (e) Molcad Surfaces of <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1MVC">1MVC</a>, RXR agonist conformation crystal structure and (f) ligand interaction pictures of docking structures of compound <b>8</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-23/acs.jmedchem.8b01387/20181207/images/large/jm-2018-013879_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01387&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-23/acs.jmedchem.8b01387/20181207/images/medium/jm-2018-013879_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-23/acs.jmedchem.8b01387/20181207/images/large/jm-2018-013879_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Chemical Synthesis and Characterization of Compound <b>8</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-23/acs.jmedchem.8b01387/20181207/images/large/jm-2018-013879_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01387&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>For the designed RXR-agonist <b>8</b>, aryl bromide <b>5</b> with acrolein diethyl acetal in the presence of <i>n</i>-Bu<sub>4</sub>OAc, K<sub>2</sub>CO<sub>3</sub>, KCl, and DMF catalyzed by Pd(OAc)<sub>2</sub> afforded cinnamaldehyde <b>6</b> in 73% yield. Bis(indolyl)methane compound <b>7</b> was obtained in 81% yield from <b>6</b> and 1-methylindole catalyzed by molecular iodine in CH<sub>3</sub>CN at room temperature. Hydrolysis of <b>7</b> with LiOH·H<sub>2</sub>O in methanol and acidification afforded the final product <b>8</b> in 91% yield.</p></p></figure><figure data-id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-23/acs.jmedchem.8b01387/20181207/images/medium/jm-2018-013879_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-23/acs.jmedchem.8b01387/20181207/images/large/jm-2018-013879_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Physicochemical characterization of Nano-RXR. (A) Synthesis of rigid nanoparticles loaded with RXR-8 to prepare Nano-RXR; (B) hydrodynamic diameter of Nano-RXR compared to nanoparticles; (C) TEM image (drop deposited over carbon grid) of Nano-RXR; (D) stability of nanoparticles and Nano-RXR formulations in 5% and 10% (v/v) concentration of fetal bovine serum (FBS); (E) XRD pattern of nanoparticles and effect of RXR-8 loading in nanoassembly.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-23/acs.jmedchem.8b01387/20181207/images/large/jm-2018-013879_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01387&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-23/acs.jmedchem.8b01387/20181207/images/medium/jm-2018-013879_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-23/acs.jmedchem.8b01387/20181207/images/large/jm-2018-013879_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Cytotoxic effect of Nano-RXR and RXR on porcine sarcoma cell lines. RXR and Nano-RXR were used at various concentrations of RXR ranging from 3.125 to 100 μM for 48 h before performing the MTT assay. Nanoparticles alone at equivalent amount were used as negative control to evaluate the safety pattern of nanoparticles in the same conditions. Biostatistical analysis showed nanoparticle-based improvement enhanced cell growth inhibition with <i>p</i> value of 0.01 as **. As an indication of cytotoxic selectivity with lowering in IC<sub>50</sub> values, Nano-RXR showed statistically lower IC<sub>50</sub> in (a) 63-3 Cre and (b) 141-10 Cre cells compared to that in noncancerous cells of the same origin, 63-3 and 141-10, respectively. <i>p</i> Values of 0.001 and 0.0001 are shown as *** and ****, respectively, as obtained after unpaired <i>t</i> test. In vivo tumor regression studies in mouse and subsequent effects on protein expression. (c) Timeline of the in vivo experiment in rodent xenograft model; (d) weight percentages of group of animals used for tumor regression studies; (e) survival (%) of group of animals treated with RXR or Nano-RXR compared to controls on 18th day of experiment; (f) tumor volume regression after treatment with RXR and Nano-RXR; nanoparticles alone (RCM) or untreated animals were used as controls; (g) protein expression in tissues collected from treated and untreated groups of animals: (1) buffer; (2) RCM; (3) RXR; (4) Nano-RXR as obtained from (i) tumor tissue and (ii) tissue collected from liver.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-23/acs.jmedchem.8b01387/20181207/images/large/jm-2018-013879_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01387&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-23/acs.jmedchem.8b01387/20181207/images/medium/jm-2018-013879_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-23/acs.jmedchem.8b01387/20181207/images/large/jm-2018-013879_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. In vivo tumor regression studies in pig and post-treatment effects on protein expression. (a) Timeline of in vivo experiment in onco-pig model. (b) Tumor appearance on day 1 of buffer injection. (c) Tumor volume regression after treatment with RXR and Nano-RXR; animals treated with buffer were used as controls. Ultrasound imaging to follow the tumor growth after treatment with buffer on (d) day 1 and (e) day 13 and animals treated with Nano-RXR on (f) day 1 and (g) day 13. (h) Protein expression in tissues collected from treated and untreated group of animals: (1) Buffer; (2) RXR; (3) Nano-RXR as obtained from tumor tissue and tissue collected from liver.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-23/acs.jmedchem.8b01387/20181207/images/large/jm-2018-013879_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01387&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-23/acs.jmedchem.8b01387/20181207/images/medium/jm-2018-013879_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-23/acs.jmedchem.8b01387/20181207/images/large/jm-2018-013879_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. RXR and Nano-RXR induced transcriptional alteration of genes involved in phase-I and phase-II drug metabolism, phase-III transport, and nuclear receptors in liver measured by qPCR. Real time (RT)-PCR was performed to analyze the expression of the 21 genes. Fold change in transcript upon RXR or Nano-RXR treatment is presented with respect to control. CYP2C33, CYP2E1, and PXR were downregulated, SULTA1, FXR, and PPARγ were unchanged, and the rest of the genes were upregulated. The values and error bars represent average and standard deviations of three independent sets of experiments. One-way analysis of variance (ANOVA) followed by Bonferroni post-test was performed to determine significant differences among control and treatments. <i>p</i> Values of 0.05, 0.01, 0.001 and 0.0001 are shown as *, **, *** and ****, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-23/acs.jmedchem.8b01387/20181207/images/large/jm-2018-013879_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01387&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-23/acs.jmedchem.8b01387/20181207/images/medium/jm-2018-013879_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-23/acs.jmedchem.8b01387/20181207/images/large/jm-2018-013879_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. RXR and Nano-RXR induced transcriptional alteration of genes involved in phase-I and phase-II drug metabolism, phase-III transport, and nuclear receptors in tumor measured by qPCR. Real time RT-PCR was performed to analyze the expression of the 21 genes. Fold change in transcript upon RXR or Nano-RXR treatment is presented with respect to control. FXR was downregulated, CYP1A2 was unchanged, and all the other genes were upregulated by treatment. The values and error bars represent average and standard deviations of three independent sets of experiments. One-way analysis of variance (ANOVA) followed by Bonferroni post-test was performed to determine significant differences among control and treatments. <i>p</i> Values of 0.05, 0.01, 0.001 and 0.0001 are shown as *, **, *** and ****, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-23/acs.jmedchem.8b01387/20181207/images/large/jm-2018-013879_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01387&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-23/acs.jmedchem.8b01387/20181207/images/medium/jm-2018-013879_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-23/acs.jmedchem.8b01387/20181207/images/large/jm-2018-013879_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. (a–e) RXR and Nano-RXR induced transcriptional alteration of downstream target genes measured by qPCR. Real time RT-PCR was performed to analyze the expression of the six genes. Fold change in transcript upon RXR or Nano-RXR treatment is presented with respect to control. CRBP-1, CRABP-1, PEPCK1, and PEPCK2 were upregulated, and BTG2 and CIP1 were downregulated by treatment (<i>n</i> = 3). One-way analysis of variance (ANOVA) followed by Bonferroni post-test was done to determine significant differences among control and treatments where <i>n</i> = 3. <i>p</i> Values of 0.05, 0.01, 0.001 and 0.0001 are shown as *, **, *** and ****, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-23/acs.jmedchem.8b01387/20181207/images/large/jm-2018-013879_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01387&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i36">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_37743" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_37743" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 67 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matushansky, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maki, R. G.</span></span> <span> </span><span class="NLM_article-title">Fighting Cancer through the Study of Sarcomas</span>. <i>Am. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>93</i></span>,  <span class="NLM_fpage">414</span>– <span class="NLM_lpage">421</span>, <span class="refDoi"> DOI: 10.1511/2005.55.972</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1511%2F2005.55.972" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2005&pages=414-421&author=I.+Matushanskyauthor=R.+G.+Maki&title=Fighting+Cancer+through+the+Study+of+Sarcomas&doi=10.1511%2F2005.55.972"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1511%2F2005.55.972&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1511%252F2005.55.972%26sid%3Dliteratum%253Aachs%26aulast%3DMatushansky%26aufirst%3DI.%26aulast%3DMaki%26aufirst%3DR.%2BG.%26atitle%3DFighting%2520Cancer%2520through%2520the%2520Study%2520of%2520Sarcomas%26jtitle%3DAm.%2520Sci.%26date%3D2005%26volume%3D93%26spage%3D414%26epage%3D421%26doi%3D10.1511%2F2005.55.972" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nathenson, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sausville, E.</span></span> <span> </span><span class="NLM_article-title">Looking for Answers: the Current Status of Neoadjuvant Treatment in Localized Soft Tissue Sarcomas</span>. <i>Cancer Chemother. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">895</span>– <span class="NLM_lpage">919</span>, <span class="refDoi"> DOI: 10.1007/s00280-016-3055-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1007%2Fs00280-016-3055-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=27206640" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=1%3ACAS%3A528%3ADC%252BC28XosVaksbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2016&pages=895-919&author=M.+J.+Nathensonauthor=E.+Sausville&title=Looking+for+Answers%3A+the+Current+Status+of+Neoadjuvant+Treatment+in+Localized+Soft+Tissue+Sarcomas&doi=10.1007%2Fs00280-016-3055-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Looking for answers: the current status of neoadjuvant treatment in localized soft tissue sarcomas</span></div><div class="casAuthors">Nathenson, Michael J.; Sausville, Edward</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">895-919</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: Sarcomas are a rare and heterogeneous variant of cancer.  The std. of care treatment involves surgical resection with radiation in high-risk patients.  Despite appropriate treatment approx. 50 % of patients will suffer and die from recurrent disease.  The purpose of this article is to review the current evidence concerning the use of neoadjuvant chemotherapy with or without radiation in soft tissue sarcomas.  Methods: An in-depth literature search was conducted using Ovid Medline and PubMed.  Results: The most active chemotherapeutic agents in sarcoma are anthracyclines and ifosfamide.  Adjuvant chemotherapy trials show only minimal benefit.  Neoadjuvant chemotherapy offers the potential advantage of reducing the extent of surgery, increasing the limb salvage rate, early exposure of micrometastatic disease to chemotherapy, and assessment of tumor response to chemotherapy.  Some retrospective and phase II trials suggest a benefit to neoadjuvant chemotherapy.  Unfortunately, no clearly pos. phase III prospectively randomized trials exist for neoadjuvant therapy in soft tissue sarcomas.  Conclusions: The current neoadjuvant chemotherapy trials that do exist are heterogeneous resulting in conflicting results.  However, neoadjuvant chemotherapy with or without radiation can be considered in patients with high-risk disease in an attempt to improve long-term outcomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkXik8NbG62bVg90H21EOLACvtfcHk0lgL9o4zWl4BIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XosVaksbc%253D&md5=c87c1b06e84cd5fe2f959f71d3849cd8</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1007%2Fs00280-016-3055-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-016-3055-1%26sid%3Dliteratum%253Aachs%26aulast%3DNathenson%26aufirst%3DM.%2BJ.%26aulast%3DSausville%26aufirst%3DE.%26atitle%3DLooking%2520for%2520Answers%253A%2520the%2520Current%2520Status%2520of%2520Neoadjuvant%2520Treatment%2520in%2520Localized%2520Soft%2520Tissue%2520Sarcomas%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2016%26volume%3D78%26spage%3D895%26epage%3D919%26doi%3D10.1007%2Fs00280-016-3055-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tseng, W. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somaiah, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engleman, E. G.</span></span> <span> </span><span class="NLM_article-title">Potential for Immunotherapy in Soft Tissue Sarcoma</span>. <i>Hum. Vaccines Immunother.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">3117</span>– <span class="NLM_lpage">3124</span>, <span class="refDoi"> DOI: 10.4161/21645515.2014.983003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.4161%2F21645515.2014.983003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=25625925" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=3117-3124&author=W.+W.+Tsengauthor=N.+Somaiahauthor=E.+G.+Engleman&title=Potential+for+Immunotherapy+in+Soft+Tissue+Sarcoma&doi=10.4161%2F21645515.2014.983003"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.4161%2F21645515.2014.983003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252F21645515.2014.983003%26sid%3Dliteratum%253Aachs%26aulast%3DTseng%26aufirst%3DW.%2BW.%26aulast%3DSomaiah%26aufirst%3DN.%26aulast%3DEngleman%26aufirst%3DE.%2BG.%26atitle%3DPotential%2520for%2520Immunotherapy%2520in%2520Soft%2520Tissue%2520Sarcoma%26jtitle%3DHum.%2520Vaccines%2520Immunother.%26date%3D2014%26volume%3D10%26spage%3D3117%26epage%3D3124%26doi%3D10.4161%2F21645515.2014.983003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiseman, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erlandson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trotz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubansky, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albritton, K.</span></span> <span> </span><span class="NLM_article-title">Gemcitabine Radiosensitization after High-Dose Samarium for Osteoblastic Osteosarcoma</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">6895</span>– <span class="NLM_lpage">6900</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-05-0628</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1158%2F1078-0432.CCR-05-0628" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=16203780" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVKiurrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2005&pages=6895-6900&author=P.+M.+Andersonauthor=G.+A.+Wisemanauthor=L.+Erlandsonauthor=V.+Rodriguezauthor=B.+Trotzauthor=S.+A.+Dubanskyauthor=K.+Albritton&title=Gemcitabine+Radiosensitization+after+High-Dose+Samarium+for+Osteoblastic+Osteosarcoma&doi=10.1158%2F1078-0432.CCR-05-0628"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Gemcitabine Radiosensitization after High-Dose Samarium for Osteoblastic Osteosarcoma</span></div><div class="casAuthors">Anderson, Peter M.; Wiseman, Gregory A.; Erlandson, Linda; Rodriguez, Vilmarie; Trotz, Barbara; Dubansky, Stephen A.; Albritton, Karen</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">19, Pt. 1</span>),
    <span class="NLM_cas:pages">6895-6900</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Osteoblastic metastases and osteosarcoma can avidly conc. bone-seeking radiopharmaceuticals.  We sought to increase effectiveness of high-dose 153Samarium ethylenediaminetetramethylenephosphonate (153Sm-EDTMP, Quadramet) on osteosarcomas using a radiosensitizer, gemcitabine.  Fourteen patients with osteoblastic lesions were treated with 30 mCi/kg 153Sm-EDTMP.  Gemcitabine was administered 1 day after samarium infusion.  Residual total body radioactivity was within the safe range of <3.6 mCi on day +14 (1.1±0.4 mCi; range, 0.67-1.8 mCi).  All patients received autologous stem cell reinfusion 2 wk after 153Sm to correct expected grade 4 hematopoietic toxicity.  Peripheral blood progenitor cells were infused in 11 patients; three patients had marrow infused.  Blood count recovery was uneventful after peripheral blood progenitor cells in 11 of 11 patients.  Toxicity from a single infusion of gemcitabine (1,500 mg/m2) in combination with 153Sm-EDTMP was minimal (pancytopenia).  However, toxicity from a daily gemcitabine regimen (250 mg/m2/d x 4-5 days) was excessive (grade 3 mucositis) in one of two patients.  There were no reported episodes of hemorrhagic cystitis (hematuria) or nephrotoxicity.  At the 6- to 8-wk follow-up, there were six partial remissions, two mixed responses, and six patients with progressive disease.  In the 12 patients followed >1 yr, there have been no durable responses.  Thus, although high-dose 153Sm-EDTMP + gemcitabine has moderate palliative activity (improved pain; radiol. responses) in this poor-risk population, addnl. measures of local and systemic control are required for durable control of relapsed osteosarcoma with osteoblastic lesions.  The strategy of radioactive drug binding to a target followed by a radiosensitizer may provide synergy and improved response rate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSL-nvfRsnfLVg90H21EOLACvtfcHk0lg9pnGx7mvJvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVKiurrL&md5=699182dc8a4661cf51850e77b0aefdf7</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-05-0628&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-05-0628%26sid%3Dliteratum%253Aachs%26aulast%3DAnderson%26aufirst%3DP.%2BM.%26aulast%3DWiseman%26aufirst%3DG.%2BA.%26aulast%3DErlandson%26aufirst%3DL.%26aulast%3DRodriguez%26aufirst%3DV.%26aulast%3DTrotz%26aufirst%3DB.%26aulast%3DDubansky%26aufirst%3DS.%2BA.%26aulast%3DAlbritton%26aufirst%3DK.%26atitle%3DGemcitabine%2520Radiosensitization%2520after%2520High-Dose%2520Samarium%2520for%2520Osteoblastic%2520Osteosarcoma%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2005%26volume%3D11%26spage%3D6895%26epage%3D6900%26doi%3D10.1158%2F1078-0432.CCR-05-0628" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Akatsuka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wada, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kokai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawaguchi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamashiro, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawada, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamawaki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishii, S.</span></span> <span> </span><span class="NLM_article-title">Erbb2 Expression is Correlated with Increased Survival of Patients with Osteosarcoma</span>. <i>Cancer</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>94</i></span>,  <span class="NLM_fpage">1397</span>– <span class="NLM_lpage">1404</span>, <span class="refDoi"> DOI: 10.1002/cncr.10360</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1002%2Fcncr.10360" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=2002&pages=1397-1404&author=T.+Akatsukaauthor=T.+Wadaauthor=Y.+Kokaiauthor=S.+Kawaguchiauthor=K.+Isuauthor=K.+Yamashiroauthor=T.+Yamashitaauthor=N.+Sawadaauthor=S.+Yamawakiauthor=S.+Ishii&title=Erbb2+Expression+is+Correlated+with+Increased+Survival+of+Patients+with+Osteosarcoma&doi=10.1002%2Fcncr.10360"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1002%2Fcncr.10360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcncr.10360%26sid%3Dliteratum%253Aachs%26aulast%3DAkatsuka%26aufirst%3DT.%26aulast%3DWada%26aufirst%3DT.%26aulast%3DKokai%26aufirst%3DY.%26aulast%3DKawaguchi%26aufirst%3DS.%26aulast%3DIsu%26aufirst%3DK.%26aulast%3DYamashiro%26aufirst%3DK.%26aulast%3DYamashita%26aufirst%3DT.%26aulast%3DSawada%26aufirst%3DN.%26aulast%3DYamawaki%26aufirst%3DS.%26aulast%3DIshii%26aufirst%3DS.%26atitle%3DErbb2%2520Expression%2520is%2520Correlated%2520with%2520Increased%2520Survival%2520of%2520Patients%2520with%2520Osteosarcoma%26jtitle%3DCancer%26date%3D2002%26volume%3D94%26spage%3D1397%26epage%3D1404%26doi%3D10.1002%2Fcncr.10360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiseman, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dispenzieri, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arndt, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartmann, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smithson, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullan, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruland, O. S.</span></span> <span> </span><span class="NLM_article-title">High-Dose Samarium-153 Ethylene Diamine Tetramethylene Phosphonate: Low Toxicity of Skeletal Irradiation in Patients with Osteosarcoma and Bone Metastases</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">189</span>– <span class="NLM_lpage">196</span>, <span class="refDoi"> DOI: 10.1200/JCO.2002.20.1.189</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1200%2FJCO.2002.20.1.189" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=11773169" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=1%3ACAS%3A528%3ADC%252BD38XnsFeruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2002&pages=189-196&author=P.+M.+Andersonauthor=G.+A.+Wisemanauthor=A.+Dispenzieriauthor=C.+A.+Arndtauthor=L.+C.+Hartmannauthor=W.+A.+Smithsonauthor=B.+P.+Mullanauthor=O.+S.+Bruland&title=High-Dose+Samarium-153+Ethylene+Diamine+Tetramethylene+Phosphonate%3A+Low+Toxicity+of+Skeletal+Irradiation+in+Patients+with+Osteosarcoma+and+Bone+Metastases&doi=10.1200%2FJCO.2002.20.1.189"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">High-dose samarium-153 ethylene diamine tetramethylene phosphonate: Low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases</span></div><div class="casAuthors">Anderson, Peter M.; Wiseman, Gregory A.; Dispenzieri, Angela; Arndt, Carola A. S.; Hartmann, Lynn C.; Smithson, William A.; Mullan, Brian P.; Bruland, Oyvind S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">189-196</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Samarium-153 ethylene diamine tetramethylene phosphonate (153Sm-EDTMP), a bone-seeking radiopharmaceutical, provides therapeutic irradn. to osteoblastic bone metastases.  Because the dose-limiting toxicity of 153Sm-EDTMP is thrombocytopenia, a dose-escalation trial using peripheral-blood progenitor cells (PBPCs) or marrow support was conducted to treat metastatic bone cancer.  Patients with locally recurrent or metastatic osteosarcoma or skeletal metastases avid on bone scan were treated with 1, 3, 4.5, 6, 12, 19, or 30 mCi/kg of 153Sm-EDTMP.  Thirty patients were treated with 153Sm-EDTMP.  Transient symptoms of hypocalcemia were seen at 30 mCi/kg.  Ests. of radioisotope bound to bone surfaces and marrow radiation dose were linear with injected amt. of 153Sm-EDTMP.  Cytopenias also occurred in all subjects and were dose-related.  At day + 13 after 153Sm-EDTMP, residual whole-body radioactivity was 1% to 65% of whole-body radioactivity considered safe for PBPC infusion, 3.6 mCi.  After PBPC or marrow infusion on day + 14 after 153Sm-EDTMP, recovery of hematopoiesis was problematic in two patients at the 30 mCi/kg dose infused with less than 2 X 106 CD34+/kg on day + 14, but not in other patients.  Redn. or elimination of opiates for pain was seen in all patients.  Patients had no adverse changes in appetite or performance status.  153Sm-EDTMP with PBPC support can provide bone-specific therapeutic irradn. (ests. of 39 to 241 Gy).  Hematol. toxicity at 30 mCi 153Sm-EDTMP/kg requires PBPC grafts with more than 2 X 106 CD34+/kg to overcome myeloablative effects of skeletal irradn.  Nonhematol. side effects are minimal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruNsJ-Ss84ibVg90H21EOLACvtfcHk0lg9pnGx7mvJvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XnsFeruw%253D%253D&md5=e4466be01392edd123ce0b39c73dc169</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1200%2FJCO.2002.20.1.189&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2002.20.1.189%26sid%3Dliteratum%253Aachs%26aulast%3DAnderson%26aufirst%3DP.%2BM.%26aulast%3DWiseman%26aufirst%3DG.%2BA.%26aulast%3DDispenzieri%26aufirst%3DA.%26aulast%3DArndt%26aufirst%3DC.%2BA.%26aulast%3DHartmann%26aufirst%3DL.%2BC.%26aulast%3DSmithson%26aufirst%3DW.%2BA.%26aulast%3DMullan%26aufirst%3DB.%2BP.%26aulast%3DBruland%26aufirst%3DO.%2BS.%26atitle%3DHigh-Dose%2520Samarium-153%2520Ethylene%2520Diamine%2520Tetramethylene%2520Phosphonate%253A%2520Low%2520Toxicity%2520of%2520Skeletal%2520Irradiation%2520in%2520Patients%2520with%2520Osteosarcoma%2520and%2520Bone%2520Metastases%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2002%26volume%3D20%26spage%3D189%26epage%3D196%26doi%3D10.1200%2FJCO.2002.20.1.189" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burgert, E. O.,  Jr</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nesbit, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garnsey, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gehan, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrmann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vietti, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cangir, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tefft, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, P.</span></span> <span> </span><span class="NLM_article-title">Multimodal Therapy for the Management of Nonpelvic, Localized Ewing’s Sarcoma of Bone: Intergroup Study IESS-II</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1514</span>– <span class="NLM_lpage">1524</span>, <span class="refDoi"> DOI: 10.1200/JCO.1990.8.9.1514</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1200%2FJCO.1990.8.9.1514" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=2099751" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=1%3ACAS%3A280%3ADyaK3czmt1WltQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1990&pages=1514-1524&author=E.+O.+Burgertauthor=M.+E.+Nesbitauthor=L.+A.+Garnseyauthor=E.+A.+Gehanauthor=J.+Herrmannauthor=T.+J.+Viettiauthor=A.+Cangirauthor=M.+Tefftauthor=R.+Evansauthor=P.+Thomas&title=Multimodal+Therapy+for+the+Management+of+Nonpelvic%2C+Localized+Ewing%E2%80%99s+Sarcoma+of+Bone%3A+Intergroup+Study+IESS-II&doi=10.1200%2FJCO.1990.8.9.1514"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Multimodal therapy for the management of nonpelvic, localized Ewing's sarcoma of bone: intergroup study IESS-II</span></div><div class="casAuthors">Burgert E O Jr; Nesbit M E; Garnsey L A; Gehan E A; Herrmann J; Vietti T J; Cangir A; Tefft M; Evans R; Thomas P</div><div class="citationInfo"><span class="NLM_cas:title">Journal of clinical oncology : official journal of the American Society of Clinical Oncology</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1514-24</span>
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    </div><div class="casAbstract">Two hundred fourteen eligible patients with previously untreated, localized Ewing's sarcoma of bone were randomized on IESS-II to receive Adriamycin (ADR; doxorubicin; Adria Laboratories, Columbus, OH), cyclophosphamide, vincristine, and dactinomycin by either a high-dose intermittent method (treatment [trt] 1) or a moderate-dose continuous method (trt 2) similar to the four-drug arm of IESS-I.  Patient characteristics (sex, primary site, type of surgery) were stratified at the time of registration; these and other patient characteristics (age, time from symptoms to diagnosis, race) were distributed similarly between treatments.  Surgical resection was encouraged, but not mandatory.  Local radiation therapy was the same as for IESS-I.  The median follow-up time is 5.6 years.  The overall outcome was significantly better on trt 1 than on trt 2.  At 5 years, the estimated percentages of patients who were disease-free, relapse-free, and surviving were 68%, 73%, and 77% for trt 1 and 48%, 56%, and 63% for trt 2 (P = .02, .03, and .05, respectively).  The major reason for treatment failure for both treatment groups was the development of metastatic disease.  The lung was the most common site of metastases followed by bone sites.  The combined incidence of severe or worse toxicity (67%) was comparable between the treatments; however, severe or worse cardiovascular toxicity was significantly greater on trt 1.  Tne only treatment-associated deaths (N = 3) were on trt 1 and were cardiac-related.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRMLN3XNXXtEcSzjBFCN0BJfW6udTcc2eZskFJ7cFhLvLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK3czmt1WltQ%253D%253D&md5=64dde0b2f89f1a9d054f202127ea25d8</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1200%2FJCO.1990.8.9.1514&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.1990.8.9.1514%26sid%3Dliteratum%253Aachs%26aulast%3DBurgert%26aufirst%3DE.%2BO.%26aulast%3DNesbit%26aufirst%3DM.%2BE.%26aulast%3DGarnsey%26aufirst%3DL.%2BA.%26aulast%3DGehan%26aufirst%3DE.%2BA.%26aulast%3DHerrmann%26aufirst%3DJ.%26aulast%3DVietti%26aufirst%3DT.%2BJ.%26aulast%3DCangir%26aufirst%3DA.%26aulast%3DTefft%26aufirst%3DM.%26aulast%3DEvans%26aufirst%3DR.%26aulast%3DThomas%26aufirst%3DP.%26atitle%3DMultimodal%2520Therapy%2520for%2520the%2520Management%2520of%2520Nonpelvic%252C%2520Localized%2520Ewing%25E2%2580%2599s%2520Sarcoma%2520of%2520Bone%253A%2520Intergroup%2520Study%2520IESS-II%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D1990%26volume%3D8%26spage%3D1514%26epage%3D1524%26doi%3D10.1200%2FJCO.1990.8.9.1514" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ferrari, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smeland, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mercuri, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertoni, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Longhi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruggieri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvegard, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Picci, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capanna, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernini, G.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Neoadjuvant Chemotherapy with High-Dose Ifosfamide, High-Dose Methotrexate, Cisplatin, And Doxorubicin for Patients with Localized Osteosarcoma of the Extremity: A Joint Study by the Italian and Scandinavian Sarcoma Groups</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">8845</span>– <span class="NLM_lpage">8852</span>, <span class="refDoi"> DOI: 10.1200/JCO.2004.00.5785</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1200%2FJCO.2004.00.5785" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=16246977" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=1%3ACAS%3A280%3ADC%252BD2Mnlt1Gqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=8845-8852&author=S.+Ferrariauthor=S.+Smelandauthor=M.+Mercuriauthor=F.+Bertoniauthor=A.+Longhiauthor=P.+Ruggieriauthor=T.+A.+Alvegardauthor=P.+Picciauthor=R.+Capannaauthor=G.+Bernini&title=Neoadjuvant+Chemotherapy+with+High-Dose+Ifosfamide%2C+High-Dose+Methotrexate%2C+Cisplatin%2C+And+Doxorubicin+for+Patients+with+Localized+Osteosarcoma+of+the+Extremity%3A+A+Joint+Study+by+the+Italian+and+Scandinavian+Sarcoma+Groups&doi=10.1200%2FJCO.2004.00.5785"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups</span></div><div class="casAuthors">Ferrari Stefano; Smeland Sigbjorn; Mercuri Mario; Bertoni Franco; Longhi Alessandra; Ruggieri Pietro; Alvegard Thor A; Picci Piero; Capanna Rodolfo; Bernini Gabriella; Muller Cristoph; Tienghi Amelia; Wiebe Thomas; Comandone Alessandro; Bohling Tom; Del Prever Adalberto Brach; Brosjo Otte; Bacci Gaetano; Saeter Gunnar</div><div class="citationInfo"><span class="NLM_cas:title">Journal of clinical oncology : official journal of the American Society of Clinical Oncology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">8845-52</span>
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    </div><div class="casAbstract">PURPOSE:  To explore the effect of high-dose ifosfamide in first-line treatment for patients < or = 40 years of age with nonmetastatic osteosarcoma of the extremity.  PATIENTS AND METHODS:  From March 1997 to September 2000, 182 patients were evaluated.  Primary treatment consisted of two blocks of high-dose ifosfamide (15 g/m2), methotrexate (12 g/m2), cisplatin (120 mg/m2), and doxorubicin (75 mg/m2).  Postoperatively, patients received two cycles of doxorubicin (90 mg/m2), and three cycles each of high-dose ifosfamide, methotrexate, and cisplatin (120 to 150 mg/m2).  Granulocyte colony-stimulating factor support was mandatory after the high-dose ifosfamide/cisplatin/doxorubicin combination.  RESULTS:  No disease progression was recorded during primary chemotherapy, 164 patients (92%) underwent limb-salvage surgery, four patients (2%) underwent rotation plasty, and 11 patients (6%) had limbs amputated.  Three (1.6%) patients died as a result of treatment-related toxicity, and one died as a result of pulmonary embolism after pathologic fracture.  Grade 4 neutropenia and thrombocytopenia followed 52% and 31% of all courses, respectively, and mild to severe nephrotoxicity was recorded in 19 patients (10%).  The median received dose-intensity compared with protocol was 0.82.  With a median follow-up of 55 months, the 5-year probability of event-free survival was 64% (95% CI, 57% to 71%) and overall survival was 77% (95% CI, 67% to 81%), whereas seven patients (4%) experienced local recurrence.  CONCLUSION:  The addition of high-dose ifosfamide to methotrexate, cisplatin, and doxorubicin in the preoperative phase is feasible, but with major renal and hematologic toxicities, and survival rates similar to those obtained with four-drug regimens using standard-dose ifosfamide.  Italian Sarcoma Group/Scandinavian Sarcoma Group study I showed that in a multicenter setting, more than 90% of patients with osteosarcoma of the extremity can undergo conservative surgery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRTzI9O1e9KT1Zoq0fPSOTvfW6udTcc2eZskFJ7cFhLvLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2Mnlt1Gqtw%253D%253D&md5=3fdde0ca71453e1940e56d1e4b64ebe5</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1200%2FJCO.2004.00.5785&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2004.00.5785%26sid%3Dliteratum%253Aachs%26aulast%3DFerrari%26aufirst%3DS.%26aulast%3DSmeland%26aufirst%3DS.%26aulast%3DMercuri%26aufirst%3DM.%26aulast%3DBertoni%26aufirst%3DF.%26aulast%3DLonghi%26aufirst%3DA.%26aulast%3DRuggieri%26aufirst%3DP.%26aulast%3DAlvegard%26aufirst%3DT.%2BA.%26aulast%3DPicci%26aufirst%3DP.%26aulast%3DCapanna%26aufirst%3DR.%26aulast%3DBernini%26aufirst%3DG.%26atitle%3DNeoadjuvant%2520Chemotherapy%2520with%2520High-Dose%2520Ifosfamide%252C%2520High-Dose%2520Methotrexate%252C%2520Cisplatin%252C%2520And%2520Doxorubicin%2520for%2520Patients%2520with%2520Localized%2520Osteosarcoma%2520of%2520the%2520Extremity%253A%2520A%2520Joint%2520Study%2520by%2520the%2520Italian%2520and%2520Scandinavian%2520Sarcoma%2520Groups%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2005%26volume%3D23%26spage%3D8845%26epage%3D8852%26doi%3D10.1200%2FJCO.2004.00.5785" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gorlick, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huvos, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heller, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aledo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beardsley, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Healey, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyers, P. A.</span></span> <span> </span><span class="NLM_article-title">Expression of HER2/Erbb-2 Correlates with Survival in Osteosarcoma</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">2781</span>– <span class="NLM_lpage">2788</span>, <span class="refDoi"> DOI: 10.1200/JCO.1999.17.9.2781</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1200%2FJCO.1999.17.9.2781" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10561353" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=1%3ACAS%3A280%3ADC%252BD3c%252FjtVSrsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1999&pages=2781-2788&author=R.+Gorlickauthor=A.+G.+Huvosauthor=G.+Hellerauthor=A.+Aledoauthor=G.+P.+Beardsleyauthor=J.+H.+Healeyauthor=P.+A.+Meyers&title=Expression+of+HER2%2FErbb-2+Correlates+with+Survival+in+Osteosarcoma&doi=10.1200%2FJCO.1999.17.9.2781"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Expression of HER2/erbB-2 correlates with survival in osteosarcoma</span></div><div class="casAuthors">Gorlick R; Huvos A G; Heller G; Aledo A; Beardsley G P; Healey J H; Meyers P A</div><div class="citationInfo"><span class="NLM_cas:title">Journal of clinical oncology : official journal of the American Society of Clinical Oncology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2781-8</span>
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    </div><div class="casAbstract">PURPOSE:  In osteosarcoma, prognostic factors at diagnosis other than clinical stage have not been clearly identified.  The aim of this study was to determine whether human epidermal growth factor receptor 2 (HER2)/erbB-2, p-glycoprotein, or p53 expression correlated with histologic response to preoperative chemotherapy or event-free survival.  PATIENTS AND METHODS:  We performed a retrospective immunohistochemical study on material obtained from patients treated on the Memorial Sloan-Kettering Cancer Center T12 protocol between 1986 and 1993.  Paraffin-embedded tissue was identified from 53 patients (73% of patients enrolled onto protocol) and stained for HER2/erbB-2, p53, and p-glycoprotein expression using standard monoclonal antibodies and methods.  RESULTS:  At the time of initial biopsy, 20 (42.6%) of 47 samples demonstrated high levels of HER2/erbB-2 expression.  Higher frequencies of expression were observed in samples from patients with metastatic disease at presentation and at the time of relapse.  Expression of HER2/erbB-2 correlated with a significantly worse histologic response (P =.03).  In patients presenting with nonmetastatic disease, expression of HER2/erbB-2 at the time of initial biopsy was associated with a significantly decreased event-free survival (47% v 79% at 5 years, P =.05). p53 and p-glycoprotein expression did not correlate with histologic response or patient event-free survival.  CONCLUSION:  The correlation of HER2/erbB-2 expression with histologic response to preoperative chemotherapy and event-free survival in this study suggests that HER2/erbB-2 should be evaluated prospectively as a prognostic indicator.  The correlation also suggests that clinical trials of antibodies that target this receptor, such as recombinant humanized anti-HER2 monoclonal antibody (Herceptin; Genentech, San Francisco, CA), should be considered for the treatment of osteosarcoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTJCWG9F5gqCNts4TFFB11gfW6udTcc2eZskFJ7cFhLvLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3c%252FjtVSrsA%253D%253D&md5=4a6955692246eb1b83143e9f7db9b249</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1200%2FJCO.1999.17.9.2781&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.1999.17.9.2781%26sid%3Dliteratum%253Aachs%26aulast%3DGorlick%26aufirst%3DR.%26aulast%3DHuvos%26aufirst%3DA.%2BG.%26aulast%3DHeller%26aufirst%3DG.%26aulast%3DAledo%26aufirst%3DA.%26aulast%3DBeardsley%26aufirst%3DG.%2BP.%26aulast%3DHealey%26aufirst%3DJ.%2BH.%26aulast%3DMeyers%26aufirst%3DP.%2BA.%26atitle%3DExpression%2520of%2520HER2%252FErbb-2%2520Correlates%2520with%2520Survival%2520in%2520Osteosarcoma%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D1999%26volume%3D17%26spage%3D2781%26epage%3D2788%26doi%3D10.1200%2FJCO.1999.17.9.2781" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grier, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krailo, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarbell, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Link, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fryer, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pritchard, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gebhardt, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickman, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perlman, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyers, P. A.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Addition of Ifosfamide and Etoposide to Standard Chemotherapy for Ewing’s Sarcoma and Primitive Neuroectodermal Tumor of Bone</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>348</i></span>,  <span class="NLM_fpage">694</span>– <span class="NLM_lpage">701</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa020890</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1056%2FNEJMoa020890" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=12594313" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhtlWjt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=348&publication_year=2003&pages=694-701&author=H.+E.+Grierauthor=M.+D.+Krailoauthor=N.+J.+Tarbellauthor=M.+P.+Linkauthor=C.+J.+Fryerauthor=D.+J.+Pritchardauthor=M.+C.+Gebhardtauthor=P.+S.+Dickmanauthor=E.+J.+Perlmanauthor=P.+A.+Meyers&title=Addition+of+Ifosfamide+and+Etoposide+to+Standard+Chemotherapy+for+Ewing%E2%80%99s+Sarcoma+and+Primitive+Neuroectodermal+Tumor+of+Bone&doi=10.1056%2FNEJMoa020890"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone</span></div><div class="casAuthors">Grier, Holcombe E.; Krailo, Mark D.; Tarbell, Nancy J.; Link, Michael P.; Fryer, Christopher J. H.; Pritchard, Douglas J.; Gebhardt, Mark C.; Dickman, Paul S.; Perlman, Elizabeth J.; Meyers, Paul A.; Donaldson, Sarah S.; Moore, Sheila; Rausen, Aaron R.; Vietti, Teresa J.; Miser, James S.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">348</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">694-701</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background: Ewing's sarcoma and primitive neuroectodermal tumor of bone are closely related, highly malignant tumors of children, adolescents, and young adults.  A new drug combination, ifosfamide and etoposide, was highly effective in patients with Ewing's sarcoma or primitive neuroectodermal tumor of bone who had a relapse after std. therapy.  We designed a study to test whether the addn. of these drugs to a std. regimen would improve the survival of patients with newly diagnosed disease.  Methods: Patients 30 yr old or younger with Ewing's sarcoma, primitive neuroectodermal tumor of bone, or primitive sarcoma of bone were eligible.  The patients were randomly assigned to receive 49 wk of std. chemotherapy with doxorubicin, vincristine, cyclophosphamide, and dactinomycin or exptl. therapy with these four drugs alternating with courses of ifosfamide and etoposide.  Results: A total of 518 patients met the eligibility requirements.  Of 120 patients with metastatic disease, 62 were randomly assigned to the std.-therapy group and 58 to the exptl.-therapy group.  There was no significant difference in five-year event-free survival between the treatment groups (P = 0.81).  Among the 398 patients with nonmetastatic disease, the mean (±SE) five-year event-free survival among the 198 patients in the exptl.-therapy group was 69 ± 3 percent, as compared with 54 ± 4 percent among the 200 patients in the std.-therapy group (P = 0.005).  Overall survival was also significantly better among patients in the exptl.-therapy group (72 ± 3.4 percent vs. 61 ± 3.6 percent in the std.-therapy group, P = 0.01).  Conclusions: The addn. of ifosfamide and etoposide to a std. regimen does not affect the outcome for patients with metastatic disease, but it significantly improves the outcome for patients with nonmetastatic Ewing's sarcoma, primitive neuroectodermal tumor of bone, or primitive sarcoma of bone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9-41yaquvoLVg90H21EOLACvtfcHk0ljNL6f_PAAhUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhtlWjt70%253D&md5=0bd0ba73197360811241a4798036a6e9</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa020890&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa020890%26sid%3Dliteratum%253Aachs%26aulast%3DGrier%26aufirst%3DH.%2BE.%26aulast%3DKrailo%26aufirst%3DM.%2BD.%26aulast%3DTarbell%26aufirst%3DN.%2BJ.%26aulast%3DLink%26aufirst%3DM.%2BP.%26aulast%3DFryer%26aufirst%3DC.%2BJ.%26aulast%3DPritchard%26aufirst%3DD.%2BJ.%26aulast%3DGebhardt%26aufirst%3DM.%2BC.%26aulast%3DDickman%26aufirst%3DP.%2BS.%26aulast%3DPerlman%26aufirst%3DE.%2BJ.%26aulast%3DMeyers%26aufirst%3DP.%2BA.%26atitle%3DAddition%2520of%2520Ifosfamide%2520and%2520Etoposide%2520to%2520Standard%2520Chemotherapy%2520for%2520Ewing%25E2%2580%2599s%2520Sarcoma%2520and%2520Primitive%2520Neuroectodermal%2520Tumor%2520of%2520Bone%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2003%26volume%3D348%26spage%3D694%26epage%3D701%26doi%3D10.1056%2FNEJMoa020890" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Le
Deley, M.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guinebretière, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gentet, J.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pacquement, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pichon, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marec-Bérard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Entz-Werlé, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brugières, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanel, D.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">SFOP OS94: A Randomised Trial Comparing Preoperative High-Dose Methotrexate Plus Doxorubicin to High-Dose Methotrexate Plus Etoposide and Ifosfamide in Osteosarcoma Patients</span>. <i>Eur. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">752</span>– <span class="NLM_lpage">761</span>, <span class="refDoi"> DOI: 10.1016/j.ejca.2006.10.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1016%2Fj.ejca.2006.10.023" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2007&pages=752-761&author=M.-C.+Le%0ADeleyauthor=J.-M.+Guinebreti%C3%A8reauthor=J.-C.+Gentetauthor=H.+Pacquementauthor=F.+Pichonauthor=P.+Marec-B%C3%A9rardauthor=N.+Entz-Werl%C3%A9author=C.+Schmittauthor=L.+Brugi%C3%A8resauthor=D.+Vanel&title=SFOP+OS94%3A+A+Randomised+Trial+Comparing+Preoperative+High-Dose+Methotrexate+Plus+Doxorubicin+to+High-Dose+Methotrexate+Plus+Etoposide+and+Ifosfamide+in+Osteosarcoma+Patients&doi=10.1016%2Fj.ejca.2006.10.023"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.ejca.2006.10.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejca.2006.10.023%26sid%3Dliteratum%253Aachs%26aulast%3DLe%2BDeley%26aufirst%3DM.-C.%26aulast%3DGuinebreti%25C3%25A8re%26aufirst%3DJ.-M.%26aulast%3DGentet%26aufirst%3DJ.-C.%26aulast%3DPacquement%26aufirst%3DH.%26aulast%3DPichon%26aufirst%3DF.%26aulast%3DMarec-B%25C3%25A9rard%26aufirst%3DP.%26aulast%3DEntz-Werl%25C3%25A9%26aufirst%3DN.%26aulast%3DSchmitt%26aufirst%3DC.%26aulast%3DBrugi%25C3%25A8res%26aufirst%3DL.%26aulast%3DVanel%26aufirst%3DD.%26atitle%3DSFOP%2520OS94%253A%2520A%2520Randomised%2520Trial%2520Comparing%2520Preoperative%2520High-Dose%2520Methotrexate%2520Plus%2520Doxorubicin%2520to%2520High-Dose%2520Methotrexate%2520Plus%2520Etoposide%2520and%2520Ifosfamide%2520in%2520Osteosarcoma%2520Patients%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2007%26volume%3D43%26spage%3D752%26epage%3D761%26doi%3D10.1016%2Fj.ejca.2006.10.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Susa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milane, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amiji, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hornicek, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, Z.</span></span> <span> </span><span class="NLM_article-title">Nanoparticles: A Promising Modality in the Treatment of Sarcomas</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">260</span>– <span class="NLM_lpage">272</span>, <span class="refDoi"> DOI: 10.1007/s11095-010-0173-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1007%2Fs11095-010-0173-z" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2011&pages=260-272&author=M.+Susaauthor=L.+Milaneauthor=M.+M.+Amijiauthor=F.+J.+Hornicekauthor=Z.+Duan&title=Nanoparticles%3A+A+Promising+Modality+in+the+Treatment+of+Sarcomas&doi=10.1007%2Fs11095-010-0173-z"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1007%2Fs11095-010-0173-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11095-010-0173-z%26sid%3Dliteratum%253Aachs%26aulast%3DSusa%26aufirst%3DM.%26aulast%3DMilane%26aufirst%3DL.%26aulast%3DAmiji%26aufirst%3DM.%2BM.%26aulast%3DHornicek%26aufirst%3DF.%2BJ.%26aulast%3DDuan%26aufirst%3DZ.%26atitle%3DNanoparticles%253A%2520A%2520Promising%2520Modality%2520in%2520the%2520Treatment%2520of%2520Sarcomas%26jtitle%3DPharm.%2520Res.%26date%3D2011%26volume%3D28%26spage%3D260%26epage%3D272%26doi%3D10.1007%2Fs11095-010-0173-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eaves, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Currier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cripe, T. P.</span></span> <span> </span><span class="NLM_article-title">Preclinical Evaluation of Nanoparticle Albumin-Bound Paclitaxel for Treatment of Pediatric Bone Sarcoma</span>. <i>Pediatric blood & cancer</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">2096</span>– <span class="NLM_lpage">2098</span>, <span class="refDoi"> DOI: 10.1002/pbc.25062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1002%2Fpbc.25062" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2014&pages=2096-2098&author=L.+M.+Wagnerauthor=H.+Yinauthor=D.+Eavesauthor=M.+Currierauthor=T.+P.+Cripe&title=Preclinical+Evaluation+of+Nanoparticle+Albumin-Bound+Paclitaxel+for+Treatment+of+Pediatric+Bone+Sarcoma&doi=10.1002%2Fpbc.25062"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1002%2Fpbc.25062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpbc.25062%26sid%3Dliteratum%253Aachs%26aulast%3DWagner%26aufirst%3DL.%2BM.%26aulast%3DYin%26aufirst%3DH.%26aulast%3DEaves%26aufirst%3DD.%26aulast%3DCurrier%26aufirst%3DM.%26aulast%3DCripe%26aufirst%3DT.%2BP.%26atitle%3DPreclinical%2520Evaluation%2520of%2520Nanoparticle%2520Albumin-Bound%2520Paclitaxel%2520for%2520Treatment%2520of%2520Pediatric%2520Bone%2520Sarcoma%26jtitle%3DPediatric%2520blood%2520%2526%2520cancer%26date%3D2014%26volume%3D61%26spage%3D2096%26epage%3D2098%26doi%3D10.1002%2Fpbc.25062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seitoku, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwadera, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamba, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamagata, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akasaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kusaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yawaka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iida, J.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Estimation of Biocompatibility of Nano-Sized Ceramic Particles with Osteoblasts, Osteosarcomas and Hepatocytes by Static and Time-Lapse Observation</span>. <i>J. Biomed. Nanotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">472</span>– <span class="NLM_lpage">480</span>, <span class="refDoi"> DOI: 10.1166/jbn.2016.2190</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1166%2Fjbn.2016.2190" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=27280245" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVKlt7rP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=472-480&author=S.+Abeauthor=E.+Seitokuauthor=N.+Iwaderaauthor=Y.+Hambaauthor=S.+Yamagataauthor=T.+Akasakaauthor=T.+Kusakaauthor=S.+Inoueauthor=Y.+Yawakaauthor=J.+Iida&title=Estimation+of+Biocompatibility+of+Nano-Sized+Ceramic+Particles+with+Osteoblasts%2C+Osteosarcomas+and+Hepatocytes+by+Static+and+Time-Lapse+Observation&doi=10.1166%2Fjbn.2016.2190"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Estimation of biocompatibility of nano-sized ceramic particles with osteoblasts, osteosarcomas and hepatocytes by static and time-lapse observation</span></div><div class="casAuthors">Abe, Shigeaki; Seitoku, Eri; Iwadera, Nobuki; Hamba, Yusuke; Yamagata, Shuichi; Akasaka, Tsukasa; Kusaka, Teruo; Inoue, Satoshi; Yawaka, Yasutaka; Iida, Junichiro; Sano, Hidehiko; Yonezawa, Tetsu; Yoshida, Yasuhiro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biomedical Nanotechnology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">472-480</span>CODEN:
                <span class="NLM_cas:coden">JBNOAB</span>;
        ISSN:<span class="NLM_cas:issn">1550-7033</span>.
    
            (<span class="NLM_cas:orgname">American Scientific Publishers</span>)
        </div><div class="casAbstract">We assessed the biocompatibility of nano-sized ceramic particles with several cells types.  Though these particles have less than 100 nm in diam., they act as submicron-sized particles in saline by aggregation that was estd. using laser diffraction particle size anal. (LDS). they act as submicro-sized particles in saline by aggregation based on laser diffraction particle size anal. (LDS).  Several types of cells (osteoblasts, osteosarcoma and hepatocyte cells) were exposed to these particles and their cytocompatibility was estd.  Not only the cytotoxic assay but also their static and dynamic morphol. under nanoparticles exposure were investigated.  The intercellular uptake of particles was detd. using a confocal fluorescence microscope.  The particles used in this study did not inhibit cellular activity or growth even when their concns. were high.  Only copper oxide particles caused acute cytotoxicity depending on the particle size.  The cytotoxicity assay, dynamic behavior of the nanoparticle-exposed cells and their examn. under a confocal fluorescence microscope suggests that the irritative reaction was induced by contact between the cells and particles, whereas eluted copper ions are not dominant factor.  These results indicate that nano-sized particles used in this study have excellent biocompatibility except copper oxide ones.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomwSUM7xsZ-bVg90H21EOLACvtfcHk0lj_mjdmpLSlJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVKlt7rP&md5=7a66b4e30c38b94075aafef3371a8b90</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1166%2Fjbn.2016.2190&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1166%252Fjbn.2016.2190%26sid%3Dliteratum%253Aachs%26aulast%3DAbe%26aufirst%3DS.%26aulast%3DSeitoku%26aufirst%3DE.%26aulast%3DIwadera%26aufirst%3DN.%26aulast%3DHamba%26aufirst%3DY.%26aulast%3DYamagata%26aufirst%3DS.%26aulast%3DAkasaka%26aufirst%3DT.%26aulast%3DKusaka%26aufirst%3DT.%26aulast%3DInoue%26aufirst%3DS.%26aulast%3DYawaka%26aufirst%3DY.%26aulast%3DIida%26aufirst%3DJ.%26atitle%3DEstimation%2520of%2520Biocompatibility%2520of%2520Nano-Sized%2520Ceramic%2520Particles%2520with%2520Osteoblasts%252C%2520Osteosarcomas%2520and%2520Hepatocytes%2520by%2520Static%2520and%2520Time-Lapse%2520Observation%26jtitle%3DJ.%2520Biomed.%2520Nanotechnol.%26date%3D2016%26volume%3D12%26spage%3D472%26epage%3D480%26doi%3D10.1166%2Fjbn.2016.2190" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunda, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Askhatova, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farokhzad, O. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parangi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, J.</span></span> <span> </span><span class="NLM_article-title">Theranostic Near-Infrared Fluorescent Nanoplatform for Imaging and Systemic Sirna Delivery to Metastatic Anaplastic Thyroid Cancer</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>113</i></span>,  <span class="NLM_fpage">7750</span>– <span class="NLM_lpage">7755</span>, <span class="refDoi"> DOI: 10.1073/pnas.1605841113</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1073%2Fpnas.1605841113" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=27342857" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFentrbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2016&pages=7750-7755&author=Y.+Liuauthor=V.+Gundaauthor=X.+Zhuauthor=X.+Xuauthor=J.+Wuauthor=D.+Askhatovaauthor=O.+C.+Farokhzadauthor=S.+Parangiauthor=J.+Shi&title=Theranostic+Near-Infrared+Fluorescent+Nanoplatform+for+Imaging+and+Systemic+Sirna+Delivery+to+Metastatic+Anaplastic+Thyroid+Cancer&doi=10.1073%2Fpnas.1605841113"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Theranostic near-infrared fluorescent nanoplatform for imaging and systemic siRNA delivery to metastatic anaplastic thyroid cancer</span></div><div class="casAuthors">Liu, Yanlan; Gunda, Viswanath; Zhu, Xi; Xu, Xiaoding; Wu, Jun; Askhatova, Diana; Farokhzad, Omid C.; Parangi, Sareh; Shi, Jinjun</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">28</span>),
    <span class="NLM_cas:pages">7750-7755</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Anaplastic thyroid cancer (ATC), one of the most aggressive solid tumors, is characterized by rapid tumor growth and severe metastasis to other organs.  Owing to the lack of effective treatment options, ATC has a mortality rate of ∼100% and median survival of less than 5 mo.  RNAi nanotechnol. represents a promising strategy for cancer therapy through nanoparticle (NP) -mediated delivery of RNAi agents (e.g., siRNA) to solid tumors for specific silencing of target genes driving growth and/or metastasis.  Nevertheless, the clin. success of RNAi cancer nanotherapies remains elusive in large part because of the suboptimal systemic siRNA NP delivery to tumors and the fact that tumor heterogeneity produces variable NP accumulation and thus, therapeutic response.  To address these challenges, the authors here present an innovative theranostic NP platform composed of a near-IR (NIR) fluorescent polymer for effective in vivo siRNA delivery to ATC tumors and simultaneous tracking of the tumor accumulation by noninvasive NIR imaging.  The NIR polymeric NPs are small (∼50 nm), show long blood circulation and high tumor accumulation, and facilitate tumor imaging.  Systemic siRNA delivery using these NPs efficiently silences the expression of V-Raf murine sarcoma viral oncogene homolog B (BRAF) in tumor tissues and significantly suppresses tumor growth and metastasis in an orthotopic mouse model of ATC.  These results suggest that this theranostic NP system could become an effective tool for NIR imaging-guided siRNA delivery for personalized treatment of advanced malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5s5UIc3a6kbVg90H21EOLACvtfcHk0lj_mjdmpLSlJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFentrbM&md5=3dcd1a8ae78921319165abb95498fdc6</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1605841113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1605841113%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DGunda%26aufirst%3DV.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DAskhatova%26aufirst%3DD.%26aulast%3DFarokhzad%26aufirst%3DO.%2BC.%26aulast%3DParangi%26aufirst%3DS.%26aulast%3DShi%26aufirst%3DJ.%26atitle%3DTheranostic%2520Near-Infrared%2520Fluorescent%2520Nanoplatform%2520for%2520Imaging%2520and%2520Systemic%2520Sirna%2520Delivery%2520to%2520Metastatic%2520Anaplastic%2520Thyroid%2520Cancer%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2016%26volume%3D113%26spage%3D7750%26epage%3D7755%26doi%3D10.1073%2Fpnas.1605841113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Makridis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tziomaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Topouridou, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yavropoulou, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yovos, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalogirou, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samaras, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angelakeris, M.</span></span> <span> </span><span class="NLM_article-title">A Novel Strategy Combining Magnetic Particle Hyperthermia Pulses with Enhanced Performance Binary Ferrite Carriers for Effective In Vitro Manipulation of Primary Human Osteogenic Sarcoma Cells</span>. <i>Int. J. Hyperthermia</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">778</span>– <span class="NLM_lpage">785</span>, <span class="refDoi"> DOI: 10.1080/02656736.2016.1216183</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1080%2F02656736.2016.1216183" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=27442884" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlaksLvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2016&pages=778-785&author=A.+Makridisauthor=M.+Tziomakiauthor=K.+Topouridouauthor=M.+P.+Yavropoulouauthor=J.+G.+Yovosauthor=O.+Kalogirouauthor=T.+Samarasauthor=M.+Angelakeris&title=A+Novel+Strategy+Combining+Magnetic+Particle+Hyperthermia+Pulses+with+Enhanced+Performance+Binary+Ferrite+Carriers+for+Effective+In+Vitro+Manipulation+of+Primary+Human+Osteogenic+Sarcoma+Cells&doi=10.1080%2F02656736.2016.1216183"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">A novel strategy combining magnetic particle hyperthermia pulses with enhanced performance binary ferrite carriers for effective in vitro manipulation of primary human osteogenic sarcoma cells</span></div><div class="casAuthors">Makridis, Antonios; Tziomaki, Magdalini; Topouridou, Konstantina; Yavropoulou, Maria P.; Yovos, John G.; Kalogirou, Orestis; Samaras, Theodoros; Angelakeris, Mavroeidis</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Hyperthermia</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">778-785</span>CODEN:
                <span class="NLM_cas:coden">IJHYEQ</span>;
        ISSN:<span class="NLM_cas:issn">0265-6736</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">The present study examines the heating efficiency of a combination of manganese or cobalt ferrites in a binary (Co- or Mn-) ferrite nanoparticle form with magnetite, covered with citric acid to improve biocompatibility.  The nanoparticle synthesis is based on the aq. co-pptn. of proper salts, a facile, low-cost, environmentally friendly and high yield synthetic approach.  By detailed structural and magnetic characterization, the direct influence of structural and magnetic features on magnetic hyperthermia concludes to optimum heating efficiency.  At a second stage, best performing magnetic nanoparticles undergo in vitro testing in three cell lines: one cancer cell line and two ref. healthy cell lines.  Both binary ferrite (MnFe2O4/Fe3O4 and CoFe2O4/Fe3O4) appear to be internalised and well tolerated by the cells while a versatile hyperthermia protocol is attempted in an effort to further improve their in vitro performance.  Within this protocol, hyperthermia sequences are split in two runs with an intermediate 48 h time interval cell incubation stage while in each run a variable field mode (single or multiple pulses) is applied.  Single-pulse field mode represents a typical hyperthermia application scheme where cells undergo the thermal shock continuously.  On the other hand multiple-pulses mode refers to multiple, much shorter in duration AC field changes (field ON/OFFs), at each hyperthermia run, resulting eventually in high heating rate and much more harmful cell treatment.  Consequently, we propose a novel series of improved performance heat mediators based on ferrite structures which show max. efficiency at cancer cells when combined with a versatile multiple-pulse hyperthermia module.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQyWFFVq0IorVg90H21EOLACvtfcHk0lj_mjdmpLSlJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlaksLvI&md5=1042c4e8fa340b0e564df755a502c765</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1080%2F02656736.2016.1216183&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F02656736.2016.1216183%26sid%3Dliteratum%253Aachs%26aulast%3DMakridis%26aufirst%3DA.%26aulast%3DTziomaki%26aufirst%3DM.%26aulast%3DTopouridou%26aufirst%3DK.%26aulast%3DYavropoulou%26aufirst%3DM.%2BP.%26aulast%3DYovos%26aufirst%3DJ.%2BG.%26aulast%3DKalogirou%26aufirst%3DO.%26aulast%3DSamaras%26aufirst%3DT.%26aulast%3DAngelakeris%26aufirst%3DM.%26atitle%3DA%2520Novel%2520Strategy%2520Combining%2520Magnetic%2520Particle%2520Hyperthermia%2520Pulses%2520with%2520Enhanced%2520Performance%2520Binary%2520Ferrite%2520Carriers%2520for%2520Effective%2520In%2520Vitro%2520Manipulation%2520of%2520Primary%2520Human%2520Osteogenic%2520Sarcoma%2520Cells%26jtitle%3DInt.%2520J.%2520Hyperthermia%26date%3D2016%26volume%3D32%26spage%3D778%26epage%3D785%26doi%3D10.1080%2F02656736.2016.1216183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiao, J.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, P.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.-Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, C.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H.-L.</span></span> <span> </span><span class="NLM_article-title">In Vivo Synergistic Antitumor Effect and Safety of Sirna and Lonidamine Dual-Loaded Hierarchical Targeted Nanoparticles</span>. <i>Int. J. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>506</i></span>,  <span class="NLM_fpage">207</span>– <span class="NLM_lpage">213</span>, <span class="refDoi"> DOI: 10.1016/j.ijpharm.2016.04.056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1016%2Fj.ijpharm.2016.04.056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=27113867" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=1%3ACAS%3A528%3ADC%252BC28XntVCrs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=506&publication_year=2016&pages=207-213&author=B.-F.+Zhangauthor=L.+Xingauthor=J.-B.+Qiaoauthor=P.-F.+Cuiauthor=F.-Z.+Wangauthor=J.-L.+Zhangauthor=C.-X.+Xuauthor=H.-L.+Jiang&title=In+Vivo+Synergistic+Antitumor+Effect+and+Safety+of+Sirna+and+Lonidamine+Dual-Loaded+Hierarchical+Targeted+Nanoparticles&doi=10.1016%2Fj.ijpharm.2016.04.056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">In vivo synergistic antitumor effect and safety of siRNA and lonidamine dual-loaded hierarchical targeted nanoparticles</span></div><div class="casAuthors">Zhang, Bing-Feng; Xing, Lei; Qiao, Jian-Bin; Cui, Peng-Fei; Wang, Feng-Zhen; Zhang, Jia-Liang; Xu, Cheng-Xiong; Jiang, Hu-Lin</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Pharmaceutics (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">506</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">207-213</span>CODEN:
                <span class="NLM_cas:coden">IJPHDE</span>;
        ISSN:<span class="NLM_cas:issn">0378-5173</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Based on development of nano-delivery system, co-delivery of chemotherapeutic drug and small interfering RNA (siRNA) has exerted a promising advantage in cancer therapy.  In this work, the superiority of synergistic therapy and safety of the hierarchical targeted co-delivery system loaded with siRNA and lonidamine (LND) were evaluated.  The in vivo tumor accumulation ability and cancer growth inhibition effect of the polymer-blend nanocarriers were evaluated by a H22 s.c. sarcoma model.  Moreover, hematoxylin and eosin (H&E) staining and transferase-mediated dUTP nick end-labeling (TUNEL) staining of tumor sections from each group were compared to assess the therapeutic efficacy.  The dual-loaded nanocarriers had better tumor accumulation ability, remarkably inhibited growth of solid tumor in a synergistic manner, even significantly decreased hepatotoxicity of LND, and had good in vivo biocompatibility whereas LND alone showed serious hepatotoxicity.  We believed that the dual-loaded hierarchical targeted delivery system with high effectiveness and biocompatibility would provide a promising approach for cancer combination therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUSZDq9uggZ7Vg90H21EOLACvtfcHk0lg4KGHecdksYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XntVCrs78%253D&md5=580610a42e5386a954b093d6c08e624c</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.ijpharm.2016.04.056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijpharm.2016.04.056%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DB.-F.%26aulast%3DXing%26aufirst%3DL.%26aulast%3DQiao%26aufirst%3DJ.-B.%26aulast%3DCui%26aufirst%3DP.-F.%26aulast%3DWang%26aufirst%3DF.-Z.%26aulast%3DZhang%26aufirst%3DJ.-L.%26aulast%3DXu%26aufirst%3DC.-X.%26aulast%3DJiang%26aufirst%3DH.-L.%26atitle%3DIn%2520Vivo%2520Synergistic%2520Antitumor%2520Effect%2520and%2520Safety%2520of%2520Sirna%2520and%2520Lonidamine%2520Dual-Loaded%2520Hierarchical%2520Targeted%2520Nanoparticles%26jtitle%3DInt.%2520J.%2520Pharm.%26date%3D2016%26volume%3D506%26spage%3D207%26epage%3D213%26doi%3D10.1016%2Fj.ijpharm.2016.04.056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reed, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokat, K. M.</span></span> <span> </span><span class="NLM_article-title">Targeting Osteosarcoma</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">18100</span>, <span class="refDoi"> DOI: 10.1073/pnas.1420596111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1073%2Fpnas.1420596111" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2014&pages=18100&author=D.+E.+Reedauthor=K.+M.+Shokat&title=Targeting+Osteosarcoma&doi=10.1073%2Fpnas.1420596111"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1420596111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1420596111%26sid%3Dliteratum%253Aachs%26aulast%3DReed%26aufirst%3DD.%2BE.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26atitle%3DTargeting%2520Osteosarcoma%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2014%26volume%3D111%26spage%3D18100%26doi%3D10.1073%2Fpnas.1420596111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">González-Fernández, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imbuluzqueta, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patiño-García, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanco-Prieto, M.</span></span> <span> </span><span class="NLM_article-title">Antitumoral-Lipid-Based Nanoparticles: A Platform for Future Application in Osteosarcoma Therapy</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">6104</span>– <span class="NLM_lpage">6124</span>, <span class="refDoi"> DOI: 10.2174/1381612821666151027152534</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.2174%2F1381612821666151027152534" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=6104-6124&author=Y.+Gonz%C3%A1lez-Fern%C3%A1ndezauthor=E.+Imbuluzquetaauthor=A.+Pati%C3%B1o-Garc%C3%ADaauthor=M.+Blanco-Prieto&title=Antitumoral-Lipid-Based+Nanoparticles%3A+A+Platform+for+Future+Application+in+Osteosarcoma+Therapy&doi=10.2174%2F1381612821666151027152534"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.2174%2F1381612821666151027152534&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1381612821666151027152534%26sid%3Dliteratum%253Aachs%26aulast%3DGonz%25C3%25A1lez-Fern%25C3%25A1ndez%26aufirst%3DY.%26aulast%3DImbuluzqueta%26aufirst%3DE.%26aulast%3DPati%25C3%25B1o-Garc%25C3%25ADa%26aufirst%3DA.%26aulast%3DBlanco-Prieto%26aufirst%3DM.%26atitle%3DAntitumoral-Lipid-Based%2520Nanoparticles%253A%2520A%2520Platform%2520for%2520Future%2520Application%2520in%2520Osteosarcoma%2520Therapy%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2015%26volume%3D21%26spage%3D6104%26epage%3D6124%26doi%3D10.2174%2F1381612821666151027152534" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhuang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span> <span> </span><span class="NLM_article-title">Polymeric Nanocarriers for Drug Delivery in Osteosarcoma Treatment</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">5187</span>– <span class="NLM_lpage">5197</span>, <span class="refDoi"> DOI: 10.2174/1381612821666150923095618</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.2174%2F1381612821666150923095618" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=5187-5197&author=X.+Guauthor=J.+Dingauthor=Z.+Zhangauthor=Q.+Liauthor=X.+Zhuangauthor=X.+Chen&title=Polymeric+Nanocarriers+for+Drug+Delivery+in+Osteosarcoma+Treatment&doi=10.2174%2F1381612821666150923095618"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.2174%2F1381612821666150923095618&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1381612821666150923095618%26sid%3Dliteratum%253Aachs%26aulast%3DGu%26aufirst%3DX.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DZhuang%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DX.%26atitle%3DPolymeric%2520Nanocarriers%2520for%2520Drug%2520Delivery%2520in%2520Osteosarcoma%2520Treatment%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2015%26volume%3D21%26spage%3D5187%26epage%3D5197%26doi%3D10.2174%2F1381612821666150923095618" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Akhtar, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahamed, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alhadlaq, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alrokayan, S. A.</span></span> <span> </span><span class="NLM_article-title">Glutathione Replenishing Potential of Ceo2 Nanoparticles in Human Breast and Fibrosarcoma Cells</span>. <i>J. Colloid Interface Sci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>453</i></span>,  <span class="NLM_fpage">21</span>– <span class="NLM_lpage">27</span>, <span class="refDoi"> DOI: 10.1016/j.jcis.2015.04.049</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1016%2Fj.jcis.2015.04.049" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=453&publication_year=2015&pages=21-27&author=M.+J.+Akhtarauthor=M.+Ahamedauthor=H.+A.+Alhadlaqauthor=M.+M.+Khanauthor=S.+A.+Alrokayan&title=Glutathione+Replenishing+Potential+of+Ceo2+Nanoparticles+in+Human+Breast+and+Fibrosarcoma+Cells&doi=10.1016%2Fj.jcis.2015.04.049"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.jcis.2015.04.049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jcis.2015.04.049%26sid%3Dliteratum%253Aachs%26aulast%3DAkhtar%26aufirst%3DM.%2BJ.%26aulast%3DAhamed%26aufirst%3DM.%26aulast%3DAlhadlaq%26aufirst%3DH.%2BA.%26aulast%3DKhan%26aufirst%3DM.%2BM.%26aulast%3DAlrokayan%26aufirst%3DS.%2BA.%26atitle%3DGlutathione%2520Replenishing%2520Potential%2520of%2520Ceo2%2520Nanoparticles%2520in%2520Human%2520Breast%2520and%2520Fibrosarcoma%2520Cells%26jtitle%3DJ.%2520Colloid%2520Interface%2520Sci.%26date%3D2015%26volume%3D453%26spage%3D21%26epage%3D27%26doi%3D10.1016%2Fj.jcis.2015.04.049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duan, Z.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Polymeric Nanoparticle-Based Delivery of Microrna-199a-3p Inhibits Proliferation and Growth of Osteosarcoma Cells</span>. <i>Int. J. Nanomed.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">2913</span>– <span class="NLM_lpage">2924</span>, <span class="refDoi"> DOI: 10.2147/IJN.S79143</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.2147%2FIJN.S79143" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=25931818" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=1%3ACAS%3A528%3ADC%252BC2MXotVyltrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=2913-2924&author=Z.+Duan&title=Polymeric+Nanoparticle-Based+Delivery+of+Microrna-199a-3p+Inhibits+Proliferation+and+Growth+of+Osteosarcoma+Cells&doi=10.2147%2FIJN.S79143"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Polymeric nanoparticle-based delivery of microRNA-199a-3p inhibits proliferation and growth of osteosarcoma cells</span></div><div class="casAuthors">Zhang, Linlin; Iyer, Arun K.; Yang, Xiaoqian; Kobayashi, Eisuke; Guo, Yuqi; Mankin, Henry; Hornicek, Francis J.; Amiji, Mansoor M.; Duan, Zhenfeng</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Nanomedicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2913-2924</span>CODEN:
                <span class="NLM_cas:coden">IJNNHQ</span>;
        ISSN:<span class="NLM_cas:issn">1178-2013</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Our prior screening of microRNAs (miRs) identified that miR-199a-3p expression is reduced in osteosarcoma cells, one of the most common types of bone tumor.  MiR-199a-3p exhibited functions of tumor cell growth inhibition, suggesting the potential application of miR-199a-3p as an anticancer agent.  In the study reported here, we designed and developed a lipid-modified dextran-based polymeric nanoparticle platform for encapsulation of miRs, and detd. the efficiency and efficacy of delivering miR-199a-3p into osteosarcoma cells.  In addn., another potent miR, let-7a, which also displayed tumor suppressive ability, was selected as a candidate miR for evaluation.  Fluorescence microscopy studies and real-time polymerase chain reaction results showed that dextran nanoparticles could deliver both miR-199a-3p and let-7a into osteosarcoma cell lines (KHOS and U-2OS) successfully.  Western blotting anal. and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays demonstrated that dextran nanoparticles loaded with miRs could efficiently downregulate the expression of target proteins and effectively inhibit the growth and proliferation of osteosarcoma cells.  These results demonstrate that a lipid-modified dextran-based polymeric nanoparticle platform may be an effective nonviral carrier for potential miR-based anticancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFuaSfnWjgtrVg90H21EOLACvtfcHk0ljUHEJ1OkVw1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXotVyltrg%253D&md5=ee35fe68362839e254bc5782a7b2061e</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.2147%2FIJN.S79143&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FIJN.S79143%26sid%3Dliteratum%253Aachs%26aulast%3DDuan%26aufirst%3DZ.%26atitle%3DPolymeric%2520Nanoparticle-Based%2520Delivery%2520of%2520Microrna-199a-3p%2520Inhibits%2520Proliferation%2520and%2520Growth%2520of%2520Osteosarcoma%2520Cells%26jtitle%3DInt.%2520J.%2520Nanomed.%26date%3D2015%26volume%3D10%26spage%3D2913%26epage%3D2924%26doi%3D10.2147%2FIJN.S79143" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, X.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, S.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, M.</span></span> <span> </span><span class="NLM_article-title">Paclitaxel and Etoposide Co-Loaded Polymeric Nanoparticles for the Effective Combination Therapy Against Human Osteosarcoma</span>. <i>J. Nanobiotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">22</span>, <span class="refDoi"> DOI: 10.1186/s12951-015-0086-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1186%2Fs12951-015-0086-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=25880868" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=1%3ACAS%3A280%3ADC%252BC2MjltVOiug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2015&pages=22&author=B.+Wangauthor=X.-C.+Yuauthor=S.-F.+Xuauthor=M.+Xu&title=Paclitaxel+and+Etoposide+Co-Loaded+Polymeric+Nanoparticles+for+the+Effective+Combination+Therapy+Against+Human+Osteosarcoma&doi=10.1186%2Fs12951-015-0086-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Paclitaxel and etoposide co-loaded polymeric nanoparticles for the effective combination therapy against human osteosarcoma</span></div><div class="casAuthors">Wang Bing; Yu Xiu-Chun; Xu Song-Feng; Xu Ming</div><div class="citationInfo"><span class="NLM_cas:title">Journal of nanobiotechnology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">22</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  The combination of chemotherapeutic drugs with different pharmacological action has emerged as a promising therapeutic strategy in the treatment of cancers.  Present study examines the antitumor potential of paclitaxel (PTX) and etoposide (ETP)-loaded PLGA nanoparticles for the treatment of osteosarcoma.  RESULTS:  The resulting drug-loaded PLGA NP exhibited a nanosize dimension with uniform spherical morphology.  The NP exhibited a sustained release profile for both PTX and ETP throughout the study period without any sign of initial burst release.  The combinational drug-loaded PLGA NP enhanced the cytotoxic effect in MG63 and Saos-2 osteosarcoma cell lines, in comparison to either native drug alone or in cocktail combinations.  Additionally, NPs showed an appreciable uptake in MG63 cells in a time-based manner.  Co-delivery of anticancer drugs resulted in enhanced cell cycle arrest and cell apoptosis.  The results clearly showed that combinational drugs remarkably improved the therapeutic index of chemotherapeutic drugs.  The greater inhibitory effect of nanoparticle combination would be of great advantage during systemic cancer therapy.  CONCLUSION:  Taken together, our study demonstrated that PTX-ETP/PLGA NP based combination therapy holds significant potential towards the treatment of osteosarcoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQsFwAQGN_t4Djk2McQZ6XmfW6udTcc2eaLjOso7ZOLJ7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MjltVOiug%253D%253D&md5=52ac22c4313eb07722a594603602c25b</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1186%2Fs12951-015-0086-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12951-015-0086-4%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DB.%26aulast%3DYu%26aufirst%3DX.-C.%26aulast%3DXu%26aufirst%3DS.-F.%26aulast%3DXu%26aufirst%3DM.%26atitle%3DPaclitaxel%2520and%2520Etoposide%2520Co-Loaded%2520Polymeric%2520Nanoparticles%2520for%2520the%2520Effective%2520Combination%2520Therapy%2520Against%2520Human%2520Osteosarcoma%26jtitle%3DJ.%2520Nanobiotechnol.%26date%3D2015%26volume%3D13%26spage%3D22%26doi%3D10.1186%2Fs12951-015-0086-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wójcik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewandowski, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Król, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pawłowski, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mieczkowski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lechowski, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zabielska, K.</span></span> <span> </span><span class="NLM_article-title">Enhancing Anti-Tumor Efficacy of Doxorubicin by Non-Covalent Conjugation to Gold Nanoparticles - In Vitro Studies on Feline Fibrosarcoma Cell Lines</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>, <span class="NLM_elocation-id">e0124955</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0124955</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1371%2Fjournal.pone.0124955" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&author=M.+W%C3%B3jcikauthor=W.+Lewandowskiauthor=M.+Kr%C3%B3lauthor=K.+Paw%C5%82owskiauthor=J.+Mieczkowskiauthor=R.+Lechowskiauthor=K.+Zabielska&title=Enhancing+Anti-Tumor+Efficacy+of+Doxorubicin+by+Non-Covalent+Conjugation+to+Gold+Nanoparticles+-+In+Vitro+Studies+on+Feline+Fibrosarcoma+Cell+Lines&doi=10.1371%2Fjournal.pone.0124955"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0124955&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0124955%26sid%3Dliteratum%253Aachs%26aulast%3DW%25C3%25B3jcik%26aufirst%3DM.%26aulast%3DLewandowski%26aufirst%3DW.%26aulast%3DKr%25C3%25B3l%26aufirst%3DM.%26aulast%3DPaw%25C5%2582owski%26aufirst%3DK.%26aulast%3DMieczkowski%26aufirst%3DJ.%26aulast%3DLechowski%26aufirst%3DR.%26aulast%3DZabielska%26aufirst%3DK.%26atitle%3DEnhancing%2520Anti-Tumor%2520Efficacy%2520of%2520Doxorubicin%2520by%2520Non-Covalent%2520Conjugation%2520to%2520Gold%2520Nanoparticles%2520-%2520In%2520Vitro%2520Studies%2520on%2520Feline%2520Fibrosarcoma%2520Cell%2520Lines%26jtitle%3DPLoS%2520One%26date%3D2015%26volume%3D10%26doi%3D10.1371%2Fjournal.pone.0124955" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zabielska-Koczywąs, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wojtalewicz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lechowski, R.</span></span> <span> </span><span class="NLM_article-title">Current Knowledge on Feline Injection-Site Sarcoma Treatment</span>. <i>Acta Vet. Scand.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">47</span>, <span class="refDoi"> DOI: 10.1186/s13028-017-0315-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1186%2Fs13028-017-0315-y" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2017&pages=47&author=K.+Zabielska-Koczyw%C4%85sauthor=A.+Wojtalewiczauthor=R.+Lechowski&title=Current+Knowledge+on+Feline+Injection-Site+Sarcoma+Treatment&doi=10.1186%2Fs13028-017-0315-y"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1186%2Fs13028-017-0315-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13028-017-0315-y%26sid%3Dliteratum%253Aachs%26aulast%3DZabielska-Koczyw%25C4%2585s%26aufirst%3DK.%26aulast%3DWojtalewicz%26aufirst%3DA.%26aulast%3DLechowski%26aufirst%3DR.%26atitle%3DCurrent%2520Knowledge%2520on%2520Feline%2520Injection-Site%2520Sarcoma%2520Treatment%26jtitle%3DActa%2520Vet.%2520Scand.%26date%3D2017%26volume%3D59%26spage%3D47%26doi%3D10.1186%2Fs13028-017-0315-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ni, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Z.</span></span> <span> </span><span class="NLM_article-title">Poly(lactic-co-glycolic acid) Nanoparticles Conjugated with CD133 Aptamers for Targeted Salinomycin Delivery to CD133+ Osteosarcoma Cancer Stem Cells</span>. <i>Int. J. Nanomed.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">2537</span>, <span class="refDoi"> DOI: 10.2147/IJN.S78498</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.2147%2FIJN.S78498" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=25848270" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=1%3ACAS%3A528%3ADC%252BC2MXotVylt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=2537&author=M.+Niauthor=M.+Xiongauthor=X.+Zhangauthor=G.+Caiauthor=H.+Chenauthor=Q.+Zengauthor=Z.+Yu&title=Poly%28lactic-co-glycolic+acid%29+Nanoparticles+Conjugated+with+CD133+Aptamers+for+Targeted+Salinomycin+Delivery+to+CD133%2B+Osteosarcoma+Cancer+Stem+Cells&doi=10.2147%2FIJN.S78498"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Poly(lactic-co-glycolic acid) nanoparticles conjugated with CD133 aptamers for targeted salinomycin delivery to CD133+ osteosarcoma cancer stem cells</span></div><div class="casAuthors">Ni, Miaozhong; Xiong, Min; Zhang, Xinchao; Cai, Guoping; Chen, Huaiwen; Zeng, Qingmin; Yu, Zuochong</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Nanomedicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2537-2554</span>CODEN:
                <span class="NLM_cas:coden">IJNNHQ</span>;
        ISSN:<span class="NLM_cas:issn">1178-2013</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Background: Cancer stem cells (CSCs) possess the characteristics assocd. with normal stem cells and are responsible for cancer initiation, recurrence, and metastasis.  CD133 is regarded as a CSCs marker of osteosarcoma, which is the most common primary bone malignancy in childhood and adolescence.  Salinomycin, a polyether ionophore antibiotic, has been shown to kill various CSCs, including osteosarcoma CSCs.  However, salinomycin displayed poor aq. soly. that hinders its clin. application.  The objective of this study was to develop salinomycin-loaded nanoparticles to eliminate CD133+ osteosarcoma CSCs.  Methods: The salinomycin-loaded PEGylated poly(lactic-co-glycolic acid) nanoparticles (SAL-NP) conjugated with CD133 aptamers (Ap-SAL-NP) were developed by an emulsion/solvent evapn. method, and the targeting and cytotoxicity of Ap-SAL-NP to CD133+ osteosarcoma CSCs were evaluated.  Results: The nanoparticles are of desired particle size (∼150 nm), drug encapsulation efficiency (∼50%), and drug release profile.  After 48 h treatment of the Saos-2 CD133+ osteosarcoma cells with drugs formulated in Ap-SAL-NP, SAL-NP, and salinomycin, the concns. needed to kill 50% of the incubated cells were found to be 2.18, 10.72, and 5.07 μg/mL, resp., suggesting that Ap-SAL-NP could be 4.92 or 2.33 fold more effective than SAL-NP or salinomycin, resp.  In contrast, Ap-SAL-NP was as effective as SAL-NP, and less effective than salinomycin in Saos-2 CD133- cells, suggesting that Ap-SAL-NP possess specific cytotoxicity toward Saos-2 CD133+ cells.  Ap-SAL-NP showed the best therapeutic effect in Saos-2 osteosarcoma xenograft mice, compared with SAL-NP or salinomycin.  Significantly, Ap-SAL-NP could selectively kill CD133+ osteosarcoma CSCs both in vitro and in vivo, as reflected by the tumorsphere formation and proportion of Saos-2 CD133+ cells.  Conclusion: Our results suggest that CD133 is a potential target for drug delivery to osteosarcoma CSCs and that it is possible to significantly inhibit the osteosarcoma growth by killing CD133+ osteosarcoma CSCs.  We demonstrated that Ap-SAL-NP have the potential to target and kill CD133+ osteosarcoma CSCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGvATMB5n44rVg90H21EOLACvtfcHk0lhKUrxu3Hs9Uw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXotVylt7s%253D&md5=6243f2f8a5b11e454145c31684d1a1ed</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.2147%2FIJN.S78498&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FIJN.S78498%26sid%3Dliteratum%253Aachs%26aulast%3DNi%26aufirst%3DM.%26aulast%3DXiong%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DCai%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DZeng%26aufirst%3DQ.%26aulast%3DYu%26aufirst%3DZ.%26atitle%3DPoly%2528lactic-co-glycolic%2520acid%2529%2520Nanoparticles%2520Conjugated%2520with%2520CD133%2520Aptamers%2520for%2520Targeted%2520Salinomycin%2520Delivery%2520to%2520CD133%252B%2520Osteosarcoma%2520Cancer%2520Stem%2520Cells%26jtitle%3DInt.%2520J.%2520Nanomed.%26date%3D2015%26volume%3D10%26spage%3D2537%26doi%3D10.2147%2FIJN.S78498" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ling, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span> <span> </span><span class="NLM_article-title">Long-Circulating Iodinated Albumin-Gadolinium Nanoparticles as Enhanced Magnetic Resonance and Computed Tomography Imaging Probes for Osteosarcoma Visualization</span>. <i>Anal. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">4299</span>– <span class="NLM_lpage">4304</span>, <span class="refDoi"> DOI: 10.1021/ac504752a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ac504752a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2015&pages=4299-4304&author=Q.+Wangauthor=L.+Lvauthor=Z.+Lingauthor=Y.+Wangauthor=Y.+Liuauthor=L.+Liauthor=G.+Liuauthor=L.+Shenauthor=J.+Yanauthor=Y.+Wang&title=Long-Circulating+Iodinated+Albumin-Gadolinium+Nanoparticles+as+Enhanced+Magnetic+Resonance+and+Computed+Tomography+Imaging+Probes+for+Osteosarcoma+Visualization&doi=10.1021%2Fac504752a"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fac504752a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fac504752a%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DLv%26aufirst%3DL.%26aulast%3DLing%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DShen%26aufirst%3DL.%26aulast%3DYan%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DY.%26atitle%3DLong-Circulating%2520Iodinated%2520Albumin-Gadolinium%2520Nanoparticles%2520as%2520Enhanced%2520Magnetic%2520Resonance%2520and%2520Computed%2520Tomography%2520Imaging%2520Probes%2520for%2520Osteosarcoma%2520Visualization%26jtitle%3DAnal.%2520Chem.%26date%3D2015%26volume%3D87%26spage%3D4299%26epage%3D4304%26doi%3D10.1021%2Fac504752a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bertrand, J.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pioche-Durieu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ayala, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petit, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girard, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malvy, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Cam, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treussart, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnault, J.-C.</span></span> <span> </span><span class="NLM_article-title">Plasma Hydrogenated Cationic Detonation Nanodiamonds Efficiently Deliver to Human Cells in Culture Functional Sirna Targeting the Ewing Sarcoma Junction Oncogene</span>. <i>Biomaterials</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">93</span>– <span class="NLM_lpage">98</span>, <span class="refDoi"> DOI: 10.1016/j.biomaterials.2014.12.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1016%2Fj.biomaterials.2014.12.007" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2015&pages=93-98&author=J.-R.+Bertrandauthor=C.+Pioche-Durieuauthor=J.+Ayalaauthor=T.+Petitauthor=H.+A.+Girardauthor=C.+P.+Malvyauthor=E.+Le+Camauthor=F.+Treussartauthor=J.-C.+Arnault&title=Plasma+Hydrogenated+Cationic+Detonation+Nanodiamonds+Efficiently+Deliver+to+Human+Cells+in+Culture+Functional+Sirna+Targeting+the+Ewing+Sarcoma+Junction+Oncogene&doi=10.1016%2Fj.biomaterials.2014.12.007"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.biomaterials.2014.12.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biomaterials.2014.12.007%26sid%3Dliteratum%253Aachs%26aulast%3DBertrand%26aufirst%3DJ.-R.%26aulast%3DPioche-Durieu%26aufirst%3DC.%26aulast%3DAyala%26aufirst%3DJ.%26aulast%3DPetit%26aufirst%3DT.%26aulast%3DGirard%26aufirst%3DH.%2BA.%26aulast%3DMalvy%26aufirst%3DC.%2BP.%26aulast%3DLe%2BCam%26aufirst%3DE.%26aulast%3DTreussart%26aufirst%3DF.%26aulast%3DArnault%26aufirst%3DJ.-C.%26atitle%3DPlasma%2520Hydrogenated%2520Cationic%2520Detonation%2520Nanodiamonds%2520Efficiently%2520Deliver%2520to%2520Human%2520Cells%2520in%2520Culture%2520Functional%2520Sirna%2520Targeting%2520the%2520Ewing%2520Sarcoma%2520Junction%2520Oncogene%26jtitle%3DBiomaterials%26date%3D2015%26volume%3D45%26spage%3D93%26epage%3D98%26doi%3D10.1016%2Fj.biomaterials.2014.12.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Altucci, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gronemeyer, H.</span></span> <span> </span><span class="NLM_article-title">The Promise of Retinoids to Fight Against Cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">181</span>– <span class="NLM_lpage">193</span>, <span class="refDoi"> DOI: 10.1038/35106036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1038%2F35106036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=11902573" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=1%3ACAS%3A528%3ADC%252BD38XlvF2qtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2001&pages=181-193&author=L.+Altucciauthor=H.+Gronemeyer&title=The+Promise+of+Retinoids+to+Fight+Against+Cancer&doi=10.1038%2F35106036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">The promise of retinoids to fight against cancer</span></div><div class="casAuthors">Altucci, Lucia; Gronemeyer, Hinrich</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">181-193</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Retinoids have a reputation for being both detrimental and beneficial: they are teratogens, but they also have tumor-suppressive capacity.  Cell biol. and genetics have significantly improved our understanding of the mechanisms that underlie the anti-proliferative action of retinoids.  Recent elucidation of the pathways that are activated by retinoids will help us to exploit the beneficial aspects of this powerful class of compds. for cancer therapy and prevention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmzWqVZp9bDbVg90H21EOLACvtfcHk0lgOZgelGpwtoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlvF2qtrw%253D&md5=d0c150df52bfb7f7e283e5bd660ccdff</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1038%2F35106036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35106036%26sid%3Dliteratum%253Aachs%26aulast%3DAltucci%26aufirst%3DL.%26aulast%3DGronemeyer%26aufirst%3DH.%26atitle%3DThe%2520Promise%2520of%2520Retinoids%2520to%2520Fight%2520Against%2520Cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2001%26volume%3D1%26spage%3D181%26epage%3D193%26doi%3D10.1038%2F35106036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Klopper, J.
P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berenz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hays, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pugazhenthi, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Said, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haugen, B. R.</span></span> <span> </span><span class="NLM_article-title">Retinoid and Thiazolidinedione Therapies in Melanoma: An Analysis of Differential Response Based on Nuclear Hormone Receptor Expression</span>. <i>Mol. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">16</span>, <span class="refDoi"> DOI: 10.1186/1476-4598-8-16</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1186%2F1476-4598-8-16" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=19267912" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=1%3ACAS%3A280%3ADC%252BD1M3gvVSrug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2009&pages=16&author=J.%0AP.+Klopperauthor=V.+Sharmaauthor=A.+Berenzauthor=W.+R.+Haysauthor=M.+Loiauthor=U.+Pugazhenthiauthor=S.+Saidauthor=B.+R.+Haugen&title=Retinoid+and+Thiazolidinedione+Therapies+in+Melanoma%3A+An+Analysis+of+Differential+Response+Based+on+Nuclear+Hormone+Receptor+Expression&doi=10.1186%2F1476-4598-8-16"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Retinoid and thiazolidinedione therapies in melanoma: an analysis of differential response based on nuclear hormone receptor expression</span></div><div class="casAuthors">Klopper Joshua P; Sharma Vibha; Berenz Andrew; Hays William R; Loi Michele; Pugazhenthi Umarani; Said Sherif; Haugen Bryan R</div><div class="citationInfo"><span class="NLM_cas:title">Molecular cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">16</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Metastatic melanoma has a high mortality rate and suboptimal therapeutic options.  Molecular targeting may be beneficial using the rexinoid LGD1069, a retinoid x receptor selective agonist, and thiazolidinediones (TZD), PPARgamma selective ligands, as novel treatments.  RESULTS:  Mouse xenograft models with human melanoma cell lines [A375(DRO) or M14(5-16)] were treated for 4 weeks with daily vehicle, RXR agonist (rexinoid, LGD1069, 30 mg/kg/d), PPARgamma agonist (TZD, rosiglitazone, 10 mg/kg/d) or combination.  A375(DRO) tumor growth was significantly inhibited by either ligand alone and the combination had an additive effect.  M14(5-16) tumors only responded to LGD1069 100 mg/kg/day.  A375(DRO) sublines resistant to rexinoid, TZD and combination were generated and all three sublines had reduced PPARgamma expression but preserved RXR expression. shRNA knockdown of PPARgamma or RXRgamma attenuated the rexinoid, TZD and combination ligand-mediated decreased proliferation in A375(DRO) cells.  Rexinoid (LGD1069) and retinoid (TTNPB) treatment of M14(5-16) cells resulted in decreased proliferation that was additive with combination of both rexinoid and retinoid. shRNA knockdown of RXRgamma resulted in a decreased response to either ligand.  CONCLUSION:  A375 (DRO) melanoma cell growth is inhibited by rexinoid and TZD treatment, and this response is dependent on RXR and PPARgamma receptor expression.  M14 (5-16) melanoma cell growth is inhibited by rexinoid and retinoid treatment, and this response is dependent on RXR expression.  These findings may help guide molecular-based treatment strategies in melanoma and provide insight for mechanisms of resistance to nuclear receptor targeted therapies in certain cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSChxG7abhlkP3jf77P2BG3fW6udTcc2eYtzw6iq7LX-7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1M3gvVSrug%253D%253D&md5=4285b5c8dd43b1132d3dd64c5f25219e</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1186%2F1476-4598-8-16&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1476-4598-8-16%26sid%3Dliteratum%253Aachs%26aulast%3DKlopper%26aufirst%3DJ.%2BP.%26aulast%3DSharma%26aufirst%3DV.%26aulast%3DBerenz%26aufirst%3DA.%26aulast%3DHays%26aufirst%3DW.%2BR.%26aulast%3DLoi%26aufirst%3DM.%26aulast%3DPugazhenthi%26aufirst%3DU.%26aulast%3DSaid%26aufirst%3DS.%26aulast%3DHaugen%26aufirst%3DB.%2BR.%26atitle%3DRetinoid%2520and%2520Thiazolidinedione%2520Therapies%2520in%2520Melanoma%253A%2520An%2520Analysis%2520of%2520Differential%2520Response%2520Based%2520on%2520Nuclear%2520Hormone%2520Receptor%2520Expression%26jtitle%3DMol.%2520Cancer%26date%3D2009%26volume%3D8%26spage%3D16%26doi%3D10.1186%2F1476-4598-8-16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mohan, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aherne, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baird, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winter, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, E. P.</span></span> <span> </span><span class="NLM_article-title">Molecular Pathways: The Role of NR4A Orphan Nuclear Receptors in Cancer</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">3223</span>– <span class="NLM_lpage">3228</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-11-2953</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1158%2F1078-0432.CCR-11-2953" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=22566377" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=1%3ACAS%3A528%3ADC%252BC38Xos1OltL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=3223-3228&author=H.+M.+Mohanauthor=C.+M.+Aherneauthor=A.+C.+Rogersauthor=A.+W.+Bairdauthor=D.+C.+Winterauthor=E.+P.+Murphy&title=Molecular+Pathways%3A+The+Role+of+NR4A+Orphan+Nuclear+Receptors+in+Cancer&doi=10.1158%2F1078-0432.CCR-11-2953"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Pathways: The Role of NR4A Orphan Nuclear Receptors in Cancer</span></div><div class="casAuthors">Mohan, Helen M.; Aherne, Carol M.; Rogers, Ailin C.; Baird, Alan W.; Winter, Des C.; Murphy, Evelyn P.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3223-3228</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Nuclear receptors are of integral importance in carcinogenesis.  Manipulation of classic ligand-activated nuclear receptors, such as estrogen receptor blockade in breast cancer, is an important established cancer therapy.  Orphan nuclear receptors, such as nuclear family 4 subgroup A (NR4A) receptors, have no known natural ligand(s).  These elusive receptors are increasingly recognized as mol. switches in cell survival and a mol. link between inflammation and cancer.  NR4A receptors act as transcription factors, altering expression of downstream genes in apoptosis (Fas-ligand, TRAIL), proliferation, DNA repair, metab., cell migration, inflammation (interleukin-8), and angiogenesis (VEGF).  NR4A receptors are modulated by multiple cell-signaling pathways, including protein kinase A/CREB, NF-κB, phosphoinositide 3-kinase/AKT, c-jun-NH2-kinase, Wnt, and mitogen-activated protein kinase pathways.  NR4A receptor effects are context and tissue specific, influenced by their levels of expression, posttranslational modification, and interaction with other transcription factors (RXR, PPAR-Υ).  The subcellular location of NR4A "nuclear receptors" is also important functionally; novel roles have been described in the cytoplasm where NR4A proteins act both indirectly and directly on the mitochondria to promote apoptosis via Bcl-2.  NR4A receptors are implicated in a wide variety of malignancies, including breast, lung, colon, bladder, and prostate cancer; glioblastoma multiforme; sarcoma; and acute and/or chronic myeloid leukemia.  NR4A receptors modulate response to conventional chemotherapy and represent an exciting frontier for chemotherapeutic intervention, as novel agents targeting NR4A receptors have now been developed.  This review provides a concise clin. overview of current knowledge of NR4A signaling in cancer and the potential for therapeutic manipulation.  Clin Cancer Res; 18(12); 3223-8. ©2012 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqduV_DWcG-SbVg90H21EOLACvtfcHk0lgOZgelGpwtoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xos1OltL4%253D&md5=682575a12521bbfd252fcdb2c3c1f8fd</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-2953&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-2953%26sid%3Dliteratum%253Aachs%26aulast%3DMohan%26aufirst%3DH.%2BM.%26aulast%3DAherne%26aufirst%3DC.%2BM.%26aulast%3DRogers%26aufirst%3DA.%2BC.%26aulast%3DBaird%26aufirst%3DA.%2BW.%26aulast%3DWinter%26aufirst%3DD.%2BC.%26aulast%3DMurphy%26aufirst%3DE.%2BP.%26atitle%3DMolecular%2520Pathways%253A%2520The%2520Role%2520of%2520NR4A%2520Orphan%2520Nuclear%2520Receptors%2520in%2520Cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D3223%26epage%3D3228%26doi%3D10.1158%2F1078-0432.CCR-11-2953" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benchetrit, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bianchini, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michiels, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, N.</span></span> <span> </span><span class="NLM_article-title">Peroxisome Proliferator-Activated Receptor Β/Δ (Pparβ/Δ) is Highly Expressed in Liposarcoma and Promotes Migration and Proliferation</span>. <i>Journal of pathology</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>224</i></span>,  <span class="NLM_fpage">575</span>– <span class="NLM_lpage">588</span>, <span class="refDoi"> DOI: 10.1002/path.2910</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1002%2Fpath.2910" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=224&publication_year=2011&pages=575-588&author=K.+D.+Wagnerauthor=M.+Benchetritauthor=L.+Bianchiniauthor=J.+F.+Michielsauthor=N.+Wagner&title=Peroxisome+Proliferator-Activated+Receptor+%CE%92%2F%CE%94+%28Ppar%CE%B2%2F%CE%94%29+is+Highly+Expressed+in+Liposarcoma+and+Promotes+Migration+and+Proliferation&doi=10.1002%2Fpath.2910"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1002%2Fpath.2910&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpath.2910%26sid%3Dliteratum%253Aachs%26aulast%3DWagner%26aufirst%3DK.%2BD.%26aulast%3DBenchetrit%26aufirst%3DM.%26aulast%3DBianchini%26aufirst%3DL.%26aulast%3DMichiels%26aufirst%3DJ.%2BF.%26aulast%3DWagner%26aufirst%3DN.%26atitle%3DPeroxisome%2520Proliferator-Activated%2520Receptor%2520%25CE%2592%252F%25CE%2594%2520%2528Ppar%25CE%25B2%252F%25CE%2594%2529%2520is%2520Highly%2520Expressed%2520in%2520Liposarcoma%2520and%2520Promotes%2520Migration%2520and%2520Proliferation%26jtitle%3DJournal%2520of%2520pathology%26date%3D2011%26volume%3D224%26spage%3D575%26epage%3D588%26doi%3D10.1002%2Fpath.2910" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gallagher, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keighley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tancabelic, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garimella, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Templeton, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tawfik, O.</span></span> <span> </span><span class="NLM_article-title">Clinicopathologic Correlation of Vitamin D Receptor Expression with Retinoid X Receptor and MIB-1 Expression in Primary and Metastatic Osteosarcoma</span>. <i>Ann. Diagn. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">323</span>– <span class="NLM_lpage">329</span>, <span class="refDoi"> DOI: 10.1016/j.anndiagpath.2012.01.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1016%2Fj.anndiagpath.2012.01.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=22542077" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=1%3ACAS%3A280%3ADC%252BC38rovVensg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2012&pages=323-329&author=R.+Gallagherauthor=J.+Keighleyauthor=J.+Tancabelicauthor=R.+Garimellaauthor=D.+Pinsonauthor=K.+Templetonauthor=O.+Tawfik&title=Clinicopathologic+Correlation+of+Vitamin+D+Receptor+Expression+with+Retinoid+X+Receptor+and+MIB-1+Expression+in+Primary+and+Metastatic+Osteosarcoma&doi=10.1016%2Fj.anndiagpath.2012.01.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Clinicopathologic correlation of vitamin D receptor expression with retinoid X receptor and MIB-1 expression in primary and metastatic osteosarcoma</span></div><div class="casAuthors">Gallagher Ryan; Keighley John; Tancabelic Jakica; Garimella Rama; Pinson David; Templeton Kimberly; Tawfik Ossama</div><div class="citationInfo"><span class="NLM_cas:title">Annals of diagnostic pathology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">323-9</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Vitamin D, in addition to its effects on bone, is important in cell cycle regulation.  Vitamin D receptor (VDR) has been identified in breast, prostate, and colon cancers, as well as in canine and human osteosarcoma (OS) cell lines; however, it has not been well investigated in human OS-archived specimens.  We correlated VDR, retinoid X receptor (RXR), and MIB-1 (Ki-67) expression in 110 archived OS cases with several clinicopathologic parameters including patient's age, sex, tumor location, tumor grade, and type and metastatic status.  The expression of VDR and RXR was identified in human OS tissue obtained from primary and metastatic OS archival tissue.  No statistically significant difference was found in VDR expression in relation with tumor grade, type, age, sex, or location.  The expression of RXR was highest in higher-grade (P = .0006) and metastatic tumors but remained unchanged when correlated with tumor type, age, sex, or location.  The expression of MIB-1 was statistically elevated in higher-grade tumors (P = .001), patients 25 years or younger (P = .04), tumors located in extremities (P = .005), and metastatic lesions, but was not impacted by tumor type or patient's sex.  Proliferative activity was significantly reduced after treatment, as the mean MIB-1 expression dropped from 11% in primary biopsy samples to 6% in resection specimens.  There appears to be a relationship between proliferative tumor activity and tumor grade, location, and metastasis.  Additional studies on the analysis of the effects of vitamin D and RXR on OS proliferation, apoptosis, and differentiation are critical to further evaluate their potential role in OS treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTqdAtsrJvhRhWfpMXQLRstfW6udTcc2eaJOrmLe3utdbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38rovVensg%253D%253D&md5=a91754d560784e9e913f7cc47cb6b7a3</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.anndiagpath.2012.01.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.anndiagpath.2012.01.001%26sid%3Dliteratum%253Aachs%26aulast%3DGallagher%26aufirst%3DR.%26aulast%3DKeighley%26aufirst%3DJ.%26aulast%3DTancabelic%26aufirst%3DJ.%26aulast%3DGarimella%26aufirst%3DR.%26aulast%3DPinson%26aufirst%3DD.%26aulast%3DTempleton%26aufirst%3DK.%26aulast%3DTawfik%26aufirst%3DO.%26atitle%3DClinicopathologic%2520Correlation%2520of%2520Vitamin%2520D%2520Receptor%2520Expression%2520with%2520Retinoid%2520X%2520Receptor%2520and%2520MIB-1%2520Expression%2520in%2520Primary%2520and%2520Metastatic%2520Osteosarcoma%26jtitle%3DAnn.%2520Diagn.%2520Pathol.%26date%3D2012%26volume%3D16%26spage%3D323%26epage%3D329%26doi%3D10.1016%2Fj.anndiagpath.2012.01.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">He, B.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuo, G.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Q.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Synergistic Antitumor Effect of the Activated Ppargamma and Retinoid Receptors on Human Osteosarcoma</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">2235</span>– <span class="NLM_lpage">2245</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-09-2499</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1158%2F1078-0432.CCR-09-2499" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=20371684" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=1%3ACAS%3A528%3ADC%252BC3cXkslSmtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=2235-2245&author=B.-C.+Heauthor=L.+Chenauthor=G.-W.+Zuoauthor=W.+Zhangauthor=Y.+Biauthor=J.+Huangauthor=Y.+Wangauthor=W.+Jiangauthor=Q.+Luoauthor=Q.+Shi&title=Synergistic+Antitumor+Effect+of+the+Activated+Ppargamma+and+Retinoid+Receptors+on+Human+Osteosarcoma&doi=10.1158%2F1078-0432.CCR-09-2499"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Synergistic Antitumor Effect of the Activated PPARγ and Retinoid Receptors on Human Osteosarcoma</span></div><div class="casAuthors">He, Bai-Cheng; Chen, Liang; Zuo, Guo-Wei; Zhang, Wenli; Bi, Yang; Huang, Jiayi; Wang, Yi; Jiang, Wei; Luo, Qing; Shi, Qiong; Zhang, Bing-Qiang; Liu, Bo; Lei, Xia; Luo, Jinyong; Luo, Xiaoji; Wagner, Eric R.; Kim, Stephanie H.; He, Connie J.; Hu, Yawen; Shen, Jikun; Zhou, Qixin; Rastegar, Farbod; Deng, Zhong-Liang; Luu, Hue H.; He, Tong-Chuan; Haydon, Rex C.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2235-2245</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: Osteosarcoma is the most common primary malignancy of bone.  The long-term survival of osteosarcoma patients hinges on our ability to prevent and/or treat recurrent and metastatic lesions.  Here, we investigated the activation of peroxisome proliferator-activated receptor γ (PPARγ) and retinoid receptors as a means of differentiation therapy for human osteosarcoma.  Exptl. Design: We examd. the endogenous expression of PPARγ and retinoid receptors in a panel of osteosarcoma cells.  Ligands or adenovirus-mediated overexpression of these receptors were tested to inhibit proliferation and induce apoptosis of osteosarcoma cells.  Osteosarcoma cells overexpressing the receptors were introduced into an orthotopic tumor model.  The effect of these ligands on osteoblastic differentiation was further investigated.  RESULTS: Endogenous expression of PPARγ and isotypes of retinoic acid receptor (RAR) and retinoid X receptor (RXR) is detected in most osteosarcoma cells.  Troglitazone, 9-cis retinoic acid (RA), and all-trans RA, as well as overexpression of PPARγ, RARα, and RXRα, inhibit osteosarcoma cell proliferation and induce apoptosis.  A synergistic inhibitory effect on osteosarcoma cell proliferation is obsd. between troglitazone and retinoids, as well as with the overexpression pairs of PPARγ/RARα, or PPARγ/RXRα.  Overexpression of PPARγ, RARα, RXRα, or in combinations inhibits osteosarcoma tumor growth and cell proliferation in vivo.  Retinoids (and to a lesser extent, troglitazone) are shown to promote osteogenic differentiation of osteosarcoma cells and mesenchymal stem cells.  CONCLUSIONS: Activation of PPARγ, RARα, and RXRα may act synergistically on inhibiting osteosarcoma cell proliferation and tumor growth, which is at least partially mediated by promoting osteoblastic differentiation of osteosarcoma cells.  Clin Cancer Res; 16(8); 2235-45.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBTaI2YHJNArVg90H21EOLACvtfcHk0lj-CNVESIN0Sw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXkslSmtbs%253D&md5=71632e7a8c14faa697c822f84bcfd8f8</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-09-2499&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-09-2499%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DB.-C.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DZuo%26aufirst%3DG.-W.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DBi%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DW.%26aulast%3DLuo%26aufirst%3DQ.%26aulast%3DShi%26aufirst%3DQ.%26atitle%3DSynergistic%2520Antitumor%2520Effect%2520of%2520the%2520Activated%2520Ppargamma%2520and%2520Retinoid%2520Receptors%2520on%2520Human%2520Osteosarcoma%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2010%26volume%3D16%26spage%3D2235%26epage%3D2245%26doi%3D10.1158%2F1078-0432.CCR-09-2499" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Querfeld, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagelli, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuzel, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guitart, J.</span></span> <span> </span><span class="NLM_article-title">Bexarotene in the Treatment of Cutaneous T-Cell Lymphoma</span>. <i>Expert Opin. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">907</span>– <span class="NLM_lpage">915</span>, <span class="refDoi"> DOI: 10.1517/14656566.7.7.907</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1517%2F14656566.7.7.907" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=16634713" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=1%3ACAS%3A528%3ADC%252BD28Xkt12hu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2006&pages=907-915&author=C.+Querfeldauthor=L.+V.+Nagelliauthor=S.+T.+Rosenauthor=T.+M.+Kuzelauthor=J.+Guitart&title=Bexarotene+in+the+Treatment+of+Cutaneous+T-Cell+Lymphoma&doi=10.1517%2F14656566.7.7.907"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Bexarotene in the treatment of cutaneous T-cell lymphoma</span></div><div class="casAuthors">Querfeld, Christiane; Nagelli, Lakshmi V.; Rosen, Steven T.; Kuzel, Timothy M.; Guitart, Joan</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">907-915</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Primary cutaneous T-cell lymphomas encompass a spectrum of non-Hodgkin's lymphomas that are characterized by clonal proliferation of skin-homing malignant T lymphocytes.  Mycosis fungoides and the leukemic variant Sezary syndrome, collectively referred to as cutaneous T-cell lymphomas, are the most common entities.  No curative therapy exists and patients ultimately develop advanced or relapsed disease that is refractory to std. treatment options.  Therefore, there is a great need for the development of novel emerging therapies.  Bexarotene is the first synthetic nuclear retinoid X receptor-selective retinoid approved by the FDA for the treatment of refractory cutaneous T-cell lymphoma in all stages, as both an oral capsule and a topical gel formulation.  Bexarotene was found to induce apoptosis in a variety of preclin. in vitro and in vivo models including cutaneous T-cell lymphoma cells, and has shown efficacy in two multi-center, open-label Phase II - III clin. trials for early and advanced stages of cutaneous T-cell lymphoma in patients who have failed or were refractory to std. therapies.  New insights into the immunomodulatory function of bexarotene have indicated opportunities for combined treatment with IFN-α, denileukin diftitox or phototherapy.  This article reviews the biol. properties, pharmacokinetics, clin. efficacy, safety and role of bexarotene in the treatment of cutaneous T-cell lymphoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAVJxHGrgWcbVg90H21EOLACvtfcHk0liO-g3U_-AiyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xkt12hu7c%253D&md5=8034a83261443a60bed1982005411d68</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1517%2F14656566.7.7.907&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14656566.7.7.907%26sid%3Dliteratum%253Aachs%26aulast%3DQuerfeld%26aufirst%3DC.%26aulast%3DNagelli%26aufirst%3DL.%2BV.%26aulast%3DRosen%26aufirst%3DS.%2BT.%26aulast%3DKuzel%26aufirst%3DT.%2BM.%26aulast%3DGuitart%26aufirst%3DJ.%26atitle%3DBexarotene%2520in%2520the%2520Treatment%2520of%2520Cutaneous%2520T-Cell%2520Lymphoma%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2006%26volume%3D7%26spage%3D907%26epage%3D915%26doi%3D10.1517%2F14656566.7.7.907" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michaels, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheinfeld, N.</span></span> <span> </span><span class="NLM_article-title">Alitretinoin: A Comprehensive Review</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">437</span>– <span class="NLM_lpage">443</span>, <span class="refDoi"> DOI: 10.1517/13543784.17.3.437</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1517%2F13543784.17.3.437" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2008&pages=437-443&author=C.+Chengauthor=J.+Michaelsauthor=N.+Scheinfeld&title=Alitretinoin%3A+A+Comprehensive+Review&doi=10.1517%2F13543784.17.3.437"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1517%2F13543784.17.3.437&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.17.3.437%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DC.%26aulast%3DMichaels%26aufirst%3DJ.%26aulast%3DScheinfeld%26aufirst%3DN.%26atitle%3DAlitretinoin%253A%2520A%2520Comprehensive%2520Review%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2008%26volume%3D17%26spage%3D437%26epage%3D443%26doi%3D10.1517%2F13543784.17.3.437" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haydon, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breyer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peabody, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montag, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simon, M. A.</span></span> <span> </span><span class="NLM_article-title">Nuclear Receptor Agonists as Potential Differentiation Therapy Agents for Human Osteosarcoma</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1288</span>– <span class="NLM_lpage">1294</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=12006550" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=1%3ACAS%3A528%3ADC%252BD38XksVWjs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2002&pages=1288-1294&author=R.+C.+Haydonauthor=L.+Zhouauthor=T.+Fengauthor=B.+Breyerauthor=H.+Chengauthor=W.+Jiangauthor=A.+Ishikawaauthor=T.+Peabodyauthor=A.+Montagauthor=M.+A.+Simon&title=Nuclear+Receptor+Agonists+as+Potential+Differentiation+Therapy+Agents+for+Human+Osteosarcoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Nuclear receptor agonists as potential differentiation therapy agents for human osteosarcoma</span></div><div class="casAuthors">Haydon, Rex C.; Zhou, Lan; Feng, Tao; Breyer, Benjamin; Cheng, Hongwei; Jiang, Wei; Ishikawa, Akira; Peabody, Terrance; Montag, Anthony; Simon, Michael A.; He, Tong-Chuan</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1288-1294</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">This study was designed to investigate whether nuclear receptor agonists can be used as potential differentiation therapy agents for human osteosarcoma.  Four osteosarcoma cell lines (143B, MNNG/HOS; MG-63; and TE-85) were treated with proliferator-activated receptor. (PPAR)-γ agonists, troglitazone and ciglitazone, and a retinoid X receptor (RXR) ligand; 9-cis retinoic acid.  The proliferation and induction of apoptosis in the treated cells were assessed, as was the induction of alk. phosphatase, a differentiation marker of osteoblasts.  The expression of PPARγ was readily detected in all tested osteosarcoma lines.  On treatment with the PPARγ and RXR ligands, all four osteosarcoma lines exhibited a significantly reduced proliferation rate and cell viability.  Among the four lines; 143B and MNNG/HOS were shown to be more sensitive to ligand-induced apoptosis, as demonstrated by the Crystal Violet and Hoechst staining assays.  Of the three tested ligands, troglitazone was shown to be the most effective in inducing cell death, followed by 9-cis retinoic acid.  Moreover, a strong synergistic effect on the induction of cell death was obsd. when both troglitazone and 9-cis retinoic-acid or ciglitazone and 9-cis retinoic acid were administered to osteosarcoma cells.  Troglitazone was shown to effectively induce alk. phosphatase activity, a well-characterized-hallmark for osteoblastic differentiation.  Our findings suggest that PPARγ and/or RXR ligands may be used as efficacious adjuvant therapeutic agents for primary osteosarcoma, as well as potential chemopreventive agents for preventing the recurrence and metastasis of osteosarcoma after the surgical removal of the primary tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrY6HncZQjxr7Vg90H21EOLACvtfcHk0liO-g3U_-AiyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XksVWjs7s%253D&md5=2d48a0a4171364e3e55252a97328edec</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHaydon%26aufirst%3DR.%2BC.%26aulast%3DZhou%26aufirst%3DL.%26aulast%3DFeng%26aufirst%3DT.%26aulast%3DBreyer%26aufirst%3DB.%26aulast%3DCheng%26aufirst%3DH.%26aulast%3DJiang%26aufirst%3DW.%26aulast%3DIshikawa%26aufirst%3DA.%26aulast%3DPeabody%26aufirst%3DT.%26aulast%3DMontag%26aufirst%3DA.%26aulast%3DSimon%26aufirst%3DM.%2BA.%26atitle%3DNuclear%2520Receptor%2520Agonists%2520as%2520Potential%2520Differentiation%2520Therapy%2520Agents%2520for%2520Human%2520Osteosarcoma%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2002%26volume%3D8%26spage%3D1288%26epage%3D1294" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nagpal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masood, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, G. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friant, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandraratna, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gill, P. S.</span></span> <span> </span><span class="NLM_article-title">Retinoid Antagonism of NF-IL6: Insight into the Mechanism of Antiproliferative Effects of Retinoids in Kaposi’s Sarcoma</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">4159</span>– <span class="NLM_lpage">4168</span>, <span class="refDoi"> DOI: 10.1128/MCB.17.7.4159</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1128%2FMCB.17.7.4159" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=9199351" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=1%3ACAS%3A528%3ADyaK2sXktFOmtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1997&pages=4159-4168&author=S.+Nagpalauthor=J.+Caiauthor=T.+Zhengauthor=S.+Patelauthor=R.+Masoodauthor=G.+Y.+Linauthor=S.+Friantauthor=A.+Johnsonauthor=D.+L.+Smithauthor=R.+Chandraratnaauthor=P.+S.+Gill&title=Retinoid+Antagonism+of+NF-IL6%3A+Insight+into+the+Mechanism+of+Antiproliferative+Effects+of+Retinoids+in+Kaposi%E2%80%99s+Sarcoma&doi=10.1128%2FMCB.17.7.4159"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Retinoid antagonism of NF-IL6: insight into the mechanism of antiproliferative effects of retinoids in Kaposi's sarcoma</span></div><div class="casAuthors">Nagpal, Sunil; Cai, Jie; Zheng, Tong; Patel, Sheetal; Masood, Rizwan; Lin, George Y.; Friant, Sylvie; Johnson, Alan; Smith, D. Lynne; Chandraratna, Roshantha A. S.; Gill, Parkash S.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">4159-4168</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">All-trans-retinoic acid (RA) is active in the treatment of Kaposi's sarcoma (KS), and retinoids inhibit KS cell growth in vitro.  To understand the mechanism of retinoid action in KS, we studied the expression of autocrine growth factors of KS cells after RA treatment.  We demonstrate that RA and its synthetic analogs inhibit the proliferation of KS cells by inhibiting the mRNA and protein levels of interleukin-6 (IL-6), an autocrine growth factor for KS cells.  We further demonstrate that nuclear retinoid receptors (RA receptors [RARs] and retinoid receptors [RXRs]) inhibit IL-6 promoter action by antagonizing the enhancer action of NF-IL6, a basic domain leucine zipper transcription factor belonging to the family of CAAT enhancer binding proteins.  Furthermore, RARs and RXRs do not bind in vitro to an NF-IL6 binding site.  However, the secondary folded structure of the DNA binding domain of RAR and RXR is obligatory for inhibiting NF-IL6 activity.  Thus, NF-IL6 is a potential therapeutic target for the treatment of KS.  Finally, using receptor-selective synthetic retinoids, we demonstrate that NF-IL6 antagonism and transactivation are separable functions of RARα, thus indicating that synthetic retinoids with properties of NF-IL6 antagonism but lacking transactivation capabilities can be synthesized.  Such retinoids might increase therapeutic potential in KS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGHId7-xIvcLVg90H21EOLACvtfcHk0liO-g3U_-AiyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXktFOmtrs%253D&md5=b032b416b9dd473b7c757f96f0ff5e59</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1128%2FMCB.17.7.4159&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.17.7.4159%26sid%3Dliteratum%253Aachs%26aulast%3DNagpal%26aufirst%3DS.%26aulast%3DCai%26aufirst%3DJ.%26aulast%3DZheng%26aufirst%3DT.%26aulast%3DPatel%26aufirst%3DS.%26aulast%3DMasood%26aufirst%3DR.%26aulast%3DLin%26aufirst%3DG.%2BY.%26aulast%3DFriant%26aufirst%3DS.%26aulast%3DJohnson%26aufirst%3DA.%26aulast%3DSmith%26aufirst%3DD.%2BL.%26aulast%3DChandraratna%26aufirst%3DR.%26aulast%3DGill%26aufirst%3DP.%2BS.%26atitle%3DRetinoid%2520Antagonism%2520of%2520NF-IL6%253A%2520Insight%2520into%2520the%2520Mechanism%2520of%2520Antiproliferative%2520Effects%2520of%2520Retinoids%2520in%2520Kaposi%25E2%2580%2599s%2520Sarcoma%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D1997%26volume%3D17%26spage%3D4159%26epage%3D4168%26doi%3D10.1128%2FMCB.17.7.4159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tontonoz, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forman, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarraf, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brun, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altiok, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oppenheim, H.</span></span> <span> </span><span class="NLM_article-title">Terminal Differentiation of Human Liposarcoma Cells Induced by Ligands for Peroxisome Proliferator-Activated Receptor Gamma and the Retinoid X Receptor</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>94</i></span>,  <span class="NLM_fpage">237</span>– <span class="NLM_lpage">241</span>, <span class="refDoi"> DOI: 10.1073/pnas.94.1.237</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1073%2Fpnas.94.1.237" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=1997&pages=237-241&author=P.+Tontonozauthor=S.+Singerauthor=B.+M.+Formanauthor=P.+Sarrafauthor=J.+A.+Fletcherauthor=C.+D.+Fletcherauthor=R.+P.+Brunauthor=E.+Muellerauthor=S.+Altiokauthor=H.+Oppenheim&title=Terminal+Differentiation+of+Human+Liposarcoma+Cells+Induced+by+Ligands+for+Peroxisome+Proliferator-Activated+Receptor+Gamma+and+the+Retinoid+X+Receptor&doi=10.1073%2Fpnas.94.1.237"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1073%2Fpnas.94.1.237&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.94.1.237%26sid%3Dliteratum%253Aachs%26aulast%3DTontonoz%26aufirst%3DP.%26aulast%3DSinger%26aufirst%3DS.%26aulast%3DForman%26aufirst%3DB.%2BM.%26aulast%3DSarraf%26aufirst%3DP.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26aulast%3DFletcher%26aufirst%3DC.%2BD.%26aulast%3DBrun%26aufirst%3DR.%2BP.%26aulast%3DMueller%26aufirst%3DE.%26aulast%3DAltiok%26aufirst%3DS.%26aulast%3DOppenheim%26aufirst%3DH.%26atitle%3DTerminal%2520Differentiation%2520of%2520Human%2520Liposarcoma%2520Cells%2520Induced%2520by%2520Ligands%2520for%2520Peroxisome%2520Proliferator-Activated%2520Receptor%2520Gamma%2520and%2520the%2520Retinoid%2520X%2520Receptor%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1997%26volume%3D94%26spage%3D237%26epage%3D241%26doi%3D10.1073%2Fpnas.94.1.237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Salbert, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fanjul, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piedrafita, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfahl, M.</span></span> <span> </span><span class="NLM_article-title">Retinoic Acid Receptors and Retinoid X Receptor-Alpha Down-Regulate the Transforming Growth Factor-Beta 1 Promoter by Antagonizing AP-1 Activity</span>. <i>Mol. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1347</span>– <span class="NLM_lpage">1356</span>, <span class="refDoi"> DOI: 10.1210/mend.7.10.8264664</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1210%2Fmend.7.10.8264664" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=8264664" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=1%3ACAS%3A528%3ADyaK2cXhtlKm" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1993&pages=1347-1356&author=G.+Salbertauthor=A.+Fanjulauthor=F.+J.+Piedrafitaauthor=X.+P.+Luauthor=S.-J.+Kimauthor=P.+Tranauthor=M.+Pfahl&title=Retinoic+Acid+Receptors+and+Retinoid+X+Receptor-Alpha+Down-Regulate+the+Transforming+Growth+Factor-Beta+1+Promoter+by+Antagonizing+AP-1+Activity&doi=10.1210%2Fmend.7.10.8264664"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Retinoic acid receptors and retinoid X receptor-α down-regulate the transforming growth factor-β1 promoter by antagonizing AP-1 activity</span></div><div class="casAuthors">Salbert, Gilles; Fanjul, Andrea; Piedrafita, F. Javier; Lu, Xian Ping; Kim, Seong Jin; Tran, Paul; Pfahl, Magnus</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Endocrinology</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1347-56</span>CODEN:
                <span class="NLM_cas:coden">MOENEN</span>;
        ISSN:<span class="NLM_cas:issn">0888-8809</span>.
    </div><div class="casAbstract">Overexpression of the multifunctional growth factor transforming growth factor-β1 (TGFβ1) has been connected to numerous diseases in human.  TGFβ1 expression is largely governed by three AP-1 binding sites located in two different promoters of this gene.  The authors have examd. the ability of retinoid receptors to inhibit the activity of the two promoters (esp. the promoter 1) by cotransfection assays in the hepatocellular carcinoma cell line HepG2.  When the TGFβ1 promoter activity is induced by 12-O-tetradecanoyl phorbol-13-acetate (an activator of AP-1-controlled gene transcription), this activity can be strongly repressed by retinoic acid receptor-α (RARα), RARβ, or retinoid X receptor-α (RXRα) as well as other members of the nuclear receptor family.  Repression was hormone dependent and a function of receptor concn.  Heterodimerization of RARα or RARβ with RXRα did not modify the inhibition activities of these receptors, indicating that heterodimer formation is not required for antagonizing of AP-1 activity.  On further examg. the anti-AP-1 activity of RXRα the authors obsd. that three different AP-1-controlled promoters (TGFβ1, collagenase, and cFos) can be inhibited.  Using gel shift assays, the authors demonstrated that RXRα inhibits Jun and Fos DNA binding and that 9-cis-RA enhances this inhibition, suggesting that a mechanism involving direct protein-protein interaction between RXR and AP-1 components mediates the inhibitory effect obsd. in vivo.  Transfection analyses with RXRα point mutations revealed that residues L422, C432, and, to a lesser extent, residues L418 and L430, are involved in ligand-induced anti-AP1 activity of RXRα in vivo.  Thus both types of retinoid receptors can inhibit AP-1-activated promoters, including the TGFβ1 gene promoter, via a mechanism that involves protein-protein interaction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXBKiJLDQPw7Vg90H21EOLACvtfcHk0liDN-fWyhmDNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXhtlKm&md5=8c375ca6e8185972ad91e57dcf557d8b</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1210%2Fmend.7.10.8264664&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fmend.7.10.8264664%26sid%3Dliteratum%253Aachs%26aulast%3DSalbert%26aufirst%3DG.%26aulast%3DFanjul%26aufirst%3DA.%26aulast%3DPiedrafita%26aufirst%3DF.%2BJ.%26aulast%3DLu%26aufirst%3DX.%2BP.%26aulast%3DKim%26aufirst%3DS.-J.%26aulast%3DTran%26aufirst%3DP.%26aulast%3DPfahl%26aufirst%3DM.%26atitle%3DRetinoic%2520Acid%2520Receptors%2520and%2520Retinoid%2520X%2520Receptor-Alpha%2520Down-Regulate%2520the%2520Transforming%2520Growth%2520Factor-Beta%25201%2520Promoter%2520by%2520Antagonizing%2520AP-1%2520Activity%26jtitle%3DMol.%2520Endocrinol.%26date%3D1993%26volume%3D7%26spage%3D1347%26epage%3D1356%26doi%3D10.1210%2Fmend.7.10.8264664" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schook, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rund, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Begnini, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Remião, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seixas, F. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collares, T.</span></span> <span> </span><span class="NLM_article-title">Emerging Technologies to Create Inducible and Genetically Defined Porcine Cancer Models</span>. <i>Front. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">28</span>, <span class="refDoi"> DOI: 10.3389/fgene.2016.00028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.3389%2Ffgene.2016.00028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=26973698" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmvFKrtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=28&author=L.+B.+Schookauthor=L.+Rundauthor=K.+R.+Begniniauthor=M.+H.+Remi%C3%A3oauthor=F.+K.+Seixasauthor=T.+Collares&title=Emerging+Technologies+to+Create+Inducible+and+Genetically+Defined+Porcine+Cancer+Models&doi=10.3389%2Ffgene.2016.00028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging technologies to create inducible and genetically defined porcine cancer models</span></div><div class="casAuthors">Schook, Lawrence B.; Rund, Laurie; Begnini, Karine R.; Remiao, Mariana H.; Seixas, Fabiana K.; Collares, Tiago</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Genetics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">28/1-28/7</span>CODEN:
                <span class="NLM_cas:coden">FGREBR</span>;
        ISSN:<span class="NLM_cas:issn">1664-8021</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">There is an emerging need for new animal models that address unmet translational cancer research requirements.  Transgenic porcine models provide an exceptional opportunity due to their genetic, anat., and physiol. similarities with humans.  Due to recent advances in the sequencing of domestic animal genomes and the development of new organism cloning technologies, it is now very feasible to utilize pigs as a malleable species, with similar anat. and physiol. features with humans, in which to develop cancer models.  In this review, we discuss genetic modification technologies successfully used to produce porcine biomedical models, in particular the Cre-loxP System as well as major advances and perspectives the CRISPR/Cas9 System.  Recent advancements in porcine tumor modeling and genome editing will bring porcine models to the forefront of translational cancer research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpt3BQVu6i0_LVg90H21EOLACvtfcHk0liDN-fWyhmDNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmvFKrtLc%253D&md5=ec2982695d12080a2d22fa00279d734d</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.3389%2Ffgene.2016.00028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffgene.2016.00028%26sid%3Dliteratum%253Aachs%26aulast%3DSchook%26aufirst%3DL.%2BB.%26aulast%3DRund%26aufirst%3DL.%26aulast%3DBegnini%26aufirst%3DK.%2BR.%26aulast%3DRemi%25C3%25A3o%26aufirst%3DM.%2BH.%26aulast%3DSeixas%26aufirst%3DF.%2BK.%26aulast%3DCollares%26aufirst%3DT.%26atitle%3DEmerging%2520Technologies%2520to%2520Create%2520Inducible%2520and%2520Genetically%2520Defined%2520Porcine%2520Cancer%2520Models%26jtitle%3DFront.%2520Genet.%26date%3D2016%26volume%3D7%26spage%3D28%26doi%3D10.3389%2Ffgene.2016.00028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schachtschneider, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madsen, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rund, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groenen, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schook, L. B.</span></span> <span> </span><span class="NLM_article-title">Adult Porcine Genome-Wide DNA Methylation Patterns Support Pigs as a Biomedical Model</span>. <i>BMC Genomics</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">743</span>, <span class="refDoi"> DOI: 10.1186/s12864-015-1938-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1186%2Fs12864-015-1938-x" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=743&author=K.+M.+Schachtschneiderauthor=O.+Madsenauthor=C.+Parkauthor=L.+A.+Rundauthor=M.+A.+Groenenauthor=L.+B.+Schook&title=Adult+Porcine+Genome-Wide+DNA+Methylation+Patterns+Support+Pigs+as+a+Biomedical+Model&doi=10.1186%2Fs12864-015-1938-x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1186%2Fs12864-015-1938-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12864-015-1938-x%26sid%3Dliteratum%253Aachs%26aulast%3DSchachtschneider%26aufirst%3DK.%2BM.%26aulast%3DMadsen%26aufirst%3DO.%26aulast%3DPark%26aufirst%3DC.%26aulast%3DRund%26aufirst%3DL.%2BA.%26aulast%3DGroenen%26aufirst%3DM.%2BA.%26aulast%3DSchook%26aufirst%3DL.%2BB.%26atitle%3DAdult%2520Porcine%2520Genome-Wide%2520DNA%2520Methylation%2520Patterns%2520Support%2520Pigs%2520as%2520a%2520Biomedical%2520Model%26jtitle%3DBMC%2520Genomics%26date%3D2015%26volume%3D16%26spage%3D743%26doi%3D10.1186%2Fs12864-015-1938-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schook, L. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collares, T. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodrigues, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rund, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schachtschneider, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seixas, F. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, K. D.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">A Genetic Porcine Model of Cancer</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>, <span class="NLM_elocation-id">e0128864</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0128864</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1371%2Fjournal.pone.0128864" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=26132737" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVSrtbvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&author=L.+B.+Schookauthor=T.+V.+Collaresauthor=W.+Huauthor=Y.+Liangauthor=F.+M.+Rodriguesauthor=L.+A.+Rundauthor=K.+M.+Schachtschneiderauthor=F.+K.+Seixasauthor=K.+Singhauthor=K.+D.+Wells&title=A+Genetic+Porcine+Model+of+Cancer&doi=10.1371%2Fjournal.pone.0128864"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">A genetic porcine model of cancer</span></div><div class="casAuthors">Schook, Lawrence B.; Collares, Tiago V.; Hu, Wenping; Liang, Ying; Rodrigues, Fernanda M.; Rund, Laurie A.; Schachtschneider, Kyle M.; Seixas, Fabiana K.; Singh, Kuldeep; Wells, Kevin D.; Walters, Eric M.; Prather, Randall S.; Counter, Christopher M.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">e0128864/1-e0128864/18</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">The large size of the pig and its similarity in anatomy, physiol., metab., and genetics to humans make it an ideal platform to develop a genetically defined, large animal model of cancer.  To this end, we created a transgenic "oncopig" line encoding Cre recombinase inducible porcine transgenes encoding KRASG12D and TP53R167H, which represent a commonly mutated oncogene and tumor suppressor in human cancers, resp.  Treatment of cells derived from these oncopigs with the adenovirus encoding Cre (AdCre) led to KRASG12D and TP53R167H expression, which rendered the cells transformed in culture and tumorigenic when engrafted into immunocompromised mice.  Finally, injection of AdCre directly into these oncopigs led to the rapid and reproducible tumor development of mesenchymal origin.  Transgenic animals receiving AdGFP (green fluorescent protein) did not have any tumor mass formation or altered histopathol.  This oncopig line could thus serve as a genetically malleable model for potentially a wide spectrum of cancers, while controlling for temporal or spatial genesis, which should prove invaluable to studies previously hampered by the lack of a large animal model of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOz8pzO1zIeLVg90H21EOLACvtfcHk0li4MhmjXRAp9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVSrtbvK&md5=38764903085778d6a194a879b735bfa2</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0128864&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0128864%26sid%3Dliteratum%253Aachs%26aulast%3DSchook%26aufirst%3DL.%2BB.%26aulast%3DCollares%26aufirst%3DT.%2BV.%26aulast%3DHu%26aufirst%3DW.%26aulast%3DLiang%26aufirst%3DY.%26aulast%3DRodrigues%26aufirst%3DF.%2BM.%26aulast%3DRund%26aufirst%3DL.%2BA.%26aulast%3DSchachtschneider%26aufirst%3DK.%2BM.%26aulast%3DSeixas%26aufirst%3DF.%2BK.%26aulast%3DSingh%26aufirst%3DK.%26aulast%3DWells%26aufirst%3DK.%2BD.%26atitle%3DA%2520Genetic%2520Porcine%2520Model%2520of%2520Cancer%26jtitle%3DPLoS%2520One%26date%3D2015%26volume%3D10%26doi%3D10.1371%2Fjournal.pone.0128864" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Misra, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, D.</span></span> <span> </span><span class="NLM_article-title">Defined Nanoscale Chemistry Influences Delivery of Peptidotoxins for Cancer Therapy</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>, <span class="NLM_elocation-id">e0125908</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0125908</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1371%2Fjournal.pone.0125908" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&author=S.+K.+Misraauthor=M.+Yeauthor=S.+Kimauthor=D.+Pan&title=Defined+Nanoscale+Chemistry+Influences+Delivery+of+Peptidotoxins+for+Cancer+Therapy&doi=10.1371%2Fjournal.pone.0125908"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0125908&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0125908%26sid%3Dliteratum%253Aachs%26aulast%3DMisra%26aufirst%3DS.%2BK.%26aulast%3DYe%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DPan%26aufirst%3DD.%26atitle%3DDefined%2520Nanoscale%2520Chemistry%2520Influences%2520Delivery%2520of%2520Peptidotoxins%2520for%2520Cancer%2520Therapy%26jtitle%3DPLoS%2520One%26date%3D2015%26volume%3D10%26doi%3D10.1371%2Fjournal.pone.0125908" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Misra, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, D.</span></span> <span> </span><span class="NLM_article-title">Enriched Inhibition of Cancer and Stem-Like Cancer Cells via STAT-3 Modulating Niclocelles</span>. <i>Nanoscale</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">7127</span>, <span class="refDoi"> DOI: 10.1039/C5NR00403A</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1039%2FC5NR00403A" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2015&pages=7127&author=S.+K.+Misraauthor=T.+W.+Jensenauthor=D.+Pan&title=Enriched+Inhibition+of+Cancer+and+Stem-Like+Cancer+Cells+via+STAT-3+Modulating+Niclocelles&doi=10.1039%2FC5NR00403A"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1039%2FC5NR00403A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC5NR00403A%26sid%3Dliteratum%253Aachs%26aulast%3DMisra%26aufirst%3DS.%2BK.%26aulast%3DJensen%26aufirst%3DT.%2BW.%26aulast%3DPan%26aufirst%3DD.%26atitle%3DEnriched%2520Inhibition%2520of%2520Cancer%2520and%2520Stem-Like%2520Cancer%2520Cells%2520via%2520STAT-3%2520Modulating%2520Niclocelles%26jtitle%3DNanoscale%26date%3D2015%26volume%3D7%26spage%3D7127%26doi%3D10.1039%2FC5NR00403A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Misra, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kus, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, D.</span></span> <span> </span><span class="NLM_article-title">Nanoscopic Poly-DNA-Cleaver for Breast Cancer Regression with Induced Oxidative Damage</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">4218</span>, <span class="refDoi"> DOI: 10.1021/mp500444c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp500444c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtl2gt7fE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2014&pages=4218&author=S.+K.+Misraauthor=J.+Kusauthor=S.+Kimauthor=D.+Pan&title=Nanoscopic+Poly-DNA-Cleaver+for+Breast+Cancer+Regression+with+Induced+Oxidative+Damage&doi=10.1021%2Fmp500444c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Nanoscopic Poly-DNA-Cleaver for Breast Cancer Regression with Induced Oxidative Damage</span></div><div class="casAuthors">Misra, Santosh K.; Kus, Joseph; Kim, Sumin; Pan, Dipanjan</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4218-4227</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel strategy for efficient "nanodelivery" of DNA-cleaving mols. for breast cancer regression is presented here.  The synthetic methodol. can be tweaked for controlled delivery and better bioavailability of EDs of these DNA-cleaving agents through a defined self-assembled polymeric nanoarchitecture.  In vitro studies in ER+ and ER- breast cancer human cell lines confirmed an efficient "nano"-delivery of DNA-cleaving mols. and indicated their capability to mediate oxidative damage to nucleobases and/or to the 2-deoxyribose moiety.  Prepd. E-poly-DNA-cleaver and C-poly-DNA-cleaver were found to be interacting with plasmid DNA pBR322 (pDNA) and active to cause oxidative cleavage of pDNA in the presence of ascorbic acid and H2O2.  They were found to be significantly active as DNA cleaving agents in vitro and showed highly improved cancer regression in MCF-7 and MD-MB231 cancer cells compared to small mol. DNA cleaver.  Surface conjugated nanoparticles were found to be more effective than noncovalent encapsulation and the small mol. agent, whereas in all the cases RCM was significantly inactive toward DNA cleavage.  Blood contact complement activation properties were evaluated to gauge their likelihood to promote acute toxicity following systemic administration.  The complement activation analyses together with the blood smear study confirm the feasibility of using these poly-DNA-cleavers without risk of induced immune response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLITqK6UGsv7Vg90H21EOLACvtfcHk0li4MhmjXRAp9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtl2gt7fE&md5=c7854be1785bdcfc550788da20777960</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Fmp500444c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp500444c%26sid%3Dliteratum%253Aachs%26aulast%3DMisra%26aufirst%3DS.%2BK.%26aulast%3DKus%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DPan%26aufirst%3DD.%26atitle%3DNanoscopic%2520Poly-DNA-Cleaver%2520for%2520Breast%2520Cancer%2520Regression%2520with%2520Induced%2520Oxidative%2520Damage%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2014%26volume%3D11%26spage%3D4218%26doi%3D10.1021%2Fmp500444c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Misra, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, D.</span></span> <span> </span><span class="NLM_article-title">Highly Efficient Anti-Cancer Therapy Using Scorpion ’NanoVenin’</span>. <i>Chem. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">13220</span>, <span class="refDoi"> DOI: 10.1039/C4CC04748F</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1039%2FC4CC04748F" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2014&pages=13220&author=S.+K.+Misraauthor=M.+Yeauthor=S.+Kimauthor=D.+Pan&title=Highly+Efficient+Anti-Cancer+Therapy+Using+Scorpion+%E2%80%99NanoVenin%E2%80%99&doi=10.1039%2FC4CC04748F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1039%2FC4CC04748F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC4CC04748F%26sid%3Dliteratum%253Aachs%26aulast%3DMisra%26aufirst%3DS.%2BK.%26aulast%3DYe%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DPan%26aufirst%3DD.%26atitle%3DHighly%2520Efficient%2520Anti-Cancer%2520Therapy%2520Using%2520Scorpion%2520%25E2%2580%2599NanoVenin%25E2%2580%2599%26jtitle%3DChem.%2520Commun.%26date%3D2014%26volume%3D50%26spage%3D13220%26doi%3D10.1039%2FC4CC04748F" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Misra, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghoshal, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gartia, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bromfield, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tangella, K. V.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Trimodal Therapy: Combining Hyperthermia with Repurposed Bexarotene and Ultrasound for Treating Liver Cancer</span>. <i>ACS Nano</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">10695</span>, <span class="refDoi"> DOI: 10.1021/acsnano.5b05974</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsnano.5b05974" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2015&pages=10695&author=S.+K.+Misraauthor=G.+Ghoshalauthor=M.+R.+Gartiaauthor=Z.+Wuauthor=A.+K.+Deauthor=M.+Yeauthor=C.+R.+Bromfieldauthor=E.+M.+Williamsauthor=K.+Singhauthor=K.+V.+Tangella&title=Trimodal+Therapy%3A+Combining+Hyperthermia+with+Repurposed+Bexarotene+and+Ultrasound+for+Treating+Liver+Cancer&doi=10.1021%2Facsnano.5b05974"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Facsnano.5b05974&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsnano.5b05974%26sid%3Dliteratum%253Aachs%26aulast%3DMisra%26aufirst%3DS.%2BK.%26aulast%3DGhoshal%26aufirst%3DG.%26aulast%3DGartia%26aufirst%3DM.%2BR.%26aulast%3DWu%26aufirst%3DZ.%26aulast%3DDe%26aufirst%3DA.%2BK.%26aulast%3DYe%26aufirst%3DM.%26aulast%3DBromfield%26aufirst%3DC.%2BR.%26aulast%3DWilliams%26aufirst%3DE.%2BM.%26aulast%3DSingh%26aufirst%3DK.%26aulast%3DTangella%26aufirst%3DK.%2BV.%26atitle%3DTrimodal%2520Therapy%253A%2520Combining%2520Hyperthermia%2520with%2520Repurposed%2520Bexarotene%2520and%2520Ultrasound%2520for%2520Treating%2520Liver%2520Cancer%26jtitle%3DACS%2520Nano%26date%3D2015%26volume%3D9%26spage%3D10695%26doi%3D10.1021%2Facsnano.5b05974" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Szebeni, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bedőcs, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rozsnyay, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiszhár, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urbanics, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosivall, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garbuzenko, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Báthori, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tóth, M.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Liposome-Induced Complement Activation and Related Cardiopulmonary Distress in Pigs: Factors Promoting Reactogenicity of Doxil and Ambisome</span>. <i>Nanomedicine</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">176</span>– <span class="NLM_lpage">184</span>, <span class="refDoi"> DOI: 10.1016/j.nano.2011.06.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1016%2Fj.nano.2011.06.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=21704590" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=1%3ACAS%3A528%3ADC%252BC38Xos12gsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2012&pages=176-184&author=J.+Szebeniauthor=P.+Bed%C5%91csauthor=Z.+Rozsnyayauthor=Z.+Weiszh%C3%A1rauthor=R.+Urbanicsauthor=L.+Rosivallauthor=R.+Cohenauthor=O.+Garbuzenkoauthor=G.+B%C3%A1thoriauthor=M.+T%C3%B3th&title=Liposome-Induced+Complement+Activation+and+Related+Cardiopulmonary+Distress+in+Pigs%3A+Factors+Promoting+Reactogenicity+of+Doxil+and+Ambisome&doi=10.1016%2Fj.nano.2011.06.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Liposome-induced complement activation and related cardiopulmonary distress in pigs: factors promoting reactogenicity of Doxil and AmBisome</span></div><div class="casAuthors">Szebeni, Janos; Bedocs, Peter; Rozsnyay, Zoltan; Weiszhar, Zsoka; Urbanics, Rudolf; Rosivall, Laszlo; Cohen, Rivka; Garbuzenko, Olga; Bathori, Gyoergy; Toth, Miklos; Buenger, Rolf; Barenholz, Yechezkel</div><div class="citationInfo"><span class="NLM_cas:title">Nanomedicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">176-184</span>CODEN:
                <span class="NLM_cas:coden">NANOBF</span>;
        ISSN:<span class="NLM_cas:issn">1549-9634</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Hypersensitivity reactions to liposomal drugs, often obsd. with Doxil and AmBisome, can arise from activation of the complement (C) system by phospholipid bilayers.  To understand the mechanism of this adverse immune reaction called C activation-related pseudoallergy (CARPA), we analyzed the relationship among liposome features, C activation in human serum in vitro, and liposome-induced cardiovascular distress in pigs, a model for human CARPA.  Among the structural variables (surface charge, presence of satd., unsatd., and PEGylated phospholipids, and cisplatin vs. doxorubicin inside liposomes), high neg. surface charge and the presence of doxorubicin were significant contributors to reactogenicity both in vitro and in vivo.  Morphol. anal. suggested that the effect of doxorubicin might be indirect, via distorting the sphericity of liposomes and, if leaked, causing aggregation.  The parallelism among C activation, cardiopulmonary reactions in pigs, and high rate of hypersensitivity reactions to Doxil and AmBisome in humans strengthens the utility of the applied tests in predicting the risk of CARPA.  From the Clin. Editor: The authors studied complement activation-related pseudoallergy (CARPA) in a porcine model and demonstrate that high neg. surface charge and drug effects leading to distortion of liposome sphericity might be the most crit. factors leading to CARPA.  The applied tests might be used to predict CARPA in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrx9nzjUZ7LrbVg90H21EOLACvtfcHk0ljWJ2XtRtSvtw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xos12gsg%253D%253D&md5=fdc3ede58cda2959a7f83e7daa82f0a6</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2Fj.nano.2011.06.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nano.2011.06.003%26sid%3Dliteratum%253Aachs%26aulast%3DSzebeni%26aufirst%3DJ.%26aulast%3DBed%25C5%2591cs%26aufirst%3DP.%26aulast%3DRozsnyay%26aufirst%3DZ.%26aulast%3DWeiszh%25C3%25A1r%26aufirst%3DZ.%26aulast%3DUrbanics%26aufirst%3DR.%26aulast%3DRosivall%26aufirst%3DL.%26aulast%3DCohen%26aufirst%3DR.%26aulast%3DGarbuzenko%26aufirst%3DO.%26aulast%3DB%25C3%25A1thori%26aufirst%3DG.%26aulast%3DT%25C3%25B3th%26aufirst%3DM.%26atitle%3DLiposome-Induced%2520Complement%2520Activation%2520and%2520Related%2520Cardiopulmonary%2520Distress%2520in%2520Pigs%253A%2520Factors%2520Promoting%2520Reactogenicity%2520of%2520Doxil%2520and%2520Ambisome%26jtitle%3DNanomedicine%26date%3D2012%26volume%3D8%26spage%3D176%26epage%3D184%26doi%3D10.1016%2Fj.nano.2011.06.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Edwardson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narendrula, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chewchuk, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mispel-Beyer, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mapletoft, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parissenti, M.</span></span> <span> </span><span class="NLM_article-title">Role of Drug Metabolism in the Cytotoxicity and Clinical Efficacy of Anthracyclines</span>. <i>Curr. Drug Metab.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">412</span>– <span class="NLM_lpage">426</span>, <span class="refDoi"> DOI: 10.2174/1389200216888150915112039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.2174%2F1389200216888150915112039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=26321196" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1OntL7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=412-426&author=D.+Edwardsonauthor=R.+Narendrulaauthor=S.+Chewchukauthor=K.+Mispel-Beyerauthor=J.+Mapletoftauthor=M.+Parissenti&title=Role+of+Drug+Metabolism+in+the+Cytotoxicity+and+Clinical+Efficacy+of+Anthracyclines&doi=10.2174%2F1389200216888150915112039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Role of Drug Metabolism in the Cytotoxicity and Clinical Efficacy of Anthracyclines</span></div><div class="casAuthors">Edwardson, Derek W.; Narendrula, Rashmi; Chewchuk, Simon; Mispel-Beyer, Kyle; Mapletoft, Jonathan P. J.; Parissenti, Amadeo M.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">412-426</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>;
        ISSN:<span class="NLM_cas:issn">1389-2002</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Many clin. studies involving anti-tumor agents neglect to consider how these agents are metabolized within the host and whether the creation of specific metabolites alters drug therapeutic properties or toxic side effects.  However, this is not the case for the anthracycline class of chemotherapy drugs.  This review describes the various enzymes involved in the one electron (semi-quinone) or two electron (hydroxylation) redn. of anthracyclines, or in their reductive deglycosidation into deoxyaglycones.  The effects of these redns. on drug antitumor efficacy and toxic side effects are also discussed.  Current evidence suggests that the one electron redn. of anthracyclines augments both their tumor toxicity and their toxicity towards the host, in particular their cardiotoxicity.  In contrast, the two electron redn. (hydroxylation) of anthracyclines strongly reduces their ability to kill tumor cells, while augmenting cardiotoxicity through their accumulation within cardiomyocytes and their direct effects on excitation/contraction coupling within the myocytes.  The reductive deglycosidation of anthracyclines appears to inactivate the drug and only occurs under rare, anaerobic conditions.  This knowledge has resulted in the identification of important new approaches to improve the therapeutic index of anthracyclines, in particular by inhibiting their cardiotoxocity.  The true utility of these approaches in the management of cancer patients undergoing anthracycline-based chemotherapy remains unclear, although one such agent (the iron chelator dexrazoxane) has recently been approved for clin. use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooT776_1sdTLVg90H21EOLACvtfcHk0ljWJ2XtRtSvtw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1OntL7I&md5=c4461a532b86122b73084d23e226a854</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.2174%2F1389200216888150915112039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389200216888150915112039%26sid%3Dliteratum%253Aachs%26aulast%3DEdwardson%26aufirst%3DD.%26aulast%3DNarendrula%26aufirst%3DR.%26aulast%3DChewchuk%26aufirst%3DS.%26aulast%3DMispel-Beyer%26aufirst%3DK.%26aulast%3DMapletoft%26aufirst%3DJ.%26aulast%3DParissenti%26aufirst%3DM.%26atitle%3DRole%2520of%2520Drug%2520Metabolism%2520in%2520the%2520Cytotoxicity%2520and%2520Clinical%2520Efficacy%2520of%2520Anthracyclines%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2015%26volume%3D16%26spage%3D412%26epage%3D426%26doi%3D10.2174%2F1389200216888150915112039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gomez-Lechon, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castell, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donato, M. T.</span></span> <span> </span><span class="NLM_article-title">Hepatocytes--The Choice to Investigate Drug Metabolism and Toxicity in Man: In Vitro Variability as a Reflection of In Vivo</span>. <i>Chem.-Biol. Interact.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>168</i></span>,  <span class="NLM_fpage">30</span>– <span class="NLM_lpage">50</span>, <span class="refDoi"> DOI: 10.1016/j.cbi.2006.10.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1016%2Fj.cbi.2006.10.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=17134688" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=1%3ACAS%3A528%3ADC%252BD2sXkvFGlsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=168&publication_year=2007&pages=30-50&author=M.+J.+Gomez-Lechonauthor=J.+V.+Castellauthor=M.+T.+Donato&title=Hepatocytes%2D%2DThe+Choice+to+Investigate+Drug+Metabolism+and+Toxicity+in+Man%3A+In+Vitro+Variability+as+a+Reflection+of+In+Vivo&doi=10.1016%2Fj.cbi.2006.10.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatocytes-the choice to investigate drug metabolism and toxicity in man: In vitro variability as a reflection of in vivo</span></div><div class="casAuthors">Gomez-Lechon, Maria Jose; Castell, Jose Vicente; Donato, Maria Teresa</div><div class="citationInfo"><span class="NLM_cas:title">Chemico-Biological Interactions</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">168</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">30-50</span>CODEN:
                <span class="NLM_cas:coden">CBINA8</span>;
        ISSN:<span class="NLM_cas:issn">0009-2797</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">A review.  The pharmaceutical industry is committed to marketing safer drugs with fewer side effects, predictable pharmacokinetic properties and quantifiable drug-drug interactions.  Drug metab. is a major determinant of drug clearance and interindividual pharmacokinetic differences, and an indirect determinant of the clin. efficacy and toxicity of drugs.  Progressive advances in the knowledge of metabolic routes and enzymes responsible for drug biotransformation have contributed to understanding the great metabolic variations existing in human beings.  Phenotypic as well genotypic differences in the expression of the enzymes involved in drug metab. are the main causes of this variability.  However, only a minor part of phenotypic variability in man is attributable to gene polymorphisms, thus making the definition of a normal liver complex.  At present, the use of human in vitro hepatic models at early preclin. stages means that the process of selecting drug candidates is becoming much more rational.  Cultured human hepatocytes are considered to be the closest model to human liver.  However, the fact that hepatocytes are located in a microenvironment that differs from that of the cell in the liver raises the question: to what extent does drug metab. variability obsd. in vitro actually reflect that of the liver in vivo By comparing the metab. of a model compd. both in vitro and in vivo in the same individual, a good correlation between the in vitro and in vivo relative abundance of oxidized metabolites and the hydrolysis of the compd. was obsd.  Thus, it is reasonable to consider that the variability obsd. in human hepatocytes reflects the existing phenotypic heterogeneity of the P 450 expression in human liver.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvhJ2qFxCzGbVg90H21EOLACvtfcHk0ljWJ2XtRtSvtw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXkvFGlsrc%253D&md5=bc5080c29e7129fc15dbc26d9527d4e3</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2Fj.cbi.2006.10.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbi.2006.10.013%26sid%3Dliteratum%253Aachs%26aulast%3DGomez-Lechon%26aufirst%3DM.%2BJ.%26aulast%3DCastell%26aufirst%3DJ.%2BV.%26aulast%3DDonato%26aufirst%3DM.%2BT.%26atitle%3DHepatocytes--The%2520Choice%2520to%2520Investigate%2520Drug%2520Metabolism%2520and%2520Toxicity%2520in%2520Man%253A%2520In%2520Vitro%2520Variability%2520as%2520a%2520Reflection%2520of%2520In%2520Vivo%26jtitle%3DChem.-Biol.%2520Interact.%26date%3D2007%26volume%3D168%26spage%3D30%26epage%3D50%26doi%3D10.1016%2Fj.cbi.2006.10.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Szotáková, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baliharová, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamka, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nožinová, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wsól, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velí, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Machala, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neča, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Souček, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Šusová, S.</span></span> <span> </span><span class="NLM_article-title">Comparison of In Vitro Activities of Biotransformation Enzymes in Pig, Cattle, Goat and Sheep</span>. <i>Res. Vet. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">43</span>– <span class="NLM_lpage">51</span>, <span class="refDoi"> DOI: 10.1016/S0034-5288(03)00143-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1016%2FS0034-5288%2803%2900143-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=14659728" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=1%3ACAS%3A528%3ADC%252BD3sXpsVSmtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2004&pages=43-51&author=B.+Szot%C3%A1kov%C3%A1author=V.+Baliharov%C3%A1author=J.+Lamkaauthor=E.+No%C5%BEinov%C3%A1author=V.+Ws%C3%B3lauthor=J.+Vel%C3%ADauthor=M.+Machalaauthor=J.+Ne%C4%8Daauthor=P.+Sou%C4%8Dekauthor=S.+%C5%A0usov%C3%A1&title=Comparison+of+In+Vitro+Activities+of+Biotransformation+Enzymes+in+Pig%2C+Cattle%2C+Goat+and+Sheep&doi=10.1016%2FS0034-5288%2803%2900143-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of in vitro activities of biotransformation enzymes in pig, cattle, goat and sheep</span></div><div class="casAuthors">Szotakova, B.; Baliharova, V.; Lamka, J.; Nozinova, E.; Wsol, V.; Velik, J.; Machala, M.; Neca, J.; Soucek, P.; Susova, S.; Skalova, L.</div><div class="citationInfo"><span class="NLM_cas:title">Research in Veterinary Science</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">43-51</span>CODEN:
                <span class="NLM_cas:coden">RVTSA9</span>;
        ISSN:<span class="NLM_cas:issn">0034-5288</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">In vitro activities of cytochromes P 450 (7-alkyl/aryloxyresorufin dealkyl(aryl)ases, testosterone hydroxylase/oxidase, 6-chlorzoxazone hydroxylase, 7-methoxy-4-trifluoromethyl-coumarin demethylase, and lauric acid hydroxylases), reductases of carbonyl group (toward metyrapone, daunorubicin, glyceraldehyde, and 4-pyridine-carboxaldehyde) and conjugation enzymes (p-nitrophenol-UDP-glucuronosyl transferase, 1-chloro-2,4-dinitrobenzene glutathione-S-transferase) in young adults, males, non-castrated (N=6) farm animals were studied and compared.  Presence of proteins cross-reacting with anti-human CYP3A4, CYP2C9, and CYP2E1 IgG was detected in all farm species.  Bovine microsomes differed from other microsomes of farm species in very high 7-ethoxyresorufin-O-deethylase activity (CYP1A1/2).  Significantly higher 7-methoxy-4-trifluoromethyl-coumarin demethylase (2-3 times) and 12-lauric acid hydroxylases (4-10 times) activities (probably corresponding to CYP2C and CYP4A, resp.) were found in ovine microsomes.  The highest 6β-testosterone hydroxylase activity, which is usually considered to be a CYP3A activity marker, was found in pig.  Reductases of all farm animals display considerable ability to reduce carbonyl group of xenobiotics.  Significant differences in level and activity of many biotransformation enzymes tested suggest that extrapolation of pharmacokinetic data obtained in one species to another (even related) could be misleading.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwA0Hh30F1NbVg90H21EOLACvtfcHk0lihPe_uTHxvtw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXpsVSmtbg%253D&md5=05a8e17f6f6cbde39953ec2b8f02334f</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2FS0034-5288%2803%2900143-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0034-5288%252803%252900143-7%26sid%3Dliteratum%253Aachs%26aulast%3DSzot%25C3%25A1kov%25C3%25A1%26aufirst%3DB.%26aulast%3DBaliharov%25C3%25A1%26aufirst%3DV.%26aulast%3DLamka%26aufirst%3DJ.%26aulast%3DNo%25C5%25BEinov%25C3%25A1%26aufirst%3DE.%26aulast%3DWs%25C3%25B3l%26aufirst%3DV.%26aulast%3DVel%25C3%25AD%26aufirst%3DJ.%26aulast%3DMachala%26aufirst%3DM.%26aulast%3DNe%25C4%258Da%26aufirst%3DJ.%26aulast%3DSou%25C4%258Dek%26aufirst%3DP.%26aulast%3D%25C5%25A0usov%25C3%25A1%26aufirst%3DS.%26atitle%3DComparison%2520of%2520In%2520Vitro%2520Activities%2520of%2520Biotransformation%2520Enzymes%2520in%2520Pig%252C%2520Cattle%252C%2520Goat%2520and%2520Sheep%26jtitle%3DRes.%2520Vet.%2520Sci.%26date%3D2004%26volume%3D76%26spage%3D43%26epage%3D51%26doi%3D10.1016%2FS0034-5288%2803%2900143-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Achour, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barber, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rostami-Hodjegan, A.</span></span> <span> </span><span class="NLM_article-title">Cytochrome P450 Pig Liver Pie: Determination of Individual Cytochrome P450 Isoform Contents in Microsomes from Two Pig Livers Using Liquid Chromatography in Conjunction with Mass Spectrometry</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">2130</span>– <span class="NLM_lpage">2134</span>, <span class="refDoi"> DOI: 10.1124/dmd.111.040618</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1124%2Fdmd.111.040618" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2011&pages=2130-2134&author=B.+Achourauthor=J.+Barberauthor=A.+Rostami-Hodjegan&title=Cytochrome+P450+Pig+Liver+Pie%3A+Determination+of+Individual+Cytochrome+P450+Isoform+Contents+in+Microsomes+from+Two+Pig+Livers+Using+Liquid+Chromatography+in+Conjunction+with+Mass+Spectrometry&doi=10.1124%2Fdmd.111.040618"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1124%2Fdmd.111.040618&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.111.040618%26sid%3Dliteratum%253Aachs%26aulast%3DAchour%26aufirst%3DB.%26aulast%3DBarber%26aufirst%3DJ.%26aulast%3DRostami-Hodjegan%26aufirst%3DA.%26atitle%3DCytochrome%2520P450%2520Pig%2520Liver%2520Pie%253A%2520Determination%2520of%2520Individual%2520Cytochrome%2520P450%2520Isoform%2520Contents%2520in%2520Microsomes%2520from%2520Two%2520Pig%2520Livers%2520Using%2520Liquid%2520Chromatography%2520in%2520Conjunction%2520with%2520Mass%2520Spectrometry%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2011%26volume%3D39%26spage%3D2130%26epage%3D2134%26doi%3D10.1124%2Fdmd.111.040618" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Werck-Reichhart, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feyereisen, R.</span></span> <span> </span><span class="NLM_article-title">Cytochromes P450: A Success Story</span>. <i>Genome biology</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">reviews3003.1</span>, <span class="refDoi"> DOI: 10.1186/gb-2000-1-6-reviews3003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1186%2Fgb-2000-1-6-reviews3003" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2000&pages=reviews3003.1&author=D.+Werck-Reichhartauthor=R.+Feyereisen&title=Cytochromes+P450%3A+A+Success+Story&doi=10.1186%2Fgb-2000-1-6-reviews3003"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1186%2Fgb-2000-1-6-reviews3003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fgb-2000-1-6-reviews3003%26sid%3Dliteratum%253Aachs%26aulast%3DWerck-Reichhart%26aufirst%3DD.%26aulast%3DFeyereisen%26aufirst%3DR.%26atitle%3DCytochromes%2520P450%253A%2520A%2520Success%2520Story%26jtitle%3DGenome%2520biology%26date%3D2000%26volume%3D1%26spage%3Dreviews3003.1%26doi%3D10.1186%2Fgb-2000-1-6-reviews3003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ortiz
de Montellano, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Voss, J. J.</span></span> <span> </span><span class="NLM_article-title">Oxidizing Species in the Mechanism of Cytochrome P450</span>. <i>Nat. Prod. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">477</span>– <span class="NLM_lpage">493</span>, <span class="refDoi"> DOI: 10.1039/b101297p</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1039%2Fb101297p" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=12195813" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=1%3ACAS%3A280%3ADC%252BD38vjvValsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2002&pages=477-493&author=P.+R.+Ortiz%0Ade+Montellanoauthor=J.+J.+De+Voss&title=Oxidizing+Species+in+the+Mechanism+of+Cytochrome+P450&doi=10.1039%2Fb101297p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Oxidizing species in the mechanism of cytochrome P450</span></div><div class="casAuthors">Ortiz de Montellano Paul R; De Voss James J</div><div class="citationInfo"><span class="NLM_cas:title">Natural product reports</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">477-93</span>
        ISSN:<span class="NLM_cas:issn">0265-0568</span>.
    </div><div class="casAbstract">This review discusses the mechanisms of oxygen activation by cytochrome P450 enzymes, the possible catalytic roles of the various iron--oxygen species formed in the catalytic cycle, and progress in understanding the mechanisms of hydrocarbon hydroxylation, heteroatom oxidation, and olefin epoxidation.  The focus of the review is on recent results, but earlier work is discussed as appropriate.  The literature through to February 2002 is surveyed, and 175 referenced are cited.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSHGez5WBT-VIMcDoIzZtNkfW6udTcc2eZNKE8i1dsSTLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD38vjvValsQ%253D%253D&md5=acd16cba1ce2d49c97e4a828cb606ec1</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1039%2Fb101297p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fb101297p%26sid%3Dliteratum%253Aachs%26aulast%3DOrtiz%2Bde%2BMontellano%26aufirst%3DP.%2BR.%26aulast%3DDe%2BVoss%26aufirst%3DJ.%2BJ.%26atitle%3DOxidizing%2520Species%2520in%2520the%2520Mechanism%2520of%2520Cytochrome%2520P450%26jtitle%3DNat.%2520Prod.%2520Rep.%26date%3D2002%26volume%3D19%26spage%3D477%26epage%3D493%26doi%3D10.1039%2Fb101297p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ashla, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoshikawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuchiya, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashiguchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Enjoji, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamuta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taketomi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maehara, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shomori, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurimasa, A.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Genetic Analysis of Expression Profile Involved in Retinoid Metabolism in Non-Alcoholic Fatty Liver Disease</span>. <i>Hepatol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">594</span>– <span class="NLM_lpage">604</span>, <span class="refDoi"> DOI: 10.1111/j.1872-034X.2010.00646.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1111%2Fj.1872-034X.2010.00646.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=20618457" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1aqurfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2010&pages=594-604&author=A.+A.+Ashlaauthor=Y.+Hoshikawaauthor=H.+Tsuchiyaauthor=K.+Hashiguchiauthor=M.+Enjojiauthor=M.+Nakamutaauthor=A.+Taketomiauthor=Y.+Maeharaauthor=K.+Shomoriauthor=A.+Kurimasa&title=Genetic+Analysis+of+Expression+Profile+Involved+in+Retinoid+Metabolism+in+Non-Alcoholic+Fatty+Liver+Disease&doi=10.1111%2Fj.1872-034X.2010.00646.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Genetic analysis of expression profile involved in retinoid metabolism in non-alcoholic fatty liver disease</span></div><div class="casAuthors">Ashla, An Afida; Hoshikawa, Yoshiko; Tsuchiya, Hiroyuki; Hashiguchi, Koich; Enjoji, Munechika; Nakamuta, Makoto; Taketomi, Akinobu; Maehara, Yoshihiko; Shomori, Kohei; Kurimasa, Akihiro; Hisatome, Ichiro; Ito, Hisao; Shiota, Goshi</div><div class="citationInfo"><span class="NLM_cas:title">Hepatology Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">594-604</span>CODEN:
                <span class="NLM_cas:coden">HPRSFM</span>;
        ISSN:<span class="NLM_cas:issn">1386-6346</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The patients with non-alc. fatty liver disease (NAFLD) have been reported to be at greater risk for progression to chronic liver disease including liver cirrhosis (LC).  To examine the mechanisms for the progression of NAFLD, a genetic anal. of hepatic expression profile in retinoid metab. in NAFLD was performed since the loss of retinoid signaling is assocd. with the progression of liver disease via reactive oxygen species (ROS) generation.  51 Genes, which are assocd. with retinoid metab. and action, were examd. in 36 subjects including 17 patients with simple steatosis, 11 with non-alc. steatohepatitis (NASH) and 8 controls were examd. by real-time reverse transcriptase polymerase chain reaction.  Immunohistochem. study was also done by 3 kinds of antibodies.  Higher expression of CRBP1 LRAT, DGT1/2, and CES1 in NAFLD suggests that mutual conversion between retinyl ester and retinal occurs actively.  Expression of ADH1/2/3, RDH5/10/11, DHRS3, and RALDH1/3 was increased in NAFLD, suggesting that oxidn. process from retinol to all-trans retinoic acid (ATRA) was enhanced.  Importantly, greater expression of CYP26A1 indicated that degrdn. of ATRA was enhanced in NAFLD.  Further, expression of SOD1/2, catalase, thioredoxin and uncoupling protein 2 was also enhanced.  Hyperdynamic state of retinoid metab. is present in the liver tissues with NAFLD, which may be a putative mechanism by which NAFLD progresses to chronic liver disease including LC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPnCE1zD7mC7Vg90H21EOLACvtfcHk0lg1LRLKssve6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1aqurfK&md5=f09228bd1a48a3fe81886523570a7dd5</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1111%2Fj.1872-034X.2010.00646.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1872-034X.2010.00646.x%26sid%3Dliteratum%253Aachs%26aulast%3DAshla%26aufirst%3DA.%2BA.%26aulast%3DHoshikawa%26aufirst%3DY.%26aulast%3DTsuchiya%26aufirst%3DH.%26aulast%3DHashiguchi%26aufirst%3DK.%26aulast%3DEnjoji%26aufirst%3DM.%26aulast%3DNakamuta%26aufirst%3DM.%26aulast%3DTaketomi%26aufirst%3DA.%26aulast%3DMaehara%26aufirst%3DY.%26aulast%3DShomori%26aufirst%3DK.%26aulast%3DKurimasa%26aufirst%3DA.%26atitle%3DGenetic%2520Analysis%2520of%2520Expression%2520Profile%2520Involved%2520in%2520Retinoid%2520Metabolism%2520in%2520Non-Alcoholic%2520Fatty%2520Liver%2520Disease%26jtitle%3DHepatol.%2520Res.%26date%3D2010%26volume%3D40%26spage%3D594%26epage%3D604%26doi%3D10.1111%2Fj.1872-034X.2010.00646.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pan, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoeppner, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, J. Y.</span></span> <span> </span><span class="NLM_article-title">Induction of Phosphoenolpyruvate Carboxykinase Gene Expression by Retinoic Acid in an Adult Rat Hepatocyte Line</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">10883</span>– <span class="NLM_lpage">10888</span>, <span class="refDoi"> DOI: 10.1021/bi00501a004</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi00501a004" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=1990&pages=10883-10888&author=C.+J.+Panauthor=W.+Hoeppnerauthor=J.+Y.+Chou&title=Induction+of+Phosphoenolpyruvate+Carboxykinase+Gene+Expression+by+Retinoic+Acid+in+an+Adult+Rat+Hepatocyte+Line&doi=10.1021%2Fbi00501a004"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1021%2Fbi00501a004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi00501a004%26sid%3Dliteratum%253Aachs%26aulast%3DPan%26aufirst%3DC.%2BJ.%26aulast%3DHoeppner%26aufirst%3DW.%26aulast%3DChou%26aufirst%3DJ.%2BY.%26atitle%3DInduction%2520of%2520Phosphoenolpyruvate%2520Carboxykinase%2520Gene%2520Expression%2520by%2520Retinoic%2520Acid%2520in%2520an%2520Adult%2520Rat%2520Hepatocyte%2520Line%26jtitle%3DBiochemistry%26date%3D1990%26volume%3D29%26spage%3D10883%26epage%3D10888%26doi%3D10.1021%2Fbi00501a004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kalaany, N. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mangelsdorf, D. J.</span></span> <span> </span><span class="NLM_article-title">LXRS and FXR: The Yin And Yang of Cholesterol and Fat Metabolism</span>. <i>Annu. Rev. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">159</span>– <span class="NLM_lpage">191</span>, <span class="refDoi"> DOI: 10.1146/annurev.physiol.68.033104.152158</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1146%2Fannurev.physiol.68.033104.152158" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2006&pages=159-191&author=N.+Y.+Kalaanyauthor=D.+J.+Mangelsdorf&title=LXRS+and+FXR%3A+The+Yin+And+Yang+of+Cholesterol+and+Fat+Metabolism&doi=10.1146%2Fannurev.physiol.68.033104.152158"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1146%2Fannurev.physiol.68.033104.152158&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.physiol.68.033104.152158%26sid%3Dliteratum%253Aachs%26aulast%3DKalaany%26aufirst%3DN.%2BY.%26aulast%3DMangelsdorf%26aufirst%3DD.%2BJ.%26atitle%3DLXRS%2520and%2520FXR%253A%2520The%2520Yin%2520And%2520Yang%2520of%2520Cholesterol%2520and%2520Fat%2520Metabolism%26jtitle%3DAnnu.%2520Rev.%2520Physiol.%26date%3D2006%26volume%3D68%26spage%3D159%26epage%3D191%26doi%3D10.1146%2Fannurev.physiol.68.033104.152158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Desvergne, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wahli, W.</span></span> <span> </span><span class="NLM_article-title">Peroxisome Proliferator-Activated Receptors: Nuclear Control of Metabolism</span>. <i>Endocr. Rev.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">649</span>– <span class="NLM_lpage">688</span>, <span class="refDoi"> DOI: 10.1210/edrv.20.5.0380</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1210%2Fedrv.20.5.0380" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10529898" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=1%3ACAS%3A528%3ADyaK1MXmvFalsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=1999&pages=649-688&author=B.+Desvergneauthor=W.+Wahli&title=Peroxisome+Proliferator-Activated+Receptors%3A+Nuclear+Control+of+Metabolism&doi=10.1210%2Fedrv.20.5.0380"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Peroxisome proliferator-activated receptors: nuclear control of metabolism</span></div><div class="casAuthors">Desvergne, Beatrice; Wahli, Walter</div><div class="citationInfo"><span class="NLM_cas:title">Endocrine Reviews</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">649-688</span>CODEN:
                <span class="NLM_cas:coden">ERVIDP</span>;
        ISSN:<span class="NLM_cas:issn">0163-769X</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">A review, with 408 refs., on the mol. and physiol. aspects of peroxisome proliferator-activated receptors (PPAR).  Mol. aspects included: PPAR isotype identity, genomic organization, and chromosomal localization; DNA binding properties; ligand binding properties; pathways for activation; and PPAR transactivation properties.  Physiol. aspects included: differential expression of PPAR mRNAs; PPAR target genes and functions in fatty acid metab.; PPARs and control of inflammatory responses; PPARs and atherosclerosis; PPARs and development of the fetal epidermal permeability barrier; and PPARs, carcinogenesis, and control of the cell cycle.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGot4PfN8bZDDbVg90H21EOLACvtfcHk0lg1LRLKssve6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXmvFalsLo%253D&md5=0007e3aa3bab709ad1eb1621d2c6cc38</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1210%2Fedrv.20.5.0380&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fedrv.20.5.0380%26sid%3Dliteratum%253Aachs%26aulast%3DDesvergne%26aufirst%3DB.%26aulast%3DWahli%26aufirst%3DW.%26atitle%3DPeroxisome%2520Proliferator-Activated%2520Receptors%253A%2520Nuclear%2520Control%2520of%2520Metabolism%26jtitle%3DEndocr.%2520Rev.%26date%3D1999%26volume%3D20%26spage%3D649%26epage%3D688%26doi%3D10.1210%2Fedrv.20.5.0380" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Brien, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imai, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Forman, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samuels, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Granner, D. K.</span></span> <span> </span><span class="NLM_article-title">A Retinoic Acid Response Element is Part of a Pleiotropic Domain in the Phosphoenolpyruvate Carboxykinase Gene</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>88</i></span>,  <span class="NLM_fpage">2184</span>– <span class="NLM_lpage">2188</span>, <span class="refDoi"> DOI: 10.1073/pnas.88.6.2184</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1073%2Fpnas.88.6.2184" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=1991&pages=2184-2188&author=P.+C.+Lucasauthor=R.+M.+O%E2%80%99Brienauthor=J.+A.+Mitchellauthor=C.+M.+Davisauthor=E.+Imaiauthor=B.+M.+Formanauthor=H.+H.+Samuelsauthor=D.+K.+Granner&title=A+Retinoic+Acid+Response+Element+is+Part+of+a+Pleiotropic+Domain+in+the+Phosphoenolpyruvate+Carboxykinase+Gene&doi=10.1073%2Fpnas.88.6.2184"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1073%2Fpnas.88.6.2184&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.88.6.2184%26sid%3Dliteratum%253Aachs%26aulast%3DLucas%26aufirst%3DP.%2BC.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DR.%2BM.%26aulast%3DMitchell%26aufirst%3DJ.%2BA.%26aulast%3DDavis%26aufirst%3DC.%2BM.%26aulast%3DImai%26aufirst%3DE.%26aulast%3DForman%26aufirst%3DB.%2BM.%26aulast%3DSamuels%26aufirst%3DH.%2BH.%26aulast%3DGranner%26aufirst%3DD.%2BK.%26atitle%3DA%2520Retinoic%2520Acid%2520Response%2520Element%2520is%2520Part%2520of%2520a%2520Pleiotropic%2520Domain%2520in%2520the%2520Phosphoenolpyruvate%2520Carboxykinase%2520Gene%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1991%26volume%3D88%26spage%3D2184%26epage%3D2188%26doi%3D10.1073%2Fpnas.88.6.2184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hall, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noisin, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Granner, D. K.</span></span> <span> </span><span class="NLM_article-title">Activation of the Phosphoenolpyruvate Carboxykinase Gene Retinoic Acid Response Element is Dependent on a Retinoic Acid Receptor/Coregulator Complex</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">5527</span>– <span class="NLM_lpage">5535</span>, <span class="refDoi"> DOI: 10.1128/MCB.12.12.5527</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1128%2FMCB.12.12.5527" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=1333043" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=1%3ACAS%3A528%3ADyaK3sXltlCltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=1992&pages=5527-5535&author=R.+K.+Hallauthor=D.+K.+Scottauthor=E.+L.+Noisinauthor=P.+C.+Lucasauthor=D.+K.+Granner&title=Activation+of+the+Phosphoenolpyruvate+Carboxykinase+Gene+Retinoic+Acid+Response+Element+is+Dependent+on+a+Retinoic+Acid+Receptor%2FCoregulator+Complex&doi=10.1128%2FMCB.12.12.5527"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of the phosphoenolpyruvate carboxykinase gene retinoic acid response element is dependent on a retinoic acid receptor/coregulator complex</span></div><div class="casAuthors">Hall, Robert K.; Scott, Donald K.; Noisin, Edouard L.; Lucas, Peter C.; Granner, Daryl K.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5527-35</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    </div><div class="casAbstract">The accessory factor 1 (AF1) element is an upstream retranscriptional control region that plays a role in the response of the phosphoenolpyruvate carboxykinase (PEPCK) gene to both glucocorticoids and retinoic acid.  Retinoic acid receptor alpha (RARα) binds to a sequence within the AF1 element, TGACCT (site B), that is a consensus retinoic acid response element (RARE) half-site.  A similar DNA sequence, TGGCCG (site C), located 1 bp downstream of site B, is not involved in the binding of RARα monomers or dimers but is required for the constitution of a functional RARE.  Site C is also required for the formation of a complex involving RARα and a liver nuclear factor designated CR, for coregulators.  Mutational anal. of the AF1 element shows that the RARα/CR complex is the trans-acting unit that mediates the retinoic acid response of the PEPCK gene.  Another member of the retinoid receptor family, retinoid X receptor alpha (RXRα), can also form a complex with RARα and the AF1 element.  Several observations, including the observation that RXRα antibody interacts with CR, indicate that RXRα and CR are identical or closely related proteins.  Though RXRα forms a complex with RARα and the AF1 element, the AF1 element is functionally distinguishable from a retinoid X response element.  Thus, the AF1 element contains an RARE that mediates a retinoic acid response by binding an RARα/coregulator complex; this coregulator is presumably RXRα.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGob71gbk_YDabVg90H21EOLACvtfcHk0ljG55I445J1aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXltlCltw%253D%253D&md5=57bf4bdaa514c530b48adc50bbd6e3a9</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1128%2FMCB.12.12.5527&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.12.12.5527%26sid%3Dliteratum%253Aachs%26aulast%3DHall%26aufirst%3DR.%2BK.%26aulast%3DScott%26aufirst%3DD.%2BK.%26aulast%3DNoisin%26aufirst%3DE.%2BL.%26aulast%3DLucas%26aufirst%3DP.%2BC.%26aulast%3DGranner%26aufirst%3DD.%2BK.%26atitle%3DActivation%2520of%2520the%2520Phosphoenolpyruvate%2520Carboxykinase%2520Gene%2520Retinoic%2520Acid%2520Response%2520Element%2520is%2520Dependent%2520on%2520a%2520Retinoic%2520Acid%2520Receptor%252FCoregulator%2520Complex%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D1992%26volume%3D12%26spage%3D5527%26epage%3D5535%26doi%3D10.1128%2FMCB.12.12.5527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shin, D.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tao, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGrane, M. M.</span></span> <span> </span><span class="NLM_article-title">Effects of Vitamin A Deficiency and Retinoic Acid Treatment on Expression of a Phosphoenolpyruvate Carboxykinase-Bovine Growth Hormone Gene in Transgenic Mice</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>213</i></span>,  <span class="NLM_fpage">706</span>– <span class="NLM_lpage">714</span>, <span class="refDoi"> DOI: 10.1006/bbrc.1995.2188</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1006%2Fbbrc.1995.2188" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=213&publication_year=1995&pages=706-714&author=D.-J.+Shinauthor=A.+Taoauthor=M.+M.+McGrane&title=Effects+of+Vitamin+A+Deficiency+and+Retinoic+Acid+Treatment+on+Expression+of+a+Phosphoenolpyruvate+Carboxykinase-Bovine+Growth+Hormone+Gene+in+Transgenic+Mice&doi=10.1006%2Fbbrc.1995.2188"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1006%2Fbbrc.1995.2188&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fbbrc.1995.2188%26sid%3Dliteratum%253Aachs%26aulast%3DShin%26aufirst%3DD.-J.%26aulast%3DTao%26aufirst%3DA.%26aulast%3DMcGrane%26aufirst%3DM.%2BM.%26atitle%3DEffects%2520of%2520Vitamin%2520A%2520Deficiency%2520and%2520Retinoic%2520Acid%2520Treatment%2520on%2520Expression%2520of%2520a%2520Phosphoenolpyruvate%2520Carboxykinase-Bovine%2520Growth%2520Hormone%2520Gene%2520in%2520Transgenic%2520Mice%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D1995%26volume%3D213%26spage%3D706%26epage%3D714%26doi%3D10.1006%2Fbbrc.1995.2188" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wolchok, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kluger, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callahan, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Postow, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizvi, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesokhin, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Segal, N. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ariyan, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, R.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reed, K.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Nivolumab Plus Ipilimumab in Advanced Melanoma</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>369</i></span>,  <span class="NLM_fpage">122</span>– <span class="NLM_lpage">133</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1302369</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1056%2FNEJMoa1302369" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=23724867" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1ektbrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=369&publication_year=2013&pages=122-133&author=J.+D.+Wolchokauthor=H.+Klugerauthor=M.+K.+Callahanauthor=M.+A.+Postowauthor=N.+A.+Rizviauthor=A.+M.+Lesokhinauthor=N.+H.+Segalauthor=C.+E.+Ariyanauthor=R.-A.+Gordonauthor=K.+Reed&title=Nivolumab+Plus+Ipilimumab+in+Advanced+Melanoma&doi=10.1056%2FNEJMoa1302369"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Nivolumab plus ipilimumab in advanced melanoma</span></div><div class="casAuthors">Wolchok, Edd D.; Kluger, Harriet; Callahan, Margaret K.; Postow, Michael A.; Rizvi, Naiyer A.; Lesokhln, Alexander M.; Segal, Nell H.; Ariyan, Charlotte E.; Gordon, Ruth-Ann; Reed, Kathleen; Burke, Matthew M.; Caldwell, Anne; Kronenberg, Stephanie A.; Agunwamba, Blessing U.; Zhang, Xiaoling; Lowy, Israel; Inzunza, Hector David; Feely, William; Horak, Christine E.; Hong, Quan; Korman, Alan J.; Wigginton, Jon M.; Gupta, Ashok; Sznol, Mario</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">369</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">122-133</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND In patients with melanoma, ipilimumab (an antibody against cytotoxic T-lymphocyte-assocd. antigen 4 [CTLA-4]) prolongs overall survival, and nivolumab (an antibody against the programmed death 1 [PD-1] receptor) produced durable tumor regression in a phase I trial.  On the basis of their distinct immunol. mechanisms of action and supportive preclin. data, we conducted a phase 1 trial of nivolumab combined with ipilimumab in patients with advanced melanoma.  METHODS We administered i.v. doses of nivolumab and ipilimumab in patients every 3 wk for 4 doses, followed by nivolumab alone every 3 wk for 4 doses (concur- rent regimen).  The combined treatment was subsequently administered every 12 wk for up to 8 doses.  In a sequenced regimen, patients previously treated with ipilimumab received nivolumab every 2 wk for up to 48 doses.  RESULTS A total of 53 patients received concurrent therapy with nivolumab and ipilimumab, and 33 received sequenced treatment The objective-response rate (according to modified World Health Organization criteria) for all patients in the concurrent-regimen group was 40%.  Evidence of clin. activity (conventional, unconfirmed, or immune-related response or stable disease for ≥24 wk) was obsd. in 65% of patients.  At the max. doses that were assocd. with an acceptable level of adverse events (nivolumab at a dose of 1 mg per kg of body wt. and ipilimumab at a dose of 3 mg per kg), 53% of patients had an objective response, all with tumor redn. of 80% or more.  Grade 3 or 4 adverse events related to therapy occurred In 53% of patients in the concurrent-regimen group but were qual. similar to previous experience with monotherapy and were generally reversible.  Among patients in the sequenced-regimen group, 18% had grade 3 or 4 adverse events related to therapy and the objective-response rate was 20%.  CONCLUSIONS Concurrent therapy with nivolumab and ipilimumab had a manageable safety pro- file and provided clin. activity that appears to be distinct from that in published data on monotherapy, with rapid and deep tumor regression in a substantial proportion of patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9OCEoj7t5FrVg90H21EOLACvtfcHk0ljG55I445J1aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1ektbrF&md5=c17b746e817f6676913d59dd058f5ff1</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1302369&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1302369%26sid%3Dliteratum%253Aachs%26aulast%3DWolchok%26aufirst%3DJ.%2BD.%26aulast%3DKluger%26aufirst%3DH.%26aulast%3DCallahan%26aufirst%3DM.%2BK.%26aulast%3DPostow%26aufirst%3DM.%2BA.%26aulast%3DRizvi%26aufirst%3DN.%2BA.%26aulast%3DLesokhin%26aufirst%3DA.%2BM.%26aulast%3DSegal%26aufirst%3DN.%2BH.%26aulast%3DAriyan%26aufirst%3DC.%2BE.%26aulast%3DGordon%26aufirst%3DR.-A.%26aulast%3DReed%26aufirst%3DK.%26atitle%3DNivolumab%2520Plus%2520Ipilimumab%2520in%2520Advanced%2520Melanoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2013%26volume%3D369%26spage%3D122%26epage%3D133%26doi%3D10.1056%2FNEJMoa1302369" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Topalian, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sznol, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDermott, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kluger, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carvajal, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharfman, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brahmer, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atkins, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powderly, J. D.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Survival, Durable Tumor Remission, and Long-Term Safety in Patients with Advanced Melanoma Receiving Nivolumab</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">1020</span>– <span class="NLM_lpage">1030</span>, <span class="refDoi"> DOI: 10.1200/JCO.2013.53.0105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1200%2FJCO.2013.53.0105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=24590637" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpsVSku74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2014&pages=1020-1030&author=S.+L.+Topalianauthor=M.+Sznolauthor=D.+F.+McDermottauthor=H.+M.+Klugerauthor=R.+D.+Carvajalauthor=W.+H.+Sharfmanauthor=J.+R.+Brahmerauthor=D.+P.+Lawrenceauthor=M.+B.+Atkinsauthor=J.+D.+Powderly&title=Survival%2C+Durable+Tumor+Remission%2C+and+Long-Term+Safety+in+Patients+with+Advanced+Melanoma+Receiving+Nivolumab&doi=10.1200%2FJCO.2013.53.0105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab</span></div><div class="casAuthors">Topalian, Suzanne L.; Sznol, Mario; McDermott, David F.; Kluger, Harriet M.; Carvajal, Richard D.; Sharfman, William H.; Brahmer, Julie R.; Lawrence, Donald P.; Atkins, Michael B.; Powderly, John D.; Leming, Philip D.; Lipson, Evan J.; Puzanov, Igor; Smith, David C.; Taube, Janis M.; Wigginton, Jon M.; Kollia, Georgia D.; Gupta, Ashok; Pardoll, Drew M.; Sosman, Jeffrey A.; Hodi, F. Stephen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1020-1030</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose Programmed cell death 1 (PD-1) is an inhibitory receptor expressed by activated T cells that downmodulates effector functions and limits the generation of immune memory.  PD-1 blockade can mediate tumor regression in a substantial proportion of patients with melanoma, but it is not known whether this is assocd. with extended survival or maintenance of response after treatment is discontinued.  Patients and Methods Patients with advanced melanoma (N = 107) enrolled between 2008 and 2012 received i.v. nivolumab in an outpatient setting every 2 wk for up to 96 wk and were obsd. for overall survival, long-term safety, and response duration after treatment discontinuation.  Results Median overall survival in nivolumab-treated patients (62% with two to five prior systemic therapies) was 16.8 mo, and 1- and 2-yr survival rates were 62% and 43%, resp.  Among 33 patients with objective tumor regressions (31%), the Kaplan-Meier estd. median response duration was 2 years.  Seventeen patients discontinued therapy for reasons other than disease progression, and 12 (71%) of 17 maintained responses off-therapy for at least 16 wk (range, 16 to 56+ weeks).  Objective response and toxicity rates were similar to those reported previously; in an extended anal. of all 306 patients treated on this trial (including those with other cancer types), exposure-adjusted toxicity rates were not cumulative.  Conclusion Overall survival following nivolumab treatment in patients with advanced treatment-refractory melanoma compares favorably with that in literature studies of similar patient populations.  Responses were durable and persisted after drug discontinuation.  Long-term safety was acceptable.  Ongoing randomized clin. trials will further assess the impact of nivolumab therapy on overall survival in patients with metastatic melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCsu2eYts347Vg90H21EOLACvtfcHk0ljG55I445J1aw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpsVSku74%253D&md5=11ebaafb4dec008334b6445949d0d939</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1200%2FJCO.2013.53.0105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2013.53.0105%26sid%3Dliteratum%253Aachs%26aulast%3DTopalian%26aufirst%3DS.%2BL.%26aulast%3DSznol%26aufirst%3DM.%26aulast%3DMcDermott%26aufirst%3DD.%2BF.%26aulast%3DKluger%26aufirst%3DH.%2BM.%26aulast%3DCarvajal%26aufirst%3DR.%2BD.%26aulast%3DSharfman%26aufirst%3DW.%2BH.%26aulast%3DBrahmer%26aufirst%3DJ.%2BR.%26aulast%3DLawrence%26aufirst%3DD.%2BP.%26aulast%3DAtkins%26aufirst%3DM.%2BB.%26aulast%3DPowderly%26aufirst%3DJ.%2BD.%26atitle%3DSurvival%252C%2520Durable%2520Tumor%2520Remission%252C%2520and%2520Long-Term%2520Safety%2520in%2520Patients%2520with%2520Advanced%2520Melanoma%2520Receiving%2520Nivolumab%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2014%26volume%3D32%26spage%3D1020%26epage%3D1030%26doi%3D10.1200%2FJCO.2013.53.0105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schachtschneider, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mäkeläinen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madsen, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rund, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groenen, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schook, L. B.</span></span> <span> </span><span class="NLM_article-title">Oncopig Soft-Tissue Sarcomas Recapitulate Key Transcriptional Features of Human Sarcomas</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">2624</span>, <span class="refDoi"> DOI: 10.1038/s41598-017-02912-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1038%2Fs41598-017-02912-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=28572589" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=1%3ACAS%3A280%3ADC%252BC1cnktVynsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=2624&author=K.+M.+Schachtschneiderauthor=Y.+Liuauthor=S.+M%C3%A4kel%C3%A4inenauthor=O.+Madsenauthor=L.+A.+Rundauthor=M.+A.+Groenenauthor=L.+B.+Schook&title=Oncopig+Soft-Tissue+Sarcomas+Recapitulate+Key+Transcriptional+Features+of+Human+Sarcomas&doi=10.1038%2Fs41598-017-02912-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Oncopig Soft-Tissue Sarcomas Recapitulate Key Transcriptional Features of Human Sarcomas</span></div><div class="casAuthors">Schachtschneider Kyle M; Liu Yingkai; Rund Laurie A; Schook Lawrence B; Schachtschneider Kyle M; Makelainen Suvi; Madsen Ole; Groenen Martien A M; Schachtschneider Kyle M; Schook Lawrence B; Liu Yingkai; Makelainen Suvi</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">2624</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Human soft-tissue sarcomas (STS) are rare mesenchymal tumors with a 5-year survival rate of 50%, highlighting the need for further STS research.  Research has been hampered by limited human sarcoma cell line availability and the large number of STS subtypes, making development of STS cell lines and animal models representative of the diverse human STS subtypes critical.  Pigs represent ideal human disease models due to their similar size, anatomy, metabolism, and genetics compared to humans.  The Oncopig encodes inducible KRAS (G12D) and TP53 (R167H) transgenes, allowing for STS modeling in a spatial and temporal manner.  This study utilized Oncopig STS cell line (fibroblast) and tumor (leiomyosarcoma) RNA-seq data to compare Oncopig and human STS expression profiles.  Altered expression of 3,360 and 7,652 genes was identified in Oncopig STS cell lines and leiomyosarcomas, respectively.  Transcriptional hallmarks of human STS were observed in Oncopig STS, including altered TP53 signaling, Wnt signaling activation, and evidence of epigenetic reprogramming.  Furthermore, master regulators of Oncopig STS expression were identified, including FOSL1, which was previously identified as a potential human STS therapeutic target.  These results demonstrate the Oncopig STS model's ability to mimic human STS transcriptional profiles, providing a valuable resource for sarcoma research and cell line development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRJ_SCYdyBBVO3MPKNEWB5RfW6udTcc2eZanG03RN871rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cnktVynsw%253D%253D&md5=b8b0fab10c643f83ce57d890d1d2a2c6</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1038%2Fs41598-017-02912-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-017-02912-9%26sid%3Dliteratum%253Aachs%26aulast%3DSchachtschneider%26aufirst%3DK.%2BM.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DM%25C3%25A4kel%25C3%25A4inen%26aufirst%3DS.%26aulast%3DMadsen%26aufirst%3DO.%26aulast%3DRund%26aufirst%3DL.%2BA.%26aulast%3DGroenen%26aufirst%3DM.%2BA.%26aulast%3DSchook%26aufirst%3DL.%2BB.%26atitle%3DOncopig%2520Soft-Tissue%2520Sarcomas%2520Recapitulate%2520Key%2520Transcriptional%2520Features%2520of%2520Human%2520Sarcomas%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26spage%3D2624%26doi%3D10.1038%2Fs41598-017-02912-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ian, F. R.</span></span> <i>Culture of Animal Cells: A Manual of Basic Technique and Specialized Applications</i>; <span class="NLM_publisher-name">Wiley-Sons</span>: <span class="NLM_publisher-loc">New York</span>, <span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=F.+R.+Ian&title=Culture+of+Animal+Cells%3A+A+Manual+of+Basic+Technique+and+Specialized+Applications"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DIan%26aufirst%3DF.%2BR.%26btitle%3DCulture%2520of%2520Animal%2520Cells%253A%2520A%2520Manual%2520of%2520Basic%2520Technique%2520and%2520Specialized%2520Applications%26pub%3DWiley-Sons%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">van
Meerloo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaspers, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cloos, J.</span></span> <span> </span><span class="NLM_article-title">Cell Sensitivity Assays: The MTT Assay</span>. <i>Methods Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>731</i></span>,  <span class="NLM_fpage">237</span>– <span class="NLM_lpage">245</span>, <span class="refDoi"> DOI: 10.1007/978-1-61779-080-5_20</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=10.1007%2F978-1-61779-080-5_20" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=21516412" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;key=1%3ACAS%3A528%3ADC%252BC3MXntVyqtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=731&publication_year=2011&pages=237-245&author=J.+van%0AMeerlooauthor=G.+J.+Kaspersauthor=J.+Cloos&title=Cell+Sensitivity+Assays%3A+The+MTT+Assay&doi=10.1007%2F978-1-61779-080-5_20"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Cell sensitivity assays: the MTT assay</span></div><div class="casAuthors">van Meerloo, Johan; Kaspers, Gertjan J. L.; Cloos, Jacqueline</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Molecular Biology (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">731</span>
        (<span class="NLM_cas:issue">Cancer Cell Culture</span>),
    <span class="NLM_cas:pages">237-245</span>CODEN:
                <span class="NLM_cas:coden">MMBIED</span>;
        ISSN:<span class="NLM_cas:issn">1064-3745</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The MTT (3-[4,5-dimethylthiazol-2-yl]-2,5 di-Ph tetrazolium bromide) assay is based on the conversion of MTT into formazan crystals by living cells, which dets. mitochondrial activity.  Since for most cell populations the total mitochondrial activity is related to the no. of viable cells, this assay is broadly used to measure the in vitro cytotoxic effects of drugs on cell lines or primary patient cells.  In this chapter the protocol of the assay is described including important considerations relevant for each step of the assay as well as its limitations and possible applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprO-kUg91O_7Vg90H21EOLACvtfcHk0ljiwudvo16rAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXntVyqtbk%253D&md5=f88b391a65df5cb01b3bba486c55ce96</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1007%2F978-1-61779-080-5_20&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-61779-080-5_20%26sid%3Dliteratum%253Aachs%26aulast%3Dvan%2BMeerloo%26aufirst%3DJ.%26aulast%3DKaspers%26aufirst%3DG.%2BJ.%26aulast%3DCloos%26aufirst%3DJ.%26atitle%3DCell%2520Sensitivity%2520Assays%253A%2520The%2520MTT%2520Assay%26jtitle%3DMethods%2520Mol.%2520Biol.%26date%3D2011%26volume%3D731%26spage%3D237%26epage%3D245%26doi%3D10.1007%2F978-1-61779-080-5_20" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1MVC" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1MVC','PDB','1MVC'); return false;">PDB: 1MVC</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i32"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b01387">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_06733"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.8b01387">10.1021/acs.jmedchem.8b01387</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Method for selection of compounds for virtual screening, chemical characterization, mass and NMR spectra, histopathology results, and clinical pathology results from Oncopigs with different treatments (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b01387/suppl_file/jm8b01387_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula string (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b01387/suppl_file/jm8b01387_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b01387/suppl_file/jm8b01387_si_001.pdf">jm8b01387_si_001.pdf (599.5 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b01387/suppl_file/jm8b01387_si_002.csv">jm8b01387_si_002.csv (0.12 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.8b01387&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2018.61.issue-23%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.8b01387" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.8b01387" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                9MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679984d7ebae3cee","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
